0001356576-22-000046.txt : 20220512 0001356576-22-000046.hdr.sgml : 20220512 20220512171535 ACCESSION NUMBER: 0001356576-22-000046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 22918971 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 10-Q 1 supn-20220331.htm 10-Q supn-20220331
0001356576false12-312022Q1http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member0.0168545http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent00013565762022-01-012022-03-3100013565762022-05-02xbrli:shares00013565762022-03-31iso4217:USD00013565762021-12-31iso4217:USDxbrli:shares0001356576us-gaap:ProductMember2022-01-012022-03-310001356576us-gaap:ProductMember2021-01-012021-03-310001356576us-gaap:RoyaltyMember2022-01-012022-03-310001356576us-gaap:RoyaltyMember2021-01-012021-03-3100013565762021-01-012021-03-310001356576us-gaap:CommonStockMember2021-12-310001356576us-gaap:AdditionalPaidInCapitalMember2021-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001356576us-gaap:RetainedEarningsMember2021-12-310001356576us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001356576us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:CommonStockMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:RetainedEarningsMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001356576us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001356576us-gaap:CommonStockMember2022-01-012022-03-310001356576us-gaap:RetainedEarningsMember2022-01-012022-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001356576us-gaap:CommonStockMember2022-03-310001356576us-gaap:AdditionalPaidInCapitalMember2022-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001356576us-gaap:RetainedEarningsMember2022-03-310001356576us-gaap:CommonStockMember2020-12-310001356576us-gaap:AdditionalPaidInCapitalMember2020-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001356576us-gaap:RetainedEarningsMember2020-12-3100013565762020-12-310001356576us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001356576us-gaap:CommonStockMember2021-01-012021-03-310001356576us-gaap:RetainedEarningsMember2021-01-012021-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001356576us-gaap:CommonStockMember2021-03-310001356576us-gaap:AdditionalPaidInCapitalMember2021-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001356576us-gaap:RetainedEarningsMember2021-03-3100013565762021-03-31supn:segment0001356576us-gaap:AccountingStandardsUpdate202006Member2022-01-010001356576us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate202006Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-01-010001356576us-gaap:AccountingStandardsUpdate202006Memberus-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-01-010001356576us-gaap:AccountingStandardsUpdate202006Memberus-gaap:ConvertibleDebtMember2022-01-012022-03-310001356576supn:AdamasPharmaceuticalsMember2021-11-242021-11-24supn:marketProduct0001356576supn:AdamasPharmaceuticalsMember2021-11-242021-11-240001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-11-24supn:right0001356576supn:AdamasPharmaceuticalsMember2021-11-240001356576supn:AdamasPharmaceuticalsMembersrt:ScenarioPreviouslyReportedMember2021-11-240001356576supn:AdamasPharmaceuticalsMembersrt:ScenarioPreviouslyReportedMember2021-11-242021-11-240001356576us-gaap:DevelopedTechnologyRightsMembersupn:AdamasPharmaceuticalsMember2021-11-240001356576us-gaap:DevelopedTechnologyRightsMembersupn:AdamasPharmaceuticalsMembersrt:MinimumMember2021-11-242021-11-240001356576us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMembersupn:AdamasPharmaceuticalsMember2021-11-242021-11-240001356576supn:AdamasPharmaceuticalsMember2021-01-012021-03-310001356576supn:TrokendiXrMember2022-01-012022-03-310001356576supn:TrokendiXrMember2021-01-012021-03-310001356576supn:OxtellarXRMember2022-01-012022-03-310001356576supn:OxtellarXRMember2021-01-012021-03-310001356576supn:GOCOVRIMember2022-01-012022-03-310001356576supn:GOCOVRIMember2021-01-012021-03-310001356576supn:APOKYNMember2022-01-012022-03-310001356576supn:APOKYNMember2021-01-012021-03-310001356576supn:QelbreeMember2022-01-012022-03-310001356576supn:QelbreeMember2021-01-012021-03-310001356576us-gaap:ManufacturedProductOtherMember2022-01-012022-03-310001356576us-gaap:ManufacturedProductOtherMember2021-01-012021-03-310001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMembersupn:TrokendiXrMember2022-01-012022-03-31xbrli:pure0001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMembersupn:TrokendiXrMember2021-01-012021-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:CardinalHealthMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:McKessonMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:AmerisourceBergenDrugCorporationMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:AmerisourceBergenDrugCorporationMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:McKessonMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001356576us-gaap:RevenueFromContractWithCustomerMembersupn:CardinalHealthMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersupn:ThreeMajorCustomersMember2022-01-012022-03-310001356576us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersupn:ThreeMajorCustomersMember2021-01-012021-03-310001356576supn:NavitorPharmaceuticalsIncMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-04-012020-04-300001356576supn:NavitorPharmaceuticalsIncMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-04-300001356576supn:NavitorPharmaceuticalsIncMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-03-3100013565762021-12-012021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001356576us-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleNotesPayableMember2022-03-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleNotesPayableMember2021-12-3100013565762020-06-092020-06-090001356576supn:SPN830RegulatoryAndCommercialActivitiesMember2020-06-092020-06-090001356576supn:SPN830FutureSalesPerformanceMember2020-06-092020-06-090001356576supn:SPN830FDAAcceptanceMilestoneMember2020-06-092020-06-090001356576supn:SPN830NDAApprovalMilestoneMember2020-06-092020-06-090001356576supn:SPN830FirstCommercialAndSaleMember2020-06-092020-06-090001356576supn:APOKYNMember2020-06-092020-06-090001356576supn:APOKYNAndSPN830Member2020-06-092020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-01-012022-03-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-12-310001356576supn:AdamasMember2021-12-310001356576supn:AdamasMember2022-01-012022-03-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-03-310001356576supn:AdamasMember2022-03-310001356576supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-03-310001356576supn:AdamasMembersupn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember2022-03-310001356576supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember2022-03-310001356576supn:SalesBasedContingentConsiderationLiabilityMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-03-310001356576supn:AdamasMembersupn:SalesBasedContingentConsiderationLiabilityMember2022-03-310001356576supn:SalesBasedContingentConsiderationLiabilityMember2022-03-310001356576us-gaap:InProcessResearchAndDevelopmentMember2022-03-310001356576us-gaap:InProcessResearchAndDevelopmentMember2021-12-310001356576us-gaap:DevelopedTechnologyRightsMember2022-01-012022-03-310001356576us-gaap:DevelopedTechnologyRightsMember2022-03-310001356576us-gaap:DevelopedTechnologyRightsMember2021-12-310001356576supn:PatentDefenseCostsMember2022-01-012022-03-310001356576supn:PatentDefenseCostsMember2022-03-310001356576supn:PatentDefenseCostsMember2021-12-310001356576us-gaap:ConvertibleDebtMember2022-03-310001356576supn:ConversionCircumstanceOneMemberus-gaap:ConvertibleDebtMember2022-01-012022-03-31supn:day0001356576supn:ConversionCircumstanceTwoMemberus-gaap:ConvertibleDebtMember2022-01-012022-03-31utr:Rate0001356576us-gaap:ConvertibleDebtMember2022-01-012022-03-310001356576us-gaap:ConvertibleDebtMember2021-12-310001356576us-gaap:ConvertibleDebtMember2021-01-012021-12-310001356576us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001356576us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001356576supn:StockOptionStockAppreciationRightsMember2021-12-310001356576supn:StockOptionStockAppreciationRightsMember2021-01-012021-12-310001356576supn:StockOptionStockAppreciationRightsMember2022-01-012022-03-310001356576supn:StockOptionStockAppreciationRightsMember2022-03-310001356576us-gaap:RestrictedStockUnitsRSUMember2021-12-310001356576us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001356576us-gaap:RestrictedStockUnitsRSUMember2022-03-310001356576supn:PerformanceBasedUnitsMember2021-12-310001356576supn:MarketBasedUnitsMember2021-12-310001356576us-gaap:PerformanceSharesMember2021-12-310001356576supn:PerformanceBasedUnitsMember2022-01-012022-03-310001356576supn:MarketBasedUnitsMember2022-01-012022-03-310001356576us-gaap:PerformanceSharesMember2022-01-012022-03-310001356576supn:PerformanceBasedUnitsMember2022-03-310001356576supn:MarketBasedUnitsMember2022-03-310001356576us-gaap:PerformanceSharesMember2022-03-310001356576us-gaap:StockCompensationPlanMember2022-01-012022-03-310001356576us-gaap:StockCompensationPlanMember2021-01-012021-03-3100013565762019-02-0100013565762021-11-24supn:renewalOption0001356576supn:AdamasPharmaceuticalsMember2022-01-012022-03-310001356576supn:LabEquipmentAndFurnitureMember2022-03-310001356576supn:LabEquipmentAndFurnitureMember2021-12-310001356576us-gaap:LeaseholdImprovementsMember2022-03-310001356576us-gaap:LeaseholdImprovementsMember2021-12-310001356576us-gaap:ComputerSoftwareIntangibleAssetMember2022-03-310001356576us-gaap:ComputerSoftwareIntangibleAssetMember2021-12-310001356576us-gaap:ComputerEquipmentMember2022-03-310001356576us-gaap:ComputerEquipmentMember2021-12-310001356576us-gaap:ConstructionInProgressMember2022-03-310001356576us-gaap:ConstructionInProgressMember2021-12-3100013565762014-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2019-03-012019-03-310001356576supn:NAMENDAXRNamzaricQuiTamLitigationMember2019-04-012019-04-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                 to              
Commission File Number: 001-35518
SUPERNUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware20-2590184
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
9715 Key West Avenue
Rockville MD20850
(Address of principal executive offices)(Zip Code)
(301) 838-2500
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes  ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ Yes No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒
Accelerated filer ☐
Non-accelerated filer ☐Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes  ☒ No
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each classOutstanding at May 2, 2022Trading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per share53,413,211SUPNThe Nasdaq Global Market

1
SUPERNUS PHARMACEUTICALS, INC.
FORM 10-Q — QUARTERLY REPORT
FOR THE QUARTERLY PERIOD ENDED March 31, 2022
Page No.


2
PART I — FINANCIAL INFORMATION

Supernus Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
March 31,December 31,
20222021
(unaudited)
Assets
Current assets
Cash and cash equivalents$115,715 $203,434 
Marketable securities196,485 136,246 
Accounts receivable, net145,149 148,932 
Inventories, net88,795 85,959 
Prepaid expenses and other current assets22,372 27,019 
Total current assets568,516 601,590 
Long-term marketable securities125,337 119,166 
Property and equipment, net17,215 16,955 
Intangible assets, net764,049 784,693 
Goodwill115,414 117,516 
Other assets48,986 49,232 
Total assets$1,639,517 $1,689,152 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable and accrued liabilities$89,432 $117,683 
Accrued product returns and rebates140,181 132,724 
Contingent consideration, current portion46,890 44,840 
Other current liabilities8,055 20,132 
Total current liabilities284,558 315,379 
Convertible notes, net400,382 379,252 
Contingent consideration, long-term9,252 35,637 
Operating lease liabilities, long-term39,891 41,298 
Deferred income tax liabilities62,843 85,355 
Other liabilities14,145 16,380 
Total liabilities811,071 873,301 
Stockholders’ equity
Common stock, $0.001 par value; 130,000,000 shares authorized; 53,386,305 and 53,256,094 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
53 53 
Additional paid-in capital383,016 434,337 
Accumulated other comprehensive earnings (loss), net of tax(773)1,539 
Retained earnings446,150 379,922 
Total stockholders’ equity828,446 815,851 
Total liabilities and stockholders’ equity$1,639,517 $1,689,152 




See accompanying notes.
3
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Earnings
(in thousands, except share and per share data)
Three Months ended
March 31,
20222021
(unaudited)
Revenues
Net product sales$147,464 $128,381 
Royalty revenues5,042 2,551 
Total revenues152,506 130,932 
Costs and expenses
Cost of goods sold (a)
17,932 14,954 
Research and development20,839 34,280 
Selling, general and administrative90,459 61,457 
Amortization of intangible assets20,644 6,007 
Contingent consideration expense665 1,020 
Total costs and expenses150,539 117,718 
Operating earnings1,967 13,214 
Other income (expense)
Interest expense(1,942)(6,097)
Interest and other income, net14,698 3,812 
Total other income (expense)12,756 (2,285)
Earnings before income taxes14,723 10,929 
Income tax (benefit) expense(10,893)5,235 
Net earnings$25,616 $5,694 
Earnings per share
Basic$0.48 $0.11 
Diluted$0.43 $0.11 
Weighted average shares outstanding
Basic53,330,837 52,927,467 
Diluted61,406,555 54,196,971 
______________________________
(a) Excludes amortization of acquired intangible assets




See accompanying notes.
4
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Comprehensive Earnings
(in thousands)
Three Months ended
March 31,
20222021
(unaudited)
Net earnings$25,616 $5,694 
Other comprehensive loss
Unrealized loss on marketable securities, net of tax(2,312)(2,726)
Other comprehensive loss(2,312)(2,726)
Comprehensive earnings$23,304 $2,968 







































See accompanying notes.
5
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
Three Months ended March 31, 2022 and 2021
(unaudited, in thousands, except share data)
jCommon StockAdditional 
Paid-in Capital		Accumulated Other
Comprehensive
Earnings (Loss)		Retained
Earnings		Total
Stockholders’
Equity
SharesAmount
Balance, December 31, 202153,256,094 $53 $434,337 $1,539 $379,922 $815,851 
Cumulative effect of adoption of ASU 2020-06— — (56,212)— 40,612 (15,600)
Balance, January 1, 202253,256,094 53 378,125 1,539 420,534 800,251 
Share-based compensation— — 4,025 — — 4,025 
Issuance of common stock in connection with the Company’s equity award plans130,211 — 866 — — 866 
Net earnings— — — — 25,616 25,616 
Unrealized loss on marketable securities, net of tax— — — (2,312)— (2,312)
Balance, March 31, 202253,386,305 $53 $383,016 $(773)$446,150 $828,446 
Common StockAdditional 
Paid-in Capital		Accumulated Other
Comprehensive
Earnings (Loss)		Retained
Earnings		Total
Stockholders’
Equity
SharesAmount
Balance, December 31, 202052,868,482 $53 $409,332 $8,975 $326,498 $744,858 
Share-based compensation— — 4,371 — — 4,371 
Issuance of common stock in connection with the Company’s equity award plans125,655 — 2,247 — — 2,247 
Net earnings— — — — 5,694 5,694 
Unrealized loss on marketable securities, net of tax— — — (2,726)— (2,726)
Balance, March 31, 202152,994,137 $53 $415,950 $6,249 $332,192 $754,444 











See accompanying notes.
6
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
Three Months ended March 31,
20222021
(unaudited)
Cash flows from operating activities
Net earnings$25,616 $5,694 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization21,362 6,592 
Navitor investment R&D expense (see Note 5)— 15,000 
Other income from Navitor (see Note 5)(12,888)— 
Amortization of deferred financing costs and debt discount526 4,287 
Realized gains from sales of marketable securities— (216)
Amortization of premium/discount on marketable securities(360)(1,706)
Change in fair value of contingent consideration665 1,020 
Other noncash adjustments, net84 (1,202)
Share-based compensation expense4,025 4,371 
Deferred income tax benefit(13,011)(2,565)
Changes in operating assets and liabilities:— — 
Accounts receivable3,812 13,805 
Inventories(2,468)(1,048)
Prepaid expenses and other assets1,061 (368)
Accrued product returns and rebates7,457 2,544 
Accounts payable and other liabilities(29,479)(10,008)
Contingent consideration(2,100)— 
Net cash provided by operating activities4,302 36,200 
Cash flows from investing activities
Purchases of marketable securities(98,063)(119,063)
Sales and maturities of marketable securities28,927 49,579 
Purchases of property and equipment and deferred legal fees paid(851)(1,961)
Net cash used in investing activities(69,987)(71,445)
Cash flows from financing activities
Payment of contingent consideration(22,900)— 
Proceeds from issuance of common stock866 2,247 
Net cash (used in) provided by financing activities(22,034)2,247 
Net change in cash and cash equivalents(87,719)(32,998)
Cash and cash equivalents at beginning of year203,434 288,640 
Cash and cash equivalents at end of period$115,715 $255,642 
Supplemental cash flow information
Cash paid for interest on convertible notes$1,258 $1,258 
Cash paid for income taxes478 301 
Cash paid for operating leases2,949 1,834 
Noncash investing and financing activities
Lease assets and tenant receivable obtained for new operating leases$27 $1,432 
Deferred legal fees and fixed assets included in accounts payable and accrued expenses— 160 
Property and equipment additions from utilization of tenant improvement allowance549 — 
See accompanying notes.
7
Supernus Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements (unaudited)
1.    Business Organization
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
Commercial Products
•Trokendi XR® (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.
•Qelbree® (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company is expecting to launch Qelbree for adult patients by the end of May 2022.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD.
•MYOBLOC® (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.
•GOCOVRI® (amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes.
•OSMOLEX ER® (amantadine) extended-release tablets is for the treatment of PD and drug-induced extrapyramidal reactions in adult patients.
Product Candidates
The Company is also developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The Company's product candidates in clinical development include the following:
•SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. In February 2022, the FDA acknowledged that it received the new drug application (NDA) resubmission for SPN-830 (apomorphine infusion device) for the continuous treatment of motor fluctuations ("off" episodes) in PD. The NDA has a PDUFA date of October 7, 2022.
•SPN-820 (NV-5138) is a first-in-class product candidate for treatment-resistant depression, currently in Phase II development. It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).
•SPN-817 (huperzine A) is a novel product candidate for treatment-resistant seizures, currently in Phase I development.
8
Adamas Acquisition and Reorganization
On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021, the Purchaser was merged with and into Adamas (Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (Adamas Acquisition). Adamas holds and markets two established commercial products in its portfolio, GOCOVRI and Osmolex ER, and has royalty rights to Namzaric®. Allergan plc markets and sells Namzaric in the U.S.

In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The legal entities reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, Income Taxes.)
COVID-19 Impact
The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of March 31, 2022.
Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.
2.    Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.
In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Consolidation
The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.
The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
9
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the valuation of the assets acquired and liabilities assumed in the Adamas Acquisition, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.
The Company incurred approximately $23.9 million and $15.3 million in advertising expense for the three months ended March 31, 2022 and 2021, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the condensed consolidated statements of earnings.
Recently Issued Accounting Pronouncements
Accounting Pronouncements Adopted
Accounting Standards Update (ASU) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.
The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method.
ASU 2021-10, Government Assistance (Topic 832) - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific US GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.
New Accounting Pronouncements Not Yet Adopted
ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers - The new standard, issued in October 2021, amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606, Revenue from Contracts with Customers, as if the acquiree had
10
initially applied recognition and measurement in their financial statements. This guidance is effective for fiscal years beginning after December 15, 2022 on a prospective basis. Early adoption is permitted.
3. Acquisition
Adamas Acquisition
On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas Pharmaceuticals, Inc., a publicly-held pharmaceutical company (Adamas), pursuant to the Adamas Agreement dated October 10, 2021. On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only U.S. FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and OSMOLEX ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.
The Company paid the Adamas shareholders $400.8 million and transferred two non-tradable contingent value rights (CVRs). Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer & Trust Company, LLC, as rights agent, (CVR Agreement). One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once.
In connection with the two CVRs, the Company recorded contingent consideration liabilities of $10.3 million as of the date of the acquisition, to reflect the estimated fair value of the contingent consideration. The estimated fair value of the liabilities were determined using Monte Carlo simulations. The fair value measurement of the contingent consideration liabilities were determined based on significant unobservable inputs and thus represents a Level 3 fair value measurement. The key assumptions considered include the estimated amount and timing of projected cash flows, volatility, estimated discount rates and risk-free interest rate. In each reporting period after the acquisition, the Company will revalue the contingent consideration liabilities and will record increases or decreases in the fair value of the liabilities in its consolidated statements of earnings. Changes in fair value will result from changes in actual and projected milestone achievement, as well as changes to forecasts. The inputs and assumptions may not be observable in the market, but they reflect the assumptions the Company believes would be made by a market participant. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.
The acquisition was accounted for as a business combination under the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The estimated fair values of the assets acquired and liabilities assumed, including goodwill, have been included in the Company's consolidated financial statements since the acquisition Closing Date.
The Company's accounting for the Adamas Acquisition is preliminary and fair value estimates for the assets acquired and liabilities assumed and the Company's estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period. During the measurement period, if the Company obtains new information regarding facts and circumstances that existed as of the Closing Date that, if known, would have resulted in revised estimated values of those assets or liabilities, the Company will accordingly revise its estimates of fair values and purchase price allocation. The effect of measurement period adjustments on the estimated fair value elements will be reflected as if the adjustments had been made as of the Closing Date. The impact of all changes that do not qualify as measurement period adjustments will be included in current period earnings.
The Company expects to finalize its purchase price allocation within one year of the Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record at fair value the assets acquired and liabilities assumed in the following areas: intangible assets, lease assets and liabilities, tax assets and liabilities, and certain existing or potential reserves, including those for legal or contract-related matters. The activities the Company is currently undertaking include, but are not limited to, the following: review of acquired contracts and other contract-related and legal matters; review and evaluation of the accounting policies, tax positions, and other tax-related matters. Further,
11
the Company continues to obtain input from third party valuation firms with respect to the fair value of the acquired tangible and intangible assets, and other information necessary to record and measure the assets acquired and liabilities assumed. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Closing Date are subject to change.
The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):
As Initially Reported
Measurement Period Adjustments (1)
As Adjusted
Cash and cash equivalents$90,064 $— $90,064 
Accounts receivable11,156 — 11,156 
Inventories20,200 — 20,200 
Prepaid expenses and other current assets5,077 — 5,077 
Property and equipment1,254 — 1,254 
Intangibles450,100 — 450,100 
Other assets (2)
6,442 (1,620)4,822 
Total fair value of assets acquired584,293 (1,620)582,673 
Accounts payable(4,592)— (4,592)
Accrued expenses and other current liabilities(8,014)— (8,014)
Current debt(138,315)— (138,315)
Operating lease liabilities, long-term(5,224)— (5,224)
Deferred income tax liabilities (3)
(56,588)3,722 (52,866)
Total fair value of liabilities assumed(212,733)3,722 (209,011)
Total identifiable net assets371,560 2,102 373,662 
Goodwill39,553 (2,102)37,451 
Total purchase price411,113 — 411,113 
Cash consideration paid400,806 — 400,806 
Fair value of contingent consideration10,307 — 10,307 
Total purchase price$411,113 $— $411,113 
______________________________
(1) Measurement period adjustments reflect changes based on information related to the facts and circumstances that existed as of the acquisition date.
(2) Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease. Refer to Note 13, Leases.
(3) Represents tax impact of the changes in the initial estimate of the fair value of the right of use asset and changes made to update certain state tax attributes which existed at the opening balance sheet date.
Acquired Inventory
The estimated fair value of the inventory was determined using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or dispose of the inventory, as well as a profit on the sale.
Acquired Intangible Assets
The acquired intangible assets include the acquired developed technology and product rights to GOCOVRI and OSMOLEX ER, as well as the right to receive royalties from Allergan plc for sales of Namzaric. The Company determined the estimated fair values for the acquired intangible assets as of the Closing Date using the income approach. This is a valuation technique that provides an estimate of fair value of the assets, based on the market participant's expectations of the cash flows that the assets are forecasted to generate. The cash flows were discounted at a rate commensurate with the level of risk associated with
12
its projected cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value.
The fair value measurements of the acquired intangible assets were determined based on significant unobservable inputs and thus represent Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the intangible assets valuation includes: the estimated future cash flows from product sales, the timing and projection of costs and expenses, discount rates and tax rates.
Acquired intangible assets consist of developed technology and product rights and are amortized over their estimated useful lives on a straight-line basis. The following table summarizes the preliminary purchase price allocation, and the average remaining useful lives for identifiable intangible assets (dollars in thousands):
Estimated Fair ValueEstimated Useful Life as of Closing Date (in years)
Acquired developed technology and product rights$450,100 
3.1 - 8.1
Goodwill
Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is primarily attributable to the anticipated cost synergies, additional growth platforms, and an expanded revenue base with the addition of the assets from the Adamas Acquisition. The goodwill is not expected to be deductible for tax purposes.
Acquired Deferred Income Tax Liabilities, net
The deferred income tax liabilities, net relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences. The acquired federal and state net operating loss carryforwards is reduced by a valuation allowance for amounts that are not expected to be realizable in the future.
Revenue and Net Earnings of Adamas
The operations of Adamas and its subsidiaries have been included in the Company's consolidated statements of earnings for the period subsequent to the Closing Date.
Pro Forma Information
The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):
Three Months ended
March 31, 2021
Pro forma total revenues$150,243 
Pro forma net loss(20,484)
The unaudited pro forma combined financial information is based on historical financial information and the Company's preliminary allocation of purchase price; therefore, it is subject to subsequent adjustment upon finalization of the purchase price allocation. In order to reflect the occurrence of the acquisition on January 1, 2020, the unaudited pro forma combined financial information reflects the recognition of additional amortization expense on intangible assets and estimated additional cost of products sold related to the inventory step-up adjustment; the estimated reduction in the Company's interest income generated from marketable securities that were liquidated to fund the purchase price of the Adamas Acquisition, and the estimated tax impact of the pro forma adjustments.
The unaudited pro forma combined financial information should not necessarily be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results.
13
4. Disaggregated Revenues
The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Net product sales
Trokendi XR$62,832 $71,819 
Oxtellar XR27,521 27,370 
GOCOVRI22,601 — 
APOKYN18,448 21,730 
Qelbree8,283 — 
Other(1)
7,779 7,462 
Total net product sales$147,464 $128,381 
Royalty revenues5,042 2,551 
Total revenues$152,506 $130,932 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and OSMOLEX ER.

Trokendi XR accounted for 43% and 56% of the Company’s total net product sales for the three months ended March 31, 2022 and 2021, respectively.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% and 25% of our total net product sales and collectively accounted for more than 75% and 85% of our total net product sales in 2022 and 2021, respectively.

The Company recognized noncash royalty revenue of $2.2 million for both the three months ended March 31, 2022 and 2021. Refer to Note 16, Commitments and Contingencies.
5. Investments
Marketable Securities
Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31, 2022December 31, 2021
(unaudited)
Corporate and U.S. government agency and municipal debt securities
Amortized cost$322,797 $253,301 
Gross unrealized gains497 2,349 
Gross unrealized losses(1,472)(238)
Total fair value$321,822 $255,412 
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31,
2022
(unaudited)
Less than 1 year$196,485 
1 year to 2 years111,584 
2 years to 3 years13,753 
3 years to 4 years— 
Greater than 4 years— 
Total$321,822 
14
As of March 31, 2022, there was no impairment due to credit loss on any available-for-sale marketable securities.
Investment in Navitor
Development Agreement
In April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million. In addition, the Company will incur certain other research and development support costs. There are certain additional payment amounts which could be incurred by the Company. These costs are contingent upon Navitor Inc. achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required.
Equity investment
In addition to entering into the Development Agreement in April 2020, the Company acquired Series D Preferred Shares of Navitor Inc. for $15 million, representing an approximately 13% ownership position in Navitor Inc.
In March 2021, Navitor Inc. underwent a legal restructuring. In the restructuring, Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals LLC (Navitor LLC), and the outstanding shares of stock in Navitor Inc. were exchanged for units of membership in Navitor LLC having equivalent rights and preferences (Navitor Restructuring). As part of the Navitor Restructuring, the Series D Preferred Shares previously held by the Company were exchanged for Series D Preferred Shares in Navitor LLC. In addition, certain assets that did not relate to NV-5138 (SPN-820) were transferred from Navitor Inc. to a newly formed entity that became a separate, wholly owned subsidiary of Navitor LLC.
The Company had determined that Navitor LLC is a VIE. The Company does not consolidate this VIE because the Company lacks the power to direct the activities that most significantly impact Navitor’s economic performance.
Prior to the Navitor Restructuring, the investment was accounted for under the practical expedient allowed for equity securities without readily determinable fair value, which is cost minus impairment plus any changes in observable price changes from an orderly transaction of similar investments in Navitor Inc. Following the legal restructuring and exchange of the preferred shares for member equity units of Navitor LLC, the investment was accounted for under the equity method of accounting due to the Company's ability to exert significant influence over but not control the financial and operating decisions of Navitor LLC. As a result of the change from a cost method investment to an equity method investment, the Company was required to measure its investment initially in accordance with the guidance in ASC 805. The majority of the assets and liabilities recorded in Navitor LLC's financial statements represent working capital items and cash that are being used for research and development purposes and are significantly lower than the Company's investment in Navitor LLC, which created a significant basis difference for the Company's investment in the underlying net assets. The Company determined that substantially all of the fair value of the investment was attributable to a single in-process research and development (IPR&D) asset. As a result, Navitor LLC was not considered a business as defined in ASC 805. In the first quarter of 2021, the $15 million investment, which was previously recorded in Other assets in the condensed consolidated balance sheets, was expensed and recorded in Research and development expense in the condensed consolidated statements of earnings.
The Company records its share of the results of Navitor LLC, a private company, on a quarter lag as the financial information of Navitor LLC is not available on a sufficiently timely basis for the Company to apply the equity method of accounting. In December 2021, Navitor LLC sold one of its subsidiaries and distributed cash to its members in accordance with each member's share of the proceeds from the sale. The Company received $12.9 million in December 2021 from Navitor LLC in connection with this sale. As the Company's policy is to record its share of the results in its equity method investment on a quarter lag as previously indicated, the Company recorded the cash amount received in Other current liabilities in the consolidated balance sheets as of December 31, 2021. In the first quarter of 2022, the Company determined its estimated share of Navitor LLC's year-end 2021 earnings and recorded a gain of $12.9 million in Interest and other income, net in the condensed consolidated statement of earnings.
The maximum exposure to losses related to Navitor LLC is a maximum of approximately $50 million in expense for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company.
15
The Company has not provided financing to Navitor LLC. Further, no additional equity investment has been made to Navitor LLC.
6.    Fair Value of Financial Measurements
The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets.
•Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves).
•Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data.
The fair value of the restricted marketable securities which are classified as Level 2 financial assets is recorded in Other assets on the condensed consolidated balance sheets. There were no Level 3 financial assets as of March 31, 2022 or December 31, 2021. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.
Financial Assets and Liabilities Recorded at Fair Value
The Company’s financial assets that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements as of March 31, 2022 (unaudited)
Total Fair Value as of March 31, 2022
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$84,218 $84,218 $— $— 
Money market securities and funds31,497 1,502 29,995 — 
Marketable securities
Corporate and municipal debt securities196,485 — 196,485 — 
Long-term marketable securities
Corporate and municipal debt securities125,337 — 125,337 — 
Other assets
Marketable securities - restricted (SERP)570 8 562 — 
Total assets at fair value$438,107 $85,728 $352,379 $— 
Liabilities:
Contingent consideration$56,142 $— $— $56,142 
Total liabilities at fair value$56,142 $— $— $56,142 
16
Fair Value Measurements as of December 31, 2021
Total Fair Value as of December 31, 2021
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$148,863 $148,863 $— $— 
Money market securities and funds54,571 54,571 — — 
Marketable securities
Corporate and municipal debt securities136,246 251 135,995 — 
Long-term marketable securities
Corporate and municipal debt securities119,166 — 119,166 — 
Other assets
Marketable securities - restricted (SERP)630 7 623 — 
Total assets at fair value$459,476 $203,692 $255,784 $— 
Liabilities:
Contingent consideration$80,477 $— $— $80,477 
Total liabilities at fair value$80,477 $— $— $80,477 
Other Financial Instruments
The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities.
Financial Liabilities Recorded at Carrying Value
The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands):
March 31, 2022December 31, 2021
Carrying ValueFair Value (Level 2)Carrying ValueFair Value (Level 2)
Convertible notes, net$400,382 $395,456 $379,252 $400,236 
The fair value has been estimated based on actual trading information, and quoted prices, both provided by bond traders. As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption.
7. Contingent Consideration
The Company's contingent consideration liabilities are related to the USWM Acquisition and the Adamas Acquisition.
On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments of up to $230 million, comprising of $130 million for the achievement of certain SPN-830 regulatory and commercial milestones (regulatory and developmental contingent consideration payments) and up to $100 million related to the future sales performance of the acquired USWM products (sales-based contingent consideration payments). The regulatory and developmental contingent consideration payments include a $25 million milestone due upon the FDA acceptance of the SPN-830 NDA for review. The remaining $105 million are due upon the FDA's regulatory approval and commercial launch of SPN-830. Based on timing of the PDUFA date of SPN-830 NDA, one of the regulatory and developmental milestones which has a time-based mechanism for full or partial achievement will not be achieved. Of the $100 million sales-based contingent consideration, a $35 million milestone due upon achievement of certain U.S. net product sales of APOKYN in 2021 was not achieved. The remaining $65 million relates to the achievement of certain net product sales of the acquired USWM products in 2022 and 2023.
17

As mentioned in Note 1, the Company received a notice from the FDA in February 2022 of its acceptance for review of the NDA for SPN-830. As such, the Company made a $25 million regulatory and developmental contingent consideration payment in the first quarter of 2022. This milestone payment is reflected in the condensed consolidated statements of cash flows as a $22.9 million under cash flows from financing activities related to the acquisition date fair value of the contingent consideration liability and a $2.1 million under cash flows from operating activities related to excess of the acquisition date fair value.
As discussed in Note 3, Acquisition, the Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI.
The Company's contingent consideration liabilities are measured at fair value on a recurring basis; i.e., the Monte Carlo simulation for the sales-based milestones, and the income approach for the other milestones. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement.
During the measurement period, changes in the fair value of contingent consideration related to the Adamas Acquisition are recorded against goodwill if such changes are related to facts and circumstances that existed at the acquisition date. In each reporting period after the acquisition, the Company remeasures the fair value of contingent consideration liabilities and records in its consolidated statements of earnings the increases or decreases in the fair value of the liabilities. The Company recorded a net expense of $0.7 million due to the change in fair value of the contingent consideration liabilities in the first quarter of 2022. The change in fair value is reported on the condensed consolidated statement of earnings in Contingent consideration expense.
The change in the fair value of contingent consideration was primarily driven by the increase in estimated fair value of regulatory and developmental USWM milestones due to the accretion to the payout amount related to the milestone achieved in the first quarter of 2022. The increase is partially offset by a decrease in the estimated fair value of sales-based Adamas milestones due to changes in market data. The key assumptions considered in estimating the fair value of regulatory and developmental milestones include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated amount and timing of projected cash flows, volatility, estimated discount rates and risk-free interest rate. Refer to Note 3, Acquisition, for further discussion of significant inputs and assumptions used in the valuation of the contingent consideration for the Adamas Acquisition.
The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2021$70,170 $10,307 $80,477 
Milestone payments(25,000)— (25,000)
Change in fair value recognized in earnings1,720 (1,055)665 
Balance at March 31, 2022 (unaudited)$46,890 $9,252 $56,142 
Regulatory and developmental contingent consideration liabilities46,890 — 46,890 
Sales-based contingent consideration liabilities— 9,252 9,252 
Balance at March 31, 2022 (unaudited)$46,890 $9,252 $56,142 
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
March 31,
2022		December 31,
2021
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$46,890 $44,840 
Contingent consideration, long-term9,252 35,637 
Total$56,142 $80,477 
18
8.    Goodwill and Intangibles Assets, Net
Goodwill
The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):
Balance as of December 31, 2021
$117,516 
Measurement period adjustments related to the acquisition of Adamas (see Note 3).(2,102)
Balance as of March 31, 2022 (unaudited)
$115,414 
Intangible Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):
March 31,
2022		December 31,
2021
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights8.49681,100 (54,913)626,187 681,100 (35,550)645,550 
Capitalized patent defense costs4.3743,820 (29,958)13,862 43,820 (28,677)15,143 
Total intangible assets8.40848,920 (84,871)764,049 848,920 (64,227)784,693 
Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Oxtellar XR and Trokendi XR will expire no earlier than 2027. In regards to Trokendi XR, the Company entered into settlement agreements that allow third parties to enter the market by January 1, 2023, or earlier under certain circumstances.
Amortization expense for intangible assets was approximately $20.6 million and $6.0 million, for the three month periods ended March 31, 2022 and 2021, respectively. The increase in expense is primarily due to amortization of the acquired developed technology and product rights from the Adamas Acquisition.
Anticipated annual amortization expense for intangible assets is estimated at $79.8 million in 2023 and 2024, $75.0 million in 2025 and 2026, and $73.2 million in 2027.
9.    Convertible Senior Notes Due 2023
The 0.625% Convertible Senior Notes Due 2023 (2023 Notes), which were issued in March 2018, bear interest at an annual rate of 0.625%, payable semi-annually in arrears on April 1 and October 1 of each year. The 2023 Notes will mature on April 1, 2023, unless earlier converted or repurchased by the Company. The Company may not redeem the 2023 Notes at its option before maturity. The total principal amount of 2023 Notes is $402.5 million.
The 2023 Notes were issued pursuant to an Indenture between the Company and Wilmington Trust, National Association, as trustee. The Indenture includes customary terms and covenants, including certain events of default upon which the 2023 Notes may be due and payable immediately. The Indenture does not contain any financial or operating covenants, or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Noteholders may convert their 2023 Notes at their option only in the following circumstances: (1) during any calendar quarter, if the last reported sale price per share of the Company's common stock for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including the last trading day of the immediately preceding
19
calendar quarter, exceeds 130% of the conversion price, or a price of approximately $77.13 per share on such trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as specified in the Indenture; and (4) at any time from and including October 1, 2022, until the close of business on the second scheduled trading day immediately before the maturity date.
At its election, the Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, based on the applicable conversion rate. The initial conversion rate is 16.8545 shares per $1,000 principal amount of the 2023 Notes, which represents an initial conversion price of approximately $59.33 per share, and is subject to adjustment as specified in the Indenture. In the event of conversion, if converted in cash, the holders would forgo all future interest payments, any unpaid accrued interest, and the possibility of further stock price appreciation.
If a “make-whole fundamental change,” as defined in the Indenture occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. If a “fundamental change,” as defined in the Indenture occurs, then noteholders may require the Company to repurchase their 2023 Notes at a cash repurchase price equal to the principal amount of the 2023 Notes to be repurchased, plus accrued and unpaid interest, if any.
Contemporaneous with the issuance of the 2023 Notes, the Company also entered into separate privately negotiated convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) with each of the call spread counterparties. The Company issued 402,500 convertible note hedge options. In the event that shares or cash are deliverable to holders of the 2023 Notes upon conversion at limits defined in the Indenture, counterparties to the convertible note hedges will be required to deliver up to approximately 6.8 million shares of the Company’s common stock, or to pay cash to the Company in a similar amount as the value that the Company delivers to the holders of the 2023 Notes, based on a conversion price of $59.33 per share.
Concurrently with entering into the Convertible Note Hedge Transactions, the Company also entered into separate privately negotiated warrant transactions (collectively, the Warrant Transactions) with each of the call spread counterparties. The Company issued a total of 6,783,939 warrants. The warrants entitle the holder to one share per warrant. The strike price of the Warrant Transactions will initially be $80.91 per share of the Company’s common stock, and is subject to adjustment.
The Convertible Note Hedge Transactions are expected to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2023 Notes, as the case may be.
The Warrant Transactions were intended to partially offset the cost to the Company of the purchased Convertible Note Hedge Transactions; however, the Warrant Transactions could have a dilutive effect with respect to the Company’s common stock, to the extent that the market price per share of the Company’s common stock, as measured under the terms of the Warrant Transactions, exceeds the strike price of the warrants.
The liability component of the 2023 Notes consists of the following, (dollars in thousands):
March 31,
2022		December 31,
2021
(unaudited) 
2023 Notes$402,500 $402,500 
Unamortized debt discount and deferred financing costs(2,118)(23,248)
Total carrying value$400,382 $379,252 
As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption. No 2023 Notes were converted as of March 31, 2022 or December 31, 2021.
20
10.    Share-Based Payments
Share-based compensation expense is as follows (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Research and development$651 $588 
Selling, general and administrative3,374 3,783 
Total$4,025 $4,371 
Stock Option and Stock Appreciation Rights
The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options		Weighted
Average
Exercise Price		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20215,774,076 $24.15 5.95
Granted 929,785 $32.20 
Exercised (47,601)$18.21 
Forfeited (48,036)$30.84 
Outstanding, March 31, 2022 (unaudited)6,608,224 $25.28 6.25
As of December 31, 2021:
Vested and expected to vest5,774,076 $24.15 5.95
Exercisable3,651,824 $21.29 4.53
As of March 31, 2022:
Vested and expected to vest6,608,224 $25.28 6.25
Exercisable 4,280,012 $22.87 4.79
Restricted Stock Units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 202121,110 $29.61 
Granted131,210 $32.20 
Vested(21,110)$29.61 
Forfeited— $— 
Nonvested, March 31, 2022131,210 $32.20 
There were no forfeited RSU awards during the three months ended March 31, 2022.




21
Performance Share Units
The following table summarizes performance share unit (PSU) activities:
Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 202153,500 $29.82 35,625 $26.34 89,125 $28.43 
Vested(21,500)$29.67 — (21,500)$29.67 
Nonvested, March 31, 202232,000$29.92 35,625$26.34 67,625$28.04 

There were no forfeited PSU awards during the three months ended March 31, 2022.
11.    Earnings per Share
The Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, whereas the Company previously calculated diluted earnings per share under the treasury stock method. Basic earnings per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock option grants, SARs, RSUs, employee stock purchase plan (ESPP) awards, and the 2023 Notes, as determined per the if-converted method for the three months ended March 31, 2022 in connection with the adoption of ASU 2020-06 and the treasury stock method for the three months ended March 31, 2021.
Effect of Convertible Notes and Related Convertible Note Hedges and Warrants
In connection with the issuance of the 2023 Notes, the Company entered into Convertible Note Hedge and Warrant Transactions as described further in Note 9, Convertible Senior Notes Due 2023. The expected collective impact of the Convertible Note Hedge and Warrant Transactions is to reduce the potential dilution that would occur if the price of the Company's common stock was between the conversion price of $59.33 per share and the strike price of the warrants of $80.91 per share.
Diluted EPS related to the 2023 Notes in the current year is calculated using the if-converted method. The number of dilutive shares is based on the initial conversion rate associated with the 2023 Notes. The Convertible Note Hedge and Warrant Transactions are excluded in the calculation of diluted EPS because inclusion would be anti-dilutive. Specifically, the denominator of the diluted EPS calculation excludes the additional shares related to the warrants because the average price of the Company's common stock was less than the strike price of the warrants of $80.91 per share. Prior to actual conversion, the Convertible Note Hedge Transactions are not considered in calculating diluted earnings per share, as their impact would be anti-dilutive.

In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards in the calculation of diluted EPS, because their inclusion would be anti-dilutive:
Three Months ended
March 31,
20222021
(unaudited)
Stock options, RSUs1,067,231 1,419,203 

As mentioned in Note 1, as a result of the adoption of ASU 06-2020 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended March 31, 2022. For the three months ended March 31, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.
22

The following table sets forth the computation of basic and diluted net earnings per share for the three months ended March 31, 2022 under the if-converted method and for the three months ended March 31, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):
Three Months ended
March 31,
20222021
(unaudited)
Numerator:
Net earnings $25,616 $5,694 
After-tax interest expense for 2023 Notes887 — 
Numerator for dilutive earnings per share$26,503 $5,694 
Denominator:
Weighted average shares outstanding, basic53,330,837 52,927,467 
Effect of dilutive securities:
Stock options, RSUs and SARs1,291,782 1,269,504 
Convertible notes6,783,936 — 
Weighted average shares outstanding, diluted61,406,555 54,196,971 
Earnings per share, basic$0.48 $0.11 
Earnings per share, diluted$0.43 $0.11 
12.    Income Tax (Benefit) Expense
The following table provides information regarding the Company’s income tax (benefit) expense for the three months ended March 31, 2022 and 2021 (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Income tax (benefit) expense$(10,893)$5,235 
Effective tax rate(74.0)%47.9 %

Income tax benefit was $10.9 million for the three months ended March 31, 2022 and income tax expense was $5.2 million for the three months ended March 31, 2021. The change for the three months ended March 31, 2022 was primarily from tax benefits associated with the Adamas legal entities reorganization in the first quarter of 2022. The reorganization resulted in favorable impact on certain state apportionment factors. The change in the effective income tax rate for the three months ended March 31, 2022 as compared to the same period in the prior year was mainly due to changes in the effective state tax rates as a result of the Adamas legal entities reorganization.
13.    Leases
Operating Leases
The Company has operating leases for its headquarters lease, certain other office space, and its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. The Company also elected to combine the lease and non-lease components for the fleet vehicle and headquarters leases.
The Company's headquarters lease commenced on February 1, 2019 (the Commencement Date) and will continue until April 30, 2034, unless earlier terminated in accordance with the terms of the lease. The lease includes options to extend the lease for up to 10 years.
23
As part of the Adamas Acquisition, the Company acquired a lease for office space. Adamas' operating lease for the office space term will continue until April 30, 2025. The lease contains an option to extend the term for one additional five-year period.
During a measurement period, changes in fair value due to measurement period adjustments are recorded against goodwill. The Company recorded in the first quarter of 2022 a measurement period adjustment associated with the valuation of the acquired Adamas lease which decreased the fair value estimate of the operating lease right of use asset by $1.6 million. Refer to Note 3, Acquisition.
Contract Manufacturing Lease
The Company has a contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz), for the manufacture and supply of rimabotulinumtoxinB finished products (Merz Agreement). The Merz Agreement will expire in July 2027 unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience.
Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility which the Company accounts for as an embedded lease.
The Company made an accounting policy election, by class of underlying asset, to not combine lease and non-lease components for the manufacturing facility. A portion of the in-substance fixed contract consideration was allocated to the lease component based on the stand-alone selling price. Accordingly, the Company classifies and accounts for the embedded lease as an operating lease.
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationMarch 31, 2022December 31, 2021
(unaudited)
Assets
Operating lease assetsOther assets$32,141 $35,365 
Total lease assets$32,141 $35,365 
Liabilities
Lease liabilities, current
Operating lease liabilities, current portionAccounts payable and accrued liabilities$6,141 $6,477 
Lease liabilities, long-term
Operating lease liabilities, long-termOperating lease liabilities, long-term39,891 41,298 
Total lease liabilities$46,032 $47,775 

14.    Composition of Other Balance Sheet Items
The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):
Accounts Receivables, Net
As of March 31, 2022 and December 31, 2021, the Company has reduced accounts receivable by approximately $11.4 million and $13.5 million, respectively. Prompt pay discount and contractual service fees, which were originally recorded as a reduction to revenues, represents estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.
24
Inventories, Net
March 31,
2022		December 31,
2021
(unaudited)
Raw materials$9,239 $7,325 
Work in process46,219 45,711 
Finished goods33,337 32,923 
Total$88,795 $85,959 

Inventories as of March 31, 2022 include acquired inventory from the Adamas Acquisition. Refer to Note 3, Acquisition, for further discussion of the acquisition.
Property and Equipment, Net
March 31,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,199 $12,287 
Leasehold improvements13,998 14,369 
Software2,185 4,776 
Computer equipment1,282 1,944 
Construction-in-progress32 33 
29,696 33,409 
Less accumulated depreciation and amortization(12,481)(16,454)
Property and equipment, net$17,215 $16,955 
Depreciation and amortization expense on property and equipment was approximately $0.7 million and $0.6 million for the three months ended March 31, 2022, and 2021, respectively. The Company retired certain fully depreciated property and equipment during the three months ended March 31, 2022.
Accounts Payable and Accrued Liabilities
March 31,
2022		December 31,
2021
(unaudited)
Accounts payable$12,323 $9,331 
Accrued professional fees16,209 26,728 
Accrued compensation14,555 28,068 
Accrued product costs12,727 18,460 
Accrued royalties (1)
11,044 13,821 
Accrued clinical trial costs (2)
7,784 9,125 
Operating lease liabilities, current portion (3)
6,141 6,477 
Other accrued expenses8,649 5,673 
Total$89,432 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
25
Accrued Product Returns and Rebates
March 31,
2022		December 31,
2021
(unaudited)
Accrued product rebates$104,948 $97,597 
Accrued product returns35,233 35,127 
Total$140,181 $132,724 
Other Liabilities
March 31,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$3,784 $5,977 
Other liabilities10,361 10,403 
Total$14,145 $16,380 
15.    Interest Expense
The following details the composition of interest expense (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Interest expense$(1,155)$(5,062)
Interest expense on nonrecourse liability related to sale of future royalties(787)(1,035)
Total$(1,942)$(6,097)

As discussed in Note 2, Summary of Significant Accounting Policies, the Company adopted ASU 2020-06 on January 1, 2022. As a result, interest expense for the three months ended March 31, 2022 significantly decreased compared to the three months ended March 31, 2021 due to the Company no longer recording interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes. For the three months ended March 31, 2022, interest expense includes noncash interest expense related to amortization of deferred financing costs of $0.5 million. For the three months ended March 31, 2021, interest expense includes noncash interest expense related to amortization of deferred financing costs and amortization of the debt discount on the 2023 Notes of $4.3 million.
16.    Commitments and Contingencies
Product Licenses
The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.
Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the condensed consolidated statements of earnings.
26
Royalty Agreement
In the third quarter of 2014, the Company received $30 million pursuant to a Royalty Interest Acquisition Agreement related to the purchase by HC Royalty of certain of the Company's rights under the Company's agreement with United Therapeutics related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets. Full ownership of the royalty rights will revert to the Company if and when a certain cumulative payment threshold is reached (see Note 2, Note 4, and Note 14).
USWM Enterprise Commitments Assumed
As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below.
The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply. Refer to Note 13, Leases for further discussion related to the Merz Agreement in connection with the MYOBLOC annual minimum purchase requirement.
In addition, USWM Enterprises had an existing license and distribution agreement for XADAGO. This included an annual minimum promotional spend to support the marketing of XADAGO for the first five years of the agreement and will end in 2022. As of March 31, 2022, there is no remaining contractual commitment.
In March 2019, MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to incur significant costs through March 2024 to maintain a broad array of processes, policies and procedures necessary to comply with the CIA.
Data Breach-related Contingency
On November 24, 2021, the Company announced that we were the target of a ransomware attack. The attack had no significant impact on our business and did not cause any long-term disruption to our operations. Based on its internal investigation, the Company believes the criminal ransomware groups ("criminal groups") copied certain data from our systems, encrypted certain data on the Company's systems, and then deployed malware designed to impede access to our systems. Thereafter the criminal groups contacted the Company and threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware attack, the Company notified government authorities, engaged third-party cybersecurity experts through our outside counsel, and commenced its recovery process. The Company maintains redundant off-site data backups, which were verified to have not been compromised by the ransomware attack and were utilized to restore the data encrypted by the criminal groups. In the fourth quarter of 2021, the Company had successfully recovered the impacted files and took additional steps designed to further protect its networks and files.
Furthermore, while the Company has not been the subject of any legal proceedings involving the attack, the likelihood that the Company could be the subject of claims from persons alleging they suffered damages from the incident, or actions by governmental authorities is possible, but the amount of such fines, penalties or costs, if any, cannot be estimated at this time. The Company continues to monitor the situation.
27
Claims and Litigation
From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.
NAMENDA XR/Namzaric Qui Tam Litigation
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022 and no decision has been reached as of the date of this filing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.
17.    Subsequent Events
On April 29, 2022, the Company announced that the FDA approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults.
28
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to help the reader understand the results of operations and the financial condition of Supernus Pharmaceuticals, Inc. (the Company, we, us, or our). The interim condensed consolidated financial statements included in this report and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2021 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 13, 2022.
In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. These forward-looking statements may include declarations regarding the Company’s belief or current expectations of management, such as statements including the words “budgeted,” “anticipate,” “project,” “forecast,” “estimate,” “expect,” “may,” “believe,” “potential,” and similar statements or expressions, which are intended to be among the statements that are forward-looking statements, as such statements reflect the reality of risk and uncertainty that is inherent in our business. Actual results may differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date this report was filed with the Securities and Exchange Commission. Our actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K and elsewhere in this report as well as in other reports and documents we file with the Securities and Exchange Commission from time to time. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q.
Solely for convenience, in this Quarterly Report on Form 10-Q, the trade names are referred to without the TM symbols and the trademark registrations are referred to without the circled R, but such references should not be construed as any indicator that the Company will not assert, to the fullest extent under applicable law, our rights thereto.

29
Overview
We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
We have a portfolio of commercial products and product candidates.
Commercial Products
•Trokendi XR® (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.
•Qelbree® (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company is expecting to launch Qelbree for adult patients by the end of May 2022.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD.
•MYOBLOC® (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.
•GOCOVRI® (amantadine) extended-release capsules is the first and only U.S. Food and Drug Administration (FDA) approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes.
•OSMOLEX ER® (amantadine) extended-release tablets is for the treatment of PD and drug-induced extrapyramidal reactions in adult patients.
30
Research and Development
We are developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The table below summarizes our product candidates in clinical development.
Product CandidateIndicationDevelopmentNDA
SPN-830
Continuous treatment of motor fluctuations ("off" episodes) in PD patients
Under Review (1)
SPN-820Treatment-resistant depressionPhase II
SPN-817Treatment-resistant seizuresPhase I
SPN-443CNSPreclinical
SPN-446CNSPreclinical
(1) PDUFA target action date in October 2022.
SPN-830 (apomorphine infusion device)
SPN-830 is a late-stage drug/device combination product candidate for the treatment of continuous treatment of motor fluctuations ("off" episodes) in PD patients patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. If approved, it would be the only continuous infusion of apomorphine available in the U.S. and an important step for PD patients that would have otherwise been candidates for potentially invasive surgical procedures, such as deep brain stimulation. Continuous infusion may also limit some of the side effects of a subcutaneous injection of apomorphine.
In December 2021, we resubmitted the NDA to the FDA. In February 2022, we received a notice from the FDA that the resubmission of the NDA for SPN-830 is considered as a Standard Review, thereby was assigned a timeline for review of 10 months by the FDA. The PDUFA target action date is October 7, 2022. The Company is preparing for the commercial launch of SPN-830 in the first quarter of 2023 assuming timely approval by the FDA.
SPN-820 (NV-5138)
SPN-820 is a first-in-class, orally active small molecule that directly activates brain mTORC1 (mechanistic target of rapamycin complex 1), a gatekeeper of cellular metabolism and renewal. SPN-820 binds to and modulates sestrin, which senses amino acid availability in the brain, a potent natural activator of mTORC1.
SPN-817 (huperzine A)
SPN-817 represents a novel mechanism of action (MOA) for an anticonvulsant. SPN-817 is a novel synthetic form of
huperzine A, whose MOA includes potent acetylcholinesterase inhibition, with pharmacological activities in CNS conditions such as epilepsy. The development will initially focus on the drug's anticonvulsant activity, which has been shown in preclinical models to be effective for the treatment of partial seizures and Dravet Syndrome. SPN-817 is in clinical development and has received Orphan Drug designation for both Dravet Syndrome and Lennox-Gastaut Syndrome from the FDA.
Adamas Reorganization
In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The legal entities reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, Income Taxes.)
COVID-19 Impact
While the impact of the ongoing COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the three months ended March 31, 2022, we continue to closely monitor the events and circumstances surrounding the COVID-19 pandemic and its impact on all aspects of our business operations. Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on
31
our business operations and financial position cannot be reasonably estimated at this time. See “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for additional information on risk factors that could impact our business and our results.
Operational Highlights
Qelbree Launch Update
•Total IQVIA prescriptions were 47,324 in the first quarter of 2022, an increase of 38% compared to total prescriptions of 34,328 in the fourth quarter of 2021. In March 2022, the most recent month available, total prescriptions reached 18,380.
•Qelbree continues to expand its base of prescribers, with approximately 6,900 prescribers in the first quarter of 2022, up from 5,600 prescribers from the fourth quarter of 2021.
•Continued progress in securing and improving managed care coverage.
•At the end of April 2022, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults. Supernus is expecting to launch Qelbree for adult patients by the end of May 2022. According to recent IQVIA Xponent® 52-week data, prescriptions for the adult market represented approximately 68% of the total ADHD market.
Product Pipeline Update
SPN-830 (apomorphine infusion device) - Continuous treatment of motor fluctuations (“off” episodes) in PD
•The Company will continue to work closely with the FDA as it reviews the New Drug Application (NDA) resubmission for SPN-830 for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease. The Company is preparing for the commercial launch of SPN-830 in the first quarter of 2023, assuming timely approval by the FDA. The FDA has established a PDUFA target action date in early October 2022.
SPN-820 - Novel first-in-class activator of mTORC1
•The Company continues to enroll patients in a Phase II multi-center, randomized double-blind placebo-controlled parallel design study of SPN-820 in adults with treatment-resistant depression. The study will examine the efficacy and safety of SPN-820 over a course of five weeks of treatment in approximately 270 patients. The primary outcome measure is the change from baseline to end of treatment period on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score, a standard depression rating scale.
SPN-817 – A novel product candidate for the treatment of epilepsy
•An open label Phase II clinical study of SPN-817 for treatment-resistant seizures is expected to start in the second half of 2022.
Critical Accounting Policies and the Use of Estimates
A summary of our significant accounting policies is included in Note 2, Summary of Significant Accounting Policies of our audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2021. There were no significant changes to the disclosures with respect to our critical accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2021.
32
Results of Operations
Comparison of the Three Months Ended March 31, 2022 and 2021
Revenues
Revenues consist primarily of net product sales of our commercial products in the U.S., supplemented by royalty revenues from our collaborative licensing arrangements. The following table provides information regarding our revenues during the three months ended March 31, 2022 (dollars in thousands):
Three Months ended March 31,Change
20222021AmountPercent
Net product sales
Trokendi XR$62,832 $71,819 $(8,987)(13)%
Oxtellar XR27,521 27,370 151 1 %
GOCOVRI22,601 — 22,601 **
APOKYN18,448 21,730 (3,282)(15)%
Qelbree8,283 — 8,283 **
Other(1)
7,779 7,462 317 4 %
Total net product sales$147,464 $128,381 $19,083 15 %
Royalty revenues5,042 2,551 2,491 98 %
Total revenues$152,506 $130,932 $21,574 16 %
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and OSMOLEX ER.
The $19.1 million and 15% increase in net product sales for the three months ended March 31, 2022, as compared to the same period in 2021, was primarily due to the inclusion of $22.6 million in net product sales of GOCOVRI, subsequent to the completion of the Adamas Acquisition in November 2021, as well as $8.3 million net product sales from Qelbree, which was launched in May 2021. Partially offsetting this increase was a $9.0 million decrease in net product sales of Trokendi XR and a $3.3 million decrease in net product sales of APOKYN.
Trokendi XR net product sales decreased by 13% to $62.8 million for the three months ended March 31, 2022 as compared to the same period in 2021. This decrease was attributable primarily to the decline in unit demand offset by the price increase taken in January 2022. APOKYN net product sales decreased by 15% to $18.4 million for the three months ended March 31, 2022 as compared to the same period in 2021. This decrease was primarily attributable to the decline in unit demand due to competitive headwinds.
Sales Deductions and Related Accruals
We record accrued product returns and accrued product rebates as current liabilities in Accrued product returns and rebates, on our condensed consolidated balance sheets. We record sales discounts as a reduction against Accounts receivable on the condensed consolidated balance sheets. Both amounts are generally affected by changes in gross product sales, changes in the provision for net product sales deductions, and the timing of payments/credits.
33
The following table provides a summary of activity with respect to sales deductions and related accruals during the periods indicated (dollars in thousands):
Accrued Product Returns and Rebates
Product
Rebates		Product
Returns		Reduction to Accounts Receivable for
Sales Discounts		Total
Balance at December 31, 2021$97,597 $35,127 $13,537 $146,261 
Provision
Provision for current year sales109,130 4,007 17,320 130,457 
Adjustments relating to prior year sales359 (902)39 (504)
Total provision$109,489 $3,105 $17,359 $129,953 
Less: Actual payments/credits(102,138)(2,999)(19,453)(124,590)
Balance at March 31, 2022$104,948 $35,233 $11,443 $151,624 
The increase in accrued product rebates liabilities was primarily attributable to greater utilization of our patient co-payment programs, as well as higher per patient payments under both government and commercial managed care programs. The increase in accrued product returns liabilities was primarily due to the timing of related return activity. The decrease to accounts receivable for sales discounts is primarily due to the timing of payments.
Royalty Revenues
Royalty revenues include a royalty from net product sales of Mydayis, a product of Takeda Pharmaceuticals Company Ltd., Namzaric royalties, and noncash royalty revenue pursuant to our agreement with Healthcare Royalty Partners III, L.P. (HC Royalty). HC Royalty receives royalty payments from United Therapeutics Corporation (United Therapeutics) based on net product sales of United Therapeutics’ product Orenitram.
Royalty revenues were $5.0 million and $2.6 million for the three months ended March 31, 2022 and 2021, respectively. The increase was primarily due to the Namzaric royalties for the three months ended March 31, 2022. Namzaric royalty rights were acquired in connection with the Adamas Acquisition.
Cost of Goods Sold
Cost of goods sold was $17.9 million and $15.0 million for the three months ended March 31, 2022 and 2021, respectively. The $2.9 million increase was primarily attributable to inclusion of cost of goods sold of the acquired commercial products from the Adamas Acquisition and of Qelbree, which launched in May 2021.
Research and Development Expenses
R&D expenses were $20.8 million and $34.3 million for the three months ended March 31, 2022 and 2021, respectively. The $13.5 million decrease was primarily due to the write-down of the $15.0 million investment in Navitor LLC which was attributable to a single in-process research and development (IPR&D) asset and recorded in R&D expense in the first quarter of 2021.
Selling, General and Administrative Expenses
The following table provides information regarding our selling, general and administrative (SG&A) expenses during the periods indicated (dollars in thousands):
Three Months ended March 31,Change
20222021AmountPercent
 Selling and marketing $60,513 $38,447 $22,066 57%
 General and administrative 29,946 23,010 $6,936 30%
 Total $90,459 $61,457 $29,002 47%
34
Selling, general and administrative expenses increased by 47% to $90.5 million for the three months ended March 31, 2022. The $29.0 million increase was primarily attributable to increased marketing expenses and professional consulting spend related to the commercial products, including the acquired commercial products from the Adamas Acquisition, and increased Qelbree costs to support current period net product sales as well launch preparation activities for the launch of Qelbree for adults. Qelbree for pediatric patients was launched in May 2021. General and administrative expenses increased due to higher professional and consulting costs to support IT and finance operations for ransomware, financial reporting and Adamas integration in 2022.
Amortization of Intangible Assets
Amortization of intangible assets was $20.6 million and $6.0 million for the three months ended March 31, 2022 and 2021, respectively. The $14.6 million increase was due to amortization of the definite-lived intangible assets acquired in the Adamas Acquisition.
Contingent Consideration Expense
Contingent consideration expense of $0.7 million and $1.0 million for the three months ended March 31, 2022 and 2021, was primarily due to changes in the estimated fair value of contingent consideration due to the passage of time, an increase in the probability of milestone achievement of certain regulatory and developmental USWM milestones, partially offset by the decrease in the estimated fair value of sales-based Adamas milestones due to volatility in the market data movements.
Other Income (Expense)
Other income (expense) was income of $12.8 million and an expense of $2.3 million for the three months ended March 31, 2022 and 2021, respectively. The $15.0 million increase in other income was primarily due to $12.9 million in connection with the gain associated with the Navitor investment and a decrease in interest expense of $4.2 million primarily related to the Company's adoption of ASU 2020-06 on January 1, 2022. As a result of the adoption, the Company no longer records interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes.
Income Tax (Benefit) Expense
Income tax (benefit) expense was a benefit of $10.9 million and an expense of $5.2 million for the three months ended March 31, 2022 and 2021, respectively. The decrease was mainly due to the Adamas reorganization in the first quarter of 2022. The effective income tax rate was (74.0)% and 47.9% for the three months ended March 31, 2022 and 2021, respectively. The effective income tax rate decrease was due to changes in the effective state tax rates as a result of the Adamas reorganization in the first quarter of 2022.
Liquidity and Capital Resources
We have financed our operations primarily with cash generated from product sales, supplemented by revenues from royalty and licensing arrangements, as well as proceeds from the sale of equity and debt securities. Continued cash generation is highly dependent on the success of our commercial products, as well as the success of our product candidates if approved by the FDA. While we expect continued profitability in future years, we anticipate there may be significant variability from year to year in the level of our profits particularly due to the commercial launch of Qelbree in May 2021; future commercial launches of Qelbree for the treatment of ADHD in adults (approved by the FDA in April 2022) and SPN-830 (apomorphine infusion device), if approved by the FDA; continued market and payor pressures for our commercial products; and the likely unfavorable impact of the upcoming loss of patent exclusivity for Trokendi XR in January 2023, or sooner under certain conditions.
The Company believes its balances of cash, cash equivalents and unrestricted marketable securities, which totaled $437.5 million as of March 31, 2022, along with cash generated from ongoing operations and continued access to debt markets, will be sufficient to satisfy its cash requirements over the next 12 months and beyond.
We may, from time to time, consider raising additional capital through: new collaborative arrangements; strategic alliances; additional equity and/or debt financings; or financing from other sources, especially in conjunction with opportunistic business development initiatives. We will continue to actively manage our capital structure and to consider all financing opportunities that could strengthen our long-term financial profile. Any such capital raises may or may not be similar to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
35
Financial Condition

Cash and cash equivalents, marketable securities, and long-term marketable securities as of the periods presented below, are as follows (dollars in thousands):
March 31December 31Change
20222021AmountPercent
Cash and cash equivalents$115,715 $203,434 $(87,719)(43)%
Marketable securities196,485 136,246 60,239 44%
Long-term marketable securities125,337 119,166 6,171 5%
Total$437,537 $458,846 $(21,309)(5)%
Total cash and cash equivalents, marketable securities and long-term marketable securities decreased by $21.3 million in the first three months of 2022 primarily due to the $25 million contingent consideration payment related to FDA acceptance of the SPN-830 NDA for review.
As of March 31, 2022 and December 31, 2021, the outstanding principal on our 0.625% Convertible Senior Notes Due 2023 (2023 Notes) was $402.5 million. No 2023 Notes have been converted as of March 31, 2022. There were no changes to the separate convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) and separate warrant transactions (the Warrant Transactions). Refer to Part I, Item 1, Unaudited Condensed Financial Statements, Note 9, Convertible Senior Notes Due 2023, in the Notes to the Condensed Consolidated Financial Statements, for further discussion of the 2023 Notes and our other indebtedness.
Summary of Cash Flows
The following table summarizes the major sources and uses of cash for the periods set forth below (dollars in thousands):
Three Months ended March 31,Change
20222021Amount
 Net cash provided by (used in):
 Operating activities $4,302 $36,200 $(31,898)
 Investing activities (69,987)(71,445)1,458 
 Financing activities (22,034)2,247 (24,281)
 Net change in cash and cash equivalents $(87,719)$(32,998)$(54,721)
Operating Activities
Net cash provided by operating activities was $4.3 million and $36.2 million for the three months ended March 31, 2022, and 2021, respectively. The decrease in cash flows provided by operating activities is primarily due to changes in working capital which reflects the timing impacts of: cash collections on receivables and settlement of payables.
Investing Activities
Net cash used in investing activities was $70.0 million and $71.4 million for the three months ended March 31, 2022 and 2021, respectively. Net cash used in investing activities primarily reflect cash flows from purchase, sale and maturities of marketable securities.
Financing Activities
Net cash used by financing activities were $22.0 million for the three months ended March 31, 2022 compared to $2.2 million provided during the same period in 2021, primarily due to the payment of a contingent consideration milestone associated with the USWM Acquisition and lower proceeds from option exercises.
Material Cash Requirements
Refer to “Part II, Item 7 — Management’s Discussion and Analysis of Liquidity and Capital Resources”, of our Annual Report on Form 10-K for the year ended December 31, 2021, and Note 16, Commitments and Contingencies, in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, Unaudited Condensed Financial Statements, of this Quarterly Report on Form 10-Q for the discussion of our contractual obligations.
36
Recently Issued Accounting Pronouncements
For a discussion of new accounting pronouncements, see Note 2 in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, Unaudited Condensed Financial Statements, of this Quarterly Report on Form 10-Q.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
The primary objective of our investment activities is to preserve our capital to fund operations and to facilitate business development activities. We also seek to maximize income from our investments without assuming significant interest rate risk, liquidity risk, or risk of default by investing in investment grade securities with maturities of four years or less. Our exposure to market risk is confined to investments in cash and cash equivalents, marketable securities, and long-term marketable securities. As of March 31, 2022, we had unrestricted cash, cash equivalents, marketable securities, and long-term marketable securities of
$437.5 million.
In connection with the 2023 Notes, we have separately entered into Convertible Note Hedge Transactions and Warrant Transactions to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and to partially offset the cost to purchase the Convertible Note Hedge Transactions, respectively.
Our cash and cash equivalents consist primarily of cash held at banks and investments in highly liquid financial instruments with an original maturity of three months or less. Our marketable securities, which are reported at fair value, consist of money market funds; corporate and municipal debt securities; and other fixed income securities. We place all investments with governmental, industrial, or financial institutions whose debt is rated as investment grade. These securities have maturities of one to four years. Because of the relatively short period that we hold our investments and because we generally hold these securities to maturity, we do not believe that an increase in interest rates would have any significant impact on the realizable value of our investments. We do not have any currency or other derivative financial instruments other than outstanding warrants to purchase common stock and the convertible note hedges.
We may contract with clinical research organizations (CROs) and investigational sites globally. Currently, we have three ongoing trials, two of which are being conducted globally, and one which is being conducted outside the U.S. We do not hedge our foreign currency exchange rate risk. Transactions denominated in currencies other than the U.S. dollar are recorded based on exchange rates at the time such transactions arise. As of March 31, 2022 and December 31, 2021, substantially all of our liabilities were denominated in the U.S. dollar.
Inflation generally affects us by increasing our cost of labor and the cost of services provided by our vendors. We do not believe that inflation has had a material effect on our business, financial condition or results of operations. Nonetheless, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures required by Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act has been appropriately recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure. We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2022, the end of the period covered by this report. Based on that evaluation, under the supervision and with the participation of our management, including our CEO and CFO, we concluded that our disclosure controls and procedures were not effective as of March 31, 2022 due to the continued material weaknesses in our internal control over financial reporting as described below and in our Annual Report on Form 10-K as of December 31, 2021, which was filed on April 13, 2022.
In light of the identified material weaknesses, we performed additional analyses and other procedures to ensure that the condensed consolidated financial statements included in this quarterly report on Form 10-Q present fairly, in all material respects, the Company's financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. generally accepted accounting principles (U.S. GAAP).
37
As discussed in Note 3 in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, of this report, the Company completed its acquisition of Adamas Pharmaceuticals, Inc. (Adamas), a publicly traded biopharmaceutical company (Adamas Acquisition) on November 24, 2021. We are in the process of integrating Adamas with our controls over financial reporting. As such, the scope of our assessment of the effectiveness of our disclosure control and procedures as of March 31, 2022 did not include the internal control over financial reporting of Adamas, as permitted by the guidance of the Office of the Chief Accountant of the SEC (not to extend more than one year beyond the date of acquisition or for more than one annual reporting period).
Previously Reported Material Weaknesses in Internal Control over Financial Reporting
As previously disclosed in Item 9A, Controls and Procedures, on Form 10-K filed April 13, 2022, as of and for the year ended December 31, 2021, we identified deficiencies resulting in the material weaknesses further described below. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.
On November 24, 2021, the Company disclosed that it was the target of a ransomware attack. The 2021 ransomware attack resulted in the unauthorized encryption of certain data used by the Company’s legacy enterprise resource planning (“ERP”) system. In addition, the Company also announced on the same date that it had completed the closing of the Adamas acquisition. As a result of these events, the Company’s financial and IT operations changed and the circumstances necessitated further re-consideration of the Company’s control environment, risk assessment, information and communication, control monitoring, and control activities. Specifically, commencing with the fourth quarter of 2021 and continuing into 2022, management was unable to adjust its controls, nor retain sufficient resources to reflect the needs arising from:
(a) the result of the ransomware incident, its effects and significant impact on the following:
i) the Company’s ability to access and reinstate its financial ERP system for an extended period to a new normal state of operation;
ii) the resource needs to rebuild its financial information from backups as a result of the ransomware incident;
iii) additional workload associated with process workflows that were previously automated but are currently manually performed as a result of the ransomware attack.
(b) the Adamas acquisition and the related preliminary purchase price accounting; and
(c) operating the financial reporting environment of Adamas.
These responsibilities were assigned to the finance organization in addition to their historical job responsibilities.
Due to the factors noted above, the Company did not have sufficient resources and as a result, the Company did not adequately perform the following:
(a) assess, redesign and timely evaluate performance of controls over financial reporting risks as a result of existing circumstances;
(b) train, monitor, and supervise newly hired contractors and employees; and
(c) generate real time information across the organization to allow the finance department to perform timely controls.
In the aggregate, these deficiencies create a reasonable possibility that material misstatements in substantially all financial reporting processes and financial statement accounts in our consolidated financial statements will not be prevented or detected on a timely basis and, therefore, we concluded that the deficiencies represent material weaknesses in our internal control over financial reporting.
Remediation Plan
Management is actively remediating the identified material weaknesses, and is committed to remediating the material weaknesses in a timely manner. Our remediation process is ongoing and includes the following steps, but is not limited to, the following:
(a) accelerated implementation of a new ERP system to reduce resource constraints and to automate certain processes that are currently being performed manually as a result of the ransomware attack;
(b) re-evaluation of all controls, including redesigning controls and control procedures, performing risk assessment procedures, as well as adding new controls as necessary;
(c) continue to actively recruit personnel or hire consultants that have requisite knowledge, experience, and expertise over financial reporting and internal control over financial reporting. We will continue to evaluate our current and future staffing needs to add personnel and/or create new roles to address our needs; and
38
(d) training/re-training, monitoring, and enhancing communication of control objectives to hired employees and contractors on internal control over financial reporting.

While the audit committee of our board of directors and senior management are closely monitoring the remediation efforts, until the remediation efforts discussed in this section, including any additional remediation efforts that our senior management identifies as necessary, are complete, tested and determined effective, we will not be able to conclude that the material weaknesses have been remediated. In addition, we will continue to incur incremental costs associated with this remediation, primarily due to the hiring and training of additional personnel, and the improvements in our IT infrastructure. The material weaknesses will not be considered remediated until the above system, controls and personnel are in place for a period of time, the applicable controls operate for a sufficient period of time and management concludes based on its testing and evaluation that these controls are properly designed and operating effectively.
Changes in Internal Control over Financial Reporting
Our management, including our CEO and CFO, evaluated changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2022.
We began the process to integrate the financial reporting systems and processes of the business acquired through the Adamas Acquisition into ours in 2021. As the phased implementation of the integration continues in 2022, we are experiencing certain changes to our processes and procedures, which, in turn, result in changes to our internal control over financial reporting. While management has extended its oversight and monitoring processes that support our internal control over financial reporting, we continue to integrate the operations of Adamas, which may result in additions and changes in our internal controls over financial reporting.
Except for: 1) the above noted and previously reported material weaknesses and the remediation activities that have already begun, including the implementation of a new ERP system which is currently in process, and 2) the ongoing integration of Adamas, there were no other changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 that occurred during the quarter ended March 31, 2022 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.
PART II — OTHER INFORMATION
Item 1.    Legal Proceedings
From time to time and in the ordinary course of business, Supernus Pharmaceuticals, Inc. ("Company") and any of its subsidiaries may be subject to various claims, charges and litigation. Parent and any of its subsidiaries may be required to file infringement claims against third parties for the infringement of our patents.
Oxtellar XR®
Supernus Pharmaceuticals, Inc. v. Apotex Inc., et al., C.A. No. 20-cv-7870 (FLW)(TJB) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug makers Apotex Inc. and Apotex Corp. (collectively, “Apotex”) dated May 13, 2020 directed to nine of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278; and 10,220,042 generally cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists all nine of the Company’s Oxtellar XR® patents as expiring on April 13, 2027. On June 26, 2020, the Company filed a lawsuit against Apotex alleging infringement of the Company’s nine patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Apotex infringed the Company’s Oxtellar XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of the Company’s patents. Filing its June 26, 2020 Complaint within 45 days of receiving Apotex’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Apotex’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On September 4, 2020, Apotex answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Apotex also asserted Counterclaims seeking declaratory judgments of non-infringement for the nine Oxtellar XR® Orange Book patents. On October 30, 2020, the Company filed its Reply, denying the substantive allegations of Apotex’s Counterclaims. On January 27, 2022, the Court issued an Order staying all litigation proceedings and administratively terminated the action until the stay is lifted. As of the date of this submission, this case remains administratively terminated.
39
Supernus Pharmaceuticals, Inc. v. Apotex Inc., et al., C.A. No. 3:22-cv-00322-FLW-TJB (FLW)(TJB) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug makers Apotex Inc. and Apotex Corp. (collectively, “Apotex”) dated December 10, 2021 directed to one of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent No. 11,166,960 generally covers once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists U.S. Patent No. 11,166,960 as expiring on April 13, 2027. On January 24, 2022, the Company filed a lawsuit against Apotex alleging infringement of U.S. Patent No. 11,166,960. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Apotex infringed the Company’s Oxtellar XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of U.S. Patent No. 11,166,960. On January 27, 2022, in related Civil Action No. 20-cv-7870 (FLW)(TJB) (D.N.J.), the Court issued an Order staying all litigation proceedings and administratively terminated that related action until the stay is lifted. That Order further indicated that this action, i.e., Civil Action No. 22-cv-00322 (FLW)(TJB) (D.N.J.), will also be stayed. As of the date of this submission, this case remains administratively terminated.
Supernus Pharmaceuticals, Inc. v. RiconPharma LLC, et al., C.A. No. 21-cv-12133 (FLW)(TJB) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker RiconPharma LLC dated April 20, 2021 directed to nine of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278; and 10,220,042 generally cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists all nine of the Company’s Oxtellar XR® patents as expiring on April 13, 2027. On June 3, 2021, the Company filed a lawsuit against RiconPharma LLC and Ingenus Pharmaceuticals, LLC (collectively, “Ricon”) alleging infringement of the Company’s nine Oxtellar XR® patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Ricon infringed the Company’s Oxtellar XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of the Company’s patents. Filing its June 3, 2021 Complaint within 45 days of receiving Ricon’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ricon’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On August 30, 2021, Ricon answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Ricon also asserted Counterclaims seeking declaratory judgments of non‑infringement for the nine Oxtellar XR® Orange Book patents. Supernus filed a motion to strike the jury demand in Ricon’s answer. On December 6, 2021, the Court signed an Order withdrawing the Jury demand from Ricon’s answer. On December 13, 2021, Ricon filed an amended Answer to Supernus’s Complaint. On December 15, 2021, the Company filed its reply, denying the substantive allegations of Ricon’s Counterclaims. Following the initial Rule 16 Scheduling Conference, the Court issued a case schedule that provides for the Final Pretrial Order being submitted on June 9, 2023, and a trial in July 2023. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. TWi Pharmaceuticals, Inc., et al., C.A. No. 17-cv-2164 (RMB)(JS) (D.N.J.)
The Company received a second Paragraph IV Notice Letter directed to its Oxtellar XR® Orange Book Patent Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; and 9,370,525 from generic drug maker TWi Pharmaceuticals, Inc. on February 16, 2017. On March 31, 2017, the Company filed a lawsuit against TWi Pharmaceuticals, Inc. and TWi International LLC (collectively “TWi”) alleging infringement of United States Patent Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; and 9,370,525. TWi filed a motion to dismiss the Company’s March 31, 2017 Complaint on May 10, 2017. On May 11, 2017, the district court administratively terminated TWi’s motion to dismiss for failure to comply with the Court’s Individual Rules and Procedures. On May 19, 2017, the district court “administratively terminate[d] this matter pending this Court’s decision in the First TWi Action [concerning United States Patent Nos. 7,722,898, 7,910,131, 8,617,600, and 8,821,930].” As of the date of this submission, Civil Action No. 17-2164 (RMB)(JS) (D.N.J.) remains administratively terminated.
Trokendi XR®
Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, et al., C.A. No. 21-cv-6964 (FLW)(LHG) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Ajanta Pharma Limited dated February 10, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683;
40
8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On March 26, 2021, the Company filed a lawsuit against Ajanta Pharma Limited and Ajanta Pharma USA Inc. (collectively “Ajanta”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Ajanta infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its March 26, 2021 Complaint within 45 days of receiving Ajanta’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ajanta’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On June 7, 2021, Ajanta answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Ajanta also asserted Counterclaims seeking declaratory judgments of non‑infringement and invalidity for the Trokendi XR® Orange Book patents. On June 28, 2021, the Company filed its reply, denying the substantive allegations of Ajanta’s Counterclaims. Following the initial Rule 16 Scheduling Conference, the Court issued a case schedule. On December 17, 2021, the Court issued an order consolidating this lawsuit and the lawsuit against Torrent, discussed in the section below, under which this lawsuit is the lead case and the 30 month stay preventing the FDA from approving Ajanta’s ANDA was extended to December 16, 2023. Under the amended scheduling order, the Final Pretrial Conference is set for April 24, 2023. A trial date has not been set. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Torrent Pharmaceuticals Ltd., et al., C.A. No. 21-cv-14268 (FLW)(LHG) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Torrent Pharmaceuticals Ltd. dated June 15, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On July 28, 2021, the Company filed a lawsuit against Torrent Pharmaceuticals Ltd. and Torrent Pharma Inc. (collectively, “Torrent”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Torrent infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its July 28, 2021 Complaint within 45 days of receiving Torrent’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Torrent’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On September 29, 2021, Torrent answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Torrent also asserted Counterclaims seeking declaratory judgments of non‑infringement for the Trokendi XR® Orange Book patents. On November 3, 2021, the Company filed its reply, denying the substantive allegations of Torrent’s Counterclaims. Following the initial Rule 16 Scheduling Conference, the Court issued a case schedule. On December 17, 2021, the Court issued an order consolidating this lawsuit with the lawsuit against Ajanta, discussed in Section V, above, under which the Ajanta lawsuit is the lead case. Under the amended scheduling order, the Final Pretrial Conference is set for April 24, 2023. A trial date has not been set. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Lupin Limited, et al., C.A. No. 21-cv-1293 (MN) (D. Del.)
The Company received a Paragraph IV Notice Letter from generic drug maker Lupin Limited dated July 29, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On September 10, 2021, the Company filed a lawsuit against Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc., and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of Delaware—alleges, inter alia, that Lupin
41
infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its September 10, 2021 Complaint within 45 days of receiving Lupin’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Lupin’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On December 20, 2021, Lupin answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Lupin also asserted Counterclaims seeking declaratory judgments of non‑infringement and invalidity for the Trokendi XR® Orange Book patents. On January 10, 2022, the Company filed its reply, denying the substantive allegations of Lupin’s Counterclaims. On February 25, 2022, the Court issued a scheduling order that provides for the Final Pretrial Order being submitted on June 06, 2023, and a trial beginning on June 20, 2023. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., et al., C.A. No. 21-cv-17104 (FLW)(LHG) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Zydus Pharmaceuticals (USA) Inc. dated August 5, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On September 17, 2021, the Company filed a lawsuit against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (collectively, “Zydus”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Zydus infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its September 17, 2021 Complaint within 45 days of receiving Zydus’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Zydus’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. The August 5, 2021 Paragraph IV Notice Letter from Zydus Pharmaceuticals (USA) Inc. concerns Zydus’s proposed generic equivalent of the 200 mg strength of Trokendi XR®.[1] The August 5, 2021 Paragraph IV Notice Letter referenced herein does not concern the same ANDA as the one that was at issue in the previous lawsuit. On December 28, 2021, Zydus answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. On April 29, 2022, the Court issued a scheduling order that provides for the Final Pretrial Order being submitted on October 05, 2023, and a trial beginning on November 07, 2023. Pretrial discovery s ongoing as of the date of this submission.
_____________________
[1] Previously, the Company was in a lawsuit against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited concerning an Abbreviated New Drug Application (“ANDA”) for Zydus’s proposed generic equivalents of the 25 mg, 50 mg, and 100 mg strengths of Trokendi XR®. A settlement agreement was entered into between the Company and Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited concerning the previous lawsuit. See https://www.sec.gov/Archives/edgar/data/1356576/000110465917031191/a17-10293_1ex10d1.htm.
XADAGO®
On June 10, 2021, Newron Pharmaceuticals S.p.A. (“Newron”), Zambon S.p.A. (“Zambon”) and Supernus Pharmaceuticals, Inc. (the “Company”), through its subsidiary MDD US Operations, LLC (collectively, “Plaintiffs”), initiated litigation against generic drug makers Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., MSN Laboratories Private Limited (“MSN”), Optimus Pharma Pvt Ltd, Prinston Pharmaceutical, Inc., RK Pharma, Inc. and Zenara Pharma Private Limited (collectively, “Defendants”) for infringement of three FDA Orange Book patents covering XADAGO®, the Company’s once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s Disease experiencing “off” episodes. U.S. Patent Nos. 8,076,515, 8,278,485 and 8,283,380 (collectively, the “XADAGO Patents”) cover the pharmaceutical formulation of and methods of treatment with safinamide. The XADAGO Patents expire between June 2027 and March 2031. The Company has a license agreement with Zambon, Newron’s partner, related to the XADAGO Patents, and as a new chemical entity, XADAGO was under the 5-year FDA exclusivity period that expired on March 21, 2022. The Complaint – filed in the U.S. District Court for the District of Delaware – alleges that the Defendants infringed the XADAGO Patents by submitting to the U.S. Food and Drug Administration (FDA) Abbreviated New Drug Applications (ANDAs) seeking to market a generic version of XADAGO prior to the expiration of the patents. Filing the Complaint within 45 days of receiving each of the Defendants’ Paragraph IV notice letters entitles the Plaintiffs to an automatic stay preventing the FDA from approving the Defendants’ ANDAs for 30 months from the date of the Plaintiffs’ receipt of the Paragraph IV Notice Letters. The parties agreed on a case
42
schedule. A trial has been set for January 8, 2024. On March 22, 2022, defendant Optimus Pharma Pvt Ltd was dismissed from the case without prejudice. Fact discovery is ongoing with the remaining defendants.
Adamas Litigation
In November 2012, Adamas Pharmaceuticals, Inc. (Adamas) granted Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc (Forest), an exclusive license to certain of Adamas's intellectual property rights relating to human therapeutics containing memantine in the United States. Under the terms of that license agreement, Forest has the right to enforce such intellectual property rights which are related to its right to market and sell Namzaric and NAMENDA XR for the treatment of moderate to severe dementia related to Alzheimer's disease. Adamas has a right to participate in, but not control, such enforcement actions by Forest.
Since 2018 multiple generic companies have launched generic versions of NAMENDA XR. A number of companies have submitted ANDAs including one or more certifications to the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(iv), requesting approval to manufacture and market generic versions of Namzaric, on which Adamas became entitled to receive royalties from Forest beginning in May 2020.
Adamas and Forest have settled with all such Namzaric ANDA filers, including all first filers on all the available dosage forms of Namzaric. Subject to those agreements, the earliest date on which any of these agreements grant a license to market a Namzaric ANDA filer's generic version of Namzaric is January 1, 2025 (or earlier in certain circumstances). Alternatively, the Namzaric ANDA filers with the earliest date have the option to launch an authorized generic version of Namzaric beginning on January 1, 2026 instead of launching their own generic version of Namzaric on January 1, 2025. Adamas and Forest intend to continue to enforce the patents associated with Namzaric.
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (Case No. 3:18-cv-03018-JCS) against it and several Forest and Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by a named individual, Zachary Silbersher, asserting rights of the Federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high prices being charged to government payors. Adamas's patents in question were licensed exclusively to Forest. The complaint includes a claim for damages of “potentially more than $2.5 billion dollars,” treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motions to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022 and no decision has been reached as of the date of this filing.
On December 10, 2019, a putative class action lawsuit alleging violations of the federal securities laws was filed by Ali Zaidi against Adamas and certain of Adamas's former directors and officers in federal court in the Northern District of California (Case No. 4:19-cv-08051). This lawsuit alleges violations of the Securities Exchange Act of 1934 by Adamas and certain of Adamas's former directors and officers. On October 8, 2021, the presiding judge dismissed the litigation, and granted Plaintiffs leave to amend their complaint. On November 5, 2021, Plaintiffs filed their second amended class action complaint. On December 10, 2021, Adamas filed a motion to dismiss the Second Amended Complaint. Plaintiffs opposed the motion to dismiss. The motion to dismiss remains pending.
On March 16, 2020, a shareholder derivative lawsuit was filed by Patrick Van Camp in federal court in the Northern District of California (Case No. 4:20-cv-01815) naming Adamas and certain of Adamas's former directors and officers as defendants. This lawsuit alleges certain of Adamas's former directors and officers breached fiduciary duties and violated the Securities Exchange Act of 1934. Adamas is named as a nominal defendant only. On April 6, 2020, another, virtually identical, shareholder derivative lawsuit was filed by James Druzbik in federal court in the Northern District of California (Case No. 4:20-cv-02320) naming Adamas and certain of Adamas's former directors and officers as defendants. This lawsuit contains the same allegations, claims, and defendants as the first derivative action. Adamas is named as a nominal defendant only. In both actions, Plaintiffs seek unspecified monetary damages and other relief. These actions have been consolidated and are stayed pending resolution of the Zaidi class action.
Adamas believes it has strong factual and legal defenses to all actions and intends to defend itself vigorously.
43
Item 1A. Risk Factors
Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and related notes; the additional information in the other reports we file with the Securities and Exchange Commission; and the risks described in our Annual Report on Form 10-K for the year ended December 31, 2021 and quarterly report on Form 10-Q for the period ended March 31, 2022. These risks may result in material harm to our business and our financial condition and results of operations. If a material, adverse event were to occur, the market price of our common stock may decline and you could lose part or all of your investment.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
(a)     Sales of Unregistered Securities.

During the three months ended March 31, 2022, the Company granted options to employees to purchase an aggregate of 929,785 shares of common stock at a weighted average exercise price of $32.20 per share. Once vested, the options are exercisable for a period of ten years from the grant date. The Company granted 131,210 restricted stock units to the board of directors at a weighted average grant date fair value of $32.20 per share. The restricted stock units vest one year from the grant date. These issuances are exempt from registration in reliance on Section 4(a)(2) of the Securities Act as transactions not involving a public offering.
Item 3.    Defaults Upon Senior Securities
None.
Item 4.    Mine Safety Disclosures
None.
Item 5.    Other Information
None.
44
Item 6.    Exhibits
The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q:
31.1
31.2
32.1
32.2
101
The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL: (i) Cover Page, (ii) Condensed Consolidated Statements of Earnings, (iii) Condensed Consolidated Statements of Comprehensive Earnings, (iv) Condensed Consolidated Balance Sheets, (v) Condensed Consolidated Statements of Changes in Stockholders' Equity, (vi) Condensed Consolidated Statements of Cash Flows, and (vii) the Notes to Condensed Consolidated Financial Statements, tagged in summary and detail.
104
The cover page of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (included with the Exhibit 101 attachments).

45
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
SUPERNUS PHARMACEUTICALS, INC.
DATED: May 12, 2022By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer
DATED: May 12, 2022By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice-President and Chief Financial Officer

46
 EX-31.1 2 supn-20220331x10qxex311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION
I, Jack A. Khattar, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Supernus Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 12, 2022By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer


 EX-31.2 3 supn-20220331x10qxex312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION
I, Timothy C. Dec, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Supernus Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 12, 2022By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice President and Chief Financial Officer


 EX-32.1 4 supn-20220331x10qxex321.htm EX-32.1 Document

EXHIBIT 32.1
SUPERNUS PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. sec. 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Supernus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack A. Khattar, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 12, 2022By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer


 EX-32.2 5 supn-20220331x10qxex322.htm EX-32.2 Document

EXHIBIT 32.2
SUPERNUS PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. sec. 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Supernus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy C. Dec, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 12, 2022By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice President and Chief Financial Officer


 EX-101.SCH 6 supn-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Business Organization link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Acquisition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Acquisition - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2113104 - Disclosure - Disaggregated Revenues link:presentationLink link:calculationLink link:definitionLink 2314302 - Disclosure - Disaggregated Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Disaggregated Revenues - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2318303 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Investments - Unrestricted Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - Investments - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2421412 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2122106 - Disclosure - Fair Value of Financial Measurements link:presentationLink link:calculationLink link:definitionLink 2323304 - Disclosure - Fair Value of Financial Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Fair Value of Financial Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Fair Value of Financial Measurements - Carrying Value (Details) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - Fair Value of Financial Measurements - Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2127107 - Disclosure - Contingent Consideration link:presentationLink link:calculationLink link:definitionLink 2328305 - Disclosure - Contingent Consideration (Tables) link:presentationLink link:calculationLink link:definitionLink 2429416 - Disclosure - Contingent Consideration - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430417 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2131108 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 2332306 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2433418 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2435420 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2136109 - Disclosure - Convertible Senior Notes Due 2023 link:presentationLink link:calculationLink link:definitionLink 2337307 - Disclosure - Convertible Senior Notes Due 2023 (Tables) link:presentationLink link:calculationLink link:definitionLink 2438421 - Disclosure - Convertible Senior Notes Due 2023 - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2439422 - Disclosure - Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2140110 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 2341308 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2443424 - Disclosure - Share-Based Payments - SAR Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2444425 - Disclosure - Share-Based Payments - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Share-Based Payments - Performance Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2146111 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 2347309 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2448427 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2149112 - Disclosure - Income Tax (Benefit) Expense link:presentationLink link:calculationLink link:definitionLink 2350310 - Disclosure - Income Tax (Benefit) Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2451428 - Disclosure - Income Tax (Benefit) Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2152113 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2353311 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2454429 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2455430 - Disclosure - Leases - Leases Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2156114 - Disclosure - Composition of Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 2357312 - Disclosure - Composition of Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 2458431 - Disclosure - Composition of Balance Sheet Items - Accounts Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 2459432 - Disclosure - Composition of Balance Sheet Items - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2460433 - Disclosure - Composition of Balance Sheet Items - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2461434 - Disclosure - Composition of Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2462435 - Disclosure - Composition of Balance Sheet Items - Accrued Product Returns and Rebates (Details) link:presentationLink link:calculationLink link:definitionLink 2463436 - Disclosure - Composition of Balance Sheet Items - Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2164115 - Disclosure - Interest Expense link:presentationLink link:calculationLink link:definitionLink 2365313 - Disclosure - Interest Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2466437 - Disclosure - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2167116 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2468438 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2169117 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 supn-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 supn-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 supn-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Agreement termination notice period Variable Interest Entity, Agreement Termination Notice, Period Variable Interest Entity, Agreement Termination Notice, Period Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Convertible Debt Convertible Debt [Member] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Net earnings Net earnings Net Income (Loss) Attributable to Parent Consolidated Entities [Axis] Consolidated Entities [Axis] Operating lease assets Operating Lease, Right-of-Use Asset Corporate and municipal debt securities Debt Securities, Available-for-sale, Current Accrued compensation Employee-related Liabilities, Current Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Current Assets Amount of increase (decrease) in prepaid expenses, and other current assets. Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Additional cash payments upon milestone achievements maximum Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Conversion price, per share of common stock (in dollars per share) Debt Instrument, Convertible, Conversion Price APOKYN and SPN-830 APOKYN And SPN-830 [Member] APOKYN And SPN-830 Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Payment of contingent consideration Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Other assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Investment, Name [Axis] Investment, Name [Axis] Acquired in-process research and development In Process Research and Development [Member] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Change in fair value recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Goodwill Goodwill, Purchase Accounting Adjustments Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Leases Lessee, Lease, Description [Line Items] Debt Conversion, Name [Domain] Debt Conversion, Name [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of intangible assets Amortization of Intangible Assets Intangibles Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill 3 years to 4 years Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value Fair value of available-for-sale debt securities maturing in the third fiscal year through the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Convertible notes Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Schedule of inventories Schedule of Inventory, Current [Table Text Block] Common stock equivalents excluded in the calculation of diluted income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Conversion Circumstance Two Conversion Circumstance Two [Member] Conversion Circumstance Two Research and development Research and Development Expense [Member] Subsequent Events [Abstract] Business Combination and Asset Acquisition [Abstract] Granted (in dollars per share) Weighted average fair value, grant date, (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Business Acquisition [Axis] Business Acquisition [Axis] SPN-830 First Commercial And Sale Milestone SPN-830 First Commercial And Sale [Member] SPN-830 First Commercial And Sale Total fair value of assets acquired Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Summary of performance stock unit Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block] Award Type [Domain] Award Type [Domain] Other Manufactured Product, Other [Member] Summary of liability component of 2023 Notes Convertible Debt [Table Text Block] Local Phone Number Local Phone Number Assets Assets [Abstract] Schedule of unrestricted available-for-sale marketable securities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Long-term marketable securities Debt Securities, Noncurrent [Abstract] NAMENDA XR/Namzaric Qui Tam Litigation NAMENDA XR/Namzaric Qui Tam Litigation [Member] NAMENDA XR/Namzaric Qui Tam Litigation Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held Investments Classified by Contractual Maturity Date [Table Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Goodwill and Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Concentration risk percentage (more than) Concentration Risk, Percentage New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Consecutive trading day period (in days) Debt Instrument, Convertible, Threshold Consecutive Trading Days Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Cash distributions received Proceeds from Divestiture of Businesses and Interests in Affiliates Retained Earnings Retained Earnings [Member] Advertising Expense Advertising Cost [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] VIE, qualitative or quantitative information, ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Accrued product returns Accrued Product Returns Represents the amount of accrued product returns. Accounts receivable Increase (Decrease) in Accounts Receivable Capital Expenditures Incurred but Not yet Paid Capital Expenditures Incurred but Not yet Paid Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business acquisition, pro forma information Business Acquisition, Pro Forma Information [Table Text Block] Property and equipment Property, Plant and Equipment [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Number of operating segments Number of Operating Segments Share-based payments Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Basic (in dollars per share) Earnings per share, basic (in dollars per share) Earnings Per Share, Basic Contingent consideration, current portion Business Combination, Contingent Consideration, Liability, Current Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Disaggregated Revenues Revenue from Contract with Customer [Text Block] Revenue Recognition Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Nonvested, beginning balance (in shares) Nonvested, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance at December 31, 2021 Balance at March 31, 2022 (unaudited) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Interest expense Interest Expense, Debt Summary of disaggregation of revenues by nature Disaggregation of Revenue [Table Text Block] Amortization of premium/discount on marketable securities Investment Income, Net, Amortization of Discount and Premium Number of RSUs Number of PSUs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Change in fair value of contingent consideration Unrealized Gain (Loss) on Derivatives Adamas Pharmaceuticals Adamas Pharmaceuticals [Member] Adamas Pharmaceuticals Cumulative effect of adoption of ASU 2020-06 Cumulative Effect, Period of Adoption, Adjustment [Member] Marketable securities - restricted (SERP) Assets for Plan Benefits, Defined Benefit Plan Purchases of property and equipment and deferred legal fees paid Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees 1 year to 2 years Available For Sale Securities Debt Maturities After One Through Two Years Fair Value Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Net deferred tax liabilities Deferred Tax Liabilities, Net Cash paid for operating leases Operating Lease, Payments Other noncash adjustments, net Other Noncash Income (Expense) Additional cash payments upon milestone achievements minimum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Accrued clinical trial costs Accrued Clinical Trial and Clinical Supply Costs Current Represents the amount of clinical trial and clinical supply costs accrued. Lease liabilities, current Lease Liabilities, Current [Abstract] Lease Liabilities, Current Total purchase price Business Combination, Consideration Transferred Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Goodwill [Roll Forward] Goodwill [Roll Forward] APOKYN APOKYN [Member] APOKYN Accrued product costs Inventory Adjustments Assets: Assets, Fair Value Disclosure [Abstract] Long-term Debt Long-term Debt Total assets at fair value Total assets at fair value Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Other accrued expenses Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional paid-in capital Additional Paid in Capital Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Earnings per Share Earnings Per Share [Text Block] Entity Interactive Data Current Entity Interactive Data Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Sales-based contingent consideration liabilities Sales-Based Contingent Consideration Liability [Member] Sales-Based Contingent Consideration Liability Minimum Minimum [Member] Accrued product rebates Accrued Rebates Represents the amount of accrued rebates. Contingent consideration expense Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Marketable securities Marketable Securities, Current Total identifiable net assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Identifiable Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Identifiable Assets SPN-830 NDA Approval Milestone SPN-830 NDA Approval Milestone [Member] SPN-830 NDA Approval Milestone Schedule of fair value of the financial assets and liabilities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Conversion rate for the notes (in shares per $1,000 principal amount) Debt Instrument, Convertible, Conversion Ratio Schedule of financial liabilities that are not carried at fair value Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Total liabilities at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Entity Address, State or Province Entity Address, State or Province Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] USWM Acquisition MDD US Enterprises LLC (Formerly USWM Enterprises) [Member] MDD US Enterprises LLC (Formerly USWM Enterprises) Leases Lessee, Finance Leases [Text Block] Regulatory and developmental contingent consideration liabilities Regulatory And Developmental Contingent Consideration Liability [Member] Regulatory And Developmental Contingent Consideration Liability Other assets Other Assets, Noncurrent [Abstract] Loss contingency, damages sought, value Loss Contingency, Damages Sought, Value Current liabilities Liabilities, Current [Abstract] Issuance of common stock in connection with the Company’s equity award plans Stock Issued During Period, Value, New Issues Market-Based Units Market Based Units [Member] Market Based Units Restatement [Axis] Revision of Prior Period [Axis] Balance (in shares) Balance (in shares) Shares, Outstanding Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Payments Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Issuance of common stock in connection with the Company’s equity award plans (in shares) Stock Issued During Period, Shares, New Issues Accrued product returns and rebates Total Accrued Product Returns and Rebates. Carrying value as of the balance sheet date of accrued product returns and rebates. Accrued professional fees Accrued Professional Fees, Current Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Lease liabilities, long-term Lease Liabilities, Noncurrent [Abstract] Lease Liabilities, Noncurrent Document Transition Report Document Transition Report Schedule of interest expense Interest Income and Interest Expense Disclosure [Table Text Block] Common stock, $0.001 par value; 130,000,000 shares authorized; 53,386,305 and 53,256,094 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total other income (expense) Nonoperating Income (Expense) Nonvested, beginning balance (in dollars per share) Nonvested, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Total PSUs Performance Shares [Member] Accumulated other comprehensive earnings (loss), net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Acquisition Business Combination Disclosure [Text Block] Accrued product returns and rebates Increase (Decrease) In Accrued Product Returns And Rebates Amount of increase (decrease) in product returns and rebates. Interest Expense Other Nonoperating Income and Expense [Text Block] SPN-830 FDA Acceptance Milestone SPN-830 FDA Acceptance Milestone [Member] SPN-830 FDA Acceptance Milestone Product Concentration Risk Product Concentration Risk [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Legal Entity [Axis] Legal Entity [Axis] Cover page. Cover [Abstract] Stock options, RSU and SAR (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities Total costs and expenses Costs and Expenses Pro forma net loss Business Acquisition, Pro Forma Net Income (Loss) Balance, January 1, 2022 Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Raw materials Inventory, Work in Process and Raw Materials, Net of Reserves Warrants issued (in shares) Class of Warrant or Right, Outstanding Work in process Inventory, Work in Process, Net of Reserves Operating lease liabilities, long-term Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Convertible note hedge options issued (in shares) Debt Conversion, Converted Instrument, Warrants or Options Issued Other liabilities Other Liabilities [Table Text Block] Other income from Navitor (see Note 5) Payments For (Proceeds From) Collaborative Arrangement, Investment Payments For (Proceeds From) Collaborative Arrangement, Investment Financial Instrument [Axis] Financial Instrument [Axis] Total Accrued Liabilities, Current Selling, general and administrative Selling, General and Administrative Expenses [Member] Entity [Domain] Entity [Domain] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Finished goods Inventory, Finished Goods, Net of Reserves Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Nonrecourse liability related to sale of future royalties, long-term Non-Recourse Liability, Noncurrent Non-Recourse Liability, Noncurrent Threshold for development costs payments Collaborative Arrangement, Threshold For Development Costs Payments Collaborative Arrangement, Threshold For Development Costs Payments Convertible Notes Convertible Notes Payable [Member] Common Stock Common Stock [Member] Other income (expense) Other Nonoperating Income (Expense) [Abstract] Operating earnings Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease liabilities, current portion Operating Lease, Liability, Current Gross unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus 2 years to 3 years Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value Fair value of available-for-sale debt securities maturing in the second fiscal year through the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Additional  Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents [Abstract] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] As Initially Reported Previously Reported [Member] Capitalized patent defense costs Patent Defense Costs [Member] Represents information concerning the capitalized patent defense costs related to the Watson litigation. Realized gains from sales of marketable securities Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Cardinal Health Cardinal Health [Member] Cardinal Health Interest and other income, net Other Nonoperating Income (Expense) Deferred legal fees and fixed assets included in accounts payable and accrued expenses Non Cash Capitalized Cost Of Intangible Assets Represents the non-cash expenses related to intangible assets that were capitalized and shown within accrued expenses. Other current liabilities Other Liabilities, Current Finite-lived and indefinite-lived intangible assets acquired as part of business combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Business Combinations [Abstract] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Contingent Consideration Contingent Consideration Disclosure [Text Block] Contingent Consideration Disclosure Total liabilities Liabilities Award Type [Axis] Award Type [Axis] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Total stockholders’ equity Balance Balance Stockholders' equity Stockholders' Equity Attributable to Parent Other assets Change in fair value of operating lease acquired Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets Additional cash payments upon milestone achievements minimum Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One Common stock shares issued (in shares) Common Stock, Shares, Issued City Area Code City Area Code Milestone payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Schedule of balance sheet information related to leases Lessee, Operating and Finance Lease, Balance Sheet Disclosure [Table Text Block] Lessee, Operating and Finance Lease, Balance Sheet Disclosure Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Commitment period Long-term Purchase Commitment, Period Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town After-tax interest expense for 2023 Notes Interest on Convertible Debt, Net of Tax Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Noncash investing and financing activities Noncash Investing and Financing Items [Abstract] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Operating lease liabilities, long-term Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Principal amount of debt 2023 Notes Debt Instrument, Face Amount Trokendi XR Trokendi Xr [Member] Represents information pertaining to Trokendi XR patent litigation. Interest expense Total Interest Expense Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Retained earnings Retained Earnings (Accumulated Deficit) Stock options, RSUs Share-based Payment Arrangement [Member] Litigation Case [Domain] Litigation Case [Domain] RSUs Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Restatement [Domain] Revision of Prior Period [Domain] Schedule of recognized identified assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Entity Filer Category Entity Filer Category Business Acquisition [Line Items] Business Acquisition [Line Items] Debt Conversion Description [Axis] Debt Conversion Description [Axis] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Weighted Average Remaining Contractual Term (in years) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Acquired in-process research and development Indefinite-lived Intangible Assets (Excluding Goodwill) Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax (benefit) expense Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Concentration Risk Type [Domain] Concentration Risk Type [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Forfeited (in shares) Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventories, net Total inventories Inventory, Net Three Major Customers Three Major Customers [Member] Three Major Customers Fair value of financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Contingent consideration, long-term Business Combination, Contingent Consideration, Liability, Noncurrent Marketable securities Debt Securities, Current [Abstract] Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Equity Component [Domain] Equity Component [Domain] Lab equipment and furniture Lab Equipment And Furniture [Member] Represents information pertaining to lab equipment and furniture. Lease assets and tenant receivable obtained for new operating leases Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Long-term marketable securities Marketable Securities, Noncurrent Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value Statement [Line Items] Statement Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Conversion option stock price trigger (in dollars per share) Debt Instrument, Convertible, Stock Price Trigger Payment to resolve U.S. Department of Justice allegations Litigation Settlement, Amount Awarded to Other Party Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Corporate and municipal debt securities Debt Securities, Available-for-sale, Noncurrent Liabilities Liabilities [Abstract] McKesson McKesson [Member] McKesson Total fair value Total Debt Securities, Available-for-sale Additional cash payments upon milestone achievements maximum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Fair Value (Level 2) Convertible Debt, Fair Value Disclosures Total intangible assets, carrying amount, gross Intangible Assets, Gross (Excluding Goodwill) Debt Disclosure [Abstract] Debt Disclosure [Abstract] Purchases of marketable securities Payments to Acquire Marketable Securities Earnings before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Number of shares per warrant entitled to holder (in shares) Class of Warrant or Right, Number of Shares in Which Holder Can be Entitled per Warrants at Strike Price Represents the information pertaining to the shares per warrant entitled to holders at strike price. Type of Adoption [Domain] Accounting Standards Update [Domain] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Allowance for expected sales discounts and allowances Allowance for Expected Sales deductions Represents the allowance for sales discounts related to prompt-pay discounts and contractual fee for service arrangements to wholesalers and distributors. Amortized cost Debt Securities, Available-for-sale, Amortized Cost Estimated Useful Life as of Closing Date (in years) Finite-Lived Intangible Asset, Useful Life Contingents value rights Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share Customer [Axis] Customer [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of computation of basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Threshold trading days (whether or not consecutive) Debt Instrument, Convertible, Threshold Trading Days Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of share-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Common stock shares authorized (in shares) Common Stock, Shares Authorized Cash paid for interest on convertible notes Interest Paid, Excluding Capitalized Interest, Operating Activities Numerator for dilutive earnings per share Net Income (Loss) Available to Common Stockholders, Basic Document Type Document Type Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Schedule of accrued product returns and rebates Schedule of Accrued Product Returns and Rebates [Table Text Block] Tabular disclosure of the accrued product returns and rebates. Composition of Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Interest rate Debt Instrument, Interest Rate, Stated Percentage Optional lease renewal term (in years) Lessee, Operating Lease, Renewal Term Contingent consideration Contingent consideration Business Combination, Contingent Consideration, Liability Share-Based Payments Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Investments Equity Securities, FV-NI, Cost Convertible notes, net Carrying Value Total carrying value Convertible Notes Payable, Noncurrent Cash Cash [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Accrued expenses and other current liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Navitor investment R&D expense (see Note 5) Research and Development in Process Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Basic (in shares) Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Earnings per share, diluted (in dollars per share) Earnings Per Share, Diluted Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Amortization of deferred financing costs and debt discount Amortization of Debt Issuance Costs and Discounts Conversion rate of the notes on trading day (as percent) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Net product sales Product [Member] Cash paid for income taxes Income Taxes Paid, Net Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Subsequent Events Subsequent Events [Text Block] Comprehensive earnings Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Deferred income tax liabilities Deferred Income Tax Liabilities, Net Conversion Circumstance One Conversion Circumstance One [Member] Conversion Circumstance One Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Summary of restricted stock units Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Corporate and municipal debt securities Corporate Debt Securities [Member] Schedule of reconciliation of income tax expense at the U.S Federal statutory income tax rate to the entity's effective income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Fair Value of Financial Measurements Fair Value Disclosures [Text Block] Number of established marketed products Number Of Established Marketed Products Number Of Established Marketed Products Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation and amortization Depreciation, Depletion and Amortization 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Annual minimum purchase quantity requirement amount Purchase Commitment, Annual Minimum Amount Committed Purchase Commitment, Annual Minimum Amount Committed Accumulated Other Comprehensive Earnings (Loss) AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Accrued royalties Accrued Royalties, Current Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Common stock shares outstanding (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Cost of goods sold Cost of Goods and Services Sold Revenues Revenues [Abstract] Other liabilities Other Sundry Liabilities, Noncurrent Software Computer Software, Intangible Asset [Member] Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Income per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Consolidated Entities [Domain] Consolidated Entities [Domain] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] AmerisourceBergen Drug Corporation AmerisourceBergen Drug Corporation [Member] AmerisourceBergen Drug Corporation Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Stock option and Stock Appreciation Rights Stock Option Stock Appreciation Rights [Member] Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights. Other liabilities Total Other Liabilities, Noncurrent Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Notes payable Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Pro forma total revenues Business Acquisition, Pro Forma Revenue Property and equipment, gross Property, Plant and Equipment, Gross Current debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Strike price of the warrant transactions (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Costs and expenses Costs and Expenses [Abstract] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Total Share-based Payment Arrangement, Expense Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Entity Current Reporting Status Entity Current Reporting Status Earnings per share Earnings Per Share, Basic and Diluted [Abstract] Weighted Average Grant Date Fair Value per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Total lease liabilities Lease, Liability Lease, Liability Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Greater than 4 years Available For Sale Securities Debt Maturities, Thereafter, Fair Value Available For Sale Securities Debt Maturities, Thereafter, Fair Value Total fair value of liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Construction in Progress Construction in Progress [Member] Performance-Based Units Performance Based Units [Member] Performance Based Units Cash and cash equivalents at beginning of year Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Deferred income tax liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities Assumed Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities Assumed Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Impairment due to credit losses Debt Securities, Available-for-sale, Allowance for Credit Loss Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets Assets, Current [Abstract] Carrying Amount, Gross Finite-Lived Intangible Assets, Gross Leases [Abstract] Leases [Abstract] Remaining Weighted Average Life (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Cash and Money market funds Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Interest expense on nonrecourse liability related to sale of future royalties Interest Expense, Other Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted (in shares) Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Conversion of debt to equity Debt Conversion, Original Debt, Amount Adamas Acquisition Adamas [Member] Adamas Recurring Fair Value, Recurring [Member] Income Tax (Benefit) Expense Income Tax Disclosure [Text Block] Nonrecourse liability related to sale of future royalties, long term Non Recourse Debt Sale of Future Royalties Noncurrent Noncurrent portion of debt, net of the amount due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property. Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Summary of stock options and SAR activities Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of common stock equivalents excluded in the calculation of diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Oxtellar XR Oxtellar X R [Member] Represents information pertaining to Oxtellar XR product. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Royalty revenues Royalty [Member] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Navitor Pharmaceuticals, Inc. Navitor Pharmaceuticals, Inc. [Member] Navitor Pharmaceuticals, Inc. Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Unrealized loss on marketable securities, net of tax Unrealized loss on marketable securities, net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent GOCOVRI GOCOVRI [Member] GOCOVRI Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Future Sales Performance SPN-830 Future Sales Performance [Member] SPN-830 Future Sales Performance Consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Spend commitment amount Purchase Commitment, Remaining Minimum Amount Committed Total current liabilities Liabilities, Current Cash consideration paid Cash consideration paid Payments to Acquire Businesses, Gross Qelbree Qelbree [Member] Qelbree Money market securities and funds Money Market Funds [Member] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Current Fiscal Year End Date Current Fiscal Year End Date Unamortized debt discount and deferred financing costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Statement [Table] Statement [Table] Advertising costs Advertising Expense Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Carrying Amount, Net Finite-Lived Intangible Assets, Net Goodwill Goodwill Balance as of December 31, 2021 Balance as of March 31, 2022 (unaudited) Goodwill Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Accounting Standards Update 2020-06 Accounting Standards Update 2020-06 [Member] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Business Organization Nature of Operations [Text Block] Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Less than 1 year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Acquired developed technology and product rights Developed Technology Rights [Member] Computer equipment Computer Equipment [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] SPN-30 Regulatory and Commercial Activities SPN-830 Regulatory And Commercial Activities [Member] SPN-830 Regulatory And Commercial Activities Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Rights per share (in dollars per share) Business Combination, Contingent Consideration, Rights Per Share Business Combination, Contingent Consideration, Rights Per Share Non-cash royalty revenue Revenue From Royalty Agreement Represents revenue from the sale of certain royalty and milestone rights. Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Convertible Senior Notes Due 2023 Long-term Debt [Text Block] Deferred income tax benefit Deferred Income Tax Expense (Benefit) Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term EX-101.PRE 10 supn-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2022
May 02, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-35518  
Entity Registrant Name SUPERNUS PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-2590184  
Entity Address, Address Line One 9715 Key West Avenue  
Entity Address, City or Town Rockville  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 20850  
City Area Code 301  
Local Phone Number 838-2500  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Entity Common Stock, Shares Outstanding   53,413,211
Trading Symbol SUPN  
Security Exchange Name NASDAQ  
Entity Central Index Key 0001356576  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 115,715 $ 203,434
Marketable securities 196,485 136,246
Accounts receivable, net 145,149 148,932
Inventories, net 88,795 85,959
Prepaid expenses and other current assets 22,372 27,019
Total current assets 568,516 601,590
Long-term marketable securities 125,337 119,166
Property and equipment, net 17,215 16,955
Intangible assets, net 764,049 784,693
Goodwill 115,414 117,516
Other assets 48,986 49,232
Total assets 1,639,517 1,689,152
Current liabilities    
Accounts payable and accrued liabilities 89,432 117,683
Accrued product returns and rebates 140,181 132,724
Contingent consideration, current portion 46,890 44,840
Other current liabilities 8,055 20,132
Total current liabilities 284,558 315,379
Convertible notes, net 400,382 379,252
Contingent consideration, long-term 9,252 35,637
Operating lease liabilities, long-term 39,891 41,298
Deferred income tax liabilities 62,843 85,355
Other liabilities 14,145 16,380
Total liabilities 811,071 873,301
Stockholders’ equity    
Common stock, $0.001 par value; 130,000,000 shares authorized; 53,386,305 and 53,256,094 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 53 53
Additional paid-in capital 383,016 434,337
Accumulated other comprehensive earnings (loss), net of tax (773) 1,539
Retained earnings 446,150 379,922
Total stockholders’ equity 828,446 815,851
Total liabilities and stockholders’ equity $ 1,639,517 $ 1,689,152
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Stockholders’ equity    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock shares authorized (in shares) 130,000,000 130,000,000
Common stock shares issued (in shares) 53,386,305 53,386,305
Common stock shares outstanding (in shares) 53,256,094 53,256,094
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Earnings - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues    
Total revenues $ 152,506 $ 130,932
Costs and expenses    
Cost of goods sold [1] 17,932 14,954
Research and development 20,839 34,280
Selling, general and administrative 90,459 61,457
Amortization of intangible assets 20,644 6,007
Contingent consideration expense 665 1,020
Total costs and expenses 150,539 117,718
Operating earnings 1,967 13,214
Other income (expense)    
Interest expense (1,942) (6,097)
Interest and other income, net 14,698 3,812
Total other income (expense) 12,756 (2,285)
Earnings before income taxes 14,723 10,929
Income tax (benefit) expense (10,893) 5,235
Net earnings $ 25,616 $ 5,694
Earnings per share    
Basic (in dollars per share) $ 0.48 $ 0.11
Diluted (in dollars per share) $ 0.43 $ 0.11
Weighted average shares outstanding    
Basic (in shares) 53,330,837 52,927,467
Diluted (in shares) 61,406,555 54,196,971
Net product sales    
Revenues    
Total revenues $ 147,464 $ 128,381
Royalty revenues    
Revenues    
Total revenues $ 5,042 $ 2,551
[1] Excludes amortization of acquired intangible assets
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Comprehensive Earnings - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net earnings $ 25,616 $ 5,694
Other comprehensive loss    
Unrealized loss on marketable securities, net of tax (2,312) (2,726)
Other comprehensive loss (2,312) (2,726)
Comprehensive earnings $ 23,304 $ 2,968
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Changes in Stockholder's Equity - USD ($)
$ in Thousands
Total
Cumulative effect of adoption of ASU 2020-06
Balance, January 1, 2022
Common Stock
Common Stock
Balance, January 1, 2022
Additional  Paid-in Capital
Additional  Paid-in Capital
Cumulative effect of adoption of ASU 2020-06
Additional  Paid-in Capital
Balance, January 1, 2022
Accumulated Other Comprehensive Earnings (Loss)
Accumulated Other Comprehensive Earnings (Loss)
Balance, January 1, 2022
Retained Earnings
Retained Earnings
Cumulative effect of adoption of ASU 2020-06
Retained Earnings
Balance, January 1, 2022
Balance (in shares) at Dec. 31, 2020       52,868,482                  
Balance at Dec. 31, 2020 $ 744,858     $ 53   $ 409,332     $ 8,975   $ 326,498    
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 4,371         4,371              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       125,655                  
Issuance of common stock in connection with the Company’s equity award plans 2,247         2,247              
Net earnings 5,694                   5,694    
Unrealized loss on marketable securities, net of tax (2,726)               (2,726)        
Balance (in shares) at Mar. 31, 2021       52,994,137                  
Balance at Mar. 31, 2021 $ 754,444     $ 53   415,950     6,249   332,192    
Increase (Decrease) in Stockholders' Equity                          
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2020-06                        
Balance (in shares) at Dec. 31, 2021       53,256,094 53,256,094                
Balance at Dec. 31, 2021 $ 815,851 $ (15,600) $ 800,251 $ 53 $ 53 434,337 $ (56,212) $ 378,125 1,539 $ 1,539 379,922 $ 40,612 $ 420,534
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 4,025         4,025              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       130,211                  
Issuance of common stock in connection with the Company’s equity award plans 866         866              
Net earnings 25,616                   25,616    
Unrealized loss on marketable securities, net of tax (2,312)               (2,312)        
Balance (in shares) at Mar. 31, 2022       53,386,305                  
Balance at Mar. 31, 2022 $ 828,446     $ 53   $ 383,016     $ (773)   $ 446,150    
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities    
Net earnings $ 25,616 $ 5,694
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation and amortization 21,362 6,592
Navitor investment R&D expense (see Note 5) 0 15,000
Other income from Navitor (see Note 5) (12,888) 0
Amortization of deferred financing costs and debt discount 526 4,287
Realized gains from sales of marketable securities 0 (216)
Amortization of premium/discount on marketable securities (360) (1,706)
Change in fair value of contingent consideration 665 1,020
Other noncash adjustments, net 84 (1,202)
Share-based compensation expense 4,025 4,371
Deferred income tax benefit (13,011) (2,565)
Changes in operating assets and liabilities:    
Accounts receivable 3,812 13,805
Inventories (2,468) (1,048)
Prepaid expenses and other assets 1,061 (368)
Accrued product returns and rebates 7,457 2,544
Accounts payable and other liabilities (29,479) (10,008)
Contingent consideration 2,100 0
Net cash provided by operating activities 4,302 36,200
Cash flows from investing activities    
Purchases of marketable securities (98,063) (119,063)
Sales and maturities of marketable securities 28,927 49,579
Purchases of property and equipment and deferred legal fees paid (851) (1,961)
Net cash used in investing activities (69,987) (71,445)
Cash flows from financing activities    
Payment of contingent consideration (22,900) 0
Proceeds from issuance of common stock 866 2,247
Net cash (used in) provided by financing activities (22,034) 2,247
Net change in cash and cash equivalents (87,719) (32,998)
Cash and cash equivalents at beginning of year 203,434 288,640
Cash and cash equivalents at end of period 115,715 255,642
Supplemental cash flow information    
Cash paid for interest on convertible notes 1,258 1,258
Cash paid for income taxes 478 301
Cash paid for operating leases 2,949 1,834
Noncash investing and financing activities    
Lease assets and tenant receivable obtained for new operating leases 27 1,432
Deferred legal fees and fixed assets included in accounts payable and accrued expenses 0 160
Capital Expenditures Incurred but Not yet Paid $ 549 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Business Organization
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Organization Business Organization
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
Commercial Products
•Trokendi XR® (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.
•Qelbree® (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company is expecting to launch Qelbree for adult patients by the end of May 2022.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD.
•MYOBLOC® (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.
•GOCOVRI® (amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes.
•OSMOLEX ER® (amantadine) extended-release tablets is for the treatment of PD and drug-induced extrapyramidal reactions in adult patients.
Product Candidates
The Company is also developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The Company's product candidates in clinical development include the following:
•SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. In February 2022, the FDA acknowledged that it received the new drug application (NDA) resubmission for SPN-830 (apomorphine infusion device) for the continuous treatment of motor fluctuations ("off" episodes) in PD. The NDA has a PDUFA date of October 7, 2022.
•SPN-820 (NV-5138) is a first-in-class product candidate for treatment-resistant depression, currently in Phase II development. It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).
•SPN-817 (huperzine A) is a novel product candidate for treatment-resistant seizures, currently in Phase I development.
Adamas Acquisition and Reorganization
On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021, the Purchaser was merged with and into Adamas (Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (Adamas Acquisition). Adamas holds and markets two established commercial products in its portfolio, GOCOVRI and Osmolex ER, and has royalty rights to Namzaric®. Allergan plc markets and sells Namzaric in the U.S.

In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The legal entities reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, Income Taxes.)
COVID-19 Impact
The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of March 31, 2022.
Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.
In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Consolidation
The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.
The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the valuation of the assets acquired and liabilities assumed in the Adamas Acquisition, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.
The Company incurred approximately $23.9 million and $15.3 million in advertising expense for the three months ended March 31, 2022 and 2021, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the condensed consolidated statements of earnings.
Recently Issued Accounting Pronouncements
Accounting Pronouncements Adopted
Accounting Standards Update (ASU) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.
The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method.
ASU 2021-10, Government Assistance (Topic 832) - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific US GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.
New Accounting Pronouncements Not Yet Adopted
ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers - The new standard, issued in October 2021, amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606, Revenue from Contracts with Customers, as if the acquiree had
initially applied recognition and measurement in their financial statements. This guidance is effective for fiscal years beginning after December 15, 2022 on a prospective basis. Early adoption is permitted.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Acquisition
 3 Months Ended
Mar. 31, 2022
Business Combinations [Abstract]  
Acquisition Acquisition
Adamas Acquisition
On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas Pharmaceuticals, Inc., a publicly-held pharmaceutical company (Adamas), pursuant to the Adamas Agreement dated October 10, 2021. On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only U.S. FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and OSMOLEX ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.
The Company paid the Adamas shareholders $400.8 million and transferred two non-tradable contingent value rights (CVRs). Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer & Trust Company, LLC, as rights agent, (CVR Agreement). One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once.
In connection with the two CVRs, the Company recorded contingent consideration liabilities of $10.3 million as of the date of the acquisition, to reflect the estimated fair value of the contingent consideration. The estimated fair value of the liabilities were determined using Monte Carlo simulations. The fair value measurement of the contingent consideration liabilities were determined based on significant unobservable inputs and thus represents a Level 3 fair value measurement. The key assumptions considered include the estimated amount and timing of projected cash flows, volatility, estimated discount rates and risk-free interest rate. In each reporting period after the acquisition, the Company will revalue the contingent consideration liabilities and will record increases or decreases in the fair value of the liabilities in its consolidated statements of earnings. Changes in fair value will result from changes in actual and projected milestone achievement, as well as changes to forecasts. The inputs and assumptions may not be observable in the market, but they reflect the assumptions the Company believes would be made by a market participant. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.
The acquisition was accounted for as a business combination under the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The estimated fair values of the assets acquired and liabilities assumed, including goodwill, have been included in the Company's consolidated financial statements since the acquisition Closing Date.
The Company's accounting for the Adamas Acquisition is preliminary and fair value estimates for the assets acquired and liabilities assumed and the Company's estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period. During the measurement period, if the Company obtains new information regarding facts and circumstances that existed as of the Closing Date that, if known, would have resulted in revised estimated values of those assets or liabilities, the Company will accordingly revise its estimates of fair values and purchase price allocation. The effect of measurement period adjustments on the estimated fair value elements will be reflected as if the adjustments had been made as of the Closing Date. The impact of all changes that do not qualify as measurement period adjustments will be included in current period earnings.
The Company expects to finalize its purchase price allocation within one year of the Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record at fair value the assets acquired and liabilities assumed in the following areas: intangible assets, lease assets and liabilities, tax assets and liabilities, and certain existing or potential reserves, including those for legal or contract-related matters. The activities the Company is currently undertaking include, but are not limited to, the following: review of acquired contracts and other contract-related and legal matters; review and evaluation of the accounting policies, tax positions, and other tax-related matters. Further,
the Company continues to obtain input from third party valuation firms with respect to the fair value of the acquired tangible and intangible assets, and other information necessary to record and measure the assets acquired and liabilities assumed. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Closing Date are subject to change.
The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):
As Initially Reported
Measurement Period Adjustments (1)
As Adjusted
Cash and cash equivalents$90,064 $— $90,064 
Accounts receivable11,156 — 11,156 
Inventories20,200 — 20,200 
Prepaid expenses and other current assets5,077 — 5,077 
Property and equipment1,254 — 1,254 
Intangibles450,100 — 450,100 
Other assets (2)
6,442 (1,620)4,822 
Total fair value of assets acquired584,293 (1,620)582,673 
Accounts payable(4,592)— (4,592)
Accrued expenses and other current liabilities(8,014)— (8,014)
Current debt(138,315)— (138,315)
Operating lease liabilities, long-term(5,224)— (5,224)
Deferred income tax liabilities (3)
(56,588)3,722 (52,866)
Total fair value of liabilities assumed(212,733)3,722 (209,011)
Total identifiable net assets371,560 2,102 373,662 
Goodwill39,553 (2,102)37,451 
Total purchase price411,113 — 411,113 
Cash consideration paid400,806 — 400,806 
Fair value of contingent consideration10,307 — 10,307 
Total purchase price$411,113 $— $411,113 
______________________________
(1) Measurement period adjustments reflect changes based on information related to the facts and circumstances that existed as of the acquisition date.
(2) Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease. Refer to Note 13, Leases.
(3) Represents tax impact of the changes in the initial estimate of the fair value of the right of use asset and changes made to update certain state tax attributes which existed at the opening balance sheet date.
Acquired Inventory
The estimated fair value of the inventory was determined using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or dispose of the inventory, as well as a profit on the sale.
Acquired Intangible Assets
The acquired intangible assets include the acquired developed technology and product rights to GOCOVRI and OSMOLEX ER, as well as the right to receive royalties from Allergan plc for sales of Namzaric. The Company determined the estimated fair values for the acquired intangible assets as of the Closing Date using the income approach. This is a valuation technique that provides an estimate of fair value of the assets, based on the market participant's expectations of the cash flows that the assets are forecasted to generate. The cash flows were discounted at a rate commensurate with the level of risk associated with
its projected cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value.
The fair value measurements of the acquired intangible assets were determined based on significant unobservable inputs and thus represent Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the intangible assets valuation includes: the estimated future cash flows from product sales, the timing and projection of costs and expenses, discount rates and tax rates.
Acquired intangible assets consist of developed technology and product rights and are amortized over their estimated useful lives on a straight-line basis. The following table summarizes the preliminary purchase price allocation, and the average remaining useful lives for identifiable intangible assets (dollars in thousands):
Estimated Fair ValueEstimated Useful Life as of Closing Date (in years)
Acquired developed technology and product rights$450,100 
3.1 - 8.1
Goodwill
Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is primarily attributable to the anticipated cost synergies, additional growth platforms, and an expanded revenue base with the addition of the assets from the Adamas Acquisition. The goodwill is not expected to be deductible for tax purposes.
Acquired Deferred Income Tax Liabilities, net
The deferred income tax liabilities, net relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences. The acquired federal and state net operating loss carryforwards is reduced by a valuation allowance for amounts that are not expected to be realizable in the future.
Revenue and Net Earnings of Adamas
The operations of Adamas and its subsidiaries have been included in the Company's consolidated statements of earnings for the period subsequent to the Closing Date.
Pro Forma Information
The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):
Three Months ended
March 31, 2021
Pro forma total revenues$150,243 
Pro forma net loss(20,484)
The unaudited pro forma combined financial information is based on historical financial information and the Company's preliminary allocation of purchase price; therefore, it is subject to subsequent adjustment upon finalization of the purchase price allocation. In order to reflect the occurrence of the acquisition on January 1, 2020, the unaudited pro forma combined financial information reflects the recognition of additional amortization expense on intangible assets and estimated additional cost of products sold related to the inventory step-up adjustment; the estimated reduction in the Company's interest income generated from marketable securities that were liquidated to fund the purchase price of the Adamas Acquisition, and the estimated tax impact of the pro forma adjustments.
The unaudited pro forma combined financial information should not necessarily be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Disaggregated Revenues
 3 Months Ended
Mar. 31, 2022
Disaggregation of Revenue [Abstract]  
Disaggregated Revenues Disaggregated Revenues
The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Net product sales
Trokendi XR$62,832 $71,819 
Oxtellar XR27,521 27,370 
GOCOVRI22,601 — 
APOKYN18,448 21,730 
Qelbree8,283 — 
Other(1)
7,779 7,462 
Total net product sales$147,464 $128,381 
Royalty revenues5,042 2,551 
Total revenues$152,506 $130,932 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and OSMOLEX ER.

Trokendi XR accounted for 43% and 56% of the Company’s total net product sales for the three months ended March 31, 2022 and 2021, respectively.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% and 25% of our total net product sales and collectively accounted for more than 75% and 85% of our total net product sales in 2022 and 2021, respectively.
The Company recognized noncash royalty revenue of $2.2 million for both the three months ended March 31, 2022 and 2021. Refer to Note 16, Commitments and Contingencies.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Investments
 3 Months Ended
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments
Marketable Securities
Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31, 2022December 31, 2021
(unaudited)
Corporate and U.S. government agency and municipal debt securities
Amortized cost$322,797 $253,301 
Gross unrealized gains497 2,349 
Gross unrealized losses(1,472)(238)
Total fair value$321,822 $255,412 
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31,
2022
(unaudited)
Less than 1 year$196,485 
1 year to 2 years111,584 
2 years to 3 years13,753 
3 years to 4 years— 
Greater than 4 years— 
Total$321,822 
As of March 31, 2022, there was no impairment due to credit loss on any available-for-sale marketable securities.
Investment in Navitor
Development Agreement
In April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million. In addition, the Company will incur certain other research and development support costs. There are certain additional payment amounts which could be incurred by the Company. These costs are contingent upon Navitor Inc. achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required.
Equity investment
In addition to entering into the Development Agreement in April 2020, the Company acquired Series D Preferred Shares of Navitor Inc. for $15 million, representing an approximately 13% ownership position in Navitor Inc.
In March 2021, Navitor Inc. underwent a legal restructuring. In the restructuring, Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals LLC (Navitor LLC), and the outstanding shares of stock in Navitor Inc. were exchanged for units of membership in Navitor LLC having equivalent rights and preferences (Navitor Restructuring). As part of the Navitor Restructuring, the Series D Preferred Shares previously held by the Company were exchanged for Series D Preferred Shares in Navitor LLC. In addition, certain assets that did not relate to NV-5138 (SPN-820) were transferred from Navitor Inc. to a newly formed entity that became a separate, wholly owned subsidiary of Navitor LLC.
The Company had determined that Navitor LLC is a VIE. The Company does not consolidate this VIE because the Company lacks the power to direct the activities that most significantly impact Navitor’s economic performance.
Prior to the Navitor Restructuring, the investment was accounted for under the practical expedient allowed for equity securities without readily determinable fair value, which is cost minus impairment plus any changes in observable price changes from an orderly transaction of similar investments in Navitor Inc. Following the legal restructuring and exchange of the preferred shares for member equity units of Navitor LLC, the investment was accounted for under the equity method of accounting due to the Company's ability to exert significant influence over but not control the financial and operating decisions of Navitor LLC. As a result of the change from a cost method investment to an equity method investment, the Company was required to measure its investment initially in accordance with the guidance in ASC 805. The majority of the assets and liabilities recorded in Navitor LLC's financial statements represent working capital items and cash that are being used for research and development purposes and are significantly lower than the Company's investment in Navitor LLC, which created a significant basis difference for the Company's investment in the underlying net assets. The Company determined that substantially all of the fair value of the investment was attributable to a single in-process research and development (IPR&D) asset. As a result, Navitor LLC was not considered a business as defined in ASC 805. In the first quarter of 2021, the $15 million investment, which was previously recorded in Other assets in the condensed consolidated balance sheets, was expensed and recorded in Research and development expense in the condensed consolidated statements of earnings.
The Company records its share of the results of Navitor LLC, a private company, on a quarter lag as the financial information of Navitor LLC is not available on a sufficiently timely basis for the Company to apply the equity method of accounting. In December 2021, Navitor LLC sold one of its subsidiaries and distributed cash to its members in accordance with each member's share of the proceeds from the sale. The Company received $12.9 million in December 2021 from Navitor LLC in connection with this sale. As the Company's policy is to record its share of the results in its equity method investment on a quarter lag as previously indicated, the Company recorded the cash amount received in Other current liabilities in the consolidated balance sheets as of December 31, 2021. In the first quarter of 2022, the Company determined its estimated share of Navitor LLC's year-end 2021 earnings and recorded a gain of $12.9 million in Interest and other income, net in the condensed consolidated statement of earnings.
The maximum exposure to losses related to Navitor LLC is a maximum of approximately $50 million in expense for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company.
The Company has not provided financing to Navitor LLC. Further, no additional equity investment has been made to Navitor LLC.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Measurements
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Measurements Fair Value of Financial Measurements
The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets.
•Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves).
•Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data.
The fair value of the restricted marketable securities which are classified as Level 2 financial assets is recorded in Other assets on the condensed consolidated balance sheets. There were no Level 3 financial assets as of March 31, 2022 or December 31, 2021. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.
Financial Assets and Liabilities Recorded at Fair Value
The Company’s financial assets that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements as of March 31, 2022 (unaudited)
Total Fair Value as of March 31, 2022
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$84,218 $84,218 $— $— 
Money market securities and funds31,497 1,502 29,995 — 
Marketable securities
Corporate and municipal debt securities196,485 — 196,485 — 
Long-term marketable securities
Corporate and municipal debt securities125,337 — 125,337 — 
Other assets
Marketable securities - restricted (SERP)570 8 562 — 
Total assets at fair value$438,107 $85,728 $352,379 $— 
Liabilities:
Contingent consideration$56,142 $— $— $56,142 
Total liabilities at fair value$56,142 $— $— $56,142 
Fair Value Measurements as of December 31, 2021
Total Fair Value as of December 31, 2021
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$148,863 $148,863 $— $— 
Money market securities and funds54,571 54,571 — — 
Marketable securities
Corporate and municipal debt securities136,246 251 135,995 — 
Long-term marketable securities
Corporate and municipal debt securities119,166 — 119,166 — 
Other assets
Marketable securities - restricted (SERP)630 7 623 — 
Total assets at fair value$459,476 $203,692 $255,784 $— 
Liabilities:
Contingent consideration$80,477 $— $— $80,477 
Total liabilities at fair value$80,477 $— $— $80,477 
Other Financial Instruments
The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities.
Financial Liabilities Recorded at Carrying Value
The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands):
March 31, 2022December 31, 2021
Carrying ValueFair Value (Level 2)Carrying ValueFair Value (Level 2)
Convertible notes, net$400,382 $395,456 $379,252 $400,236 
The fair value has been estimated based on actual trading information, and quoted prices, both provided by bond traders. As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Contingent Consideration
 3 Months Ended
Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Contingent Consideration Contingent Consideration
The Company's contingent consideration liabilities are related to the USWM Acquisition and the Adamas Acquisition.
On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments of up to $230 million, comprising of $130 million for the achievement of certain SPN-830 regulatory and commercial milestones (regulatory and developmental contingent consideration payments) and up to $100 million related to the future sales performance of the acquired USWM products (sales-based contingent consideration payments). The regulatory and developmental contingent consideration payments include a $25 million milestone due upon the FDA acceptance of the SPN-830 NDA for review. The remaining $105 million are due upon the FDA's regulatory approval and commercial launch of SPN-830. Based on timing of the PDUFA date of SPN-830 NDA, one of the regulatory and developmental milestones which has a time-based mechanism for full or partial achievement will not be achieved. Of the $100 million sales-based contingent consideration, a $35 million milestone due upon achievement of certain U.S. net product sales of APOKYN in 2021 was not achieved. The remaining $65 million relates to the achievement of certain net product sales of the acquired USWM products in 2022 and 2023.
As mentioned in Note 1, the Company received a notice from the FDA in February 2022 of its acceptance for review of the NDA for SPN-830. As such, the Company made a $25 million regulatory and developmental contingent consideration payment in the first quarter of 2022. This milestone payment is reflected in the condensed consolidated statements of cash flows as a $22.9 million under cash flows from financing activities related to the acquisition date fair value of the contingent consideration liability and a $2.1 million under cash flows from operating activities related to excess of the acquisition date fair value.
As discussed in Note 3, Acquisition, the Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI.
The Company's contingent consideration liabilities are measured at fair value on a recurring basis; i.e., the Monte Carlo simulation for the sales-based milestones, and the income approach for the other milestones. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement.
During the measurement period, changes in the fair value of contingent consideration related to the Adamas Acquisition are recorded against goodwill if such changes are related to facts and circumstances that existed at the acquisition date. In each reporting period after the acquisition, the Company remeasures the fair value of contingent consideration liabilities and records in its consolidated statements of earnings the increases or decreases in the fair value of the liabilities. The Company recorded a net expense of $0.7 million due to the change in fair value of the contingent consideration liabilities in the first quarter of 2022. The change in fair value is reported on the condensed consolidated statement of earnings in Contingent consideration expense.
The change in the fair value of contingent consideration was primarily driven by the increase in estimated fair value of regulatory and developmental USWM milestones due to the accretion to the payout amount related to the milestone achieved in the first quarter of 2022. The increase is partially offset by a decrease in the estimated fair value of sales-based Adamas milestones due to changes in market data. The key assumptions considered in estimating the fair value of regulatory and developmental milestones include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated amount and timing of projected cash flows, volatility, estimated discount rates and risk-free interest rate. Refer to Note 3, Acquisition, for further discussion of significant inputs and assumptions used in the valuation of the contingent consideration for the Adamas Acquisition.
The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2021$70,170 $10,307 $80,477 
Milestone payments(25,000)— (25,000)
Change in fair value recognized in earnings1,720 (1,055)665 
Balance at March 31, 2022 (unaudited)$46,890 $9,252 $56,142 
Regulatory and developmental contingent consideration liabilities46,890 — 46,890 
Sales-based contingent consideration liabilities— 9,252 9,252 
Balance at March 31, 2022 (unaudited)$46,890 $9,252 $56,142 
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
March 31,
2022		December 31,
2021
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$46,890 $44,840 
Contingent consideration, long-term9,252 35,637 
Total$56,142 $80,477 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets, Net
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangibles Assets, Net
Goodwill
The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):
Balance as of December 31, 2021
$117,516 
Measurement period adjustments related to the acquisition of Adamas (see Note 3).(2,102)
Balance as of March 31, 2022 (unaudited)
$115,414 
Intangible Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):
March 31,
2022		December 31,
2021
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights8.49681,100 (54,913)626,187 681,100 (35,550)645,550 
Capitalized patent defense costs4.3743,820 (29,958)13,862 43,820 (28,677)15,143 
Total intangible assets8.40848,920 (84,871)764,049 848,920 (64,227)784,693 
Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Oxtellar XR and Trokendi XR will expire no earlier than 2027. In regards to Trokendi XR, the Company entered into settlement agreements that allow third parties to enter the market by January 1, 2023, or earlier under certain circumstances.
Amortization expense for intangible assets was approximately $20.6 million and $6.0 million, for the three month periods ended March 31, 2022 and 2021, respectively. The increase in expense is primarily due to amortization of the acquired developed technology and product rights from the Adamas Acquisition.
Anticipated annual amortization expense for intangible assets is estimated at $79.8 million in 2023 and 2024, $75.0 million in 2025 and 2026, and $73.2 million
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Senior Notes Due 2023
 3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Convertible Senior Notes Due 2023 Convertible Senior Notes Due 2023
The 0.625% Convertible Senior Notes Due 2023 (2023 Notes), which were issued in March 2018, bear interest at an annual rate of 0.625%, payable semi-annually in arrears on April 1 and October 1 of each year. The 2023 Notes will mature on April 1, 2023, unless earlier converted or repurchased by the Company. The Company may not redeem the 2023 Notes at its option before maturity. The total principal amount of 2023 Notes is $402.5 million.
The 2023 Notes were issued pursuant to an Indenture between the Company and Wilmington Trust, National Association, as trustee. The Indenture includes customary terms and covenants, including certain events of default upon which the 2023 Notes may be due and payable immediately. The Indenture does not contain any financial or operating covenants, or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Noteholders may convert their 2023 Notes at their option only in the following circumstances: (1) during any calendar quarter, if the last reported sale price per share of the Company's common stock for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including the last trading day of the immediately preceding
calendar quarter, exceeds 130% of the conversion price, or a price of approximately $77.13 per share on such trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as specified in the Indenture; and (4) at any time from and including October 1, 2022, until the close of business on the second scheduled trading day immediately before the maturity date.
At its election, the Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, based on the applicable conversion rate. The initial conversion rate is 16.8545 shares per $1,000 principal amount of the 2023 Notes, which represents an initial conversion price of approximately $59.33 per share, and is subject to adjustment as specified in the Indenture. In the event of conversion, if converted in cash, the holders would forgo all future interest payments, any unpaid accrued interest, and the possibility of further stock price appreciation.
If a “make-whole fundamental change,” as defined in the Indenture occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. If a “fundamental change,” as defined in the Indenture occurs, then noteholders may require the Company to repurchase their 2023 Notes at a cash repurchase price equal to the principal amount of the 2023 Notes to be repurchased, plus accrued and unpaid interest, if any.
Contemporaneous with the issuance of the 2023 Notes, the Company also entered into separate privately negotiated convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) with each of the call spread counterparties. The Company issued 402,500 convertible note hedge options. In the event that shares or cash are deliverable to holders of the 2023 Notes upon conversion at limits defined in the Indenture, counterparties to the convertible note hedges will be required to deliver up to approximately 6.8 million shares of the Company’s common stock, or to pay cash to the Company in a similar amount as the value that the Company delivers to the holders of the 2023 Notes, based on a conversion price of $59.33 per share.
Concurrently with entering into the Convertible Note Hedge Transactions, the Company also entered into separate privately negotiated warrant transactions (collectively, the Warrant Transactions) with each of the call spread counterparties. The Company issued a total of 6,783,939 warrants. The warrants entitle the holder to one share per warrant. The strike price of the Warrant Transactions will initially be $80.91 per share of the Company’s common stock, and is subject to adjustment.
The Convertible Note Hedge Transactions are expected to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2023 Notes, as the case may be.
The Warrant Transactions were intended to partially offset the cost to the Company of the purchased Convertible Note Hedge Transactions; however, the Warrant Transactions could have a dilutive effect with respect to the Company’s common stock, to the extent that the market price per share of the Company’s common stock, as measured under the terms of the Warrant Transactions, exceeds the strike price of the warrants.
The liability component of the 2023 Notes consists of the following, (dollars in thousands):
March 31,
2022		December 31,
2021
(unaudited) 
2023 Notes$402,500 $402,500 
Unamortized debt discount and deferred financing costs(2,118)(23,248)
Total carrying value$400,382 $379,252 
As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption. No 2023 Notes were converted as of March 31, 2022 or December 31, 2021.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Payments
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Share-Based Payments Share-Based Payments
Share-based compensation expense is as follows (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Research and development$651 $588 
Selling, general and administrative3,374 3,783 
Total$4,025 $4,371 
Stock Option and Stock Appreciation Rights
The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options		Weighted
Average
Exercise Price		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20215,774,076 $24.15 5.95
Granted 929,785 $32.20 
Exercised (47,601)$18.21 
Forfeited (48,036)$30.84 
Outstanding, March 31, 2022 (unaudited)6,608,224 $25.28 6.25
As of December 31, 2021:
Vested and expected to vest5,774,076 $24.15 5.95
Exercisable3,651,824 $21.29 4.53
As of March 31, 2022:
Vested and expected to vest6,608,224 $25.28 6.25
Exercisable 4,280,012 $22.87 4.79
Restricted Stock Units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 202121,110 $29.61 
Granted131,210 $32.20 
Vested(21,110)$29.61 
Forfeited— $— 
Nonvested, March 31, 2022131,210 $32.20 
There were no forfeited RSU awards during the three months ended March 31, 2022.
Performance Share Units
The following table summarizes performance share unit (PSU) activities:
Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 202153,500 $29.82 35,625 $26.34 89,125 $28.43 
Vested(21,500)$29.67 — (21,500)$29.67 
Nonvested, March 31, 202232,000$29.92 35,625$26.34 67,625$28.04 
There were no forfeited PSU awards during the three months ended March 31, 2022.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings per Share
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
The Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, whereas the Company previously calculated diluted earnings per share under the treasury stock method. Basic earnings per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock option grants, SARs, RSUs, employee stock purchase plan (ESPP) awards, and the 2023 Notes, as determined per the if-converted method for the three months ended March 31, 2022 in connection with the adoption of ASU 2020-06 and the treasury stock method for the three months ended March 31, 2021.
Effect of Convertible Notes and Related Convertible Note Hedges and Warrants
In connection with the issuance of the 2023 Notes, the Company entered into Convertible Note Hedge and Warrant Transactions as described further in Note 9, Convertible Senior Notes Due 2023. The expected collective impact of the Convertible Note Hedge and Warrant Transactions is to reduce the potential dilution that would occur if the price of the Company's common stock was between the conversion price of $59.33 per share and the strike price of the warrants of $80.91 per share.
Diluted EPS related to the 2023 Notes in the current year is calculated using the if-converted method. The number of dilutive shares is based on the initial conversion rate associated with the 2023 Notes. The Convertible Note Hedge and Warrant Transactions are excluded in the calculation of diluted EPS because inclusion would be anti-dilutive. Specifically, the denominator of the diluted EPS calculation excludes the additional shares related to the warrants because the average price of the Company's common stock was less than the strike price of the warrants of $80.91 per share. Prior to actual conversion, the Convertible Note Hedge Transactions are not considered in calculating diluted earnings per share, as their impact would be anti-dilutive.

In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards in the calculation of diluted EPS, because their inclusion would be anti-dilutive:
Three Months ended
March 31,
20222021
(unaudited)
Stock options, RSUs1,067,231 1,419,203 

As mentioned in Note 1, as a result of the adoption of ASU 06-2020 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended March 31, 2022. For the three months ended March 31, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.
The following table sets forth the computation of basic and diluted net earnings per share for the three months ended March 31, 2022 under the if-converted method and for the three months ended March 31, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):
Three Months ended
March 31,
20222021
(unaudited)
Numerator:
Net earnings $25,616 $5,694 
After-tax interest expense for 2023 Notes887 — 
Numerator for dilutive earnings per share$26,503 $5,694 
Denominator:
Weighted average shares outstanding, basic53,330,837 52,927,467 
Effect of dilutive securities:
Stock options, RSUs and SARs1,291,782 1,269,504 
Convertible notes6,783,936 — 
Weighted average shares outstanding, diluted61,406,555 54,196,971 
Earnings per share, basic$0.48 $0.11 
Earnings per share, diluted$0.43 $0.11 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Income Tax (Benefit) Expense
 3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Tax (Benefit) Expense Income Tax (Benefit) Expense
The following table provides information regarding the Company’s income tax (benefit) expense for the three months ended March 31, 2022 and 2021 (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Income tax (benefit) expense$(10,893)$5,235 
Effective tax rate(74.0)%47.9 %

Income tax benefit was $10.9 million for the three months ended March 31, 2022 and income tax expense was $5.2 million for the three months ended March 31, 2021. The change for the three months ended March 31, 2022 was primarily from tax benefits associated with the Adamas legal entities reorganization in the first quarter of 2022. The reorganization resulted in favorable impact on certain state apportionment factors. The change in the effective income tax rate for the three months ended March 31, 2022 as compared to the same period in the prior year was mainly due to changes in the effective state tax rates as a result of the Adamas legal entities reorganization.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
 3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Leases Leases
Operating Leases
The Company has operating leases for its headquarters lease, certain other office space, and its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. The Company also elected to combine the lease and non-lease components for the fleet vehicle and headquarters leases.
The Company's headquarters lease commenced on February 1, 2019 (the Commencement Date) and will continue until April 30, 2034, unless earlier terminated in accordance with the terms of the lease. The lease includes options to extend the lease for up to 10 years.
As part of the Adamas Acquisition, the Company acquired a lease for office space. Adamas' operating lease for the office space term will continue until April 30, 2025. The lease contains an option to extend the term for one additional five-year period.
During a measurement period, changes in fair value due to measurement period adjustments are recorded against goodwill. The Company recorded in the first quarter of 2022 a measurement period adjustment associated with the valuation of the acquired Adamas lease which decreased the fair value estimate of the operating lease right of use asset by $1.6 million. Refer to Note 3, Acquisition.
Contract Manufacturing Lease
The Company has a contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz), for the manufacture and supply of rimabotulinumtoxinB finished products (Merz Agreement). The Merz Agreement will expire in July 2027 unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience.
Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility which the Company accounts for as an embedded lease.
The Company made an accounting policy election, by class of underlying asset, to not combine lease and non-lease components for the manufacturing facility. A portion of the in-substance fixed contract consideration was allocated to the lease component based on the stand-alone selling price. Accordingly, the Company classifies and accounts for the embedded lease as an operating lease.
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationMarch 31, 2022December 31, 2021
(unaudited)
Assets
Operating lease assetsOther assets$32,141 $35,365 
Total lease assets$32,141 $35,365 
Liabilities
Lease liabilities, current
Operating lease liabilities, current portionAccounts payable and accrued liabilities$6,141 $6,477 
Lease liabilities, long-term
Operating lease liabilities, long-termOperating lease liabilities, long-term39,891 41,298 
Total lease liabilities$46,032 $47,775 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Composition of Balance Sheet Items Composition of Other Balance Sheet ItemsThe following details the composition of other balance sheet items (dollars in thousands for amounts in tables):
Accounts Receivables, Net
As of March 31, 2022 and December 31, 2021, the Company has reduced accounts receivable by approximately $11.4 million and $13.5 million, respectively. Prompt pay discount and contractual service fees, which were originally recorded as a reduction to revenues, represents estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.
Inventories, Net
March 31,
2022		December 31,
2021
(unaudited)
Raw materials$9,239 $7,325 
Work in process46,219 45,711 
Finished goods33,337 32,923 
Total$88,795 $85,959 

Inventories as of March 31, 2022 include acquired inventory from the Adamas Acquisition. Refer to Note 3, Acquisition, for further discussion of the acquisition.
Property and Equipment, Net
March 31,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,199 $12,287 
Leasehold improvements13,998 14,369 
Software2,185 4,776 
Computer equipment1,282 1,944 
Construction-in-progress32 33 
29,696 33,409 
Less accumulated depreciation and amortization(12,481)(16,454)
Property and equipment, net$17,215 $16,955 
Depreciation and amortization expense on property and equipment was approximately $0.7 million and $0.6 million for the three months ended March 31, 2022, and 2021, respectively. The Company retired certain fully depreciated property and equipment during the three months ended March 31, 2022.
Accounts Payable and Accrued Liabilities
March 31,
2022		December 31,
2021
(unaudited)
Accounts payable$12,323 $9,331 
Accrued professional fees16,209 26,728 
Accrued compensation14,555 28,068 
Accrued product costs12,727 18,460 
Accrued royalties (1)
11,044 13,821 
Accrued clinical trial costs (2)
7,784 9,125 
Operating lease liabilities, current portion (3)
6,141 6,477 
Other accrued expenses8,649 5,673 
Total$89,432 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
Accrued Product Returns and Rebates
March 31,
2022		December 31,
2021
(unaudited)
Accrued product rebates$104,948 $97,597 
Accrued product returns35,233 35,127 
Total$140,181 $132,724 
Other Liabilities
March 31,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$3,784 $5,977 
Other liabilities10,361 10,403 
Total$14,145 $16,380 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Interest Expense
 3 Months Ended
Mar. 31, 2022
Other Income and Expenses [Abstract]  
Interest Expense Interest Expense
The following details the composition of interest expense (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Interest expense$(1,155)$(5,062)
Interest expense on nonrecourse liability related to sale of future royalties(787)(1,035)
Total$(1,942)$(6,097)

As discussed in Note 2, Summary of Significant Accounting Policies, the Company adopted ASU 2020-06 on January 1, 2022. As a result, interest expense for the three months ended March 31, 2022 significantly decreased compared to the three months ended March 31, 2021 due to the Company no longer recording interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes. For the three months ended March 31, 2022, interest expense includes noncash interest expense related to amortization of deferred financing costs of $0.5 million. For the three months ended March 31, 2021, interest expense includes noncash interest expense related to amortization of deferred financing costs and amortization of the debt discount on the 2023 Notes of $4.3 million.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Product Licenses
The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.
Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the condensed consolidated statements of earnings.
Royalty Agreement
In the third quarter of 2014, the Company received $30 million pursuant to a Royalty Interest Acquisition Agreement related to the purchase by HC Royalty of certain of the Company's rights under the Company's agreement with United Therapeutics related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets. Full ownership of the royalty rights will revert to the Company if and when a certain cumulative payment threshold is reached (see Note 2, Note 4, and Note 14).
USWM Enterprise Commitments Assumed
As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below.
The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply. Refer to Note 13, Leases for further discussion related to the Merz Agreement in connection with the MYOBLOC annual minimum purchase requirement.
In addition, USWM Enterprises had an existing license and distribution agreement for XADAGO. This included an annual minimum promotional spend to support the marketing of XADAGO for the first five years of the agreement and will end in 2022. As of March 31, 2022, there is no remaining contractual commitment.
In March 2019, MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to incur significant costs through March 2024 to maintain a broad array of processes, policies and procedures necessary to comply with the CIA.
Data Breach-related Contingency
On November 24, 2021, the Company announced that we were the target of a ransomware attack. The attack had no significant impact on our business and did not cause any long-term disruption to our operations. Based on its internal investigation, the Company believes the criminal ransomware groups ("criminal groups") copied certain data from our systems, encrypted certain data on the Company's systems, and then deployed malware designed to impede access to our systems. Thereafter the criminal groups contacted the Company and threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware attack, the Company notified government authorities, engaged third-party cybersecurity experts through our outside counsel, and commenced its recovery process. The Company maintains redundant off-site data backups, which were verified to have not been compromised by the ransomware attack and were utilized to restore the data encrypted by the criminal groups. In the fourth quarter of 2021, the Company had successfully recovered the impacted files and took additional steps designed to further protect its networks and files.
Furthermore, while the Company has not been the subject of any legal proceedings involving the attack, the likelihood that the Company could be the subject of claims from persons alleging they suffered damages from the incident, or actions by governmental authorities is possible, but the amount of such fines, penalties or costs, if any, cannot be estimated at this time. The Company continues to monitor the situation.
Claims and Litigation
From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.
NAMENDA XR/Namzaric Qui Tam Litigation
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022 and no decision has been reached as of the date of this filing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
 3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events On April 29, 2022, the Company announced that the FDA approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.
In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Consolidation
Consolidation
The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.
The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the valuation of the assets acquired and liabilities assumed in the Adamas Acquisition, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.
Advertising Expense
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.
The Company incurred approximately $23.9 million and $15.3 million in advertising expense for the three months ended March 31, 2022 and 2021, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the condensed consolidated statements of earnings.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
Accounting Pronouncements Adopted
Accounting Standards Update (ASU) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.
The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method.
ASU 2021-10, Government Assistance (Topic 832) - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific US GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.
New Accounting Pronouncements Not Yet Adopted
ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers - The new standard, issued in October 2021, amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606, Revenue from Contracts with Customers, as if the acquiree had
initially applied recognition and measurement in their financial statements. This guidance is effective for fiscal years beginning after December 15, 2022 on a prospective basis. Early adoption is permitted.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Acquisition (Tables)
 3 Months Ended
Mar. 31, 2022
Business Combinations [Abstract]  
Schedule of recognized identified assets acquired and liabilities assumed
The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):
As Initially Reported
Measurement Period Adjustments (1)
As Adjusted
Cash and cash equivalents$90,064 $— $90,064 
Accounts receivable11,156 — 11,156 
Inventories20,200 — 20,200 
Prepaid expenses and other current assets5,077 — 5,077 
Property and equipment1,254 — 1,254 
Intangibles450,100 — 450,100 
Other assets (2)
6,442 (1,620)4,822 
Total fair value of assets acquired584,293 (1,620)582,673 
Accounts payable(4,592)— (4,592)
Accrued expenses and other current liabilities(8,014)— (8,014)
Current debt(138,315)— (138,315)
Operating lease liabilities, long-term(5,224)— (5,224)
Deferred income tax liabilities (3)
(56,588)3,722 (52,866)
Total fair value of liabilities assumed(212,733)3,722 (209,011)
Total identifiable net assets371,560 2,102 373,662 
Goodwill39,553 (2,102)37,451 
Total purchase price411,113 — 411,113 
Cash consideration paid400,806 — 400,806 
Fair value of contingent consideration10,307 — 10,307 
Total purchase price$411,113 $— $411,113 
______________________________
(1) Measurement period adjustments reflect changes based on information related to the facts and circumstances that existed as of the acquisition date.
(2) Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease. Refer to Note 13, Leases.
(3) Represents tax impact of the changes in the initial estimate of the fair value of the right of use asset and changes made to update certain state tax attributes which existed at the opening balance sheet date.
Finite-lived and indefinite-lived intangible assets acquired as part of business combination The following table summarizes the preliminary purchase price allocation, and the average remaining useful lives for identifiable intangible assets (dollars in thousands):
Estimated Fair ValueEstimated Useful Life as of Closing Date (in years)
Acquired developed technology and product rights$450,100 
3.1 - 8.1
Business acquisition, pro forma information
The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):
Three Months ended
March 31, 2021
Pro forma total revenues$150,243 
Pro forma net loss(20,484)
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Disaggregated Revenues (Tables)
 3 Months Ended
Mar. 31, 2022
Disaggregation of Revenue [Abstract]  
Summary of disaggregation of revenues by nature
The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Net product sales
Trokendi XR$62,832 $71,819 
Oxtellar XR27,521 27,370 
GOCOVRI22,601 — 
APOKYN18,448 21,730 
Qelbree8,283 — 
Other(1)
7,779 7,462 
Total net product sales$147,464 $128,381 
Royalty revenues5,042 2,551 
Total revenues$152,506 $130,932 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and OSMOLEX ER.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Investments (Tables)
 3 Months Ended
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of unrestricted available-for-sale marketable securities Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31, 2022December 31, 2021
(unaudited)
Corporate and U.S. government agency and municipal debt securities
Amortized cost$322,797 $253,301 
Gross unrealized gains497 2,349 
Gross unrealized losses(1,472)(238)
Total fair value$321,822 $255,412 
Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
March 31,
2022
(unaudited)
Less than 1 year$196,485 
1 year to 2 years111,584 
2 years to 3 years13,753 
3 years to 4 years— 
Greater than 4 years— 
Total$321,822 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Measurements (Tables)
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of fair value of the financial assets and liabilities The Company’s financial assets that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements as of March 31, 2022 (unaudited)
Total Fair Value as of March 31, 2022
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$84,218 $84,218 $— $— 
Money market securities and funds31,497 1,502 29,995 — 
Marketable securities
Corporate and municipal debt securities196,485 — 196,485 — 
Long-term marketable securities
Corporate and municipal debt securities125,337 — 125,337 — 
Other assets
Marketable securities - restricted (SERP)570 8 562 — 
Total assets at fair value$438,107 $85,728 $352,379 $— 
Liabilities:
Contingent consideration$56,142 $— $— $56,142 
Total liabilities at fair value$56,142 $— $— $56,142 
Fair Value Measurements as of December 31, 2021
Total Fair Value as of December 31, 2021
Level 1
Level 2
Level 3
Assets:
Cash and cash equivalents
Cash$148,863 $148,863 $— $— 
Money market securities and funds54,571 54,571 — — 
Marketable securities
Corporate and municipal debt securities136,246 251 135,995 — 
Long-term marketable securities
Corporate and municipal debt securities119,166 — 119,166 — 
Other assets
Marketable securities - restricted (SERP)630 7 623 — 
Total assets at fair value$459,476 $203,692 $255,784 $— 
Liabilities:
Contingent consideration$80,477 $— $— $80,477 
Total liabilities at fair value$80,477 $— $— $80,477 
Schedule of financial liabilities that are not carried at fair value
The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands):
March 31, 2022December 31, 2021
Carrying ValueFair Value (Level 2)Carrying ValueFair Value (Level 2)
Convertible notes, net$400,382 $395,456 $379,252 $400,236 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Contingent Consideration (Tables)
 3 Months Ended
Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration
The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2021$70,170 $10,307 $80,477 
Milestone payments(25,000)— (25,000)
Change in fair value recognized in earnings1,720 (1,055)665 
Balance at March 31, 2022 (unaudited)$46,890 $9,252 $56,142 
Regulatory and developmental contingent consideration liabilities46,890 — 46,890 
Sales-based contingent consideration liabilities— 9,252 9,252 
Balance at March 31, 2022 (unaudited)$46,890 $9,252 $56,142 
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
March 31,
2022		December 31,
2021
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$46,890 $44,840 
Contingent consideration, long-term9,252 35,637 
Total$56,142 $80,477 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets, Net (Tables)
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):
Balance as of December 31, 2021
$117,516 
Measurement period adjustments related to the acquisition of Adamas (see Note 3).(2,102)
Balance as of March 31, 2022 (unaudited)
$115,414 
Schedule of Intangible Assets and Goodwill The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):
March 31,
2022		December 31,
2021
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights8.49681,100 (54,913)626,187 681,100 (35,550)645,550 
Capitalized patent defense costs4.3743,820 (29,958)13,862 43,820 (28,677)15,143 
Total intangible assets8.40848,920 (84,871)764,049 848,920 (64,227)784,693 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Senior Notes Due 2023 (Tables)
 3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Summary of liability component of 2023 Notes The liability component of the 2023 Notes consists of the following, (dollars in thousands):
March 31,
2022		December 31,
2021
(unaudited) 
2023 Notes$402,500 $402,500 
Unamortized debt discount and deferred financing costs(2,118)(23,248)
Total carrying value$400,382 $379,252 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Payments (Tables)
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of share-based compensation expense Share-based compensation expense is as follows (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Research and development$651 $588 
Selling, general and administrative3,374 3,783 
Total$4,025 $4,371 
Summary of stock options and SAR activities The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options		Weighted
Average
Exercise Price		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20215,774,076 $24.15 5.95
Granted 929,785 $32.20 
Exercised (47,601)$18.21 
Forfeited (48,036)$30.84 
Outstanding, March 31, 2022 (unaudited)6,608,224 $25.28 6.25
As of December 31, 2021:
Vested and expected to vest5,774,076 $24.15 5.95
Exercisable3,651,824 $21.29 4.53
As of March 31, 2022:
Vested and expected to vest6,608,224 $25.28 6.25
Exercisable 4,280,012 $22.87 4.79
Summary of restricted stock units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 202121,110 $29.61 
Granted131,210 $32.20 
Vested(21,110)$29.61 
Forfeited— $— 
Nonvested, March 31, 2022131,210 $32.20 
Summary of performance stock unit
The following table summarizes performance share unit (PSU) activities:
Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 202153,500 $29.82 35,625 $26.34 89,125 $28.43 
Vested(21,500)$29.67 — (21,500)$29.67 
Nonvested, March 31, 202232,000$29.92 35,625$26.34 67,625$28.04 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings per Share (Tables)
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Schedule of common stock equivalents excluded in the calculation of diluted earnings per share
In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards in the calculation of diluted EPS, because their inclusion would be anti-dilutive:
Three Months ended
March 31,
20222021
(unaudited)
Stock options, RSUs1,067,231 1,419,203 

As mentioned in Note 1, as a result of the adoption of ASU 06-2020 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended March 31, 2022. For the three months ended March 31, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.
Schedule of computation of basic and diluted earnings per share The following table sets forth the computation of basic and diluted net earnings per share for the three months ended March 31, 2022 under the if-converted method and for the three months ended March 31, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):
Three Months ended
March 31,
20222021
(unaudited)
Numerator:
Net earnings $25,616 $5,694 
After-tax interest expense for 2023 Notes887 — 
Numerator for dilutive earnings per share$26,503 $5,694 
Denominator:
Weighted average shares outstanding, basic53,330,837 52,927,467 
Effect of dilutive securities:
Stock options, RSUs and SARs1,291,782 1,269,504 
Convertible notes6,783,936 — 
Weighted average shares outstanding, diluted61,406,555 54,196,971 
Earnings per share, basic$0.48 $0.11 
Earnings per share, diluted$0.43 $0.11 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Income Tax (Benefit) Expense (Tables)
 3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of reconciliation of income tax expense at the U.S Federal statutory income tax rate to the entity's effective income tax rate The following table provides information regarding the Company’s income tax (benefit) expense for the three months ended March 31, 2022 and 2021 (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Income tax (benefit) expense$(10,893)$5,235 
Effective tax rate(74.0)%47.9 %
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Schedule of balance sheet information related to leases
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationMarch 31, 2022December 31, 2021
(unaudited)
Assets
Operating lease assetsOther assets$32,141 $35,365 
Total lease assets$32,141 $35,365 
Liabilities
Lease liabilities, current
Operating lease liabilities, current portionAccounts payable and accrued liabilities$6,141 $6,477 
Lease liabilities, long-term
Operating lease liabilities, long-termOperating lease liabilities, long-term39,891 41,298 
Total lease liabilities$46,032 $47,775 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items (Tables)
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of inventories
Inventories, Net
March 31,
2022		December 31,
2021
(unaudited)
Raw materials$9,239 $7,325 
Work in process46,219 45,711 
Finished goods33,337 32,923 
Total$88,795 $85,959 
Schedule of property and equipment
Property and Equipment, Net
March 31,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,199 $12,287 
Leasehold improvements13,998 14,369 
Software2,185 4,776 
Computer equipment1,282 1,944 
Construction-in-progress32 33 
29,696 33,409 
Less accumulated depreciation and amortization(12,481)(16,454)
Property and equipment, net$17,215 $16,955 
Schedule of accrued expenses and other current liabilities
Accounts Payable and Accrued Liabilities
March 31,
2022		December 31,
2021
(unaudited)
Accounts payable$12,323 $9,331 
Accrued professional fees16,209 26,728 
Accrued compensation14,555 28,068 
Accrued product costs12,727 18,460 
Accrued royalties (1)
11,044 13,821 
Accrued clinical trial costs (2)
7,784 9,125 
Operating lease liabilities, current portion (3)
6,141 6,477 
Other accrued expenses8,649 5,673 
Total$89,432 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
Schedule of accrued product returns and rebates
Accrued Product Returns and Rebates
March 31,
2022		December 31,
2021
(unaudited)
Accrued product rebates$104,948 $97,597 
Accrued product returns35,233 35,127 
Total$140,181 $132,724 
Other liabilities Other Liabilities
March 31,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$3,784 $5,977 
Other liabilities10,361 10,403 
Total$14,145 $16,380 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Interest Expense (Tables)
 3 Months Ended
Mar. 31, 2022
Other Income and Expenses [Abstract]  
Schedule of interest expense
The following details the composition of interest expense (dollars in thousands):
Three Months ended
March 31,
20222021
(unaudited)
Interest expense$(1,155)$(5,062)
Interest expense on nonrecourse liability related to sale of future royalties(787)(1,035)
Total$(1,942)$(6,097)
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Basis of Presentation (Details)
 3 Months Ended
Mar. 31, 2022
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Advertising Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Accounting Policies [Abstract]    
Advertising costs $ 23.9 $ 15.3
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Jan. 01, 2022
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]          
Operating lease assets $ 32,141     $ 35,365  
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity $ 828,446 $ 754,444   815,851 $ 744,858
Convertible notes 6,783,936 0      
Accounting Standards Update 2020-06          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Long-term Debt     $ 20,600    
Net deferred tax liabilities     (5,000)    
Accounting Standards Update 2020-06 | Convertible Debt          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Convertible notes 6,800,000        
Cumulative effect of adoption of ASU 2020-06          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity       (15,600)  
Retained Earnings          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity $ 446,150 $ 332,192   379,922 326,498
Retained Earnings | Cumulative effect of adoption of ASU 2020-06          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity       40,612  
Retained Earnings | Cumulative effect of adoption of ASU 2020-06 | Accounting Standards Update 2020-06          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity     40,600    
Additional  Paid-in Capital          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity $ 383,016 $ 415,950   434,337 $ 409,332
Additional  Paid-in Capital | Cumulative effect of adoption of ASU 2020-06          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity       $ (56,212)  
Additional  Paid-in Capital | Cumulative effect of adoption of ASU 2020-06 | Accounting Standards Update 2020-06          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Stockholders' equity     $ (56,200)    
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Acquisition - Narrative (Details)
Nov. 24, 2021
USD ($)
marketProduct
$ / shares
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Business Acquisition [Line Items]      
Contingent consideration   $ 56,142,000 $ 80,477,000
Adamas Pharmaceuticals      
Business Acquisition [Line Items]      
Number of established marketed products | marketProduct 2    
Adamas Pharmaceuticals      
Business Acquisition [Line Items]      
Cash consideration paid $ 400,806,000    
Rights per share (in dollars per share) | $ / shares $ 0.50    
Additional cash payments upon milestone achievements minimum $ 150,000,000    
Additional cash payments upon milestone achievements maximum 225,000,000    
Contingent consideration 10,300,000    
Additional cash payments upon milestone achievements minimum 0    
Additional cash payments upon milestone achievements maximum $ 50,900,000    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
 3 Months Ended
Nov. 24, 2021
Jun. 09, 2020
Mar. 31, 2022
Dec. 31, 2021
Business Acquisition [Line Items]        
Goodwill     $ 115,414 $ 117,516
Goodwill     (2,102)  
Fair value of contingent consideration   $ 230,000    
Property and equipment, net     17,215 $ 16,955
Adamas Pharmaceuticals        
Business Acquisition [Line Items]        
Cash and cash equivalents $ 90,064      
Accounts receivable 11,156      
Inventories 20,200      
Prepaid expenses and other current assets 5,077      
Property and equipment 1,254      
Intangibles 450,100      
Other assets (1,620)   $ (1,600)  
Deferred income tax liabilities 3,722      
Other assets 4,822      
Total fair value of assets acquired 582,673      
Accounts payable (4,592)      
Accrued expenses and other current liabilities (8,014)      
Current debt (138,315)      
Operating lease liabilities, long-term (5,224)      
Deferred income tax liabilities (52,866)      
Total fair value of liabilities assumed (209,011)      
Total identifiable net assets 2,102      
Total identifiable net assets 373,662      
Goodwill 37,451      
Goodwill (2,102)      
Total purchase price 411,113      
Cash consideration paid 400,806      
Fair value of contingent consideration 10,307      
Total purchase price 411,113      
Adamas Pharmaceuticals | As Initially Reported        
Business Acquisition [Line Items]        
Cash and cash equivalents 90,064      
Accounts receivable 11,156      
Inventories 20,200      
Prepaid expenses and other current assets 5,077      
Property and equipment 1,254      
Intangibles 450,100      
Other assets 6,442      
Total fair value of assets acquired 584,293      
Accounts payable (4,592)      
Accrued expenses and other current liabilities (8,014)      
Current debt (138,315)      
Operating lease liabilities, long-term (5,224)      
Deferred income tax liabilities (56,588)      
Total fair value of liabilities assumed (212,733)      
Total identifiable net assets 371,560      
Goodwill 39,553      
Total purchase price 411,113      
Cash consideration paid 400,806      
Fair value of contingent consideration 10,307      
Total purchase price $ 411,113      
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) - Adamas Pharmaceuticals
$ in Thousands
Nov. 24, 2021
USD ($)
Business Acquisition [Line Items]  
Intangibles $ 450,100
Acquired developed technology and product rights  
Business Acquisition [Line Items]  
Intangibles $ 450,100
Acquired developed technology and product rights | Minimum  
Business Acquisition [Line Items]  
Estimated Useful Life as of Closing Date (in years) 3 years 1 month 6 days
Acquired developed technology and product rights | Maximum  
Business Acquisition [Line Items]  
Estimated Useful Life as of Closing Date (in years) 8 years 1 month 6 days
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Acquisition - Pro Forma Information (Details) - Adamas Pharmaceuticals
$ in Thousands
 3 Months Ended
Mar. 31, 2021
USD ($)
Business Acquisition [Line Items]  
Pro forma total revenues $ 150,243
Pro forma net loss $ (20,484)
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Disaggregated Revenues - Summary of Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Total revenues $ 152,506 $ 130,932
Net product sales    
Disaggregation of Revenue [Line Items]    
Total revenues 147,464 128,381
Trokendi XR    
Disaggregation of Revenue [Line Items]    
Total revenues 62,832 71,819
Oxtellar XR    
Disaggregation of Revenue [Line Items]    
Total revenues 27,521 27,370
GOCOVRI    
Disaggregation of Revenue [Line Items]    
Total revenues 22,601 0
APOKYN    
Disaggregation of Revenue [Line Items]    
Total revenues 18,448 21,730
Qelbree    
Disaggregation of Revenue [Line Items]    
Total revenues 8,283 0
Other    
Disaggregation of Revenue [Line Items]    
Total revenues 7,779 7,462
Royalty revenues    
Disaggregation of Revenue [Line Items]    
Total revenues $ 5,042 $ 2,551
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Disaggregated Revenues - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue Recognition    
Non-cash royalty revenue $ 2.2 $ 2.2
Revenue from Contract with Customer Benchmark | Product Concentration Risk | Trokendi XR    
Revenue Recognition    
Concentration risk percentage (more than) 43.00% 56.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | AmerisourceBergen Drug Corporation    
Revenue Recognition    
Concentration risk percentage (more than) 20.00% 25.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Cardinal Health    
Revenue Recognition    
Concentration risk percentage (more than) 20.00% 25.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | McKesson    
Revenue Recognition    
Concentration risk percentage (more than) 20.00% 25.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Three Major Customers    
Revenue Recognition    
Concentration risk percentage (more than) 75.00% 85.00%
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Investments - Unrestricted Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Amortized cost $ 322,797 $ 253,301
Gross unrealized gains 497 2,349
Gross unrealized losses (1,472) (238)
Total fair value $ 321,822 $ 255,412
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Investments - Contractual Maturities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Less than 1 year $ 196,485  
1 year to 2 years 111,584  
2 years to 3 years 13,753  
3 years to 4 years 0  
Greater than 4 years 0  
Total $ 321,822 $ 255,412
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Investments - Narrative (Details) - USD ($)
 1 Months Ended
Dec. 31, 2021
Apr. 30, 2020
Mar. 31, 2022
Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]        
Impairment due to credit losses     $ 0  
Variable Interest Entity [Line Items]        
Cash distributions received $ 12,900,000      
Navitor Pharmaceuticals, Inc. | Variable Interest Entity, Not Primary Beneficiary        
Variable Interest Entity [Line Items]        
Agreement termination notice period   30 days    
Threshold for development costs payments   $ 50,000,000    
Investments   $ 15,000,000   $ 15,000,000
VIE, qualitative or quantitative information, ownership percentage   13.00%    
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Measurements - Narrative (Details) - USD ($)
Mar. 31, 2022
Jan. 01, 2022
Dec. 31, 2021
Accounting Standards Update 2020-06      
Fair value of financial instruments      
Long-term Debt   $ 20,600,000  
Recurring      
Fair value of financial instruments      
Total assets at fair value $ 438,107,000   $ 459,476,000
Recurring | Level 3      
Fair value of financial instruments      
Total assets at fair value $ 0   $ 0
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Measurements - Carrying Value (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Liabilities:    
Contingent consideration $ 56,142,000 $ 80,477,000
Recurring    
Other assets    
Marketable securities - restricted (SERP) 570,000 630,000
Total assets at fair value 438,107,000 459,476,000
Liabilities:    
Contingent consideration 56,142,000 80,477,000
Total liabilities at fair value 56,142,000 80,477,000
Recurring | Corporate and municipal debt securities    
Marketable securities    
Corporate and municipal debt securities 196,485,000 136,246,000
Long-term marketable securities    
Corporate and municipal debt securities 125,337,000 119,166,000
Recurring | Cash    
Cash and cash equivalents    
Cash and Money market funds 84,218,000 148,863,000
Recurring | Money market securities and funds    
Cash and cash equivalents    
Cash and Money market funds 31,497,000 54,571,000
Recurring | Level 1    
Other assets    
Marketable securities - restricted (SERP) 8,000 7,000
Total assets at fair value 85,728,000 203,692,000
Liabilities:    
Contingent consideration 0 0
Total liabilities at fair value 0 0
Recurring | Level 1 | Corporate and municipal debt securities    
Marketable securities    
Corporate and municipal debt securities 0 251,000
Long-term marketable securities    
Corporate and municipal debt securities 0 0
Recurring | Level 1 | Cash    
Cash and cash equivalents    
Cash and Money market funds 84,218,000 148,863,000
Recurring | Level 1 | Money market securities and funds    
Cash and cash equivalents    
Cash and Money market funds 1,502,000 54,571,000
Recurring | Level 2    
Other assets    
Marketable securities - restricted (SERP) 562,000 623,000
Total assets at fair value 352,379,000 255,784,000
Liabilities:    
Contingent consideration 0 0
Total liabilities at fair value 0 0
Recurring | Level 2 | Corporate and municipal debt securities    
Marketable securities    
Corporate and municipal debt securities 196,485,000 135,995,000
Long-term marketable securities    
Corporate and municipal debt securities 125,337,000 119,166,000
Recurring | Level 2 | Cash    
Cash and cash equivalents    
Cash and Money market funds 0 0
Recurring | Level 2 | Money market securities and funds    
Cash and cash equivalents    
Cash and Money market funds 29,995,000 0
Recurring | Level 3    
Other assets    
Marketable securities - restricted (SERP) 0 0
Total assets at fair value 0 0
Liabilities:    
Contingent consideration 56,142,000 80,477,000
Total liabilities at fair value 56,142,000 80,477,000
Recurring | Level 3 | Corporate and municipal debt securities    
Marketable securities    
Corporate and municipal debt securities 0 0
Long-term marketable securities    
Corporate and municipal debt securities 0 0
Recurring | Level 3 | Cash    
Cash and cash equivalents    
Cash and Money market funds 0 0
Recurring | Level 3 | Money market securities and funds    
Cash and cash equivalents    
Cash and Money market funds $ 0 $ 0
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Measurements - Financial Instruments (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Fair value of financial instruments    
Carrying Value $ 400,382 $ 379,252
Convertible Notes | Level 2    
Fair value of financial instruments    
Carrying Value 400,382 379,252
Fair Value (Level 2) $ 395,456 $ 400,236
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Contingent Consideration - Narrative (Details)
$ in Thousands
 3 Months Ended
Jun. 09, 2020
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Nov. 24, 2021
right
Business Acquisition [Line Items]        
Fair value of contingent consideration $ 230,000      
Contingent consideration   $ 665 $ 1,020  
Payment of contingent consideration   22,900 $ 0  
SPN-30 Regulatory and Commercial Activities        
Business Acquisition [Line Items]        
Fair value of contingent consideration 130,000      
SPN-830 FDA Acceptance Milestone        
Business Acquisition [Line Items]        
Fair value of contingent consideration 25,000      
SPN-830 NDA Approval Milestone        
Business Acquisition [Line Items]        
Fair value of contingent consideration 105,000      
SPN-830 First Commercial And Sale Milestone        
Business Acquisition [Line Items]        
Fair value of contingent consideration 100,000      
Future Sales Performance        
Business Acquisition [Line Items]        
Fair value of contingent consideration 100,000      
APOKYN        
Business Acquisition [Line Items]        
Fair value of contingent consideration 35,000      
APOKYN and SPN-830        
Business Acquisition [Line Items]        
Fair value of contingent consideration $ 65,000      
USWM Acquisition        
Business Acquisition [Line Items]        
Contingents value rights | right       2
Contingent consideration   $ 700    
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at December 31, 2021 $ 80,477  
Milestone payments (25,000)  
Change in fair value recognized in earnings 665  
Balance at March 31, 2022 (unaudited) 56,142  
Contingent consideration, current portion 46,890 $ 44,840
Contingent consideration, long-term 9,252 35,637
Contingent consideration 56,142 $ 80,477
Regulatory and developmental contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 46,890  
Sales-based contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 9,252  
USWM Acquisition    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at December 31, 2021 70,170  
Milestone payments (25,000)  
Change in fair value recognized in earnings 1,720  
Balance at March 31, 2022 (unaudited) 46,890  
Contingent consideration 46,890  
USWM Acquisition | Regulatory and developmental contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 46,890  
USWM Acquisition | Sales-based contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 0  
Adamas Acquisition    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at December 31, 2021 10,307  
Milestone payments 0  
Change in fair value recognized in earnings (1,055)  
Balance at March 31, 2022 (unaudited) 9,252  
Contingent consideration 9,252  
Adamas Acquisition | Regulatory and developmental contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 0  
Adamas Acquisition | Sales-based contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration $ 9,252  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
USD ($)
Goodwill [Roll Forward]  
Balance as of December 31, 2021 $ 117,516
Goodwill (2,102)
Balance as of March 31, 2022 (unaudited) $ 115,414
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 8 years 4 months 24 days  
Accumulated Amortization $ (84,871) $ (64,227)
Total intangible assets, carrying amount, gross 848,920 848,920
Intangible assets, net 764,049 784,693
Acquired in-process research and development    
Indefinite-lived Intangible Assets [Line Items]    
Acquired in-process research and development $ 124,000 124,000
Acquired developed technology and product rights    
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 8 years 5 months 26 days  
Carrying Amount, Gross $ 681,100 681,100
Accumulated Amortization (54,913) (35,550)
Carrying Amount, Net $ 626,187 645,550
Capitalized patent defense costs    
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 4 years 4 months 13 days  
Carrying Amount, Gross $ 43,820 43,820
Accumulated Amortization (29,958) (28,677)
Carrying Amount, Net $ 13,862 $ 15,143
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets, Net - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible assets $ 20,644 $ 6,007
2023 79,800  
2024 79,800  
2025 75,000  
2026 75,000  
2027 $ 73,200  
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Senior Notes Due 2023 - Narrative (Details)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
day
$ / shares
Rate
shares
Dec. 31, 2021
USD ($)
Jan. 01, 2022
USD ($)
Notes payable      
Strike price of the warrant transactions (in dollars per share) | $ / shares $ 80.91    
Accounting Standards Update 2020-06      
Notes payable      
Long-term Debt | $     $ 20,600,000
Convertible Debt      
Notes payable      
Interest rate 0.625%    
Principal amount of debt | $ $ 402,500,000 $ 402,500,000  
Conversion rate for the notes (in shares per $1,000 principal amount) 0.0168545    
Conversion price, per share of common stock (in dollars per share) | $ / shares $ 59.33    
Warrants issued (in shares) | shares 6,783,939    
Number of shares per warrant entitled to holder (in shares) | shares 1    
Conversion of debt to equity | $ $ 0 $ 0  
Convertible note hedge options issued (in shares) | shares 402,500    
Convertible Debt | Conversion Circumstance One      
Notes payable      
Threshold trading days (whether or not consecutive) 20    
Consecutive trading day period (in days) 30    
Conversion rate of the notes on trading day (as percent) 130.00%    
Conversion option stock price trigger (in dollars per share) | $ / shares $ 77.13    
Convertible Debt | Conversion Circumstance Two      
Notes payable      
Threshold trading days (whether or not consecutive) 5    
Consecutive trading day period (in days) 10    
Conversion rate of the notes on trading day (as percent) | Rate 98.00%    
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Total carrying value $ 400,382,000 $ 379,252,000
Convertible Debt    
Debt Instrument [Line Items]    
2023 Notes 402,500,000 402,500,000
Unamortized debt discount and deferred financing costs (2,118,000) (23,248,000)
Total carrying value 400,382,000 379,252,000
Convertible Notes | Level 2    
Debt Instrument [Line Items]    
Total carrying value 400,382,000 379,252,000
Fair Value (Level 2) $ 395,456,000 $ 400,236,000
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Payments - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-based payments    
Total $ 4,025 $ 4,371
Research and development    
Share-based payments    
Total 651 588
Selling, general and administrative    
Share-based payments    
Total $ 3,374 $ 3,783
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Payments - SAR Activity (Details) - Stock option and Stock Appreciation Rights - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Number of Options    
Outstanding at the beginning of the period (in shares) 5,774,076  
Granted (in shares) 929,785  
Exercised (in shares) (47,601)  
Forfeited (in shares) (48,036)  
Outstanding at the end of the period (in shares) 6,608,224 5,774,076
Exercisable (in shares) 4,280,012 3,651,824
Vested and expected to vest (in shares) 6,608,224 5,774,076
Weighted Average Exercise Price    
Outstanding at the beginning of the period (in dollars per share) $ 24.15  
Granted (in dollars per share) 32.20  
Exercised (in dollars per share) 18.21  
Forfeited (in dollars per share) 30.84  
Outstanding at the end of the period (in dollars per share) 25.28 $ 24.15
Exercisable (in dollars per share) 22.87 21.29
Vested and expected to vest (in dollars per share) $ 25.28 $ 24.15
Weighted Average Remaining Contractual Term (in years)    
Outstanding at the end of the period 6 years 3 months 5 years 11 months 12 days
Vested and expected to vest 6 years 3 months 5 years 11 months 12 days
Exercisable 4 years 9 months 14 days 4 years 6 months 10 days
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Payments - Restricted Stock Units (Details) - RSUs
 3 Months Ended
Mar. 31, 2022
$ / shares
shares
Number of RSUs  
Nonvested, beginning balance (in shares) | shares 21,110
Granted (in shares) | shares 131,210
Vested (in shares) | shares (21,110)
Forfeited (in shares) | shares 0
Nonvested, ending balance (in shares) | shares 131,210
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 29.61
Granted (in dollars per share) | $ / shares 32.20
Vested (in dollars per share) | $ / shares 29.61
Forfeited (in dollars per share) | $ / shares 0
Nonvested, ending balance (in dollars per share) | $ / shares $ 32.20
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Payments - Performance Stock Units (Details)
 3 Months Ended
Mar. 31, 2022
$ / shares
shares
Total PSUs  
Number of PSUs  
Nonvested, beginning balance (in shares) 89,125
Nonvested, ending balance (in shares) 67,625
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 28.43
Vested (in shares) (21,500)
Weighted average fair value, grant date, (in dollars per share) | $ / shares $ 29.67
Nonvested, ending balance (in dollars per share) | $ / shares $ 28.04
Forfeited (in shares) 0
Performance-Based Units  
Number of PSUs  
Nonvested, beginning balance (in shares) 53,500
Nonvested, ending balance (in shares) 32,000
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 29.82
Vested (in shares) (21,500)
Weighted average fair value, grant date, (in dollars per share) | $ / shares $ 29.67
Nonvested, ending balance (in dollars per share) | $ / shares $ 29.92
Market-Based Units  
Number of PSUs  
Nonvested, beginning balance (in shares) 35,625
Nonvested, ending balance (in shares) 35,625
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 26.34
Vested (in shares) 0
Weighted average fair value, grant date, (in dollars per share) | $ / shares
Nonvested, ending balance (in dollars per share) | $ / shares $ 26.34
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income per share    
Strike price of the warrant transactions (in dollars per share) $ 80.91  
Numerator:    
Net earnings $ 25,616 $ 5,694
After-tax interest expense for 2023 Notes 887 0
Numerator for dilutive earnings per share $ 26,503 $ 5,694
Denominator:    
Weighted average shares outstanding, basic (in shares) 53,330,837 52,927,467
Effect of dilutive securities:    
Stock options, RSU and SAR (in shares) 1,291,782 1,269,504
Convertible notes 6,783,936 0
Weighted average shares outstanding, diluted (in shares) 61,406,555 54,196,971
Earnings per share, basic (in dollars per share) $ 0.48 $ 0.11
Earnings per share, diluted (in dollars per share) $ 0.43 $ 0.11
Stock options, RSUs    
Income per share    
Common stock equivalents excluded in the calculation of diluted income per share (in shares) 1,067,231 1,419,203
Convertible Debt    
Income per share    
Conversion price, per share of common stock (in dollars per share) $ 59.33  
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.1
Income Tax (Benefit) Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Tax Disclosure [Abstract]    
Income tax (benefit) expense $ (10,893) $ 5,235
Effective tax rate (74.00%) 47.90%
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Narrative (Details)
$ in Thousands
 3 Months Ended
Nov. 24, 2021
USD ($)
renewalOption
Mar. 31, 2022
USD ($)
Feb. 01, 2019
Leases [Abstract]      
Optional lease renewal term (in years) 5 years   10 years
Number of renewal options | renewalOption 1    
Adamas Pharmaceuticals      
Leases      
Change in fair value of operating lease acquired | $ $ (1,620) $ (1,600)  
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Leases Balance Sheet Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Assets    
Operating lease assets $ 32,141 $ 35,365
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Other assets Other assets
Lease liabilities, current    
Operating lease liabilities, current portion $ 6,141 $ 6,477
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Lease liabilities, long-term    
Operating lease liabilities, long-term $ 39,891 $ 41,298
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating lease liabilities, long-term Operating lease liabilities, long-term
Total lease liabilities $ 46,032 $ 47,775
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items - Accounts Receivables (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Allowance for expected sales discounts and allowances $ 11.4 $ 13.5
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items - Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Raw materials $ 9,239 $ 7,325
Work in process 46,219 45,711
Finished goods 33,337 32,923
Total inventories $ 88,795 $ 85,959
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items - Property and Equipment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Property and equipment      
Property and equipment, gross $ 29,696   $ 33,409
Less accumulated depreciation and amortization (12,481)   (16,454)
Property and equipment, net 17,215   16,955
Depreciation and amortization expense 700 $ 600  
Lab equipment and furniture      
Property and equipment      
Property and equipment, gross 12,199   12,287
Leasehold improvements      
Property and equipment      
Property and equipment, gross 13,998   14,369
Software      
Property and equipment      
Property and equipment, gross 2,185   4,776
Computer equipment      
Property and equipment      
Property and equipment, gross 1,282   1,944
Construction in Progress      
Property and equipment      
Property and equipment, gross $ 32   $ 33
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts payable $ 12,323 $ 9,331
Accrued professional fees 16,209 26,728
Accrued compensation 14,555 28,068
Accrued product costs 12,727 18,460
Accrued royalties 11,044 13,821
Accrued clinical trial costs 7,784 9,125
Operating lease liabilities, current portion 6,141 6,477
Other accrued expenses 8,649 5,673
Total $ 89,432 $ 117,683
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items - Accrued Product Returns and Rebates (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued product rebates $ 104,948 $ 97,597
Accrued product returns 35,233 35,127
Total $ 140,181 $ 132,724
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.22.1
Composition of Balance Sheet Items - Other Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Nonrecourse liability related to sale of future royalties, long-term $ 3,784 $ 5,977
Other liabilities 10,361 10,403
Total $ 14,145 $ 16,380
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.22.1
Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Other Income and Expenses [Abstract]    
Interest expense $ (1,155) $ (5,062)
Interest expense on nonrecourse liability related to sale of future royalties (787) (1,035)
Total 1,942 6,097
Amortization of deferred financing costs and debt discount $ 526 $ 4,287
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
Apr. 01, 2019
Mar. 31, 2019
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2014
Long-term Purchase Commitment [Line Items]          
Nonrecourse liability related to sale of future royalties, long term         $ 30.0
NAMENDA XR/Namzaric Qui Tam Litigation          
Long-term Purchase Commitment [Line Items]          
Loss contingency, damages sought, value $ 2,500.0        
USWM Acquisition          
Long-term Purchase Commitment [Line Items]          
Annual minimum purchase quantity requirement amount       $ 3.9  
Commitment period     5 years    
Spend commitment amount     $ 0.0    
Payment to resolve U.S. Department of Justice allegations   $ 17.5      
XML 87 supn-20220331_htm.xml IDEA: XBRL DOCUMENT 0001356576 2022-01-01 2022-03-31 0001356576 2022-05-02 0001356576 2022-03-31 0001356576 2021-12-31 0001356576 us-gaap:ProductMember 2022-01-01 2022-03-31 0001356576 us-gaap:ProductMember 2021-01-01 2021-03-31 0001356576 us-gaap:RoyaltyMember 2022-01-01 2022-03-31 0001356576 us-gaap:RoyaltyMember 2021-01-01 2021-03-31 0001356576 2021-01-01 2021-03-31 0001356576 us-gaap:CommonStockMember 2021-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001356576 us-gaap:RetainedEarningsMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:CommonStockMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2021-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001356576 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001356576 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001356576 us-gaap:CommonStockMember 2022-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001356576 us-gaap:RetainedEarningsMember 2022-03-31 0001356576 us-gaap:CommonStockMember 2020-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001356576 us-gaap:RetainedEarningsMember 2020-12-31 0001356576 2020-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001356576 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001356576 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001356576 us-gaap:CommonStockMember 2021-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001356576 us-gaap:RetainedEarningsMember 2021-03-31 0001356576 2021-03-31 0001356576 us-gaap:AccountingStandardsUpdate202006Member 2022-01-01 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member us-gaap:RetainedEarningsMember 2022-01-01 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member us-gaap:AdditionalPaidInCapitalMember 2022-01-01 0001356576 us-gaap:AccountingStandardsUpdate202006Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001356576 supn:AdamasPharmaceuticalsMember 2021-11-24 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember 2021-11-24 2021-11-24 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember 2021-11-24 0001356576 srt:ScenarioPreviouslyReportedMember supn:AdamasPharmaceuticalsMember 2021-11-24 0001356576 srt:ScenarioPreviouslyReportedMember supn:AdamasPharmaceuticalsMember 2021-11-24 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember us-gaap:DevelopedTechnologyRightsMember 2021-11-24 0001356576 srt:MinimumMember supn:AdamasPharmaceuticalsMember us-gaap:DevelopedTechnologyRightsMember 2021-11-24 2021-11-24 0001356576 srt:MaximumMember supn:AdamasPharmaceuticalsMember us-gaap:DevelopedTechnologyRightsMember 2021-11-24 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember 2021-01-01 2021-03-31 0001356576 supn:TrokendiXrMember 2022-01-01 2022-03-31 0001356576 supn:TrokendiXrMember 2021-01-01 2021-03-31 0001356576 supn:OxtellarXRMember 2022-01-01 2022-03-31 0001356576 supn:OxtellarXRMember 2021-01-01 2021-03-31 0001356576 supn:GOCOVRIMember 2022-01-01 2022-03-31 0001356576 supn:GOCOVRIMember 2021-01-01 2021-03-31 0001356576 supn:APOKYNMember 2022-01-01 2022-03-31 0001356576 supn:APOKYNMember 2021-01-01 2021-03-31 0001356576 supn:QelbreeMember 2022-01-01 2022-03-31 0001356576 supn:QelbreeMember 2021-01-01 2021-03-31 0001356576 us-gaap:ManufacturedProductOtherMember 2022-01-01 2022-03-31 0001356576 us-gaap:ManufacturedProductOtherMember 2021-01-01 2021-03-31 0001356576 supn:TrokendiXrMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001356576 supn:TrokendiXrMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001356576 supn:CardinalHealthMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001356576 supn:McKessonMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001356576 supn:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001356576 supn:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001356576 supn:McKessonMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001356576 supn:CardinalHealthMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001356576 supn:ThreeMajorCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001356576 supn:ThreeMajorCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001356576 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember supn:NavitorPharmaceuticalsIncMember 2020-04-01 2020-04-30 0001356576 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember supn:NavitorPharmaceuticalsIncMember 2020-04-30 0001356576 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember supn:NavitorPharmaceuticalsIncMember 2021-03-31 0001356576 2021-12-01 2021-12-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001356576 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleNotesPayableMember 2022-03-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001356576 2020-06-09 2020-06-09 0001356576 supn:SPN830RegulatoryAndCommercialActivitiesMember 2020-06-09 2020-06-09 0001356576 supn:SPN830FutureSalesPerformanceMember 2020-06-09 2020-06-09 0001356576 supn:SPN830FDAAcceptanceMilestoneMember 2020-06-09 2020-06-09 0001356576 supn:SPN830NDAApprovalMilestoneMember 2020-06-09 2020-06-09 0001356576 supn:SPN830FirstCommercialAndSaleMember 2020-06-09 2020-06-09 0001356576 supn:APOKYNMember 2020-06-09 2020-06-09 0001356576 supn:APOKYNAndSPN830Member 2020-06-09 2020-06-09 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2022-01-01 2022-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2021-12-31 0001356576 supn:AdamasMember 2021-12-31 0001356576 supn:AdamasMember 2022-01-01 2022-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2022-03-31 0001356576 supn:AdamasMember 2022-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember 2022-03-31 0001356576 supn:AdamasMember supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember 2022-03-31 0001356576 supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember 2022-03-31 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember supn:SalesBasedContingentConsiderationLiabilityMember 2022-03-31 0001356576 supn:AdamasMember supn:SalesBasedContingentConsiderationLiabilityMember 2022-03-31 0001356576 supn:SalesBasedContingentConsiderationLiabilityMember 2022-03-31 0001356576 us-gaap:InProcessResearchAndDevelopmentMember 2022-03-31 0001356576 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001356576 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-03-31 0001356576 us-gaap:DevelopedTechnologyRightsMember 2022-03-31 0001356576 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001356576 supn:PatentDefenseCostsMember 2022-01-01 2022-03-31 0001356576 supn:PatentDefenseCostsMember 2022-03-31 0001356576 supn:PatentDefenseCostsMember 2021-12-31 0001356576 us-gaap:ConvertibleDebtMember 2022-03-31 0001356576 supn:ConversionCircumstanceOneMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001356576 supn:ConversionCircumstanceTwoMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001356576 us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001356576 us-gaap:ConvertibleDebtMember 2021-12-31 0001356576 us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2021-12-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2021-01-01 2021-12-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2022-01-01 2022-03-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2022-03-31 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001356576 supn:PerformanceBasedUnitsMember 2021-12-31 0001356576 supn:MarketBasedUnitsMember 2021-12-31 0001356576 us-gaap:PerformanceSharesMember 2021-12-31 0001356576 supn:PerformanceBasedUnitsMember 2022-01-01 2022-03-31 0001356576 supn:MarketBasedUnitsMember 2022-01-01 2022-03-31 0001356576 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0001356576 supn:PerformanceBasedUnitsMember 2022-03-31 0001356576 supn:MarketBasedUnitsMember 2022-03-31 0001356576 us-gaap:PerformanceSharesMember 2022-03-31 0001356576 us-gaap:StockCompensationPlanMember 2022-01-01 2022-03-31 0001356576 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001356576 2019-02-01 0001356576 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember 2022-01-01 2022-03-31 0001356576 supn:LabEquipmentAndFurnitureMember 2022-03-31 0001356576 supn:LabEquipmentAndFurnitureMember 2021-12-31 0001356576 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001356576 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001356576 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-03-31 0001356576 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-12-31 0001356576 us-gaap:ComputerEquipmentMember 2022-03-31 0001356576 us-gaap:ComputerEquipmentMember 2021-12-31 0001356576 us-gaap:ConstructionInProgressMember 2022-03-31 0001356576 us-gaap:ConstructionInProgressMember 2021-12-31 0001356576 2014-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2019-03-01 2019-03-31 0001356576 supn:NAMENDAXRNamzaricQuiTamLitigationMember 2019-04-01 2019-04-01 shares iso4217:USD iso4217:USD shares supn:segment supn:marketProduct supn:right pure supn:day utr:Rate supn:renewalOption 0001356576 false --12-31 2022 Q1 http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member 0.0168545 http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent 10-Q true 2022-03-31 false 001-35518 SUPERNUS PHARMACEUTICALS, INC. DE 20-2590184 9715 Key West Avenue Rockville MD 20850 301 838-2500 Yes Yes Large Accelerated Filer false false false Common Stock, $0.001 par value per share 53413211 SUPN NASDAQ 115715000 203434000 196485000 136246000 145149000 148932000 88795000 85959000 22372000 27019000 568516000 601590000 125337000 119166000 17215000 16955000 764049000 784693000 115414000 117516000 48986000 49232000 1639517000 1689152000 89432000 117683000 140181000 132724000 46890000 44840000 8055000 20132000 284558000 315379000 400382000 379252000 9252000 35637000 39891000 41298000 62843000 85355000 14145000 16380000 811071000 873301000 0.001 0.001 130000000 130000000 53386305 53386305 53256094 53256094 53000 53000 383016000 434337000 -773000 1539000 446150000 379922000 828446000 815851000 1639517000 1689152000 147464000 128381000 5042000 2551000 152506000 130932000 17932000 14954000 20839000 34280000 90459000 61457000 20644000 6007000 665000 1020000 150539000 117718000 1967000 13214000 1942000 6097000 14698000 3812000 12756000 -2285000 14723000 10929000 -10893000 5235000 25616000 5694000 0.48 0.11 0.43 0.11 53330837 52927467 61406555 54196971 25616000 5694000 -2312000 -2726000 -2312000 -2726000 23304000 2968000 53256094 53000 434337000 1539000 379922000 815851000 -56212000 40612000 -15600000 53256094 53000 378125000 1539000 420534000 800251000 4025000 4025000 130211 866000 866000 25616000 25616000 -2312000 -2312000 53386305 53000 383016000 -773000 446150000 828446000 52868482 53000 409332000 8975000 326498000 744858000 4371000 4371000 125655 2247000 2247000 5694000 5694000 -2726000 -2726000 52994137 53000 415950000 6249000 332192000 754444000 25616000 5694000 21362000 6592000 0 15000000 12888000 0 526000 4287000 0 216000 360000 1706000 -665000 -1020000 -84000 1202000 4025000 4371000 -13011000 -2565000 -3812000 -13805000 2468000 1048000 -1061000 368000 7457000 2544000 -29479000 -10008000 2100000 0 4302000 36200000 98063000 119063000 28927000 49579000 851000 1961000 -69987000 -71445000 22900000 0 866000 2247000 -22034000 2247000 -87719000 -32998000 203434000 288640000 115715000 255642000 1258000 1258000 478000 301000 2949000 1834000 27000 1432000 0 160000 549000 0 Business Organization<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Products</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company is expecting to launch Qelbree for adult patients by the end of May 2022.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">GOCOVRI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">OSMOLEX ER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amantadine) extended-release tablets is for the treatment of PD and drug-induced extrapyramidal reactions in adult patients.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The Company's product candidates in clinical development include the following: </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. In February 2022, the FDA acknowledged that it received the new drug application (NDA) resubmission for SPN-830 (apomorphine infusion device) for the continuous treatment of motor fluctuations ("off" episodes) in PD. The NDA has a PDUFA date of October 7, 2022.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-820 (NV-5138) is a first-in-class product candidate for treatment-resistant depression, currently in Phase II development. It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-817 (huperzine A) is a novel product candidate for treatment-resistant seizures, currently in Phase I development. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adamas Acquisition and Reorganization</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021, the Purchaser was merged with and into Adamas (Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (Adamas Acquisition). Adamas holds and markets two established commercial products in its portfolio, GOCOVRI and Osmolex ER, and has royalty rights to Namzaric</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Allergan plc markets and sells Namzaric in the U.S.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The legal entities reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">COVID-19 Impact</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of March 31, 2022. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.</span></div> Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, which is primarily located in the U.S., operates in one operating segment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the valuation of the assets acquired and liabilities assumed in the Adamas Acquisition, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $23.9 million and $15.3 million in advertising expense for the three months ended March 31, 2022 and 2021, respectively. These expenses are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of earnings.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Adopted</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific US GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in October 2021, amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as if the acquiree had </span></div>initially applied recognition and measurement in their financial statements. This guidance is effective for fiscal years beginning after December 15, 2022 on a prospective basis. Early adoption is permitted. <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, which is primarily located in the U.S., operates in one operating segment.</span></div> 1 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the valuation of the assets acquired and liabilities assumed in the Adamas Acquisition, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $23.9 million and $15.3 million in advertising expense for the three months ended March 31, 2022 and 2021, respectively. These expenses are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of earnings.</span></div> 23900000 15300000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Adopted</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific US GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in October 2021, amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as if the acquiree had </span></div>initially applied recognition and measurement in their financial statements. This guidance is effective for fiscal years beginning after December 15, 2022 on a prospective basis. Early adoption is permitted. 20600000 40600000 -56200000 -5000000 6800000 Acquisition<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adamas Acquisition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas Pharmaceuticals, Inc., a publicly-held pharmaceutical company (Adamas), pursuant to the Adamas Agreement dated October 10, 2021. On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only U.S. FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and OSMOLEX ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid the Adamas shareholders $400.8 million and transferred two non-tradable contingent value rights (CVRs). Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer &amp; Trust Company, LLC, as rights agent, (CVR Agreement). One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the two CVRs, the Company recorded contingent consideration liabilities of $10.3 million as of the date of the acquisition, to reflect the estimated fair value of the contingent consideration. The estimated fair value of the liabilities were determined using Monte Carlo simulations. The fair value measurement of the contingent consideration liabilities were determined based on significant unobservable inputs and thus represents a Level 3 fair value measurement. The key assumptions considered include the estimated amount and timing of projected cash flows, volatility, estimated discount rates and risk-free interest rate. In each reporting period after the acquisition, the Company will revalue the contingent consideration liabilities and will record increases or decreases in the fair value of the liabilities in its consolidated statements of earnings. Changes in fair value will result from changes in actual and projected milestone achievement, as well as changes to forecasts. The inputs and assumptions may not be observable in the market, but they reflect the assumptions the Company believes would be made by a market participant. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as a business combination under the acquisition method of accounting, in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The estimated fair values of the assets acquired and liabilities assumed, including goodwill, have been included in the Company's consolidated financial statements since the acquisition Closing Date. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounting for the Adamas Acquisition is preliminary and fair value estimates for the assets acquired and liabilities assumed and the Company's estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period. During the measurement period, if the Company obtains new information regarding facts and circumstances that existed as of the Closing Date that, if known, would have resulted in revised estimated values of those assets or liabilities, the Company will accordingly revise its estimates of fair values and purchase price allocation. The effect of measurement period adjustments on the estimated fair value elements will be reflected as if the adjustments had been made as of the Closing Date. The impact of all changes that do not qualify as measurement period adjustments will be included in current period earnings.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to finalize its purchase price allocation within one year of the Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record at fair value the assets acquired and liabilities assumed in the following areas: intangible assets, lease assets and liabilities, tax assets and liabilities, and certain existing or potential reserves, including those for legal or contract-related matters. The activities the Company is currently undertaking include, but are not limited to, the following: review of acquired contracts and other contract-related and legal matters; review and evaluation of the accounting policies, tax positions, and other tax-related matters. Further, </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company continues to obtain input from third party valuation firms with respect to the fair value of the acquired tangible and intangible assets, and other information necessary to record and measure the assets acquired and liabilities assumed. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Closing Date are subject to change.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Initially Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,293 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,673 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of liabilities assumed</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,733)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209,011)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,102)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Measurement period adjustments reflect changes based on information related to the facts and circumstances that existed as of the acquisition date. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents tax impact of the changes in the initial estimate of the fair value of the right of use asset and changes made to update certain state tax attributes which existed at the opening balance sheet date.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Inventory</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the inventory was determined using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or dispose of the inventory, as well as a profit on the sale.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangible Assets</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets include the acquired developed technology and product rights to GOCOVRI and OSMOLEX ER, as well as the right to receive royalties from Allergan plc for sales of Namzaric. The Company determined the estimated fair values for the acquired intangible assets as of the Closing Date using the income approach. This is a valuation technique that provides an estimate of fair value of the assets, based on the market participant's expectations of the cash flows that the assets are forecasted to generate. The cash flows were discounted at a rate commensurate with the level of risk associated with </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its projected cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the acquired intangible assets were determined based on significant unobservable inputs and thus represent Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the intangible assets valuation includes: the estimated future cash flows from product sales, the timing and projection of costs and expenses, discount rates and tax rates. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets consist of developed technology and product rights and are amortized over their estimated useful lives on a straight-line basis. The following table summarizes the preliminary purchase price allocation, and the average remaining useful lives for identifiable intangible assets (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life as of Closing Date (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 - 8.1</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is primarily attributable to the anticipated cost synergies, additional growth platforms, and an expanded revenue base with the addition of the assets from the Adamas Acquisition. The goodwill is not expected to be deductible for tax purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Deferred Income Tax Liabilities, net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred income tax liabilities, net relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences. The acquired federal and state net operating loss carryforwards is reduced by a valuation allowance for amounts that are not expected to be realizable in the future. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Net Earnings of Adamas</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of Adamas and its subsidiaries have been included in the Company's consolidated statements of earnings for the period subsequent to the Closing Date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Information</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,484)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined financial information is based on historical financial information and the Company's preliminary allocation of purchase price; therefore, it is subject to subsequent adjustment upon finalization of the purchase price allocation. In order to reflect the occurrence of the acquisition on January 1, 2020, the unaudited pro forma combined financial information reflects the recognition of additional amortization expense on intangible assets and estimated additional cost of products sold related to the inventory step-up adjustment; the estimated reduction in the Company's interest income generated from marketable securities that were liquidated to fund the purchase price of the Adamas Acquisition, and the estimated tax impact of the pro forma adjustments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined financial information should not necessarily be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results.</span></div> 2 400800000 2 0.50 150000000 225000000 2 10300000 0 50900000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Initially Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,293 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,673 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of liabilities assumed</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,733)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209,011)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,102)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Measurement period adjustments reflect changes based on information related to the facts and circumstances that existed as of the acquisition date. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents tax impact of the changes in the initial estimate of the fair value of the right of use asset and changes made to update certain state tax attributes which existed at the opening balance sheet date.</span></div> 90064000 90064000 11156000 11156000 20200000 20200000 5077000 5077000 1254000 1254000 450100000 450100000 6442000 -1620000 4822000 584293000 -1620000 582673000 4592000 4592000 8014000 8014000 138315000 138315000 5224000 5224000 56588000 3722000 52866000 212733000 3722000 209011000 371560000 2102000 373662000 39553000 -2102000 37451000 411113000 411113000 400806000 400806000 10307000 10307000 411113000 411113000 The following table summarizes the preliminary purchase price allocation, and the average remaining useful lives for identifiable intangible assets (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life as of Closing Date (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 - 8.1</span></div></td></tr></table> 450100000 P3Y1M6D P8Y1M6D <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,484)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 150243000 -20484000 Disaggregated Revenues <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,464 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,381 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,506 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Includes net product sales of MYOBLOC, XADAGO and OSMOLEX ER.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trokendi XR accounted for 43% and 56% of the Company’s total net product sales for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% and 25% of our total net product sales and collectively accounted for more than 75% and 85% of our total net product sales in 2022 and 2021, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized noncash royalty revenue of $2.2 million for both the three months ended March 31, 2022 and 2021. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Commitments and Contingencies</span>. <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,464 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,381 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,506 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Includes net product sales of MYOBLOC, XADAGO and OSMOLEX ER.</span></div> 62832000 71819000 27521000 27370000 22601000 0 18448000 21730000 8283000 0 7779000 7462000 147464000 128381000 5042000 2551000 152506000 130932000 0.43 0.56 0.20 0.20 0.20 0.25 0.25 0.25 0.75 0.85 2200000 2200000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and U.S. government agency and municipal debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,822 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years to 3 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years to 4 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 4 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,822 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, there was no impairment due to credit loss on any available-for-sale marketable securities. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Navitor</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Development Agreement </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million. In addition, the Company will incur certain other research and development support costs. There are certain additional payment amounts which could be incurred by the Company. These costs are contingent upon Navitor Inc. achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity investment</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to entering into the Development Agreement in April 2020, the Company acquired Series D Preferred Shares of Navitor Inc. for $15 million, representing an approximately 13% ownership position in Navitor Inc. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Navitor Inc. underwent a legal restructuring. In the restructuring, Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals LLC (Navitor LLC), and the outstanding shares of stock in Navitor Inc. were exchanged for units of membership in Navitor LLC having equivalent rights and preferences (Navitor Restructuring). As part of the Navitor Restructuring, the Series D Preferred Shares previously held by the Company were exchanged for Series D Preferred Shares in Navitor LLC. In addition, certain assets that did not relate to NV-5138 (SPN-820) were transferred from Navitor Inc. to a newly formed entity that became a separate, wholly owned subsidiary of Navitor LLC.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had determined that Navitor LLC is a VIE. The Company does not consolidate this VIE because the Company lacks the power to direct the activities that most significantly impact Navitor’s economic performance. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Navitor Restructuring, the investment was accounted for under the practical expedient allowed for equity securities without readily determinable fair value, which is cost minus impairment plus any changes in observable price changes from an orderly transaction of similar investments in Navitor Inc. Following the legal restructuring and exchange of the preferred shares for member equity units of Navitor LLC, the investment was accounted for under the equity method of accounting due to the Company's ability to exert significant influence over but not control the financial and operating decisions of Navitor LLC. As a result of the change from a cost method investment to an equity method investment, the Company was required to measure its investment initially in accordance with the guidance in ASC 805. The majority of the assets and liabilities recorded in Navitor LLC's financial statements represent working capital items and cash that are being used for research and development purposes and are significantly lower than the Company's investment in Navitor LLC, which created a significant basis difference for the Company's investment in the underlying net assets. The Company determined that substantially all of the fair value of the investment was attributable to a single in-process research and development (IPR&amp;D) asset. As a result, Navitor LLC was not considered a business as defined in ASC 805. In the first quarter of 2021, the $15 million investment, which was previously recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated balance sheets, was expensed and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records its share of the results of Navitor LLC, a private company, on a quarter lag as the financial information of Navitor LLC is not available on a sufficiently timely basis for the Company to apply the equity method of accounting. In December 2021, Navitor LLC sold one of its subsidiaries and distributed cash to its members in accordance with each member's share of the proceeds from the sale. The Company received $12.9 million in December 2021 from Navitor LLC in connection with this sale. As the Company's policy is to record its share of the results in its equity method investment on a quarter lag as previously indicated, the Company recorded the cash amount received in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets as of December 31, 2021. In the first quarter of 2022, the Company determined its estimated share of Navitor LLC's year-end 2021 earnings and recorded a gain of $12.9 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of earnings. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum exposure to losses related to Navitor LLC is a maximum of approximately $50 million in expense for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company.</span></div>The Company has not provided financing to Navitor LLC. Further, no additional equity investment has been made to Navitor LLC. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and U.S. government agency and municipal debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,822 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 322797000 253301000 497000 2349000 1472000 238000 321822000 255412000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years to 3 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years to 4 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 4 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,822 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 196485000 111584000 13753000 0 0 321822000 0 P30D 50000000 15000000 0.13 15000000 12900000 12900000 50000000 Fair Value of Financial Measurements<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels: </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets. </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves). </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the restricted marketable securities which are classified as Level 2 financial assets is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. There were no Level 3 financial assets as of March 31, 2022 or December 31, 2021. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Recorded at Fair Value</span></div><div style="margin-top:10pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022 (unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market securities and funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,995 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market securities and funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,995 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial Liabilities Recorded at Carrying Value</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value has been estimated based on actual trading information, and quoted prices, both provided by bond traders. As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further discussion of the accounting standard adoption.</span></div> 0 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022 (unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market securities and funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,995 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market securities and funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,995 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 84218000 84218000 0 0 31497000 1502000 29995000 0 196485000 0 196485000 0 125337000 0 125337000 0 570000 8000 562000 0 438107000 85728000 352379000 0 56142000 0 0 56142000 56142000 0 0 56142000 148863000 148863000 0 0 54571000 54571000 0 0 136246000 251000 135995000 0 119166000 0 119166000 0 630000 7000 623000 0 459476000 203692000 255784000 0 80477000 0 0 80477000 80477000 0 0 80477000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 400382000 395456000 379252000 400236000 20600000 Contingent Consideration<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contingent consideration liabilities are related to the USWM Acquisition and the Adamas Acquisition. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments of up to $230 million, comprising of $130 million for the achievement of certain SPN-830 regulatory and commercial milestones (regulatory and developmental contingent consideration payments) and up to $100 million related to the future sales performance of the acquired USWM products (sales-based contingent consideration payments). The regulatory and developmental contingent consideration payments include a $25 million milestone due upon the FDA acceptance of the SPN-830 NDA for review. The remaining $105 million are due upon the FDA's regulatory approval and commercial launch of SPN-830. Based on timing of the PDUFA date of SPN-830 NDA, one of the regulatory and developmental milestones which has a time-based mechanism for full or partial achievement will not be achieved. Of the $100 million sales-based contingent consideration, a $35 million milestone due upon achievement of certain U.S. net product sales of APOKYN in 2021 was not achieved. The remaining $65 million relates to the achievement of certain net product sales of the acquired USWM products in 2022 and 2023.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned in Note 1, the Company received a notice from the FDA in February 2022 of its acceptance for review of the NDA for SPN-830. As such, the Company made a $25 million regulatory and developmental contingent consideration payment in the first quarter of 2022. This milestone payment is reflected in the condensed consolidated statements of cash flows as a $22.9 million under cash flows from financing activities related to the acquisition date fair value of the contingent consideration liability and a $2.1 million under cash flows from operating activities related to excess of the acquisition date fair value.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's contingent consideration liabilities are measured at fair value on a recurring basis; i.e., the Monte Carlo simulation for the sales-based milestones, and the income approach for the other milestones. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the measurement period, changes in the fair value of contingent consideration related to the Adamas Acquisition are recorded against goodwill if such changes are related to facts and circumstances that existed at the acquisition date. In each reporting period after the acquisition, the Company remeasures the fair value of contingent consideration liabilities and records in its consolidated statements of earnings the increases or decreases in the fair value of the liabilities. The Company recorded a net expense of $0.7 million due to the change in fair value of the contingent consideration liabilities in the first quarter of 2022. The change in fair value is reported on the condensed consolidated statement of earnings in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contingent consideration expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of contingent consideration was primarily driven by the increase in estimated fair value of regulatory and developmental USWM milestones due to the accretion to the payout amount related to the milestone achieved in the first quarter of 2022. The increase is partially offset by a decrease in the estimated fair value of sales-based Adamas milestones due to changes in market data. The key assumptions considered in estimating the fair value of regulatory and developmental milestones include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated amount and timing of projected cash flows, volatility, estimated discount rates and risk-free interest rate. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of significant inputs and assumptions used in the valuation of the contingent consideration for the Adamas Acquisition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and developmental contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported under the following captions in the condensed consolidated balance sheets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 230000000 130000000 100000000 25000000 105000000 100000000 35000000 65000000 25000000 22900000 2100000 2 700000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and developmental contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported under the following captions in the condensed consolidated balance sheets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 70170000 10307000 80477000 -25000000 0 -25000000 1720000 -1055000 665000 46890000 9252000 56142000 46890000 0 46890000 0 9252000 9252000 46890000 9252000 56142000 46890000 44840000 9252000 35637000 56142000 80477000 Goodwill and Intangibles Assets, Net<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments related to the acquisition of Adamas (see Note 3).</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,102)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022 (unaudited)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Weighted<br/>Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized patent defense costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,871)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764,049 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,227)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Oxtellar XR and Trokendi XR will expire no earlier than 2027. In regards to Trokendi XR, the Company entered into settlement agreements that allow third parties to enter the market by January 1, 2023, or earlier under certain circumstances. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was approximately $20.6 million and $6.0 million, for the three month periods ended March 31, 2022 and 2021, respectively. The increase in expense is primarily due to amortization of the acquired developed technology and product rights from the Adamas Acquisition. </span></div>Anticipated annual amortization expense for intangible assets is estimated at $79.8 million in 2023 and 2024, $75.0 million in 2025 and 2026, and $73.2 million <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments related to the acquisition of Adamas (see Note 3).</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,102)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022 (unaudited)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 117516000 -2102000 115414000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Weighted<br/>Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized patent defense costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,871)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764,049 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,227)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 124000000 124000000 124000000 124000000 P8Y5M26D 681100000 54913000 626187000 681100000 35550000 645550000 P4Y4M13D 43820000 29958000 13862000 43820000 28677000 15143000 P8Y4M24D 848920000 84871000 764049000 848920000 64227000 784693000 20600000 6000000 79800000 79800000 75000000 75000000 73200000 Convertible Senior Notes Due 2023<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 0.625% Convertible Senior Notes Due 2023 (2023 Notes), which were issued in March 2018, bear interest at an annual rate of 0.625%, payable semi-annually in arrears on April 1 and October 1 of each year. The 2023 Notes will mature on April 1, 2023, unless earlier converted or repurchased by the Company. The Company may not redeem the 2023 Notes at its option before maturity. The total principal amount of 2023 Notes is $402.5 million.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes were issued pursuant to an Indenture between the Company and Wilmington Trust, National Association, as trustee. The Indenture includes customary terms and covenants, including certain events of default upon which the 2023 Notes may be due and payable immediately. The Indenture does not contain any financial or operating covenants, or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noteholders may convert their 2023 Notes at their option only in the following circumstances: (1) during any calendar quarter, if the last reported sale price per share of the Company's common stock for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including the last trading day of the immediately preceding </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">calendar quarter, exceeds 130% of the conversion price, or a price of approximately $77.13 per share on such trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as specified in the Indenture; and (4) at any time from and including October 1, 2022, until the close of business on the second scheduled trading day immediately before the maturity date. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At its election, the Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, based on the applicable conversion rate. The initial conversion rate is 16.8545 shares per $1,000 principal amount of the 2023 Notes, which represents an initial conversion price of approximately $59.33 per share, and is subject to adjustment as specified in the Indenture. In the event of conversion, if converted in cash, the holders would forgo all future interest payments, any unpaid accrued interest, and the possibility of further stock price appreciation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a “make-whole fundamental change,” as defined in the Indenture occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. If a “fundamental change,” as defined in the Indenture occurs, then noteholders may require the Company to repurchase their 2023 Notes at a cash repurchase price equal to the principal amount of the 2023 Notes to be repurchased, plus accrued and unpaid interest, if any.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneous with the issuance of the 2023 Notes, the Company also entered into separate privately negotiated convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) with each of the call spread counterparties. The Company issued 402,500 convertible note hedge options. In the event that shares or cash are deliverable to holders of the 2023 Notes upon conversion at limits defined in the Indenture, counterparties to the convertible note hedges will be required to deliver up to approximately 6.8 million shares of the Company’s common stock, or to pay cash to the Company in a similar amount as the value that the Company delivers to the holders of the 2023 Notes, based on a conversion price of $59.33 per share.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with entering into the Convertible Note Hedge Transactions, the Company also entered into separate privately negotiated warrant transactions (collectively, the Warrant Transactions) with each of the call spread counterparties. The Company issued a total of 6,783,939 warrants. The warrants entitle the holder to one share per warrant. The strike price of the Warrant Transactions will initially be $80.91 per share of the Company’s common stock, and is subject to adjustment.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Note Hedge Transactions are expected to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2023 Notes, as the case may be. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Warrant Transactions were intended to partially offset the cost to the Company of the purchased Convertible Note Hedge Transactions; however, the Warrant Transactions could have a dilutive effect with respect to the Company’s common stock, to the extent that the market price per share of the Company’s common stock, as measured under the terms of the Warrant Transactions, exceeds the strike price of the warrants.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability component of the 2023 Notes consists of the following, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,382 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further discussion of the accounting standard adoption. No 2023 Notes were converted as of March 31, 2022 or December 31, 2021.</span></div> 0.00625 0.00625 402500000 20 30 1.30 77.13 5 10 10 0.98 59.33 402500 6800000 59.33 6783939 1 80.91 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability component of the 2023 Notes consists of the following, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,382 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 402500000 402500000 2118000 23248000 400382000 379252000 20600000 0 0 Share-Based Payments<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option and Stock Appreciation Rights </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option and stock appreciation rights (SAR) activities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,608,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,608,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,280,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit (RSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no forfeited RSU awards during the three months ended March 31, 2022. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit (PSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:24.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total PSUs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>There were no forfeited PSU awards during the three months ended March 31, 2022. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 651000 588000 3374000 3783000 4025000 4371000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option and stock appreciation rights (SAR) activities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2022 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,608,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,608,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,280,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79</span></td></tr></table> 5774076 24.15 P5Y11M12D 929785 32.20 47601 18.21 48036 30.84 6608224 25.28 P6Y3M 5774076 24.15 P5Y11M12D 3651824 21.29 P4Y6M10D 6608224 25.28 P6Y3M 4280012 22.87 P4Y9M14D <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit (RSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 21110 29.61 131210 32.20 21110 29.61 0 0 131210 32.20 0 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit (PSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:24.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total PSUs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 53500 29.82 35625 26.34 89125 28.43 21500 29.67 0 21500 29.67 32000 29.92 35625 26.34 67625 28.04 0 Earnings per Share<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, whereas the Company previously calculated diluted earnings per share under the treasury stock method. Basic earnings per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock option grants, SARs, RSUs, employee stock purchase plan (ESPP) awards, and the 2023 Notes, as determined per the if-converted method for the three months ended March 31, 2022 in connection with the adoption of ASU 2020-06 and the treasury stock method for the three months ended March 31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effect of Convertible Notes and Related Convertible Note Hedges and Warrants </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, the Company entered into Convertible Note Hedge and Warrant Transactions as described further in Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The expected collective impact of the Convertible Note Hedge and Warrant Transactions is to reduce the potential dilution that would occur if the price of the Company's common stock was between the conversion price of $59.33 per share and the strike price of the warrants of $80.91 per share.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted EPS related to the 2023 Notes in the current year is calculated using the if-converted method. The number of dilutive shares is based on the initial conversion rate associated with the 2023 Notes. The Convertible Note Hedge and Warrant Transactions are excluded in the calculation of diluted EPS because inclusion would be anti-dilutive. Specifically, the denominator of the diluted EPS calculation excludes the additional shares related to the warrants because the average price of the Company's common stock was less than the strike price of the warrants of $80.91 per share. Prior to actual conversion, the Convertible Note Hedge Transactions are not considered in calculating diluted earnings per share, as their impact would be anti-dilutive. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards in the calculation of diluted EPS, because their inclusion would be anti-dilutive: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As mentioned in Note 1, as a result of the adoption of ASU 06-2020 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended March 31, 2022. For the three months ended March 31, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net earnings per share for the three months ended March 31, 2022 under the if-converted method and for the three months ended March 31, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax interest expense for 2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for dilutive earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,330,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,927,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and SARs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,406,555 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,196,971 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 59.33 80.91 80.91 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards in the calculation of diluted EPS, because their inclusion would be anti-dilutive: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As mentioned in Note 1, as a result of the adoption of ASU 06-2020 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended March 31, 2022. For the three months ended March 31, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.</span></div> 1067231 1419203 6800000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net earnings per share for the three months ended March 31, 2022 under the if-converted method and for the three months ended March 31, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax interest expense for 2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for dilutive earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,330,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,927,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and SARs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,406,555 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,196,971 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 25616000 5694000 887000 0 26503000 5694000 53330837 52927467 1291782 1269504 6783936 0 61406555 54196971 0.48 0.11 0.43 0.11 Income Tax (Benefit) Expense<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the Company’s income tax (benefit) expense for the three months ended March 31, 2022 and 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit was $10.9 million for the three months ended March 31, 2022 and income tax expense was $5.2 million for the three months ended March 31, 2021. The change for the three months ended March 31, 2022 was primarily from tax benefits associated with the Adamas legal entities reorganization in the first quarter of 2022. The reorganization resulted in favorable impact on certain state apportionment factors. The change in the effective income tax rate for the three months ended March 31, 2022 as compared to the same period in the prior year was mainly due to changes in the effective state tax rates as a result of the Adamas legal entities reorganization.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the Company’s income tax (benefit) expense for the three months ended March 31, 2022 and 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> -10893000 5235000 -0.740 0.479 Leases<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its headquarters lease, certain other office space, and its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. The Company also elected to combine the lease and non-lease components for the fleet vehicle and headquarters leases. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's headquarters lease commenced on February 1, 2019 (the Commencement Date) and will continue until April 30, 2034, unless earlier terminated in accordance with the terms of the lease. The lease includes options to extend the lease for up to 10 years. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Adamas Acquisition, the Company acquired a lease for office space. Adamas' operating lease for the office space term will continue until April 30, 2025. The lease contains an option to extend the term for one additional five-year period. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During a measurement period, changes in fair value due to measurement period adjustments are recorded against goodwill. The Company recorded in the first quarter of 2022 a measurement period adjustment associated with the valuation of the acquired Adamas lease which decreased the fair value estimate of the operating lease right of use asset by $1.6 million. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Lease</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a contract manufacturing agreement with Merz Pharma GmbH &amp; Co. KGaA (Merz), for the manufacture and supply of rimabotulinumtoxinB finished products (Merz Agreement). The Merz Agreement will expire in July 2027 unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility which the Company accounts for as an embedded lease. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made an accounting policy election, by class of underlying asset, to not combine lease and non-lease components for the manufacturing facility. A portion of the in-substance fixed contract consideration was allocated to the lease component based on the stand-alone selling price. Accordingly, the Company classifies and accounts for the embedded lease as an operating lease.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMy0xLTEtMS02MzkxNw_432e3a7f-cbab-4836-a1e9-b284f1826d54"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMy0xLTEtMS02MzkxNw_d8e08fad-1bf6-4d1e-81a8-d17498d6ac96">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,141 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfOS0xLTEtMS02MzkxNw_2c85e97f-7d89-4579-8d12-16d2a8e6adac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfOS0xLTEtMS02MzkxNw_9515a6c3-1c02-4ed5-ac3b-b79a4f840030">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMTItMS0xLTEtNjM5MTc_7a4c8f77-c9d8-43ee-9e22-9d712434f1b0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMTItMS0xLTEtNjM5MTc_e8b9a896-54aa-4828-acda-ad78d54a4f24">Operating lease liabilities, long-term</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,032 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P10Y 1 P5Y -1600000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMy0xLTEtMS02MzkxNw_432e3a7f-cbab-4836-a1e9-b284f1826d54"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMy0xLTEtMS02MzkxNw_d8e08fad-1bf6-4d1e-81a8-d17498d6ac96">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,141 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfOS0xLTEtMS02MzkxNw_2c85e97f-7d89-4579-8d12-16d2a8e6adac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfOS0xLTEtMS02MzkxNw_9515a6c3-1c02-4ed5-ac3b-b79a4f840030">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMTItMS0xLTEtNjM5MTc_7a4c8f77-c9d8-43ee-9e22-9d712434f1b0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2ZThjNDU1NWUwZTRhMzFiODRmOWY3NTYyOTZjNDMxL3NlYzo0NmU4YzQ1NTVlMGU0YTMxYjg0ZjlmNzU2Mjk2YzQzMV83MC9mcmFnOjAyZjIxYzdlYzBmNTQyN2Q5M2UxODg3NjMwMTAyMGM2L3RhYmxlOjA5ZDk0MmVkNTI3OTQ2ZDA5OGYyYTI4YTg5MTkzMmMwL3RhYmxlcmFuZ2U6MDlkOTQyZWQ1Mjc5NDZkMDk4ZjJhMjhhODkxOTMyYzBfMTItMS0xLTEtNjM5MTc_e8b9a896-54aa-4828-acda-ad78d54a4f24">Operating lease liabilities, long-term</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,032 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 32141000 35365000 32141000 35365000 6141000 6477000 39891000 41298000 46032000 47775000 Composition of Other Balance Sheet ItemsThe following details the composition of other balance sheet items (dollars in thousands for amounts in tables):<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivables, Net </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the Company has reduced accounts receivable by approximately $11.4 million and $13.5 million, respectively. Prompt pay discount and contractual service fees, which were originally recorded as a reduction to revenues, represents estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,795 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories as of March 31, 2022 include acquired inventory from the Adamas Acquisition. Refer to Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the acquisition.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment and furniture</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense on property and equipment was approximately $0.7 million and $0.6 million for the three months ended March 31, 2022, and 2021, respectively. The Company retired certain fully depreciated property and equipment during the three months ended March 31, 2022. </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes preclinical and all clinical trial-related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Product Returns and Rebates</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,181 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,724 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other Liabilities</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonrecourse liability related to sale of future royalties, long-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11400000 13500000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,795 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9239000 7325000 46219000 45711000 33337000 32923000 88795000 85959000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment and furniture</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12199000 12287000 13998000 14369000 2185000 4776000 1282000 1944000 32000 33000 29696000 33409000 12481000 16454000 17215000 16955000 700000 600000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes preclinical and all clinical trial-related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> 12323000 9331000 16209000 26728000 14555000 28068000 12727000 18460000 11044000 13821000 7784000 9125000 6141000 6477000 8649000 5673000 89432000 117683000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Product Returns and Rebates</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,181 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,724 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 104948000 97597000 35233000 35127000 140181000 132724000 Other Liabilities<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonrecourse liability related to sale of future royalties, long-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3784000 5977000 10361000 10403000 14145000 16380000 Interest Expense <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details the composition of interest expense (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on nonrecourse liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,097)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As discussed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Summary of Significant Accounting Policies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">the Company adopted ASU 2020-06 on January 1, 2022. As a result, interest expense for the three months ended March 31, 2022 significantly decreased compared to the three months ended March 31, 2021 due to the Company no longer recording interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes. For the three months ended March 31, 2022, interest expense includes noncash interest expense related to amortization of deferred financing costs of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$0.5 million. For the three months ended March 31, 2021, interest expense includes noncash interest expense related to amortization of deferred financing costs and amortization of the debt discount on the 2023 Notes of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$4.3 million.</span></div> <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details the composition of interest expense (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on nonrecourse liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,097)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1155000 5062000 787000 1035000 1942000 6097000 500000 4300000 Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Licenses</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the condensed consolidated statements of earnings. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Agreement</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2014, the Company received $30 million pursuant to a Royalty Interest Acquisition Agreement related to the purchase by HC Royalty of certain of the Company's rights under the Company's agreement with United Therapeutics related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets. Full ownership of the royalty rights will revert to the Company if and when a certain cumulative payment threshold is reached (see Note 2, Note 4, and Note 14).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">USWM Enterprise Commitments Assumed</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion related to the Merz Agreement in connection with the MYOBLOC annual minimum purchase requirement. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, USWM Enterprises had an existing license and distribution agreement for XADAGO. This included an annual minimum promotional spend to support the marketing of XADAGO for the first five years of the agreement and will end in 2022. As of March 31, 2022, there is no remaining contractual commitment.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to incur significant costs through March 2024 to maintain a broad array of processes, policies and procedures necessary to comply with the CIA.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data Breach-related Contingency</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 24, 2021, the Company announced that we were the target of a ransomware attack. The attack had no significant impact on our business and did not cause any long-term disruption to our operations. Based on its internal investigation, the Company believes the criminal ransomware groups ("criminal groups") copied certain data from our systems, encrypted certain data on the Company's systems, and then deployed malware designed to impede access to our systems. Thereafter the criminal groups contacted the Company and threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware attack, the Company notified government authorities, engaged third-party cybersecurity experts through our outside counsel, and commenced its recovery process. The Company maintains redundant off-site data backups, which were verified to have not been compromised by the ransomware attack and were utilized to restore the data encrypted by the criminal groups. In the fourth quarter of 2021, the Company had successfully recovered the impacted files and took additional steps designed to further protect its networks and files.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, while the Company has not been the subject of any legal proceedings involving the attack, the likelihood that the Company could be the subject of claims from persons alleging they suffered damages from the incident, or actions by governmental authorities is possible, but the amount of such fines, penalties or costs, if any, cannot be estimated at this time. The Company continues to monitor the situation. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Claims and Litigation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NAMENDA XR/Namzaric Qui Tam Litigation </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022 and no decision has been reached as of the date of this filing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.</span></div> 30000000 3900000 P5Y 0 17500000 2500000000 Subsequent Events On April 29, 2022, the Company announced that the FDA approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults. Excludes amortization of acquired intangible assets EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
K-UDM_1ZMB_]8<9CDMM*H*GE)7 M558&C_CZ))7BGBEK3E 'QB I+=*ZP%(8D/&BMJ]9UREMG8K()F>@%*^^\0XP MW'-9Z^*Q50/IPUI(C?133H6QRFI @/I)OP2#^N2*:I[NDWQ]?;-\0[CN;K1% M;>-*&X\H' 13$5&7*\C"]U26)5!P6C0!Z6E#10;!/GD?#(7J_U5S1+A(BSIK M=#A ;!39>HUX-A$)*/[\TSP>S=[J@ 3RQ4;M#F$V.B++RUO\WBX_X9>552$? M&0LKJUJE.>B.5 45 &AY<_.&T U5&=;"$K<)TB,A'Z5A]ID&&QJF0%)PJ J1 M.)08+DJY8C8G'7G#4^ @1&#P#3>Y3\ L^ %?NUG:F+4W_$=O M.^J3ZQ;*=]YXOBJ8=]1MW%AY($-N_N1/VT)4[>9]D'1J>(K:%C7"HJ51=7)+J(=?4LF."#R M7KZO@T5]QSCLP7(%=*#?%($U..SKYMNW68:2@#]PK$Z94U!!2!A.BY#1P,KD MU*"KUP6X*4UK6.[WJA3?XA9P^D6W)>."OH'K*V8VC FWS&>AFR5:\5>313]) M.CS0)!!: __R9)]-$T\K.!_V%Z.MX&ZUJY =\&\WL!9Y9TNM%'PECZ"B@]RP MIW)\++88;,TW9 M++'$Y'+5^]FPOR_5K(/1BJ6TULQSF;/,QWEEMS#\I'&M3Y;(/#0MZ"H>?65D M3$BP##52-<'IJN[N&BP*?2O+7&L#(@&P)Y%J0]Q8YZ0"-1^;= 73=CLJOC.3 M;I2M0E@$9.N=X$7/%=I7P1#26%G-LT ?1S=CWX>Y:BK\4&1 ; VD#8)T)>]9 MAW)V>U*G$II*4\\RZ<%TVZ5(6FBY33Y?[9VHV-GEGA8L0&[?KT%C=#M_^X9F=;#WE="XK>#N5OR++3LD.; MQDPWG,ZB.!GA:CQ:1/$P(9<:_"#L*A]GA]_(Q9$"8(T/E,;OIYUS.#VQS7/? MU-@%^,CYZV7NFO;G^(HI"FL"+'U*8/N(J4->>])(!0H)K--8]]5@U4_B,!&A55!E>.H'3N\V1;GX9:2H"? .9?$1SSNB^)1>&@0MMBNG3O9QJL;5?0J"^>#&* M9O/87DT7L'*\TYB$L:S6YETJS<=ZXQZ!P4(5YW[CC,SC#()G]FU#YM3]PN M_4'3=KD_KD..WW%AQYTU1(?]V:1'E#\"\S=&5N[8:26-D:6[S!E%)=@%>+^6 M0#/&ULK591;]M&#/XKA-8-,1!8LFPW:68;B-,, MRT. H.VVAZ(/9XFR#I7N5!X5)_OUXYUD5=W6;"GZ8MWI^'W\2)Y(KPZ6/KH2 MD>&AKHQ;1R5S0'45ITGR,JZ5-M%F M%=[=T69E6ZZTP3L"U]:UHL M6')=HW':&B LUM'E[&*[\/;!X'>-!S=:@X]D9^U'O[G)UU'B!6&%&7L&)8][ MO,*J\D0BXU//&0TN/7"\/K+_$F*76';*X96M_M YE^OH/((<"]56_,8>?L4^ MGJ7GRVSEPB\<.MOY/(*L=6SK'BP*:FVZIWKH\S "G"=? :0]( VZ.T=!Y6O% M:K,B>P#RUL+F%R'4@!9QVOBBO&624RTXWMR8S-8([]0#G&S18*%Y M+LYYMV[&E7V&;PZTU7#JX-CGF7^)C43;(2X_RMNF3A+>*IC"?G4*: MI.D3?/,AW'G@F_]WN*^URRKK6D)X?[ES3')!/CSA8C&X6 07B^^4T6]G@WQ]"$D!<$B+477G1EQ>D.%DY5 >4R?UB!B>Y:%+DB05F6RS1(YK754^3<^+=92VH[9 N9RFSV:<34,Q MLU*9_7-R[ATVI*6?ZNH1"K+U.$0'RCF;:4E(+GV%R\!ZF2OIZU#)G:B$E35K MN2Z$TMF5T7]V-R:43I1H<@R?6D6,!+8(7CNM?P,0.FF$Z-,"A;JW%&ZCEIN6 M,)_V=Q3YC2^Z+'/0"<"CM*-VAPL\HEH/,7WF2([8! MY)10-4C:YD=/DD9A?$1%(:M^H$E*\Q8]IA/E_JFJ"^>-36:Z1]&%X^EM9PU^&'M\-\O.S&PF?S;KA*1O;:>!&%0)/IV3("Z@96 MMV';A"&QLRPC)RQ+F?%(WD#."VOYN/$.AG\-F[\ 4$L#!!0 ( .V)K%3I M?HY7J@8 %H0 9 >&PO=V]R:W-H965TD2R M-[X62&R*G!G.?/.D+_?._QYV6D=ZR&T1KD:[&,O7TVE(=CI78>)*7> D>W]]Z:IH3:'?>PI5GBM_N-'6[:]& M\U&[\<%L=Y$WIM>7I=KJCSK^4K[W^)IV4E*3ZR(85Y#7V=5H/7]]LV)Z(?BW MT?O06Q-;LG'N=_[X(;T:S5@A;74268+"KWM]JZUE05#C4R-SU%W)C/UU*_U; ML1VV;%30M\[^:M*XNQJ]'%&J,U79^,'MO]>-/6::&-%Z(J<(-Y4S! M3OD8/4X-^.+U6PV3PN4T0A;O3).&[Z;F6WR!;TEWKHB[0/\L4IT.^:?0H5-D MT2IRLWA6X)WR$UK.Q[28+1;/R%MVABU%WO)9P^@_ZTV('K[_[S,R5YW,EM@N]*[54TQ9::C9]WFFY=7JKB0#L5R'4$ MMB9 )I*)@7;(P4^5\E'[4)^-*=$^(A/)Q9WVY++,))KDZC&I(A6^S'*RW^N= M2:P.$_K5Q!WR*Y1(%(J.P#JD:2X>TQ8)5,CYO;-5KG$!F2(U]R:ME&WU,P5. M[S4NJVG=/0RPEI3WJMAJ9'0J63'"NDLTY*\ M%K1)XJHB"@@B?(@.J1 T;&1;K5$;8TTT;&0?564#A')=@)*0G[A\ X^)O$8* MV M7G-9?."]= ;5#=^T0'R9_ZHWAK5\?5;%W(^>62XS$3QB[- M$\^?-80]@W6(!AU6MT(>N]5S;^7#JDUQVASHJ_GD'#W1 MHEX4$_J@,XYQ1_]R$+0<]^.+)H"BD#Y =ZJH,BQJMTC1?5)SE02 D.<#L$$)^,N+#\+JXM&J%#Z M#FR8A_T;%RNTCBJ/[L$4-_!28=#94T(I3*L$+A=YM&Z5.*F]/-RL(UT_E/ " M^_O'"C? OQ=M.1BD&I00]KR**.%<8%G.D6 /1^_*U0&%$M[0_>K"Y@) - O# ME6M"OV!(\$\K3(?F,/]-0, V401%RLHC3=CQ/ "9O,HY3F.C'):^G1G&&LE"E.0X490@IE9AYP01<; M6 232JCR74?2 SEG$MD:QA%6W)H.36(,JY]TN+K7**E .M_HE-.W5Y);\ERE M6LRLV5AXB0Z:'*B=?,><*XF%>I)![ I[D&#F1!HSQ.S"M@O^Q0YXW!Y49FGB MO8+PUP'F^D0TA[PX8]#*-+ MD#"9#!PP<@ WTPW!;CSPJ"!->F/;T[E#-GK3!\M 5 &6SYK#\A1/FQJ, (>E M8O1&6<%)!OJZQ"M6#:CLD?XI%NBH=1EW50UW31<'^49=]L8F-2H8K!& MA+63-;W1"5OHVYTYO:@*5:&!Z?0$G5K,^()U[V2J;#Z^HN5B/%_->7$V7IZ? MT<\NME/@EXG>]G!Y^Q@I-,3*>W;S8PV.$K61MFY]6*J#VC0#&1SK*ST8 Z'% M>:/-^7AU<7%, <32]E2Z^[,J_&VRY:OQRU=S6LW'BUSBOZ_?B9_+ZU8WHV/*<8W4&UMGD MXFQ4=]OV([I27H]H3GB+RI+G6.V9 .>90[MM/OB"[L\)UW\"4$L#!!0 ( M .V)K%1K=$89?P8 +,. 9 >&PO=V]R:W-H965T>Z:NS59.M<^WHVL\56UL). M=2L;O%EK4PN'1[.9V=9(47JCNII%\_ER5@O53*XO_=B=N;[4G:M4(^\,V:ZN MA=G?RDKOKB;AY#!PKS9;QP.SZ\M6;.2#=#^W=P9/LQ&E5+5LK-(-&;F^FMR$ MKV\3GN\G_*+DSA[=$T>RTOI/?GA;7DWF[)"L9.$80>#R*-_(JF(@N/'7@#D9 MEV3#X_L#^H\^=L2R$E:^T=6OJG3;JTDVH5*N15>Y>[W[20[Q+!BOT)7U_[0; MYLXG5'36Z7HPA@>U:OJK^#SDX24&T6 0>;_[A;R7WPLGKB^-WI'AV4#C&Q^J MMX9SJN&B/#B#MPIV[OJ-KEMME<^07M.MJ$132'KPA'CK9&TO9P[K\.Q9,6#> M]IC1-S!C>J\;M[7T0U/*\M1^!O]&)Z.#D[?1LX#OA9E2' 84S:/H&;QX##KV M>/$W\#Z:C6C4WX*C#NB-;JRN5"EZFC0EW1EI9>/$(2L_J@994:*B!PQ*<-)9 M^NUF99T!JWY_QJ-D]"CQ'B7_:QF>Q>1V?FU;46 M^[25M-85>E8U&]#<"559PFPJ3A&T1U@-"+V0*$:@\Q+VPEA2#0QU9Y%:"U!# MHM8=IY!?B%4E[<5KNBF*?O!>%E(]^N& /@#MQO(ZX$"Q'4G@R_0]9M8KK#Z, MXI\=Y!!%LZ>ML)"-LBMDB>8?T,V(3JL]B;8U^K-"<\MJ3V=A.$W09%5U(,)9 M&$\7AY$ QK:57D:J_10LP4*.6K&G4EF/[XT*D)]YT8$OG'6%O*PE1[/;*L2P MDT:2-FH#5E58%BYI4[*3ED3OL4^NTWAXE$W'ID:V/2DM2>N\Q^68QT8[DI_9 M-0S";"7AE2HY0MV904:DL5/Z])2?[^S3"Q)PJ36 -0H>M5L!P2MDYU2!('9; MC6*(RD]$@(C6&;7JG!X&."OH#C=:*HFUWC9P'G/4H9!/)3RIW'G7B*X$9\H+ MNA<[XM@,X"R=41Y$<8YK&L31@GZ%P#-I4+1"6DO),HC"G))%D(8A=ZD"_TK: M: VBQ7$0QRG%49!',7W2#I&<498%:;[@FT60+_)C)SG__R:::HJJ*R48]%>G M4!P,]!9[6H, GG$WIAY&<41D&8Y_U- ME*7T3F*+0[T19XTT/PYB%\9!GF<4)D&\S.E!K]V.*0/C;$%)D*9+3ZL.E3M: M+ 1DA/\\2;S*.M-3^Y5J7@%\8[B(<812490'RWS)14OF.;S "_1L5W>59WK) M] ?'1HD&]8T;))S.X7R2A1>X60;)(KDXS9E\REF#G"'6%+QA$F!ZOE@@=\^A M-M> MVD[%YZB1\<9Y9A9P#9]AJ"_+RI@RO/F&WV5G6-U?Y,KT2:'OQ-X+*(-AT'28 M_$Z)E:K 6/31"T@Y8K4#EB=@C$;EGH_C< 2&ZVOIFP/]RS+*18O D6@9I%$V MSN-M"67J2P:>+E#7* OFR^P8BK454RU3.H)]2F$6),OY.,?H/82,HS@'G\(P MF(.[8'\6/;E48*?UPNA8I@:X\^@"*I5F"?P/H54?D7 X@_16W%)4/24H@/ : MPP5HF69,X/B"ED&8A/A/TG38EL6PWD! 2UFP3'):!,OT2-#R($$+(7]@]3*+ MZ8_G?SZN4W%"0IE+M7)]LW-=T:[LO&Q8RVGJPWO;2R&*!F(=)4*0U/P/NU!DV&!UY@/*=>_P-0 M2P,$% @ [8FL5+R(#C.+ P A@@ !D !X;"]W;W)K&ULO5;?;]LV$/Y7#D(?$L"S9-E.TL VX&0ME@)=@[K='H8]T.+) M(DJ1'DG%\?[ZWE&RXC4_D&' 7B12O/ON^^Z.I&8[Z[[Y"C' ?:V-GR=5"-O+ M-/5%A;7P0[M%0RNE=;4(-'6;U&\="AF=:IWF67:6UD*99#&+WV[=8F:;H)7! M6P>^J6OA]E>H[6Z>C)+#A\]J4P7^D"YF6['!%8:OVUM'L[1'D:I&XY4UX+"< M)\O1Y=6$[:/!;PIW_F@,K&1M[3>>W,AYDC$AU%@$1A#TNL-KU)J!B,9?'6;2 MAV3'X_$!_7W43EK6PN.UU;\K&:IY7/(HC%S-D=.+8F-!Y$ MJ=&;R"G#15D%1ZN*_,+BQ@1TZ .\NZYRE@5!Y+2TZA*L6(7\&80P?K0F5 MAW=&HORG?TIL>DKY@=)5_B+@1^&&,!X-(,_R_ 6\<2]Q'/'&S^!]"A4ZN#&% MK1&$D0>I'OY8KGUPU!A_OA!FTH>9Q#"3_Y#)?X< 7RJ$TFK:.,ILJ->"4-H# MR0'2LK5>Q<:V):B#)W:>)Y+0HW/R*^@9/18#2=GO)H.LC.\B>,B(VQQF%A&T=3K<1::17VM'VU(%P( M%KS0R)S+)C0.P=F]T$%1-4[.+\Y/.4HVIBA?;!"ZC?IVDL>H9X/L+5DL/4CE M:6]X B1]O]J D ]@U9XKC+U2&Z-*50@38%D0&Q,X@[=6JX)"#6(.KRF'PNQ! M2+ME;LO55\Y#]E-VQD(^"-,P7->(0XXK2(BG_3YXG'$Z'R-JB!FNCS-,#5U4 M?4>#?R"G]U35@@Y3EL(U%:Y-TFN01B ;/!@?Q!@+VIH--3Q7P4F6_8BK-=&' M3O$[1;VA]YTQ1>#,6QRUD:BM"^IO<=@"=!*CX^R5R@A3L.["^N!Y[4TVG-+A MJ379OI[BZ'^CR(?2C\;,4.(Z/%3D4;:CM,EPW$M[ZA1+C^Z&&MTFWH >(F1[ M3?1?^TMVV=XM#^;M#4W9V2CC06-)KMGP?)J :V^]=A+L-MXT:QOHWHK#BGX4 MT+$!K9>6:'<3#M#_>BR^ U!+ P04 " #MB:Q4P4K$=^$. ":) &0 M 'AL+W=OVM?/#.=KW2CWEKANKJ6=OM256;S_.#L('WP M3J]*3Q^U:IPVC;"J>'XP/_OQY06MYP5_U6KC M1J\%W61IS$=ZB%P5LJO\.[-YH^)]GI"\S%2._XI-6/MD=B"RSGE3 MQ\W0H-9-^"\_1SN,-CP]_<*&6=PP8[W#0:SEI?3RQ3-K-L+2:DBC%WQ5W@WE M=$-.N?<63S7V^1<+4]?:P\K>"=GD8F$:KYN5:C*MW+,3CR-HX4D6Q;T,XF9? M$'EL]A5YY_U]SUG> M^>^YK[C4+JN,ZZP2?Y\OG;< S3^^HXO<5'F;)T%R%KTY$UNM:$ M0V56:K5F2<(4%*=\XUI7"C'5*#<55T4\.ZH.6\+OB&:-8%<5A,/,RF9:5OHW ME>_JH[&Z<@:VK/0*RWN-K-G*BNV&#W8,.2&!;4=KX00I6LB&>J ^TK ! 2<; M.EG1VDP_M-H6[K>E6):O[X?Z7&S'/8#2GB05W+R&S M:,T@!1 :V1]$Y$MAL![N+R48,%.=UYFL^!ZR2=B8O[W[\]]N)^+7^>7\I[L) M(_+F;WY6QN1..%/E*1HR VT@.*=7>,"QD@OG\2_8 M'=N4M V\ 97>177F24UQ%>0$6WWJ8"Q<#GMFIV<7N^Z%2@I7S<4WYZ>$_(K2 M8-M9UTG(@;UE+_ZJ@11$QA@KHS.MJI+3V+*=S4 D2BRWXLVB%P(E4CQ&%PRA M'TEC<,7PJ/= 0-R'1M-1\(65+2/.[9\_#DS)JN*\.ZNPT\I:''JKX!H'3M35 MD7CUV2O*1L?O4 N0UN_ELE+D[]==50FS:91UI6Z3T@D!4>4-# <%ULKZ='X/ MZ(+!OBD5&*B_>];5'=3E:)5;OI@O8=R244"7 4AQF4.GE+@U7HG9)/R_",'# MK\\NCJ8A?%^1;\"^C@_NB7_N4$A!S-QQQ"3M_TW$QTTA&*AHHZ#/1F(A9N_4 MD&,TGKENZ72NI>7PW)0:P4:VCNPQB;1.*A):&P&$,CGGXH]_>'K^W<6?SJ<_],@.PJOM9(0RQ!@G<>2/ MIBOPHK,[+!<@=Z/L;QS?PRK%EZ8$5VT1A:H@@2:ZYGPBK@E)@?^*SC))1BN$ M:G4'KRQ_B";"B&F:6)>R!KPJW/H_,=*46$#F>?3P X>5,F=S?=:.K=>3'>X$ M-;W5RRX4Q;U2=)/ X.0^3=D;Q4&N6-"^2B@2#.W'9R#4)M\O!E#??U1\,KP9 MI";^%(6VX)F"PF,+GG,)N(,J'%,4=209QJ+2;THX)VA(6*,O"!G<\!74;'3V,!>#M'D4X> K1K#KP#JJP)E-)V(?[(W&(,KT*B8?PR=[&V?>C>#K" M;8F#Z<9,S0MC84_ B,EY9?5.%CA<7,V/!NS<%06=#P-=-9SB8.R?%(@-!DC$ M,+V?BDM%7)'B[(T"T95\I3<=L"_NE5U#CAO59@('/:YQ\%@>0I/2MD:F.?M^ M^J2/2$\^08Y;/WKZSUTP&F)6K8+]<8Y$?'BQUB9&$ Y^C4H+>E12UZ"]+ D MN'449. &\+IV98\ATZP,H8%0@10@FV A"HRBB&4 U1B5YD= ]0KI([ 7E8MB M(UVX%O+H:(MP?(^'I[V?I6#&Q=5)6O9I'$W0542[N0/4,9;50 MK,>L,\K'L'3;!8O6J'ZYCD?@QM(KEB;(<6$7Z4"'!"_0T7N$,U:6(S7C#J13 M9 NNF(33J(8 2BHU,N1B\FVH2U,$SBYH-3N'2WBQM(9XRUK)M03\ 2@Z"J06 M=1+W-@PT^CP'12/H%:V@RY /R)7;(29P T .3;%XR2GW.+'RT"YMQ5T#3D>? ML 3:9Q?,*F=[SF@:)*&,W0%P;@ +HARNP:1=J6 Q826JN7I#Z5!Z+[./ 4?A M-1,R&&IL% WQP#(5+S#7$GT8NA(7*9I64R_5,6EO104L'X,>:J)OV[4^AA=M M-3U]3<5+25D8SXBB"/66.%HW:\J< 4:[MT/"IC[)A6QI-2@>&T:76<%IK1.' M!_W#\,G!$0S>:JIC(\9R,C7WCZ25VSH4M/ =S&RWK=]?:/:;PWX#6U(;FRL<4GPK+?8CLN@(>!S8@>05 VB;06.=+ M ^KG@DLU*W0_>2C]CXE.T*-N@5RG$'$Z-BUV%&H,C\Z#L(CI.I0 U:1G3\6@ M)J!0[X(CMRGD=@NX%*&T+D=I)9DDBF,PEPH66>(N,&LJ"3D^("_TTUXO;QRT3:@"2@SJ%V^^83)#80NSQP0.VHJ ]1T]3MU08*M)V MVZ7]0*<8=1WCJ4!CL$UFB2@)\4J.IQE" (LQ'WM6I%K(*X!KC-)4&^+"! :V M-NB79ZXL@H51)\+K:MR.K5BI/=7<8#]Z@.KCGR0ODC4ET"IX3^74.%+((^]R MY5SNPJW2'Q'S)1K30&CC^@ M8":141YRO2>>&$1,^K$(502('1^(S20\HG<=@0R MI=-N?S:QI@%[,+&7OHMS#_AVG"3#\7RXI%* FAN* MH=;0M4E5( '5&[T"^?'H-DWV1HM0G45$LJ_)[A,6:,D(\'37I'<,TWT7$"9I M7 ,@Q[G/DJNMF*H2.J%R&%)*1 @6; ?H/5(S(7595$QRY*C4(PV()RFLR4-A)(J;E@EUU)7 M?'_=A*^%.#S&X90;E1B+ZXM -?3$I*EK0C,KP1E"TF=(&P3 ?$UI+1;JJ4@: M? U/ZX>G4F"0\1V7!+L(Z&V\VYN/%"$S!0EKFK6$A_WUPTDQ0=(M0F<3^HL@ M(&7=43S#GS&.%%*WEW/QZ[N3 M6UG_!A++Q%\Z+=[+>LR'B/TY^J)*<(].;?:<IRMCT_/3_'BYP6:=+FB(H?;3Y[]T,@/!IDCS]D5-8U $@==G_F& M_H@.+U"/VDB>/,X5!3>N,7E*&A0?OEZ@;?_" .C1L>9@]3 ;3)9'!DV:!6A6 M,G8]+0/=]%P\EKG8('$@W2?./&,Y6JZS[@X4K M#@_=KAKD;63T%55CP&/OX!M$&&#Q- [IG)*Q)(TH03LKD4LE%X-1DUXF=051 M=D!2.'.X);M&Q3E"R(U.E*K*Q_8:'\<5'MW]2W;F(I3"O@N%8 CQPLJN9\Q= MO+X-&9F$O+54KR"?T:>CA,.!O%8TR8$NH_%DF)M]26EJ M76QHYTG!Q_=S/N2A4RH3P]@N#M5@L(U%4@^U,']5R*DP"2.C*Q^H(K *)TI8 MUU(?0S#&OA*0HC$)+K]4/)HKJ6EF^AT!JY5;0X5#\,JWO64@[E-''$QQ0E:* MD\S1=Y<5-_^O#7]]<2V7-#,S/)UY8ZJ0 *_1%/B'8(D33HH7CE'FEE2_PKH' MO0=P1AT:#Z#GF]GTB5C&$5=NJDJB/CH0'B:K5+\_L4 '94:S%NA@J'=1.R$V M4,8HGD)2S%56Z=3SDK/@51684KM83\>);4;D1O_I"RO.,)!)_3.-:,GVT;I! MN10-W\9!006(LZZR;=4P-MRE4"R^5%D8EYR%(>PIPIPB&37^]FN'A(DQ72/7 M#MV?2YP7O!'')>%L2H11YT=S0D@%T'#.Z]V0%2"I% MM,^*+@>YG9\=/3T]/ MGQP!8G;5A=&_C-0 K7Y&9- 8Z>PT#)99^<:0]35/]$NF)M7TW][(GB?9F_P: M:H/GH/7>]YXT?S6B510&FJL2!>: M"EJ:5 YCTE3 #6TK!^"H ID^]NN%D]'O19!Q5ORK&,<3 A]^.M)_VO_P9AY^ M;S(L#[_:N4$TTVB@4@6VGDZ_?W(0TDAZXTW+OSY9&N]-S2]+!5JTM #/"X,@ MBV_H@/[G2"_^!5!+ P04 " #MB:Q4$@JPD:$" "X!0 &0 'AL+W=O M\>#6A84'.EX6(DE/B)]J>X=6VF+(E6)QBMK MP.%BE$QZE]-!B(\!7Q6N_<$:0B=S:Y^"\4&.DFX@A!IS"@B"?RN\0JT#$--X MWF$F;+C>H]_$WKF7N?!X9?4W):D8)><)2%R(6M.#7=_BKI_3@)=;[>,7 MUDUL=I% 7GNRY2Z9&93*-'^QV9W#0<)Y]Y6$;)>01=Y-H[BO-H_%C//3[7: BN5_SUPY08-FRF^0YBVD!DKT#T MXCW3B#K9MD;>/VVQW[$Z_]MC_!] M,O?D^$7\> -^T,(/(OS@?X[P'R$ /AJ85$YIR"Z:@S@!*A"N;%D)LP5AC*U- MCI*]@N+6S6P"HJJ<7;%7&, -1_*-@#)2Y2**@%4,GU#/'2(R8*8"0+!2HF$=LD!4OH7?.1"58S:$=^+QKHA >#-]!V\R>\8M4 M0H& GQ=*2X<&CCP)1\HLF64H V?')US=OP+4$L#!!0 ( .V)K%1:K$@-6 X .(F 9 M >&PO=V]R:W-H965TJHBA* MMF3%5Y5\)/'N)G:L.%M;6_L!G %)V#,#!L#HV%^_K[L!S%"FF#A?)!Y W_WZ M&#Z[=OYS6!L3U4W;=.'Y9!WCYLG14:C6IM5AYC:FPS=+YUL=\=:OCL+&&UWS MI;8Y.IG/SXY:;;O)BV?\V7O_XIGK8V,[\]ZKT+>M]K.NGT^.)_F##W:U MCO3!T8MG&[TRER9^W+SW>'=4J-2V-5VPKE/>+)]/+HZ?O#RG\WS@5VNNP^BU M(DT6SGVF-V_KYY,Y"60:4T6BH/'ORKPR34.$(,9OB>:DL*2+X]>9^G>L.W19 MZ&!>N>9?MH[KYY/SB:K-4O=-_."N?S!)GU.B5[DF\%]U+6=/'TU4U8?HVG09 M$K2VD__Z)MEA=.%\?L^%DW3AA.461BSE:QWUBV?>72M/IT&-7K"J?!O"V8Z< M*I. MYB^@]+'9XR/0>WD-OE\+_N5B$Z!$W_]W#X%%A\(@9/+J'P4L=;" SO_N7:CN]N__N7\Y/CQTZ#Z3O>UC:96E8/1NR"O K2K M-7V\M)WN*JL;%4#&(--B4&M]9=3"F$XAQS?:XYREW*FVT@6U%VMWMQ4:]VM6,#6!L[F!Y=O7ATH0 J(1^-M M.Q+&=@(U.#=3%T%MC&]M)(%[J.'5]Z8S7C?-+06IV= 78^=Y"S*;!LPA-\O4 ML1$N24<$,8OX_<7%^X.IJHR/P"W5N9B$=;CAQR*,#.*2&$OO6J:<9?]SEMZ( M \7 <0VO_MQK#XK0[(/9.!\5V!/TJ./YX<\S[!?!6WL'9]4T,1 M1=!-+''G4]\)-A:GW@VBUH6(&Y4A3.BZ'D2_E.T?4W8EW;\UVBM#.:Y>XU:[ M@#53EN+OTC;XHC!#$,S4VPYPU@'_2<["UVUL!\%8TZ_2$]YO^MHH! C<"BDI0'3]":@JASN(& +!'\FOU5);G_TBWD]Q?=NU(YARUQT8A'X1;&UA62.F1P*3:U' N4.Y,CB* M_#:>,#=-8]!79T=78=!(BOV\GB$TZY&0=V1[&P@DI!J N0392 ') ,+H4/0Q! M832N!%#%A,@@49M(A:"C(]=KPSA-?PS%[.]1F&[Q)!$M2@E$6L)12896?W(H M6[(U_D3DN(*#]:(QY5[^]L&O;]\<2&AL92Q=H[>2 M=K?P26?@2@3*[1=ZWW..)-,*]+?5-%>ZZ3E5L[V2K@M4N2="S%V3&9VJ4M-9]RBL2L) M#7#5B^#\ C@3 G-CHW)O0;TTG:#28SE225LXH13?(E3%A6V#$@Y#0JJMBI3 6!A# MA96[ C:(E>F+8/]7B@+$,E+KGBJ\0.!$\6JJ#D-=DKMZ81M2!P9 ZP=,LQO< M()8;ZHEO6_V9A*Y-9:F-"X-?V6$E8'(71=RA\ YZ="J348GLQCNJ<'?-4V*A ML6@X"86VTA#9I#<;2$=9AXSY(KFH=NY)G!1+4JAWNH"(T'A+K>)0#3/_T@BF MDZE.$%0B6J1EY?,0/MY*!.%DBXQT-5M,E^YU2F@/;;R#L%!T*UPY\FS7(Y(0 MXYI2)FSG]OU(4A""&$@[SEXQ-S8PRGG32!<"Q0,)F2)DJX"T&GR72TH1R@_( M S]Q(.RK^6>EYI_M+=H? \?MFQRGN\K^UU'8LAZ-[H'E'F5"]T2A\4:,4OF& M-:CE,IQ*U&D6F\ &D!V[O=93'A=H1*QTJV;,;EARA(O+O& MK:BPF';3N%M)II3]6YX1LN:&,)WB=-0WO/OU[>O#XV\!*%".Z@Q%I90OZ7*I M-T[O4G&"-=4"@=HQN@S= ;6"5G9#/"+L:LJ14VL $(AA5DKC(IU&._R'F&.8&9QY%^TXC!@5"3Z"ID$6TU1?I=/C14TYS&<^ W0=5'K%CAP0 M_TE^"CF0+]549AZ/2-9L/415;5;>F%P-"R87->IJA'W@F#< !HP,NQ#IJXFH\6=[9.U7=G(]_UG(R6FO"0&*Z]; M.8G61W\VOGR8>W^1900"Z#GT6(4E C4*]"1U*,!)I9Y&F6V$R)]*E;MA!R*W MOCEY./M6M1;]>\K&;XY/9P_+)Y1T.\R6MPYQ3;'5RH91M@\_:@^[Y 4ADY0= M1&KR>-[*[XWYC[PM@9&?8NLO[L<0V]..,:,=X7S7M+T M@.!) *2:YQ/N2?V5F?QQ?ON^J=W=1=XE:E6M/5JDCQMN^AY<7'X\("?.#^=G M4_7:+*(ZE'_/-+[OQ3>ZUWUWCC?1Q \'SX]/#1R#X9"P]1:8(%"U5XK<# M20BBMP7)M6@G MD(OQ@*TD#NP!5*TX)K<*"$26!G9B1U6==FJ[:DIKLD,2O&B+E7=KXZL+XS&O5! M)I!(9:^G=BVZZG/J<,3@NJGZ1K9BM6UZ"NVT9#+2]_"0)887Q6<<=T8C<,963:9$5MB#,LM MGL0CP7V0-3ZKO#"C=37CXF!G)SB7-DM*'B62!1]8D$^SV;A;H2[R9/[4+@^3 M\J;FCXZ??KT-"<%IQALEB4+MH\5!ZRBM<^R+Q;@[*6U?"2KA6((EIR84_PUM MLEW>EDI3%\10H4*;"+BG9Q!E5Y;KG$Z %E,&KVAR)?-H#L&_ZZZG1C^7IS[D M_J]%_XP\I@8H>I=+538,69 F,NE:I2M&LXT!/FVPT>2ST:[,H9%);=AWRR*$ M-[:\3 U$PD^&V6#A5K[2#IO&1-,K/9(8^ETM<8:H2T]R7#CB4G@$-S2)? MI!Z1E_);D3?."7XT,X4-HUI0GS"?G>6N8#JB]J4"=/K1UFE/;33%;RWNI^V] MMO4A;3WUAMLDNG1Z-CL9+G$393*;NNQG]?F0%:++9[/SK/ S:%(1]M.K!&"E4E4/?A%2NC# MDX/?*7<_X3X_3F;[V JMM+#(9'G=9FDA8T=9 ^ MVZL;N)3 2^)3H2>F $W[/[OHF3ZRU7#4:$236]TF.)(1)C\]*.L_B,7F'?'6 MQ193C*B1X"0- F.94S(*XE % RS0=E-]O.1'F<,40'$)O@3HW-3L6$;M[+%> M,>PDG$:G]>I /7XTY^<9KC7J%WU#I?D[BI5]@L4O/?BE-^@,%_M\8T1RW%YL M[7"-3W/*@-Z\+;M&2\Z*KW/]*N.,F&C' PM%?:VR>!/2/@L&6MS>E25- ZE" M2!5,H29C#3Q=BDJ%WEX7O*2BUK7GQR8]Y]#!#YW6]5()=#W-FZB>0O[]5_PE4 M_PTT+BU[SO+Y^52]3%L6PK4%=4_2?*[&J2N=H2*I@[S;'ZYPAA>1%=%-V"';F5$++YSW1<=570["T61-U6G79'HT^MT1;J_XUU4,?UV4GR"53\L/N"[D M=TO#!D[9:A M68,V[3X,PT!+9XNK)"HD%2?[ZW='/2RWB=M\B'7D\5[\W8.G.Z4_FPS LHC6;F22#0IBIJJ#$G8W2A;!(ZNW,5!I$Z@X5^2SPO/FL$+(;C-+"[/STTILX0/8C]6-1FK6 M2TEE :61JF0:-F>CE?_J8D[\CN&3A)T9?#/R9*W49R*NTK.11P9!#HDE"0)_ M[N$2\IP$H1EWK,Z>KY*[6AKI(C2^%>LERFDA^=G:%%O5M"9=1$<%7@M])2%/F>!%P1' MY(6]FZ&3%SXC[Z(VN&(,NU3%6I:"_#7LK]7:6(W ^/N(BJA7$3D5T3,J/F"^ MI'4.3&T0K8G:EO(_2)E,H;1R(_%3& /6(! QY)KH,F6Y%&N98_S!T'Y=?!F^ M)EK'5=]FP#8JQP23Y999ND6&*6I0LV$6-]'K2I2//QE:SB7B"!.0@;$2<8V: MT61BVPBIV;W(:^?$=YJ+O]WYRUP9L@"1"([=U&L#=S7:P0H0IM90T'<%6BH\ MF/Z+ "^X<>//RP#/_AYO[1* M$E6W1@*>H/#Z/O?C><_;DE?E/4I3FL(3>!PK8\_1DC<:*B%3!@]85@U%$:U1 M&#R-V:XU^='&/>;>8M$?;Z@;C=58VT=WBLROG.<^#^)H;XNCKDHKRJVDA&91 M['%_8$M'OW-Z6WWC8,+F/(H"C!J?!]Z$17P9!.Q669%_ QKQ,N+!2=B?C)0J\>C"-HYX?(**.DLZ&AEU#4?#,H3>>,D]/QJ(:>G+EC>%M45CPB4/ M_7C UJ^\PS!B$4"LYH@@& KG+%?E]J4%7;!QS(-@J*>E?X$-:')QWXJL:IUD M%(Y*RP181*CVPSUL6MIE48(%%$W0KI0RA^G(\_C2VR=%1[\Y\!4/4N#IF@YE M^!X/O3WB6_))RU[TM@S3M5O[Y^B?*PK7WZI&&QH;&.I$2XWK^XC'$N^[F8.: MD2075%2L:HMG8AO<)E(G=6$P_Q*@^BLLXEJZ K2OE6+0>%.4,W4)^!XV6-N= M62U?5Z2)/@0-[6H:.HBH,38. /1?)=)9MI,VVRLCO*Y2@3,=RW!\NZL%EE L MM"X#IJ0:LPV=^4.A-C_D["UM U<,:2VW<41+O$AI+T1G9Q1UI^W+?\^&C??4..PLLUSW?QUBXRT*0Z?'";VBQ\;-6_E!MJ4.1@M MQBCM$5 L-8XVG"GI44N#V&ALHX1+B$:%/ MZ3@L7G1W(#!AVD1LBJ#IY$+**?"RV6RKQO"MD FLAXGKS:XP_B[*FE#5C.S> MLQ=_FVF [K4 ]%J@H::UV;I:K_$FRQKHJGR\JB *!RS4Z! *-*YX/%I&DZ=($YJ)N7 M7D-85;G7U5I9?*NY3ZJNH(D!]S<*RVE+D(+^N7W^/U!+ P04 " #MB:Q4 M'PG30AL# "#!@ &0 'AL+W=O%N MVS80?I6#5@P)($02)=M*9ANPDRP-UE2IXW8IAF&@I;,D1")=DJJ3/7V/DJVF M2.--/\@C[^Z[[WCD:;R5ZD$7B 8>ZTKHB5,8LSGS/)T66'-](CW$"9S] MQJ+,"V,WO.EXPW.\0_-Q_3?V]PIEQ77 M>"ZK/\O,%!,G=B##-6\JLY#;M[C+9V#Q4EGI=H1M9QN1<=IH(^N=,S&H2]'- M_'%W#L\<8O\5![9S8"WO+E#+\H(;/ATKN05EK0G-"FVJK3>1*X4MRIU1I"W) MSTPO2LWS7&'.#6:PP*\H&M1PM.2K"O7QV#,4Q)IZZ0YPW@&R5P!#N)'"%!HN M18;9C_X>D>L9LCW#.3L(>,/5"82!"\QG[ !>V&<?)I\4U,.8._0!^_25F ?L-9K?)'Y_? M0Q"[410#"]Q1Z,,'K%:68.RR..Q-$SH"!4?!,8SB4QFC(8"D-KT"\X/D& M@LA:1%9BL1O& 2SD$Z_,T_=3&[A^1%F[@T&P ^I5Y#4@A3^T4NB[IY3F/___ M:WE>B[1J,@)[28]J=_,YF;]+SEVXGUW,KA*@VD!R=Y.\N[R'R\7)S^ZL]ZPQ MU*CRMOUI2&4C3-&ULM59M;]LV$/XK M!VT8;$"U+$JNGWONC>?Y7ILG6R$Z^%A+91=1Y5QSG22VJ+#F=J0;5,39:%-S1Z39)K8Q MR,N@5,N$C<[>+.>Z=5(HO#=@V[KFYG"+4N\741J=+MZ+;>7\ M1;*<-WR+*W2/S;TA*NFME*)&98568'"SB&[2Z]N)EP\"OPK$$HLG+? Z;/#.Y32&R(8'XXVH]ZE5SP_GZS_%&*G6-;%?<%*!N^T [ M;D:0I3&P,6,7[&5]F%FPE_U[F#&\PK4#KDIX_:$5[@ K+%HCG$ +O]^LK3/4 M*G]<<)KW3O/@-/^"TQ5-4-E*!+V!5AD"8$3AL 2^XT+Z7+^@J7IA.8G01#RA M\W=@>SC/%>*B2S_"U[;A!2XBFE&+9H?1\O%;?$.%LH3U 5R%<*?KAJL#<(/ M+6RTI&&F3 Y*.G%C02B2TZVEK-KA-5#YBJJO'R6\P'J-YG23PJ!5O"T% 1J2 M<=-HPQV&FCR.5B/8ZAT:YRH@F=8;VIMG/B3PBNT M=? ]9(S%TZLIG=@DB[-Q"C\;;6TH Y=!-"._&^X,+#CLL7@*XUG%*7W-8GSE,&%WIGTO3/YZMXI:+9\3[;D MF=ZA4]#$\;7YILX*U7VNO2ZB>KZ]'@C$_P7QOS?@>:>]1:JPJ[B"% [(#94L MO7H9Y[/)Z<)I8.%D(4W3>#++>YI8V8F5Q=-)UI/$R8_''[Z;L93]2,V$U-"F M<_9W9M=#GQOGN79)SI[T<V+"Y+>6Z5ZU[W_K;?C3?=2O@LWBU6RL76M[K$ M#:F.1U.JL>F654X-T7R12Y)RYG>%0XY603RH'T.1[651J,LBU7IX-ARK-H63J M5"RAPI6YD"73.)6+H5I*8)D5*HLA==UH6#)>#:9C^^U.3L>BU@6OX$X259#(3XLE,_L@F ]<8! 6DVB P?#W#)12% 4(SOK68@TZE M$>R/U^C7UG?T9<847(KB;Y[I?#)(!B2#.:L+?2]6OT/KCS4P%86R3[)J]D:C M 4EKI479"J,%):^:-_O>QJ$GD+A[!&@K0*W=C2)KY173;#J68D6DV8UH9F!= MM=)H'*],4AZTQ%6.06F*HE8/BU(L>/;%: M.AD/-:HT@L.TA;]HX.D>>)_W_GO6SS_Q_Y?<946PGBMR#_G,Z4E4N;? SJ"3D=@=01[=#Q@)65U M82,\-_J>U_'6.9!Y%W.F%&"T6961@K,9+[CFH'8%_: ^4\=G:LE2F RP4!7( M9QA,'U'5I2B7K'KY]9>$>O%G]5:USIDF3 *6V[>:2\B(%F0&I&S8D!%<[GN M585;TUI*7BU,=7!EQ1EBBP(+'KF3X8!)17B%\*)6Z)XZ.2.]P&]Q#44Q,)CF M-._R3([KBM49UY"=D$>AT>">^$Z)&WB&@GCM>SWWR;EU](Q<,I7;2*=F8+Q% MEZP!=N6()(%#O:0_L&&CGWLCY#:\8#7*)SP]E8F#S9C%G=?HI[$G&,7$*'*"9(/V>GXCJL4G M#;)L[?NP'AHZOA]O]+R:_XD'9' 3QS/C4TZ0B>F)AU^2!T_'O72<;,I&DPPGCM(2DPI207V MD S06=,'CE"KXP5T9T:[Q<::7AF^,>D]*(=)?@4IE#.,7LM:;Q^WWV[\W_3V M@L1)(G]K]!&"AX$3QM[ZM9;[213W(X<&$:&AA^-PJWA^&KV]D>-%T8;>K^8? MI'?DNR0F$?7?2>]PY 1QA"/J^DXT,K2B(3(]"3[ [\1%L'@/,]O%'_/[/2@' MFF/8-=V(=K7(@UKWM\BF;9ENMLZS-KU,ZMPV M:Z/^Q:PV4;)U\*:CMVWV-_5AA_9VS5==[NW!<+DVL#D_>D?)<7M6G+QOCZB> M06IN8H!F@G)(A6< 4M5U'3\Q!/5'H1.$AK1X##LTI.TJ]:.=Q!CV;JDER(6] MBRMD;UWIYL+:?>VN^^?-+7>SO?E7P# L>*5( 7,4=4]CS+9L[M_-1(NEO?/. MA,8;M!WF^,L"TFS ];E G]J)4=#]!$W_ U!+ P04 " #MB:Q4D*LQW:X# M @"0 &0 'AL+W=O]5"4UN%6'0%<* M:.Z42A[$83@)2LJ$MUJXLR>U6LC:<";@21%=ER55KQO@\K3T(J\[V+%#8>Q! ML%I4] #/8#Y53PIW06\E9R4(S:0@"O9+;QW--XF5=P)_,CCIBS6Q3%(IO]C- M'_G2"RT@X) 9:X'BZPA;X-P:0AA?6YM>[](J7JX[Z[\Y[L@EI1JVDG]FN2F6 MWLPC.>QISBK#1:LPM'U6DC."9L4IZ-PJ\,]Z(:]3:WQ1&MD7*9,-'RIR,E::VR#=?:U M9IJYT[_6J38*2^?O.WZ3WF_B_"8W_.X@DR)CG#4>Y9Z8 L@&#DP(S(&#@#&S MRPWE5&2@R0XX-9 3(YWPK72]E:6[8&RSSW5%,UAZV,T:U!&\U0NZV$N.G6I! M&%L!I%+RB'XTH=B$;Q%(KPA 0R#M"*AK MF90'95;WB_.(%/SY\?KU+@$I-3 MO(JNC@XF(5^,IV21X9]8:3 T-!7O)^,)H-X[(=A."0__S2+H_B7\\&V MH,C6@MQ3ILB1\AI<' ^"_8-AP0] E8V>)I$_C4,RB/QP/!Z2R61\"1&;("OZ M+B"#6M Z9QC9(2)+)O[L@\7ZP8_',;['$S]*8JR>0XWAE^K5A3&'(]["E<6, M_&^F O.;8I(-P_2UECM>[?:98@C>V]LP_S$SG7Z#KWG^5W)WB]756JV4A66I M25Z5VPXL(L11XW79>#JSRFC5@'6V',@<)V(3=BTY MRQV%MMN(FP-Z?A7 [0U>?A^?-B*7H4X2?Y:$=W3/\6RR,AK[D]&T[:P^17W/ MO'5[!A=3JP1U<+-9HZ-:F&: ]:?]^%\W4^\LWOP[8&CQ#M*$PQY5PX?IV".J MF&ULK5;; M;MM&$/V5 1L4$L"(=XER)0&RW:1Y<O-0]&%%CL1-2"ZSN[3B?'UGEQ0E M)['0%GV1]C)SYLQMAXN]D)]4@:CA2U76:ND46C<7GJ>R BNF)J+!FFZV0E9, MTU;N/-5(9+E5JDHO]/VI5S%>.ZN%/;N5JX5H=ON MGWWIXW"BD/HO*(2]0FAY=X8LRVNFV6HAQ1ZDD28TL["N6FTBQVN3E'LMZ9:3 MGEZ]%2+?\[($5N?PKM:LWO%-B;!6"K5RX3W5Q>B!T9$:+SQ-%HV>E_7HEQUZ M^ )Z!#>BUH6"7^L<\^?Z'C$=Z(8'NI?A6< ;)B<0!2Z$?AB>P8L&]R.+%_TG M]^&:JZP4JI4(?ZXW2DLJHK_.F(T'L[$U&[]@]IYZ*V_)CMC"@<*/HGL6Q?3K MA6I8ADN'&E*A?$1G]5 @;$5)S<;K'6B3N;[C^%=4H.DZ*\A-6O.ZVS(IGXPP MJT1;:\-I=PC+*"6?6ZYXK9A"7B=,WJ"8*00 MX;W0"-%X J/0#?QP_ T'JHRL&$H#1FW-VIP3]-B22=PXB.%,ZI(A=%4M_FL2-SB"_+LK9J^W5%FOPK.T29#VZ0 M3N?'2WD_1OE9SD^C?8=F%A@>'^R32 :O#LS6EID+;RWA]0FG]2FG[^3-*_2_ M@*Q-?4D2Y?7K1HH,E2E!A=8M$Z\<'VE0-;9ET8=4M9N/-(I,I9\FX.+(J;=MN@&SHA:EV#U94L0T;TE5FG@J2"?Q'*9I M0&W@PRB)W7D0C6$:3MT@G1TOHL1-$I\N8KN@@#1 4*D>)&'-+YHOM(3 M(!3AQI-H!G'DIB%IAW-WGJ1C"&@_#8_'J3N=S>@X<8,X@@=!B"<%='"6*/J0 MQJD[-TII[*:S8 RS*06'N \7M ]#0IN1Q'0>_; _O9/A5J'*V@Q"VI^I,9M:/LQG:WT:*QHW(C- U>NRSH2P>E M$:#[K:!'J-\8 \.WT^IO4$L#!!0 ( .V)K%37BASHJP( )8% 9 M>&PO=V]R:W-H965T]Q_AD,]4X^7 MH[+AR_:=[V0:L;RU#NM#,#&HI>Y.\7+HPTG +#D3P \!//#N$@66&^'$:F%P MSXSW)C0OA%)#-)&3VO^4K3-DE13G5K>HG\$XF2E@6] 2#?N&#BS;M,!XPE,V M>!!DM,-%["B?CXKS _:ZP^9GL%/V%;6K+/NH"RC^CX^)9T^6'\FN^47 K\)< ML70\\L3X!;RT+SX->.D9O UDCFVDS17:U@#[>9-99^BA_+H /NG!)P%\<@9\ MVSUSAB534F122??*S(9WIB$](>$ G%,N%,:_>ZUDH>JL^33)*9YRD]/K# MB$\Y>^LOQB>S4H/9A8W@&T(\NK'I;_NE<]/-VC_W;F-11W926Z:@I-#DZIIF MW'1;H%,<-F'R,G0TQT&L:'&"\0YD+Y%Z=5!\@GX5K_X"4$L#!!0 ( .V) MK%0>RU7==P0 /L+ 9 >&PO=V]R:W-H965T8 BCQ792VG5J[4=CPIY5G' M@_MBDRM],)Q-MFP#2U"/VX7 W;"SDA45U++@-1&PGEIS;WP;:WDC\+F @SQ9 M$YW)BO,GO?D]FUJN#@A*2)6VP/!O#^^A++4A#./OUJ;5N=2*I^NC]5],[IC+ MBDEXS\LO1:;RJ958)(,UVY7JGA]^@S:?4-M+>2G-+SDTLD%HD70G%:]:98R@ M*NKFGSVW=3A12-PK"K15H";NQI&)\@-3;#81_$"$ED9K>F%2-=H87%%K4)9* MX&V!>FJVS)F GVXQKXPLV%L6<3^YX MK7))/M899.?Z0PRMBX\>X[NEO0;OF'"([]F$NI3VV/.[?'UCS^_-=W6:+YD+ MP>H-F/6?\Y54 KGR5X^SH',6&&?!-6?80MFN!,+71)XX3GF%3269X24\ZS5< MJG6O==VN8[EE*4PM[$<)8@_667Z7W)!"$B;)FI?8CHATA@LF)"EJHG*^DZS. MY&!,'G(!<,02-)8& /WCD9M=S799H2 ;D'MTS$2:$U3$;MACEV]-(=^1*/3P M-TP2LL2F*^J-3390@V"E$689TKG0Q=9]27S;CP/\C1.?/'"%0N](8+LT-/]^ M[)$>0,(.D+ ?D.;I,7@HGCX1OM7%D2:@Y?R^>20*58"\A$>_\8<^ZR3!>0QWAA#'ICVC M2X06$YO20 <3.C0AD8,0SZ5.[4WL8_(9I/:GRZ4)G.J-XF2/Q]<2:Q,PY?=M M)*&=-.X\AXY(X(1^Z^X\S'Y?5^(^]178-'%MUZ-:A#I)C+[B40]IHXZTT?>2 M%MMLW0#[Q>F^*?(FG MU+,]S]7%&SF1U_'30P%JSAM^MBC=-.*#3OZ%G#_^D%"/_HPWQ]6)WU?_HS=^H_BX31PWN$B9X7_V+U!+ P04 " #MB:Q4>"-IY_T$ #]# &0 M 'AL+W=OZ"E8TNH)*HD%2?_?A^IBYTN<=/UQ:*H<_G.[2-]MI/J MJTZ8#=WG6:'/>XDQY>E@H*.$49X-@.)P, M-SQ)6>9-008WQJ;O%O53W#=Y>(E"T"@$#G?M MR*%\*XQ8G"FY(V6E8G&:509? M^; RVF)]JB#'\7Q V\=QZDP;Z;R)M;QC]*V.5+JV;C8;#(AU;+\BSR%]DH8U MB2)V6XJ!#8*7LKAC95+TAI.@]QQOV8E]$4J)PM M?K5PXZ8]IWPI\U(4#R0R M+?>!NZB?2T^#9",S$ 820* 2;>#&KIWXB1W#F,1.J%C_((M7URN/UAR)2K.5 M2Q44 ,.1RDY668RO",*D)TX%%'%*MXEB;GN9;2^[!K0_/KVN"E$AIQR_H95# M+\LFXIO59TV^-YQ,O2#TL1KY0$;H>$G3]%48$XJ9F'1PENPX?]YQN($#:2:/72S4E4%Q22.9M$ MQGW$S33IS\ S668A &F;E-H X&HMH]3YV:4F:4II#>D&]/=M!+3,EY4JI6Z$V[KC^Y'(6U7C2IL?EA8D$R4=R_3I MW0M%?>^7*F!PANH*Y:SCK&M NX05-RW]?U.^@XG]L*'''DVBQOG;S."A3CL* MFHW)+':T*T;_@9"-4BB#%6!%0B?](T0Y[HAR_#-$65:FFUP,=QHY6ODY)CSJ MT-YM3G4I(C[OX?*B6=UQ;W'[B&>,/?9L_-IV2Y?H'X K<''ZE7ZC"IOJN9ET MKEYJRS^P]71WO8X1K5 -:Q-_@@6>\Q$M-X;5B1'W@(,5:PC?X[:IZ_0==.=L-J7??YL% M?O#'WKP3ZOCIB1K X<0;@WY;AV^YD+A#U=B^/$= >\+QFGJ/0R\,A]XLG-(X M\.;!U!M-IG35G9Q[DN2H4CAN69\^>3;8W*Z6-_:0".:^-YT%=C69 ^7HT0%; MN+ GD B]>3CI@G\1Z+8U)SB ALC >$SCD>?/)]Y\ZM/5?Q+5AOF*AOW1S#W\ MI^5:RTXR;"6?XH/!P944]=JZB[?&.*&;ZMMIM]O=[9?UE78O7O\Q0(]OTT)3 MQANH#OM33+JJ+]OUBY&EN^"NI<%UV2T3_#]A907P?2.1S>;%.NC^\2S^!5!+ M P04 " #MB:Q4TKPM\, " #W!0 &0 'AL+W=O"D6^(#TM+RSO(I;EDR6J)TT&BSFD^A\<#8;>?_@ M\%7BRNW8X#.9&_/L%S?9).I[0:@P)<\@^/>"%ZB4)V(9/QO.J WI@;OVEOTZ MY,ZYS(7#"Z.^R8R*270208:YJ!3=F]47;/(Y\GRI42Y\8=7X]B-(*T>F;,"L MH)2Z_HMUS.;-T*J D;4 8@'8 M7+<@H +AJ?< UYBA%0H<":K(V,VNOQ7$A@G.J$G2YJ,#S',,%?ZWYVN/MU_X M(_/F1G&_2KU@'JX!6%KS(C-TS%Y/@KHI%\)FP8DA%Z9<"KWY\.XD&1Q_=KLZ M.O-M:6US99( HL(B0ED7"_IB 7[JM&C?&H3.O#& 3L::A/7$##.5XQ/7/8/' M0'&[2Q& -:C2HLHD8=:%FWV"WD-GT#\\.1UVV3PZ3(9'<-5>:7OKG>-1K]^% M Q@=]T[AX+4JB7>:L42[""/'06HJ375?MKOM5#NOF_FW>ST2^2864CM0F#.T MWSL^BL#68Z9>D%F&UIX;XD$1S((G,UKOP.>Y,;1=^ #MK)_^ E!+ P04 M" #MB:Q49TZ5T_(" #6!@ &0 'AL+W=OK8F>V4]K_? MV0D9K!1I+W"V[[[[OK/O,MDJ_61R1 LOA9!F&N36EN,H,FF.!3,7JD1))VNE M"V9IJ3>1*36RS <5(HH[G4%4,"Z#V<3OW>O91%56<(GW&DQ5%$R_+E"H[33H M!KN-![[)K=N(9I.2;7")]EMYKVD5M2@9+U :KB1H7$^#>7>\Z#E_[_"=X];L MV>"4K)1ZA.<-+]=%$CDMW*4NKZ913 MG)W=($DRL_<.YI)Z M(ZL$@EK3FQ!,I@AU#W%9-TK]9@6SF(%5(#R)8]4]F7"=>88K%"O=OIPEDE695Q2G\.\UK&.^KNB+G>+3Y $H?=7M<9_3 9].%1 M628.(]XZW>S5Y>;?2H74;EJCM&\8''5R)742YVFJ*DGI2O;J>LA? TM375%) M]R_B PP:-H.P-QP>(R"4W'RTJ(O3%/[;+;D,1Y==Z'7#^')T4*I#@KU!V$EB M9PS#X; /QSHEVILU!>J-GZ@&?!'JL=/NMD-[7L^JO^[UQ*?7L>'2$)4UA78N MAOT =#U%ZX55I9]<*V5I#GHSIP\/:N= YVNE[&[A$K2?LMD?4$L#!!0 ( M .V)K%3Z5$^6004 "L- 9 >&PO=V]R:W-H965T>^^YYUY2%SNEOYJ-$)9\:^K67,XVUFY?S^>FW(B&FW.U M%2W>K)1NN,6M7L_-5@M>^45-/8^"()TW7+:SJPO_;*&O+E1G:]F*A2:F:QJN MGVY$K7:7LW"V?W OUQOK'LRO+K9\+1Z$_76[T+B;CRB5;$1KI&J)%JO+V77X M^B9W\_V$WZ38F8,Q<9$LE?KJ;NZJRUG@'!*U**U#X+@\BEM1UPX(;OPU8,Y& MDV[AX7B/_L['CEB6W(A;57^1E=U_E&V[YU856.Z+=;*"Y@0_5 MKX9SLG5)>; :;R76V:M;U6R5D9XAM2(WO.9M*NSPD+*8F" M*)K 8V/TS..Q'^!]TFO>RK^Y"Y^26]4:5B2O MR0,>"HC3&O+[]=)8#7G],>%1/'H4>X_B'WCT@*JKNEHX:[)]A &EI3#'N)\$ M%?A2SJ[MG1$H^(L,@M-QX1M^(4C1+H?W-2=?RKI)65*?D MGN\@."LTPC;D%2EHQ I<,\JBA'Q!S<%1LM6J%,:0.*516) XH5D8.KXDM%F1 MM5*5(8Q1QC+"(EI$C'Q6%D2^(GE.LR)Q@X0624$F6$Q&%I,7LPC/MD+;)Y]0 M\5_,7^%9WOD^>R?8,X&OMLLDBY(Q$!4V+U&4O#@IX@1>\++NFJR&+"CT0 M?* HQJKAC=)VJ"IR N?C/#S%(*5Q$I^2Q=&$4-*",\2:04!.#9A>),F4&M)1 M#>F+U0#'=0>GQ3=L:T88[X2R&W!3=EH[9FK)E[)&2SQ>=M.VKLM2=2XK"_[D MVJ;'OQZ,OG]&?HDZ1JSM@.65P% ZK@H9"T=@)&R%M(!O5-1* ![L14A6E-(L MRL=Y)72 L/O,0# )"(YR&J3Y(50%)6"J<=J*L#XC84[C-!CG:/7$:Q_%"1(; MAC2 B"##/'IVJ00SLH0[UC6. >XD.D7?R/(8_H?H'I\@!#C3KDGMM'U(/1WS ML75JH*Z-&VK[J7%Y1-\YY@2T!AL]]>'=M67<5;EU1[#GP55'7 MWY%RID5?09Z<Z!.%D(V%D/UT(>SSK06Z3MO'I<42?AU5_Z2! MXSURKXC%8.G^P-)];^F%U?"=P_U2)#6(T<9R5Q4938KLR-3>(DNP=S%W"2'J MO3C".$"K#-V(.;G'4STG'ZG.)ZGNQ?D_K602XCB9/>Y/-I*/JH485:BV+5^:UGK&]*:M6NS[!S-*"'^&UL?53?;]HP$/Y73M$>0$)-"%#:"I!*UVD\5*M:MCU,>S#D0JPZ=F9? M1OGO=W8@8Q/PDOCL^[[O?O@\V1K[Y@I$@O=2:3>-"J+J+H[=NL!2N"M3H>:3 MW-A2$)MV$[O*HL@"J%1QFB37<2FDCF:3L/=L9Q-3DY(:GRVXNBR%WTT MZD>'C1>Y*K9LQ2U+)DO43AH-%O-I=-^_FP^]?W#X)G'K MCM;@,UD9\^:-13:-$A\0*ER39Q#\^XT/J)0GXC!^[3FC5M(#C]<']D\A=\YE M)1P^&/5=9E1,HYL(,LQ%K>C%;#_C/I^1YUL;Y<(7MHWO8!S!NG9DRCV8(RBE M;O[B?5^'(\!-<@:0[@%IB+L1"E%^%"1F$VNV8+TWL_E%2#6@.3BI?5->R?*I M9!S-%IK0HB-X?.<^.X3.4JP4NNXD)J;W3O%Z3S5OJ-(S5 -X,IH*!X\ZP^Q? M?,QAM;&EA]CFZ47")V&O8-#O09JDZ06^09OK(/ -SO!]H0(M+/3:E A"9X>< M'?RX7SFR?$-^7I 9MC+#(#,\(_/*@Y/5"L'D( _EQ4;J5%4OLRT+A-PH'AZI M-WS?2$CE@#,!3J,R3H;+?4(*.AG#A'5\POZF=IRRZ][!LK"(AUZA[U4HL/_T MH5-K46>2,.O"XG_&#]#I]_JC4=>O1KWD.CWAQ-%HHRVN36W95%*LI)*TXQ%6 M@GF!##C1E">OJ;8(UNR$(LF-Z(QOQEVOD@Q896E(J$;U=I@&U>M>(+]Y&:@<*&PO=V]R:W-H965T-,N_7S_24*1M+XG'GN\Q MDW'R09LGVP(@>99"V772(G:WE-JR!@W$FMC63H0M-0VQE@50!)0;,T M_4 EXRHI\K"W,T6N>Q11[@#(3R1L_%GY$PF20\\7Y_8/X?:72T'9N%.BY^\PG:=?$Q(!37K!3[J MX0N,]=QXOE(+&YYDB+FK54+*WJ*6(]@YD%S%-WL>^W &R.87 -D(R(+O*!1< MWC-D16[T0(S/=FQ^$4H-:&>.*_]1]FC<*7 C O[-J?H''E>6H[JVZB>75!? MD >ML+7DDZJ@^A]/7253.=FIG&UVE?"!F1E9S-^1+,TR"XT;'[Q"NYBZM BT MBPNTK[7CU^9@T;BI^GU%8#D)+(/ \H+ MUX>P/C6NNMF6% :[=O7VAK9;@*; MOW?'8I[3X[D!>C83$DP3)M^24$<0W+UOT@P/@$=UYKC:? "TR_G.(%4$L#!!0 ( .V) MK%39M$;I1 ( #(% 9 >&PO=V]R:W-H965TZFELI.@0MS>AZ'-*JBY'>@M*-HIM*DYDFG* MT&X-\-R#:AE&P^&'L.9"!6GB?2N3)GJ'4BA8&69W=U4RX9;F&OY7>18 M38)/ M '(A[0WM/ZT7[/KJAETQH=A22$F-LDF(I--E"[-6TZS1%)W1%+.E5EA9]J!R MR/_&AU1?5V1T+'(6721<@=BX91=$+/_/_AHPMRXN[,8\\7G^$[=;@_ MIAN+AB[USPL)QEV"L4\P/I>@UZ=,6SS9@X;BSE.X6=^G43RX2\)]_V#^#1K= M#N(NJ%$7]JY?#:;T4VF9+[)I4N?M!G_J[_L;_XP>A&9^_] TKPFUH!3*,@D% M40X''VF<3#.AC8%ZZR_Y1B.-C%]6]*B!<0&T7VB-1\,EZ)[)]#=02P,$% M @ [8FL5$WX+,\6!0 :!@ !D !X;"]W;W)K&ULS5EM;^HV%/XK%KO:[I5&B>TD0$>16FBU3K=W55FW#U?[8!(#UDULKFU* M*^W'SPEI'$)B(;6;Z(?BA',>GS<_Y]0=;87\IE:4:O"<)EQ==%9:K\][/16M M:$K4F5A3;KY9")D2;1[ELJ?6DI(X5TJ3'O*\L)<2QCOC4?[N7HY'8J,3QNF] M!&J3ID2^7-%$;"\ZL//ZXH$M5SI[T1N/UF1)9U0_KN^E>>J5*#%+*5=,<"#I MXJ)S"<]O<) IY!)_,KI5E37(7)D+\2U[N(TO.EYF$4UHI#,(8CZ>Z(0F289D M[/A>@';*/3/%ZOH5_29WWC@S)XI.1/(7B_7JHC/H@)@NR";1#V+[*RT[B@)B 69LR=F"181K M5)AZM3,5M9B*P9W@>J7 -8]IO*_?,VZ7OJ-7WZ^0$_".R#. X<\ >0@UV#,Y M7ATVJ$_=ZK\1?@:\]MVOW>I3&CEWOSE>W7/$$I=UA',\W(+75#!?+^=*2\,= M?SLV\,L-_'P#OV6#W]=4DAP_H89) %&*ZL8JVN&$.4Y&K$]CC*!O8O14C6Z# M5(##H)3:,S(HC0R<4?ABF+3]4 @))BO"ES0["'MBC$=LG5#P];,!!+>:ILH5 ML[ T)W3&;*9%]&TEDIA*]1.@WS=,OS1%+#R(Q0 -?#_<#]GD4*P?^.:G%MF= M6%!%@\$@J"7@I@'-]P?!H#D#_=+EOM/EB>!/5&HV-]'D0M/&"ND?6!CV!WB( MZPX?RGG-U@U*ZP9.ZRI)GVG#@D3&"CRN8Z)I?A"[7NA(^[#<97@*50@]VV,\ MI]N?!5]V-94IF-*Y;J+* J!:#<@+O99PPTIW@\Z=OYC9S,P95$K3KC1Y!@DC M#;Q6.Y"U [TU\> ?4"W>PTCM;VV)&;J9^?^J!DODT,WD M1QW1 F/OC X\KST5EJ)AX-Y^DVX2DLVS@"X69L#-9A\2BW4^Z9KUY>SQB,,( M+0G#\"028"D2NCGRR+9P#0_YKPN#]E-I61"Z:? A&PZY.9'71'+CK'*Y95D/ MG@3M(4M[R$U[Q[9?=$A^IOG"P*NUHP8Y;$:;(:HUX$*NFC?<'PY13>ZF20Z% M_K"E!2/+NLC-N@?YS;CM?8X=LI2+T$F4@R5BA-_EV!4PU;3X7@A12U8L[R(W M[[XU*T;\;?,+LAR-3F*.1I;#T;M,TE-T./SZ[7,,LI2-W)1]&<$A.PZP!^M#?8.<#X-A MG6VO"[F]5&(?XWZ=11OPO*$AYN:<8]L^L+M]')7S]V-6;.D=PU,H$6RI'KNG MZV.9M8"IIJH;A*B-6G'E\L--[?]%JMY,M]AV!NR?1$(M_V/WC'XLW18P]80> M\&VO6;\OK\LO\DKCV_@J>3W:7WA9F=P=_1^22<042 MNC"0WEG?F"9WU]J[!RW6^37L7&@MTGRYHL1XF F8[Q?"_"U4/&0;E/]<&/\+ M4$L#!!0 ( .V)K%3&PO=V]R:W-H965T@K_NNNRB4EL35*N>MC/')3PC)G/K5C*SF?BD)SEM&5 M1*I(4R*?%I2+_!&[9-M!EPY].<;.DMU7?Y2D+/K5%BEM),,9$A234TT@:"P&='+RGG!@EX/%2@ M3NW3&#;;S^B?[>9A,VNBZ*7@/UBLDYDS<5!,-Z3@^D;LO]!J0Y9@)+BR_VA? MKAV!QZA06J25,?13EI5?\E@)T3 (@@X#OS+P_S+PNSP,*X/AOQH$E4%@E2FW M8G58$DWF4RGV2)K5@&8:5DQK#=MGF8G[K98PR\!.SR^BAX(I9F/P"5T3*8D) M!#I94DT85Z=35X,;L]B-*LA%">EW0%Z+W0#YP4?D8]^[NUVBDP^GD%/W)FM$ M7$3Z W*12HBDJ@7\LA_\&Y$#-/0LN%^!MZ L^U&6-*I1O%84%W2LQ?1K,7T+ M.^R 710*1I1"355_?H4Q=*5IJG[U^!C6/H;61]#AXU)DFF5;FFD4"3A^,341 M$UF;E"72R"*9 K";AR,O@)* I^ZNJ=;QP@D.QN/FPA=D@YILT$OV(B90I= * M@IV2B!::182K'A7"&CA\-Z5'M8]1+_GK(EU3B<0&4:7)FC,X93$J,QD:>9G, M"OU&+[*[[<"4CL*&OGZ[L..:V_AMA9W4P)-W$_:L]G'6G\)$)2^3%^6$Q6W" MG1TE9H#Q!(\Z,]/#A\*'>UG8*TZA'$)LBQ$Z81F*!>=$-D9/(;R]]6I1N9DT M..)!V,&N49:]5P(<6^T)1Y&1*R=/<-L"WR('N5+&(2<%!(5$":,[6L[!_<#2 M(FUEZ1TIZ86X_'5P/50]SW\'KN2QDZM_?%S\L)?KH7IZ;U8^%Q54DX>'AWTT M#G71>ZTPOG%X@R.J71P/)=8+_V]8P^/K")^UR>DVWC/F]0F7_I9E"G&Z 5,\ M& .2+!]T94>+W#YQUD+#@\DV$W@$4VD6P/Q&"/W<,:^F^ED]_P-02P,$% M @ [8FL5!8.MY.&!@ N!\ !D !X;"]W;W)K&ULM9E;;]LV%,>_"F'LH06:6+S)=I$$R*7=,K1KD+;;P[ '1J9MH;+H4E0N MPS[\2-D5G9(\=E(T#[%NA^?/0_+'CYL5EJ*:6>TK(8DR_+A4I3UX.2HNW:E3XY4:ZJR MEE<:->UR*?3#F:S4W?$ #[Y=N"[G"^,N#$^.5F(N/TKS>76E[=FP;V5:+F7= ME*I&6LZ.!Z?X]1O.G$'WQ)^EO&NVCI'KRHU27]S)Y?1XD#E%LI*%<4T(^W,K MSV55N9:LCJ^;1@>]3V>X??RM];==YVUG;D0CSU7U5SDUB^/!>("FHJNG^H[O-L]D %6UCU')C;!4LRWK]*^XW@=@RP"QA0#8&9%\# MNC&@^QJPC0';UX!O#+JN#]=][P)W(8PX.=+J#FGWM&W-'731[ZQMO,K:392/ M1MN[I;4S)Z?%U[9LRF[0#M!'.P^G;261FJ%K6:AY7?XKI^AR*FM3SDI[>-HT MTC2H,]/V7-13]*X4-V5EVY"-N]\N[?47%]*(LFI>VE8_?[Q +WYYB7Y!98T^ M+53;6*OF:&BL?J=B6&RTGJVUDH36/]3M(2+L%2(9P1'S<]C\][8^1-FD,\\B MYA>P^7NA#Q'%G3F)F+^!S2]DT9M_)WYHQZP?.-(/'.G:HXGVSMK&7FDV0[$9 MP;_?V6OHTLAE\P_@@_8^:.>#)7S\JM3TKJRJ6+#6EGEGZ6AT>X(Q9Y@=#6^W M@Q)[;,1QWC_V2!CKA;%G"UM;\BV/!P1G).Z0]PXYZ/"M*#6Z%57;+8U"V>50 MS^VB<(=-.95:N/C'YB0/ D!H9O_B>O)>3P[JN=)VJ]#FH5M_TDZ E86W>85J M:6(QR8.8X!'!_+NQRL.QRB>J4C4.GI5-B=#5TMA,5Z(5M3%J)J@,DY M[AL>_[0%,.E]3$#QYZ)9="$NW(&+LYT#-M!1>$V"\$WL;LWBX<.9!W0&![ H M5&M=VFVYD-;_326CZ,S",;8K,K'0\-;^@$'WE_6M[;#2%NY1MSAPZ_":F-[8 MTPV3'1-&HJ>.IA&'N7M1'UO+0S(-[M$'V,9S@Y&!Y^&*;?AR[N0+QY MR%R9R&&87@A9U*[9*2L"[64R(A[5/F<)*HX)"(=D<0F M@3WK, R[G8$:A2,T3KKU),1CT.TG942%9H_VJ+4(FXBO$[6HFG&X3,8D']&$ M'D]-#&.S1]9*/"1Y-0GG#..31"R(QR79B4O=2A <.^8&"4EZ,,YP8O423U(" MD_1\XWXJ;Z+0("%*#S =4YS8@'QBI MEU%-(4D/."&I6'B4$ABESUBR)&2JE3+.$SL<\50E,%5CJV=+BUM)KJ2):HHE MF]DDPS@ARB.7P,A=BRHWA9=;1"ZW ]!"0@:GTU[BV4I@MCY=1XRL-,]32CQ; M"U196HJ@=T+5=*F^]I M]=BE)R-E/^\=@T<=A5'WI"*+AI@#JBSJ.4=ASNU99=%()9VNLJB'&X7AMJ/* MHB'?@"J+>KY1F&\_5&712/J8K+*HYQ^%^;=_E45# J:K+.;YQV#^[:BR6(1Y M0)7%//,8S+Q=Q0,+R98SEMAOF <;VP=L3RX>6*3&'C,R27".>*<"KXX\4#BV2$Z>*!>4BR'9#<43RP6 D.% _,DY'!9'Q^\WKIO6?QP*())!G1U!+R"&7[I)!/ M2-I92%(ZLMM:@FG>XYRF*/[9FH\Y"F4J7%/5 X3 M]0D)-(]DBT "S3U%.4S1YR?0//+N,IU <\]6OD^9O<>PL. M8718AEL?/=TW M[?="S\NZL92:6?B=&ULO5;?3]LP$/Y73A$/(&WD1TLIJ*W4EDU#@JF" ML3U,>W"32V/AV,%V6BKMC]_9+:&3VK)IL)?$/ON^[^Z[^)S>0NE[4R!:>"R% M-/V@L+8Z#T.3%E@RJ11A$D6=L&1MTWT MH*=J*[C$B093ER73RQ$*M>@'\'P_A\%"?.P>_XRG%A-L;@4IDJ=>\FEUD_B%Q$*#"U#H+1:XYC%,(A M41P/:]"@X72.F^,G](\^>4IFR@R.E?C&,UOT@VX &>:L%O9&+3[A.J$3AYUT)L."2M'0[)VL$+$:Z(?)07S+)!3ZL% M:+>;T-S I^J]*3@N755NK:953GYV,$P?:FZX5^@]C%59*8G2&E Y7$K+Y(Q/ M!<+0&"0CDQE\,):3&IC!G<&\%G!%LAHXO$#+N#!'!#/,&'TZ,"D8Z99B;7G* MA($#X!*^%*HVA&-ZH:7X711ANHYUM(HUV1'K9S4_AJ3]#I(HB>]N+^#PX.AW ME)"R;R1(&@D2#]O: 3NJ#5F,@4TMOE^1#2XMEN;''HY6P]'R'.T=',]2;LU[ MY=SQSNXTE]/IH*E>&H&E^\=5"C) M7S,]X]* P)R0H^-3ZA9Z=2^N)E95_BZ:*DLWFQ\6]"^!VFV@]5PI^S1QUUOS M=S+X!5!+ P04 " #MB:Q4/&R;U48" '!0 &0 'AL+W=OQ M*RJLA;LP&]1\LC*V%L1;NX[=QJ(H0U"MXC1)+N-:2!WE6; M;)Z9AI34N+#@ MFKH6]N<,E=E-HD&T-]S+=47>$.?91JSQ >EQL["\BWN44M:HG30:+*XFT71P M/1M[_^#P5>+.':S!9[(TYLEO;LM)E'A!J+ @CR#XM\4;5,H#L8SG#C/J*7W@ MX7J/_C'DSKDLA<,;H[[)DJI)=!5!B2O1*+HWNT_8Y1,$%D:Y\(5=YYM$4#2. M3-T%LX):ZO8O7KHZ' 2D@R,!:1>0!MTM45 Y%R3RS)H=6._-:'X14@W1+$YJ M?RD/9/E4TU)P4\"B$GQ: M8$.R$,K!"4@-7RK3.*%+E\7$TCQ!7'0R9JV,](B,(=P9396##[K$\L_XF%/J M\TKW> =I$DZ>'R8P^G)V1NPP[Y@<^ M7QE#^XTGZ-^^_!=02P,$% @ [8FL5/)80@BP P Z@\ !D !X;"]W M;W)K&ULM9?;;N,V$(9?A1#V8A=H(Y$Z>F$;2)P> M@G;7J;.[;5'T@K'&EA!)=$DZ3MZ^U"&B(DO, H9O8HF:^3GS*?[-F1X8?Q ) M@$1/>5:(F95(N?MHVV*=0$[%!=M!H9YL&,^I5+=\:XL=!QI727EF$\<)[)RF MA36?5FNW?#YE>YFE!=QR)/9Y3OGS%63L,+.P];*P2K>)+!?L^71'MW '\NON MEJL[NU6)TQP*D;("<=C,K$O\<4&B,J&*^);"072N4=G*/6,/YM\6S73=D1>.KHB M1L%/E%\@%_^ B$/(0#V+[T_'AG+<%K!;Z;EO R[_;35.],_O*A3=2,C%OX:- MO'8CK]K(&]GH"Y,T4]^L^ET-O8@Z/ZCRRZ_WXQS[Q'>"J?W8Y3,0YCH3E[1A MK\KSV_)\8WF?E27M.(OW:XD$S?H5OM(,6LW@O&S#=J/P1+9UOM^%YH5>X/78 M#H21R(WP,-NH+2\RE\?9 Q1QBOY:&9J=M&J3\U+%CC8?YT2NC4"76*"(D1[7 M@; 01W@RS!5WW!$;"UP^2?4+0[F9+"9:CYR9K?8=[)[*UCV"1D*?X#[;H3 W M=$;8:K_"9L/Z9;E8?EO=F)K5YH+],W/5GH.#4[D&Q\!(X!QQ/0X;8ZI]"IN- MZO)V^=O?GTU]:D_!T9F1:L/!DU.13HZ-,_*\J(_T.(S@T!W!2K1/$;-/_0'9 M/0*= M&:BV&6(^Q'P'4/_XAR@,)WV@ U%>,'+"(MJ:B-F:5NR99O)YI,#7HMI22'AF MO-IRR!OGF+?Q1D>'4]_Q^J>!@2CB^_U#EMV9FG+@VVJ8%&C-]H6LQXUVM1U8 M+ZLQK;=^I0;9>NS4,O44K(:);5H(E,%&23H7H7KCO!XLZQO)=M5L=L^DFO2J MRT0-X\#+ /5\PYA\N2DW:,?[^?]02P,$% @ [8FL5#M+&ULO5==C]HX%/TK5M1*,]*6 M? $#%2 -L*NN5E0CIMWMJR>Y).XD-FL[0T?:'[_73DB8%DP?F+Y ;-]S?.X] ML1U/=D(^JAQ DV]EP=74R[7>OO=]E>104M436^ XLA&RI!J;,O/55@)-+:@L M_"@(AGY)&?=F$]MW)V<34>F"<;B31%5E2>7S' JQFWJAM^]8LRS7IL.?3;8T M@WO0G[=W$EM^RY*R$KAB@A,)FZEW&[Y?A&,#L!%_,]BI@V=B4GD0XM$T_DRG M7F 400&)-A04_YY@ 45AF%#'OPVIU\YI@(?/>_8_;/*8S -5L!#%/RS5^=0; M>22%#:T*O1:[#] D-#!\B2B4_26[)C;P2%(I+8X# MH@80?0_HGP#$#2"VB=;*;%I+JNEL(L6.2!.-;.;!UL:B,1O&C8WW6N(H0YR> M+9FB628AHQI2LH8GX!4H\HY\I%)24V)RM01-6:&NL??S_9)L_1.L'P5_ MEU"5$RF>::&?<1G9:8[5OV8:6R:SE)]F40\+\W18$W?,"XF#5N+ *7&?^$:* MDBS08XGK%%]IG9.%?9E!DCGP),<]XY'\1^ZD2"N,P- $3+1=VVNFS. G*1Z! MIXQ\63NJ-VRE#2_HR4W+>N-,^*5P:81O09HNW 3)52DD$)U3?GW,)#=U/^X% MP=MC+[,;-QC^B'N1VZC-;711,]O.HV[>X@A3HL+BS$%FP,E25AG&RJVH(QV2 MQZWD\05-#H-NEPQ>S^8SW%%PRN=SP,$9H\.#4R#\A58OJ$P9IP7Y +A/Y2Z% M4:P9X%EGNS,C=!\:EW5VE?P%2KE+WYT5X>"2EG8; M?3A\14O=W Y+SP#/6MH=.:%[@[^LI9]R"4!6]*N0;:1RZ>R.CW!T27^[/3X< MOZ*_;NZ;(S8U_KJ!HY/^^@=?YZ4Y^_ZY^;" M9+_Z.YKZMH7?KQGCBA2P0 1Z$1H/M8XZ7/I F ,&ULE97?;YLP$,?_%0OUH97: @:2MB*1VF0_ M^C"I:MKM8=J#0R[!JL&I;9)V?_W.AB+:D&Q[ 9^Y[]WGSG"D6ZF>= Y@R$LA M2CWR=7@U&5A_Y_"=PU9WUL16,I?RR1JWBY$76" 0D!D;@>%M Q,0 MP@9"C.FM,+N^BWZ9U<[UC)G&B92_. +DX^\"X\L8,DJ8>[E]BLT]20V M7B:%=E>R;7P#CV25-K)HQ$A0\+*^LY>F#QU!&.\1T$9 _U40-8+(%5J3N;*F MS+!QJN26*.N-T>S"]<:IL1I>VE.<&85/.>K,^+;<@#9X+$:3,_)8*K04SPPL MR#>FGL"PN0 R@ZQ2W'#0Y'B*>USH$^L^FY+CHQ-R1'A)'G)9:58N=.H;!+/A M_:R!N*DAZ!X(S'1.HO"4T(#2'OGDL'P*62L/W\M];$?;$]KVA+IXT=][I->%5(;_QKYG4IN^'M;Z M@=/;CW,SCB@=7@Y3?]/MU:X;3:(H"%NW=WAQBQ#"4>YP@G1 M>]1UG*23/]YAW/6A47S93YBTA,G_$0JTH1E5:J:=KN8=N&0DV 5<&H? MDN;?SS:$90MAO0FV.>_[^!S'AW@KY(O* )"\%7FIQDZ&N+YV795F4#!U)=90 MZC=+(0N&>BI7KEI+8 LK*G*7#@9#MV"\=)+8KCW()!85YKR$!TE4511,[FXA M%]NQXSG[A4>^RM LN$F\9BN8 3ZO'Z2>N:W+@A=0*BY*(F$Y=FZ\ZTEDXFW M=PY;=3 F)I.Y$"]F/ ]&,#$\AS8Z2W\=IX.BW2" _'>_?/ M-G>=RYPIF(C\!U]@-G8BARQ@R:H<'\7V*S3YA,8O%;FROV1;QXZH0])*H2@: ML=Y!PJTX[L@,TGTI?M[,E2W1 MKQZHWT)]"PU.0+^!4@0S5A*/[(#)KBK6#D/K8*[D)O$^#H,HC-U-!SEHR4$O MN>81%(3:4>T50=8GW0,>O1<"H%_PDD.5=I.CH3^53+S+W M<'-X!8_#:!@&'OUG5^Y!^S&M7U_M%2\5R6&IA8.KD4Y)UNVTGJ!8VXXT%ZC[ MFQUF^@L$T@3H]TLA<#\Q3:[]IB6_ 5!+ P04 " #MB:Q4$8R19H0# !; M"@ &0 'AL+W=O_K.,6,"V\Z=FL;-1W+TF1$+WZ?&+OC3 M<<'V>(/FMM@HFOD-2\)S%)I+ 0IW$V\67JW"R +@TE!SD7URW[6@3@!$$\[ M(*H!T4O X!5 OP;TWPH8U(#!6P'#&N!<]RO?7>"6S+#I6,DC*+N;V.S 1=^A M*5Y:/A(UPSI9C-'+Q?HF$\TQ]H]?9F">__^C#V M#1FT,#^NR><5>?0*>0B?I3"IAI5(,'F.]TEHHS9Z5#N/.@F7&)]!/^Q!%$1A MBYY%-WQ6*(('#AZTP)?=\,],-=:C%OCJ[?"P(QC])G5]Q]?_?>IZL,2M 282 M6-V7W#S #<:EXH:CAN^SK3:*;N2_'48'C=&!,SIXS6A>,*ZL44A*!",A5IAP M YG4&G5;4"O"D2.T=>LPI=@?6C0,&PW#3L?OF.)LFR&LA4%%,:#S9:S3WS_1 M3E@;S'67KZ/&SJC3UP73*22<@L>WI2UKFDICC'0]DK:[,/K%SS"Z#.Q?N[OG MC8SS3AG7[,"-5+!)&57&&$E*S#+*^5K0;?@/7@M'#ZZE@8WBM@/ ' 7N>,QI MW!&:BT;3Q1]-P65CY[+3]]E>(;K31F:H_#'7782D$" 4J+AL2\6BF[0?0,(> M=(>\,'@JGT$GU]>4O$]EE@ U;>I0!VJ]A1,<2TTUM6 /[H:VJ:RI3T_,, @Z M3DQX4M7#[FOZ5!M:+8>_GM7A"\M527O+SN<:HR>-4:?&N_6J!_@X% MD*;V'%5S+JJ'$*6\!_(H4.F4%S;M,3E&SYA6U[J-AOVS('C7EGK_I(GFJ/;N M]:(IC:4P58=J5IL7TLR]"UZLS\.K1?7.>:*IGEW4 ?:&ULM55= M;]HP%/TK5K2'5EK))P&J$*EK5&U3.U5E[9Y-<@-6'9O9#G32?OQL)WAL@Z@/ M*P_$7^><>\]-KK,=%\]R#:#02T.9G'MKI3:7OB_+-318CO@&F-ZIN6BPTE.Q M\N5& *XLJ*%^% 2IWV#"O#RS:_P /6XN1=ZYCN6BC3 ).$,":CGWE5X682! =@33P1V\F",3"I+ MSI_-Y%,U]P(3$5 HE:' ^K&%:Z#4,.DXOO>DGM,TP,/QGOW&)J^366()UYQ^ M(Y5:S[VIARJH<4O5 ]]]A#ZAL>$K.97V'^VZL^G,0V4K%6]ZL(Z@(:Q[XI?> MB - F)P 1#T@>BT@[@'Q:P%)#TBL,UTJUH<"*YQG@N^0,*KCHD!G[\XS7^E(#)]?]JH?.M7HA.H=%B,4A^]1%$31$?CU,/PS9B,4 MG(87P_ "2J<>_@GWM7W.P\AY&%F^Y 3?55GREBG"5FBA,*NPJ"1ZW%18@9$( M+H)T0"5V*K%5B8O>WB,GQ[-DDIZT>.H"GK[.8O03W<(6 M*(H';)@YUMD;FAT&OSM5\!_M[LD.7?S;Y\$C79#^06G?[H+/?P%02P,$% M @ [8FL5!(]\*&J!@ RH !D !X;"]W;W)K&ULM9IM;]LV$,>_"N$-0PNLM?@HNTL"K.F*#6BQ(%F[UXI-QT)ER97HI 7V MX4?)BD\JJ9.E.&\2R3Z>CT?RQ_^).GO(\B_%6FM#OFV2M#B?K(W9OIE.B\5: M;Z+B=;;5J?UFE>6;R-C;_&Y:;',=+:M&FV3*@D!--U&<3B[.JL^N\HNS;&>2 M.-57.2EVFTV4?W^KD^SA?$(GCQ]_TS64HRP:5Q>=8/Q2-:U)VY3;+OI0W?RW/)T$9D4[TPI0N M(OOO7E_J)"D]V3B^UDXGA]\L&S:O'[V_KSIO.W,;%?HR2_Z-EV9]/IE-R%*O MHEUBKK.'/W7=H2K 1984U5_RL+<-Q80L=H7)-G5C&\$F3O?_HV]U(AH-:%<# M5C=@QS;@=0->=70?6=6M=Y&)+L[R[('DI;7U5EY4N:E:V][$:3F,-R:WW\:V MG;EX'\4Y^1PE.TVR%7D?IU&ZB*.$?-11L*=- M%"?%2_O5IYMWY,7/+\^FQH93.ITNZI]^N_]IUO'3'Z/\->'T5\("QCS-+_'F M[_3BT)RVFT]M$@Z98(=,L,H?[_#W(8YNXR0VL2[>(.[XP1VOW(D.=Y=9:FS" M;/[((K.S?JGSJ)RXOCSM/:G*4[GN[B^DHL*NQ.!L>M_,B&LX"T08-@U;P8I# ML (-]EHO=GENPT4Z+@^^))K'O\U:YR0J"FT*Q)TZN%-H:':6?+&3[3;1I"BC MK ;(3KM<%R:/%T8OR8N;/ZZOO!-P[UHV$ULFZ\>TNF:*!YU)#0^1AVCD_V3& M+J1](DADR*I<:O?E^O&%&CHQ"#ZC0>A&Z[&4+?6M:2P?9' IX)+BO/0N3,PSD)/VH7-$+^H1X4Z>Z5R) MF?0,B<>4*R:ZUQ$%G%*!KZ0LO7ME=+ZQ6_7 + %FJ7RV+$FWZTQR[H&-SY3. MJ4*R!&2G.-I;,SR>RRED"'M' /6$)?LZ#'XH.]U M\LM/5 6_H<(5@,GX*207 WXQ7 \^2735OMM[G9MKUZI[-V1 1893<9CH8B[= M9C)DOG!=2Q9P-6?=,0,'F3J%[F+ 0(8KSR'*B[ERTND[9M(.$4#*<)".4%O, M1:03*6;2CA3HR8ZG9W/EGD1N<4 JQY$Z5&YQP"GOP>EX(<%=8#HEJVO"9#=1 M.1"5]]3KHS46;]3PSZ9$N2LOG=1@)NV(@=S\R$K>,UMQB<6!L1RO\,?L[AQH MR'%5.'!WYV[QWB&Q/)8]$HL#<3E.7"3M3U%<''C*\=I]U)@ WE/*3]P3-PJ MGC@DL +P5>SG>,"$/R(0"9@IY"< F F<#EX9,$5^V[_1C"DVV/ MG6+=LU\ )@6.R6&B2[C8XY+Q<.Z)V#5E4H8ST1UTXY%G3XU^G.H2@$715Y ? MK[J$*R>=OF,F[1"!K0)GZPC5)5QJ.I%B)NU( :AB%%#92527 *P*'*M#59< MI(J^IZ.CI87PX+7C(9?/E,OY7'8N( F$E;@B'2_ )(!6/ILVE:[P['K(Y3/% M'W))(+L<5?BS?D$F@;\2K__';/X20"EQ23EP\Y=N8>_D&S-I1]DX=<+IB^3Y M*0I, ELE7L6/&@3@H>PIZ0<.@ENRL_D/R[X>BZ.+>PG4E'AQ[XP%X5@2@)ER M?I*C14"8PD7BTPX7W3,=YV 1,VG'#$A4.!*'B2W57Z&C)NT@@7KJ)(?I"A"G M3G>92C0-_ M'*1#-9<"B*J^YZ*CU83J?TR*FK0C!I*JGB/YT1I+ 575LRE1Y' G3QTBW;GA1#,I!TE\#;$>>M/ M\5.45 CH#/'*?%3^ 7!A3YD^,/][;PK+/V:RCW+:>$.O?#W2,NXN3@N2Z)5M M$[PN7>3[-P[W-R;;5B_MW6;&9)OJY\7_P-0 M2P,$% @ [8FL5'=-;&%T @ L@8 !D !X;"]W;W)K&ULM55A3]LP$/TK5H8FD#:2)DT*K(TT6J$AC:F"P3Z[Z:6Q<.S. M=EJ0]N-W=M(0*&3[L'UI?/:]=^^>F\MX*]6]+@ ,>2BYT!.O,&9]YOLZ*Z"D M^EBN0>!)+E5)#89JY>NU KITH)+[81 D?DF9\-*QVYNK="PKPYF N2*Z*DNJ M'L^!R^W$&WB[C6NV*HS=\-/QFJ[@!LSM>JXP\EN6)2M!:"8%49!/O,^#L^G( MYKN$.P9;W5D3V\E"RGL;7"XG7F % 8?,6 :*CPU,@7-+A#)^-IQ>6]("N^L= M^X7K'7M94 U3R7^PI2DFWHE'EI#3BIMKN?T"33^QY- M0V,W3-A;O#$*3QGB3'I!F2)WE%= 9$XNF* B8Y23*Z"Z4H#W933YV#FX%-JH MJMX_G(&AC.LCS+B]F9'#@R-R0)@@WPM9:2J6>NP;%&E+^5DCZ+P6%+XAZ(JJ M8Q(-/I P",-7X--^^ RR%CYX#O?1FM:?L/4G='Q1GS^;G3]Y:P-[LJ&G2M16 MB5R5X1M5IE2I1R96[]\-DN"3NX[7G*M)$D=B7\]-.@R"Z 1MVG0=VD^+1J=A M_)3V3..PU3CLURC%!I1A"P[DFS2@R2_R%3; :]%ACPUQ6R+^CV8G;97D7YA= MD\1_,GL_K<_L4:MQU*O1.M'11PZ[3A^])G>T?^FG\3!.7LC=3\.NPBAY(=?O M3!0[S?&M7.$M$ XY H/C$3:LZ@E9!T:NW9!92(,CRRT+_*B L@EXGDO\RS2! MG5OM9RK]#5!+ P04 " #MB:Q4R)-YB? # #:$0 &0 'AL+W=OFQ/2 IA&19%:P89#0O?_'W2HA& ((M :@*0)<& MA%5 >&E OPKH_R\ CEH"HBK E.Z7M1OAYECBZ9BS(^#Z;H6F!T9]$ZWTHKEN ME)7DZBI5<7(Z8[FD^9;D$JBAH&O"L9G!-V"!N1X?"'@Y)Q+35+P"+P#-P=\[ M5@B0/T2A>NV?([AJPFI9P75LX(,:-@">ET(=48( M<)5\*ZB@9D8^_Z7.@0^29.*+(T=8YPA-CGY+CAM,.3C@M"" ;4!B^R!I]L&Y M*2YQ8X.KC>@P16&@/F/_<(9/O^;3=_*97V18HE MXX] /;3J,<\RPA.*4]5=ZO%6S46$HY\&=;9!9ST[K',,.^K9XM$,.Y.:.M <-"5T(,S0K?[ [2&!7_B6(4L.#&2"K D MW"SME4>XZK7N T>=J8JL_Z"@(U4KX$M51=:LD-NLKI8?__QWX:JNL=+J;JF% MK-&@KA9;%7!3P[#= 9 U)>0VI5)"LR*HS,!5J#46%'4GI[43Y%[9_(:<\>G2 MT2&GM1[DMI[[U:?;9LVN,JUYH&%W8EH70>Y%C%UXBTI3LXT1X#]P9C]3[HDJ MR&?_^>O-=O\Z9_@!02P,$% @ M[8FL5)E^KF(3!0 EAL !D !X;"]W;W)K&UL MU9E=3^,X%(;_BE7-!4A $CO]8%0J0=G1CK1=(5AF+E9[X29N:TUB=VRG'5;[ MX]=.0MR2Q+10+GI#$R?G^+6/SW-,/%QS\4,N"%'@5YHP>=59*+7\['DR6I 4 MRPN^)$P_F7&18J5OQ=R32T%PG!NEB0=]O^>EF++.:)BWW8G1D&=57F*:$B8I9T"0V57G M.O@\#J$QR-_X1LE:;EP#,Y0IYS_,S=?XJN,;120AD3(NL/Y9D3%)$N-)Z_A9 M.NU4?1K#S>MG[U_RP>O!3+$D8YY\I[%:7'4&'1"3&;R!B>8141JFP0K$@/%\Y=; MO9_<$H5I(D]U/X\/M^#DTRGX!"@#?RUX)K5G.?24'IX1Z47E4&Z*H<"6H2 P MT=TMI!%%XFU[3T]+-3?P>6YNH-/A!(L+@((S 'T(&_2,W>:W)*K, X<<5(4* MY?Y0B[\OF KP#2<9.0-_Z@2_)8*NL,D"<"VE;CCY@^*ICI=Z.@43@F4F="3T M9.M 9D(4<9)4GH%'QJ>2B!6>)@1\9&CN]'U.>SZOM_<=Z_JN^?L>[S .A',$I^9.*Y,'#4'(SYG M]%\=)_V 8&$2JU%4KR:JU^LV*^I7BOJ[AD2O]&A1+75PDC&*B+1)\65-\27LPA>"ZR^A;@^U)$'@6^3[;Y+Z8K"Q5->;F*RTAN/I4E=G!CQC>, 2P=2- AXLW>B65MC58_ =N_C]@C=YSL^&*WQTWB_N@>X1QLQ4C M>*5D[!.W>H'8 LJV!%LB G>->'SX/@'7T<^,2EKO>MNI)7TP.,*P6. ';N+O MNY4)ZACO^T&_):6@Q3AT8WRWW0RL ]RUG8$6S="-YG=N:$KOF[J"/FQ395$- MX<=L:DJ_.X(/6OC"P\$7[@5?:.$+W?!]F<7@/_"1A15:0,,C!#2T@(:' S2L M ]H56TMHN!^A=6P/6&NAA3H\0JA#"W7XMFU\8RCK0&\)([(P1VZ87\*!C_R6?T/0QI<7-\1W*[6HCN^V=6'1C=SH M?F>5+;UO5?_ [[9\.4 6W,C])>7-91;5OZZT[U.1)3$Z'(G1/EME9$&,W""N M9_ 'EUEDV8R.D,W(LAD=CLUH9S:'ELWAOFP^;)$-+<[#(\1Y:'$>NG&^3R!+ M5SUWEGH;)Q\I$?/\0$AJ[QE3Q2%(U5H=.EWG1RV>?;TXL=(&PO=V]R:W-H965TI'XV)F=66DW;[5YL!6 (T^U5'8:5)< M\5%KW@HI"5.<7"O'U%HL)9 K:\'94_(9_XLSLL!_@3=XK%=D0!S/P3$A[0DY M(D*1+Y5N+++8/'8HS-/'92]BUHF@+X@8D1NM7&7)>\6!/\?':&AP1;>N9O0@ MX0TSYV24GA*:4'J_F)/CHY,#M*.A6*- ._I7L;[?:7SB;]$RPW\<8!X/S./ M/'Z!><8D4R409GV)YU!"O03S^E6:)6]['^F^NG:L66#U_?=8I.G%),WR^'&/ MFLF@9G)0S=;GOHP=63WS3LEQHUC#A0-^LD]5 MMJ<.DW$Z_DM6O-,H-9AU& >6E+I1KNN9X728.%==H_T)[\85BEP+98F$%4*3 M\PLLB>E&0+=Q>A/:;JD=-G%85C@UP?@ O%]I[;8;GV"8P\5O4$L#!!0 ( M .V)K%0Q?Q'N7 0 &40 9 >&PO=V]R:W-H965T;%'9\OM'GA3,9+.F?W3']:WDIX@JU7=B_8Z5 07&7BQ29?^B M=2GK#E"\4EIDI3(@R'A>_-+OY49L*9!@CP(I%4A# ?M[%+Q2P;.!%LAL6%=4 MT\E8BC621AJLF87=&ZL-T?#2_C*04]/W@J1K'F:(IHGZ#K7-)_SAY2A M"Z685B?H U32*>J70F^E4 I-J91//)^CBTRLU:3RZ8IKR5!V#ET_W5^CHU3%ZA7B./B[$2H$)-78TQ&G0.G$9TV41$]D3 MDX?>BUPO%/H[3UBRJ^_ _E2;1#:;=$EZ#;ZG\@QY^ 01EY ./--^]2L65^JX M!XY7Y@/UWY6-?V] 'EUKEJG_>KSYE3??>O/W>+MCA@U, M7C_;GC 9?&02>OS//W#H_G7#9PP=?6%4JN.N7/5;C]"3T40^RHJ<$1\E]$GU M \JX$&OZ7TUUP6RL!1:2X;Y'B>GD1\-(5N/VWGN$ M]0H:5V [0L (:]@+] M*#1-H>:K1-*R^>)-1U';42=H;AJM"W_A(-@"!O!'Q&W@/RBV@W]8X1_VXK]N M(\^9[H(Y;/D?AK[KCQHP.\0B/QQYW3"C"F9TH!Z^K;B$8N#YZ5**F %G2::@ M_.*%):N$/<)86\*0TCWE-ZK"8 M^*[;K*-2+M@OMQO UC3"SPN@! HKS>)%+E(Q?[(10%C)*M9(&B[JHPE,:J?D M-_ IKND;>R_*J ?,;R@UJ"@U/$2IN!X&N)^O&T/^I)C]G2C]5BV%$<;M6O); MM=20VX5:TS_^=?Q?FMH&<1KX(^PUP7;(>4$0[ -;CP#%PSTG,E+/!$)^23^69G8FIA>%I(FS0RS M?O-$XVQ=Y#(FY_9^JZ"Q $)QIZO>5G?H"WMS=&KQX@(.=Y8YSQ5*V0Q4W;,A M[)$L[K3%@Q9+>RU\$!HNF7:Y8#1AT@C ]YD0>O-@'%3_69C\#U!+ P04 M" #MB:Q4U]U!+*$" !J!P &0 'AL+W=O''""56-GMBGM?OUL M0[RT(./HD!(@N>24#%R"BDWUZXKL@*54%RQ#:+JRXKQ M$DHUY6M7;#B"N0&5Q/4]+W)+B*F3)F9MSM.$59)@BN8%U(O>"FR0:NT0+)A\V 0M(# )-HX,VG-H(1IPED-N(Y6;'I@:F/0*AM, M]2XN)%=?L<+)]#-C>8T) 9#FX(9*2-=X21 8"X&DN 1WZB!] '>0YFK8=)X\$_X"$ MXS*0H"/ M-$?Y:[RK\K%)^=ND)OY1PEO(KT#0NP2^Y_L=?J;_#N\=L1/8&@>&+_BO&H,9 M%AEAHN((_!@OA>3J:/\\(AM:V=#(A@=DQR7C$O^&YG=A*[5)5AD:Y:Z=:B@C M0ZD[P%/J>U$8)N[3;OWVHR+/BVW0*[M]:[=_U*XJ=M#EJ$'U=[3BX<#SNL4B M*Q:=$@N[Q*+WB,56+#XEUN\2B_?%^MXAL8$5&YP2B[K$!N\1&UJQX2FQN$ML MN'<^XL#?$W-WVE:)^-IT3"3;F.:X9%*U6C,LU&6(N Y0WU>,R>U$"]CK-?T# M4$L#!!0 ( .V)K%284LFBY@0 /D2 9 >&PO=V]R:W-H965T9Q[/>)XQGNV$?%09I1K]*G*N+@:9UIO/ MGJ>2C!9$#<6&P5A?#"?V6>W4_VPN95PY]4H*2LH5TQP M).GJ8G 9?%[@B3&P(_YA=*=:U\A,92G$H[GYDEX,?,.(YC31!H+ SQ.]IGEN MD(#'SPIT4/LTANWK%_0_[.1A,DNBZ+7(?[!49Q>#R0"E=$6VN;X3NS]I-:'( MX"4B5_8;[:JQ_@ E6Z5%41D#@X+Q\I?\J@+1,AB->@QP98#_9X"#'H.P,@B/ M-1A5!B,;F7(J-@X+HLE\)L4.23,:T,R%#::UANDS;O)^KR6\96"GY]>"/U&I MV3*GZ)YR)B2Z$9HJM-A2A'T@+-PH7PD?(G^?HF/F89WT MT,*&/;!EAC?DF4#:'7BC&F]D\48]>'#-'BG:2)90)%9(9Q3MS*+A&FGX5L06 MN4(GC*-4Y#F1X)[*,LZGZ%_4!+UK997>)]:[$;*G^<0?3H.9]]1!.JI)1T[2 METDBMEPSOD;WFO"4R%2AATT*23?A]L_]V!&:N/82?TBHQS7>V,GZ+\'7YYK* M BWH4IO(=:VJ$B-N!0S[L6\^W3&;U-XG3N]MM3#^'1.:UI#3#PE0X#>*YCM) M?N$0'ZHT M&BG4+EMO>',8Y^MW90#;"]L37.;*U/$9:W:&OX4G(%+4_Q[ M4^UN$:5?DX":M3_T@W@2C:(>UHVH!>&QK*T2G3428^*>B** 5]!1D\?W"E'% MH*U$T708ACW4&_T,W +ZHQ1+A9A26YJV0FPX.?B4L%&+3SR>A--PVL.H$-!(;! ?F_B7^@)B M].>6Z>?>2HL/RN>@PEQ#]JDVZAVXY;LMH*::4$;3-2S/3=D?WYK^\4$P2PWH MH=G(?/ VG0<6K2!?,YEL"P5-$]K]W]RIVDT;"#ZF#^"F#V"WCG_/(&QF>9H] M2&KZ/.SN0+YV&04Q@[4M30I %[BBR=;L;SLUJ_(2[373[@#CIC%@=V.X;IRV MV9DJ8Z)< (9L-Z'@@%#81ZB1?/PVR:]V<:7BP\,VR1-BY2"A/2K_BJL@!,GW M70T6-YJ/C];\LH8J?2^WHK M7:\K<7J'VN-#M1^/AT&/VN-&[;%;[=]07=]W MPA6G1LYQ]#'5U8@N=HON1U57?+"8>S8"N!%9_*K(OK^X#B4UZ"NN1D[Q,7+Z M]N*"A7'7LX=]Q>-TTE=B7NNLH*!R;<]<%++_A2@$ M?Z#7#+I63E=@Z@_'$#59GK.4-UIL[,G#4F@M"GN940+;!3, WJ\$1*"Z,0[J MTZ[Y?U!+ P04 " #MB:Q4O#R*H # "2"0 &0 'AL+W=O "P ^%! 4@" SFBO+;$V))N.A M%%LD;;5ALS=9-AG:N*'<_HTS+#UUM ME-KWN5&AZCQ7A?>H^D;D*0K\SY88-\ G[? I1"7.J506^ PYW*':F=4FJG56JU76PJ+>[#DC)\ MCW"[)7VW5?%+:S9%FF/#G4AQZ'GU2 ^IW!'8*P7V6@7><9(($^E?6)CUQV2Q MH"H2J4F"<#L3@Y3F44PYX9'MCT@HW6BF5Y-X@GV_7_?25!C@3G^OEW[II?\F MG=QO"+.YD^N5KW3RH)0Z.+B3\Y7K'[J&#;!/'_RN]P6WM)[OO2RNWGOTME]9 MO?TW";R@.23QAM)7(O=?UE$?M\J](%3F^=Y;I>BHFGCS/H'K2]D@[(3=!N'U M4N,1!]VZ<+>R8=K3BMEOEI0KQ" V6.^T9]S+_ "0#[189WOH7&BS(V>W*W-H M FD+S/-8F!8J!G9;+H]AX_]02P,$% @ [8FL5) "B"RJ @ J@< !D M !X;"]W;W)K&ULK57;3N,P$/T5*^(!)""WWD!I M)%I8[3X@511VG]UDFE@D=M9V6_A[QDX:0K=$*\1+8D_F')\Y26:BG9#/*@?0 MY*4LN)HZN=;5M>NJ)(>2JDM1 <BQ(]&46O[W8M9 SF]!4U9H"ZUR1.YY"^A'O8EUM<<&^N%G02WA/Y24)_7,2 M>$%P1,_\_^%^CYRP]3JT?&&OU[6I5>-U#^V@I1U8VL$GM(]"T^*8VS5L9&'F M=][& R\81NZV:\&1I'#LMTD?% U;1<->10^@@,HD)_@=X#^UQ691F6I[BAVU MU*/O]'#U^QL<-W/+0S'@P-#CV6-)^&!I6ZG MZY4@,SL,%$G$ANNZ1[31=N#,P!6D2\/E:"+W?F /:\1R_ 5!+ P04 " #M MB:Q4'UNIV4H$ !9$0 &0 'AL+W=O?A7T!3VR+2@*2?U])=FP" MMG!V^@*6K'ONN5?2N9*G!\:?Q 9 HN(ZX9.0;-R-)N:O@6?3=E.YED)"X[$KB@H?[F%G!UN M1GCTVO&0K3=2=SBSZ9:NX1'D/]L%5RVG04FS DJ1L1)Q6-V,YOCC'2':P(SX MEL%!'#TC'202 U!U=\>[B#/-9+B\6\-.FI\:L/CYU?T MSR9X%9LI.SAXWE,/UK4I$BA;T14V0%.@:/0U5;?$BOB%\C'R\*^( MN(1T$;*;WT/2F&,+':^9.<_@>3UX?^V*)?!??L*A^QM;H:]F2H0%V&^ ?0/L M]P!_W4DAU=1FY1I1B>0&T!+665GJ#N5)=VR!9RQ%'[*RGN"KKAFN_ 3&C]:3 M_2R((M^-PJFS[R 8- 0#*\'?.2TE7/0>G'F?D$D4!]W.P\9Y:'7^Z1EXDHG+ M[L,S]]=^%+JXVWW4N(^L[I5VK2 ;$'W4X3YVO9[4QXW[^+UK Y0(O&M5Q&?, MPM"-"?$;:M5V.A]G73V3)H3)D FDRQPN,9V<,?!)[+J8G# ]'^>% 8Z/(GK# M%+NM.+M6KM] Z*G6.@O/6U7Y5$,RM%?=E[C7R)?3W#'0FF=\5%JP5:&^FQJJ M*,_WP-69 +WNG4JT%CQ+P*)7F+2.R/^I6"G+<\J%[JHRV)W RF=\E!?BCW&/ M?.!6MK$W6+T&,JD ,3Y>8&1,>IBT.H_M0O]6R@9R\<^YX'A,>F0-MYJ.[:+^ M5M@&D@DZ$N..X[Y]UVH\MHO\8)D;R#,\YTF",8E/MV+XKB77U@QL+QJGDC>0 M==3!FHSCZ)1UUS@\)I,>VFVMP?9BU*_<=PRRY;ZL-GKQ/!!] MWZ[TRKI3YU.N[C$[FJ._@1>5+*K(JH<74,%=V0ZN;1TA]CHR9#UWY>X";(@, M1^2APARU.P_%=HB@AL"XQD#JX)[2%]M!EK05B. ?74&=X=K1!H5KA_BA<-LZ M2.QU\&B?=X9GM_9K;I.&FM]!K0YS&%380+F]43I'E]<"^-K4V7]02P,$% @ [8FL5"?D:F,, P . H !D M !X;"]W;W)K&ULI99M;]HP$(#_BI5-4R>U)'9X M:P=(I5VW?>B$BMI^-LE!K#HVLPVTTG[\;"<$*B"B[$L2O]S=9,?.K,-1)!CG5#3D'85>F4N74V*&:A7JN@*9>*.AL"EZM^@(/UQ .;9<9-A(/>G,Y@#.9Q/E)V M%%9:4I:#T$P*I&#:#Z[QU1 WG8#?\<1@I;>^D7-E(N6+&_Q*^T'DB(!#8IP* M:E]+N '.G2;+\:=4&E0VG>#V]UK[G7?>.C.A&FXD?V:IR?I!-T I3.F"FP>Y M^@FE0RVG+Y%<^R=:%7O;K0 E"VUD7@I;@IR)XDU?RT!L"<31 0%2"A#/71CR ME+?4T$%/R152;K?5YCZ\JU[:PC'A3F5LE%UE5LX,QAE5<#&T?J5H1-]LO(U& M%^@!M%$L,79V;&3R@AX%LPMGMV HX_JKVS)^U+W06 :G*4Q*>\/"'CE@+T;W M4IA,H^\BA?2]?&C9*P?(VH$AJ55X3U4#Q?@-_K@*4.SU MQP?T_U[D$U!?/N%V]$U.]WC]3FNSTMKT6IN'M$JQM"&&]!Q-8,:$8&)F;Q>G M(@%TQD3IQ5?T%^WSI A,8:+E3;CL6PX(QCCJA$X@-"M$+K' MWA,0Z2F7I/NA\[FLN"YKL^+95SL;F>LE*%N]D;\VR)8@0'>4*?1$^0+0'!3R M%:8F97"T*571_R5-*CFG2GNS/B(N-)N:L+=:%2:[VTETV6CC_>'!6V45'YU& MIV"551MO<<6D00Y@D0T6.3:O3J$BNU1UT=K46!Q_(--.(8N/S3R\*='XZ!J] M)_=.@6SNW+4]9QIN_&PO=V]R:W-H965T.YH[SP.=ULE;G@SR8%W< 2U%VQ$/K,KU62- 2F!-=YGZS ]_0S6@@=&+>2;M M7W0HGQT./13OI.)Y%:P=Y"DK?^FWJA!' 7J@S0&D"B#6=YG(NGQ/%9U-!#\@ M89[6:N; #M5&:W,I,UU9*J'OICI.S99;*N!ZKL>5H 7]KNNM)+I&"Q"VXRP& MM%0\?D!W+-5WWKP'1=-,OIWX2FU MZ]HZ>;0^)YV"'ZGHH1!?(1(0\@?RD31CD>7?#OVP+DUH]?LM^O]R13.T6-YU MB?5KL;X5"UO$/NWR%0C$US\2'-2"@TYWGSC;@U207*$5;%+&4K;1\S.S+7N3 MLJH:C8TJE0=6V2S;_6PTQF0P\?<-AJ+:4'2N(6#),]Q$)VZB8=3F9EB[&7;6 M^XM=CGI2W^Y!:+R@OP1E"NDU N@#306ZI]D.4*%[8I= 1T=&=HO^0F[A-M2DSCHYJ0T:]?MA#'7]+^D@'79#^L5A%S90N:'Y_M'>0 YB8W= )(KY MCJERFZ"^6N^RW)9["^[Q MV\,MT 2$>4#?7W.N'D],@GKO:?8_4$L#!!0 ( .V)K%0@@.1Q>P0 )0/ M 9 >&PO=V]R:W-H965T^_O[$A0 F0G'0OB8&9\7PSGF\\ MB[V0[VK+F$:?69JKF\E6Z]VUXZAXRS*JIF+'Y7(A"IWRG#U+I(HLH_*?.Y:*_Y;PY-16$IZQ7'&1(\G6-Y-;?'U/B%&P$G]SME>M-3)0WH1X-P\_ MDIN):SQB*8NU,4'A[X/=LS0UEL"/WY712;VG46RO#];_L. !S!M5[%ZDOWBB MMS>3<((2MJ9%JE_$_D]6 ?*-O5BDROZB?27K3E!<*"VR2AD\R'A>_M//*A M M!;#3KT J!=)5F TH>)6"9X&6GEE8#U33Y4**/9)&&JR9A8V-U08T/#=I7&D) M7SGHZ>4CE3G/-PKMF$2K+94,73PP37FJ+M%W]+IZ0!??+M$WY"!EOBK$<_2: M]^5>Y.!O3WT4^1ZJ]!CGK#DJ[X#.&HP MY #FCHP:_$GE%'GX"A&7D!Y_[L]7QR/N>'5L/6O/&[#W(X]%QFQD;>Q&3,YJ MDS-K/_W:3W\4^E.1,4FUD-1W33^A$F#%%#CZ"0RK& *& M->?(0T]"LUZW2]-^._#AO./TL8S;[W%8>QR.Q_*0&.M@PM/"T&@=WJ'#6GH< M'@VU(JO_;63[51.T>^YWENZ'63V2=)(C*?!?/^Z. 6B^/1 M^#RNU] 7#2/4*54L+B37G*G1B)%F"W*">D3\CL3.\LL5>EF](H@36MV^G(P0 M.<*-283G(>D&J$\PB'QWX/3@AHFQ-^K\O<@ASYJ_I0SE0P59V6AO'\Q#+_*Z M5-(C.%"6N"%V/,[L9QU(FUR0.17PV3$0/',#W_>[2(XE_1F.@F@^T !PTP&P M/PKH\8A2V@5U7F^JMF@W)W#P_[K9X(;B<72B1K,,+O;*^LQ^%_R#IBS7"EIJ MG!9P0S3737/AB6D:%RFU8\"!\>S7KTZ=K)+HF&W<8$X\W$U.CR 4"6EUOJ_7 MU:8+D?$NU*:E!_:FQ^[ 32\@X[W@/R2'-.Q/QMF_]-0.;_;R>=6*,^0@;N?N M_.*H-FT?>S^:>MVX.JWY!JXO&SOV*=BTR'4Y'=1OZ]'RU@Y4G?=W,'*6 V)C MIIQ7X>Z_X7!O3MD:3+K3.61;EB-@^:#%SDY1;T+#3&:76QB;F30"\'TMH*U4 M#V:#>A!?_@M02P,$% @ [8FL5#7Y\\QE @ Y04 !D !X;"]W;W)K M&ULC53;;MLP#/T5PFB!!%ACQTZ:MG ,Y-)A?2@0 M]+(]#'M0;#H6*DN9)#?9WT^2'2_M4F\OMBX\AX>DR'@GY(LJ$#7L2\;5U"NT MWM[XODH++(D:B"UR&7REN%-':["1K(5XL9N[;.H%5A R3+5E(.;WB@MDS!(9&3\; M3J]U:8''ZP/[9Q>[B65-%"X$^T8S74R]*P\RS$G%](/8?<$F'BK#!3P_+J%WUH"E$IPC,5^]J(L%1^VCBB-UW$H==TJ]S7-TC>K42J)/"NSFZ$U&@R X[Y^J M;3=R-!EG,NX?=4R)[96'F,$IK8.YS(?1A8QVTDSWY M#5!+ P04 " #MB:Q4IAX@E*0" &!P &0 'AL+W=OI%*ZWA*Q_;1)":1-4F;5W4KMO%M L' M#L&JP=0VH97VXV<;BM**L-V #7X?G_/:/HX:+AYDCJC@J6"E7#JY4M5'UY5) MC@61$UYAJ?]D7!1$Z:[8N[(22%(K*I@;>-[<+0@MG3BRW[8BCGBM&"UQ*T#6 M14'$\PH9;Y:.[[Q\N*7[7)D/;AQ59(]WJ.ZKK= ]MZ>DM,!24EZ"P&SI7/D? M-PLSW@[X0;&11VTPF>PX?S"=S^G2\4Q R#!1AD#TZX!K9,R =!B/'=/IIS3" MX_8+_=KFKG/9$8EKSG[25.5+Y[T#*6:D9NJ6-Y^PRV=F> EGTCZA:2 M6BI>=&(=04'+]DV>.A^.!.'TA"#H!,$;0>"?$(2=('PC\$_-,.T$4^M,FXKU M84,4B2/!&Q!FM*:9AC73JG7ZM#3+?J>$_DNU3L5?4)LFX1)NB!#$K &<;U 1 MRN0%G $MX7O.:TG*5$:NTA,:F9MT\%4+#T[ ;_AA L'T'01>X-_?;>#\[$)@ MB0UAWRJS[ /(]3CR*Q$3"'V+##KD &4S3KG&W00\2_$_O):[VL#>Q:!W,;"\ M<-S%7U<[J83>RK]'F&'/#"US>H+9.D08, .'SC=0* HXU^ORC$3(H=Q7X]Q9 MJQPR;5SH>T/*5[E-^]RFHZB;NMBA )[U:7&;K80_\*\-LFK1,XLV5>T0^Y%[ M&(AFUD/9D'7M+/,CZR[]>>#U]K4G<'"4 MY[TQV3TJ.N:&T"=S3_4*,LRTSILLM.FBK;IM1_'*UJ$=5[JJV6:N+RH49H#^ MGW&N7CJFM/577_P74$L#!!0 ( .V)K%13HGCH'0, .X* 9 >&PO M=V]R:W-H965T?%2"UL&J5 MN@V5=GN8]F#"!:PZ=F:;TO[[73MI!B6P4K4O8"?WG'OO\7'L[DJJ>[T ,.0Q MY4+WO(4QV9GOZV0!*=6G,@.!;V92I=3@5,U]G2F@4P=*N1\%0=-/*1->O^N> MC52_*Y>&,P$C1?0R3:EZN@ N5STO])X?W+#YPM@'?K^;T3F,P=QE(X4SOV29 MLA2$9E(0!;.>=QZ>#4('F=,"U\?/[)>N>6QF0C4,)/_)IF;1\]H>F<*,+KFYD:LO4#34 ML'R)Y-K]DE41&W@D66HCTP*,%:1,Y/_TL1!B#5 /=P"B A"]%A 7@-@UFE?F MVAI20_M=)5=$V6ADLP.GC4-C-TS891P;A6\9XDS_&E #34Y(,;B@G(H$R-AY MZ$KD1K&"'PW!4,;U,0;?C8?DZ-,Q^428(+<+N=143'77-UB1Y?63(OM%GCW: MD?TK5:.+=_"=:PU&[R&*2Z+8 M$=5W$'W/0*%J8DZXE970"N)UF6HB&K$S489M5%D MO2RR_LHBW=K7B-O#)W)V=)(I?":)+1)VIY\+.#)T&BEC!=5[/*1A_!O"%FNQ2S?:C%N!3S M$P,JW4/?*>D[;S?9CD2Y]IWMKTRGW7GIK^VH>AAUVM4&"X-_YU#P9HM]DR)Y M5Y>]NI8#)1Q\ /&FGFOG>K@WU:TT*,M6FDHUPNTE;09Q]&+AJ\):K=;+4\A? MNXS8FR">\7,F-)8R0UQPVL(/L,HO5_G$R,S=3R;2X&W'#1=X(05E _#]3$KS M/+%7GO**V_\+4$L#!!0 ( .V)K%1,B:/(3 ( -P$ 9 >&PO=V]R M:W-H965TN.I'$5]3P@E%LY'X/3;XQ2E](&(QN\V M9M1=Z8'GZU/TQY [Y;+B%J=:_A"EVXZBSQ&4N.8[Z1;Z\!7;?(8^7J&E#5\X MM+[]"(J==;IJP<2@$JKY\V.KPQD@'EP!)"T@^5] V@*"%LQAP1]->PHB4S M:<@D5\@\<].#-+Z'I)\D%^#3]^$S+#IX_"^=-^JH2Y08O*\9-XCT*1>()+6-(F4J^39#_'*^L,=>NO=QBE M':,T,!I<8326-'6A0#2_@,>:A@%+L-P7I!2V+9,GQT^N%^O07/,E7.,'?9_' M<6^0L?VYVA>]Y^>>:K@1RH+$-<'ZO4_#"$PS2XWA=!W:<:4= M-7=8;NGY0>,=Z'RMM3L9OL.[!RW_"U!+ P04 " #MB:Q4*IF_YIX" "' M!@ &0 'AL+W=OM?%TIH+D3E=P/ M>[W$+RD37CIR8S.5CN3:<"9@IHA>ER55[W? Y7;L!=YNX)&M"F,'_'14T17, MP3Q7,X4]O\V2LQ*$9E(0!Q 6&D8J#)^10,95Q?X/CS?$K.SR[(&6&"/!5R MK:G(]<@W"&;3^UD#<5=#A$<@OE%U1:+@DH2],.R03T[+IY"U\N"CW$<[6D_" MUI/0Y8N.Y/NN5E2P/]2:"32-44[F. BX MQXTF/V\7VBC2(^D>('ND6%]V PDDZ_:WEB9/;@[M)AV$T'/F; M?1<_!PVB,&Z#/I#U6[+^2;(7/*1V]2LE,]"=;'6">&_:?A(&AW =4?$@"+KI MXI8N/DF'*\/P;.1D)67WQHP_31OA;W UQ$5HL'=<$D+EYR$>Y(&MPS[=[:Z M^))/:W9]/1C&!WP=4?$P'A[P^7O7A+VB\=BMF-"$PQ)UO:L!%JCJ:Z_N&%FY MFV,A#=Y#KEG@EP*4#<#W2RG-KF,OH_;;D_X%4$L#!!0 ( .V)K%1B;,F> MNP, *,. 9 >&PO=V]R:W-H965TVF4SWUZ\Q! (A=%KQDH"Y M]W#NL7WPG9^X^"X/ H]9VDN%]9!J>.];!9)%E5/Q<0PWN/[#2%E@HGXA\%)7ERCLI1' MSK^7-Y^3A>64C""%6)405/\]P1K2M$32/'[4H%;SSC+Q\OJ,_M$4KXMYI!+6 M//V7)>JPL$(+);"C1:J^\M,GJ N:E7@Q3Z7Y1:M$OHITWEJN>;9D4MFYH#OT(JF-(\!;A!ZG0GU M$]$\01]^%.RH9UZAUQM0E*7RC0[YMMV@UZ_>H%>(Y>CO R^DCI5S6VF.Y9OL MN.:SJOB0&WQ<](7GZB#1ASR!I)MOZ]J: LFYP!49!?Q"Q1UR\5M$'$(&^*Q? MGHX'TC?CZ1N(;Z5WJG&;Z7(-GGL#KS,3<)Z)$6"O ?8,L/=;P&_17G Y.(T5 MG&_@2G-Y6I+(C_RY_72ISG64ZWI.U$1UN,X:KK-1KG^!E-HPXB(K4JH@T?M< M>U[,:.4DN@":<:'8?V9@B'R%/[N@]0X3+\0]]D-AOC?SANG[#7W_CZ3.00UQ M]:](X(#@68_J0)0?S6;#3(.&:3#*=#.F*X)G_?&1,,0YN&(3.$Z7\3JX6AK^ M14R';]CP#<<7!GUL!36$=X7(F2H$C&R1J$&/IMU[V&E-V)EV]]5XG?DF.(IZ MJV(PC(3!L,SXXJ.!?[$#]:?VP-,$L>PH^!.4=.68%*2%)A.KW'HG=B=6V;V6 MSXVBL*_R0)CG^C=<#K>6C,<]>Y9+E,).0SIW@9YT475$U8WB1],C/'*E.PYS>=!=)(@R0#_?<:[.-^4+FKYT M^3]02P,$% @ [8FL5!?.DJU= P _@D !D !X;"]W;W)K&ULC99;C]HZ$,>_BA7UH97V;!+G2@5(NZRJ5CI'1:67A^H\ MF&0 JTZ.U-Y^ZL:6:3^7>"%[# M4A&]KRJFGN]!R,/,"[V7@4]\NS-VP)]/&[:%%9@OS5)AS^^\E+R"6G-9$P6; MF7<7OEV$3N LOG(XZ),VL4M92_G#=CZ4,R^P1""@,-8%P[]'6( 0UA-R_#PZ M];IO6N%I^\7[.[=X7,R::5A(\8V79C?S = 3P'Z9N213>$!I0.B!?7)8_0-')PS_E/H:J MBQ?MXD6=OVC$WT>U937_C]F W9"%K+44O&1M2F)8E@HTU(:]!/0=KS&@G FR MPD' V T^7ZWUD9A!O][@2CJB")'%(\0X4;(O?7:M+LS%.+60^H\V(/]. ]I M1*.I_W@:R;[5)(K"SN@/NKBCB_^/SJ5)H^0&M#W\&(H-P& FM*Z24\R4!I,S MS+X533.:#W,F'6=R%6>!YP$O*;=_0XA)'S%.DN0,L6]%\R =04P[Q/3:4);[ MPB"J-H-A3/N,-*/9&>. 51ZGP3!CUC%F5S$J^DL$8)4BXOX-U02F\2$@CU5B>3GI,:1B'9^ #1G&6#8.'P>^*$EQ&-SM0 M6)_;2,.3/4_#B7!T= J0I_'Y>1^P2M(L&L$\*7SA1:UQ7SNU-%C]77.' M#S10U@#G-U*:EXY] G1/OODO4$L#!!0 ( .V)K%0/$5HT@@( T& 9 M >&PO=V]R:W-H965TSK51/ MN@(PY*7F0D^]RICFRO=U44%-]85L0.#,6JJ:&NRJC:\;!;1THIK[41!<^C5E MPLLS-[90>29;PYF A2*ZK6NJ?M\ E]NI%WJ[@7NVJ8P=\/.LH1M8@GEL%@I[ M_I"E9#4(S:0@"M93[SJ\FJ4VW@5\8[#5>VUB*UE)^60[=^74"RP0<"B,S4#Q M\PPSX-PF0HQ??4YO6-(*]]N[[+>N=JQE137,)/_.2E--O;%'2EC3EIM[N?T, M?3T.L)!>/46 T3=A>71N$L0YW)9[)NI&;.4KDF-Y1340!9 MNA-T9Z#6Y!.Y+@K50DD62I9M8<@]F%8)3:@HL;VB!C0YG8.AC.LSC']'I_?D 4#T2Q(TJ.$.TVINDW1G6;<!LDD&6?^\[ZC[\,FHW0R&J)>828#9O*?F.[\',+L$J5[Z\=I%,=O* ]% MA=$1RG2@3#^D?)"&\D-,Z7OKDB Y?5/I1XR#<,+Q.' M-0J#BQ'F4=WCTW6,;-S]74F#KX%K5OA>@[(!.+^6TNPZ]DD8_@'ROU!+ P04 M " #MB:Q4B]XI89L" =!@ &0 'AL+W=O(%2$ >VS+45H)6:$C;J"AL+Z:]<)-+8^'8F>U0 MV*>?[:19@;3:F\8/][_[W?GLCC="/JD"4<-+R;B:>(76U:7OJ[3 DJAS42$W M.[F0)=%F*M>^JB22S(E*YD=!,/1+0KDW';NUA9R.1:T9Y;B0H.JR)/+U&IG8 M3+S0VR[<8:,64<&XW?KT^M"6N'N>.O]QN5N M\M'78$83)'D'4"J+_%<2M(':)-F0NK3G19#J68@/26AMO=N!JX]0F&\KM M*2ZU-+O4Z/1T)LI**.I**G*X)HSP%&'I.NA68ZG@#.YT@1*^4+*BS)BB@N,Y M:D*9.C&[C\LY'!^=P!%0#@^%J!7AF1K[VN#9('[:HEPW*-$>E*]$GD,TDX=OY;XI2E>9J*M,Y/S%>_S=R37A] ^QI3F%F>!*,)J1IOEX M!@N)"KDFV]+=4&Y*1PF#I5E$T^E:P<^KE=+2].JO T1Q1Q0[HF0/T3?!)::B ME@J!M8?Q:JX2,^$RT (486A1\EK7$D&*5\+L<9T"$WQ]IE&6? MGU42Q/U\@XYO<)#O06C"^I@&'XH1)F$R>,?48S6,+X)W3/[.Y;4/I[D&:\H5 M,,R-+C@?&3>R>8R:B1:5N\\KH;]16@.SGPNAMQ/[1'3_"-._4$L# M!!0 ( .V)K%1*8W(0SP( #T' 9 >&PO=V]R:W-H965T2C/71Z$/:"-9$E M*JU#TE_?E0PN 8>V%Y#D?6_?6TFKP4J;)UL ('LII;+#H$!<7H2AS0HHN3W5 M2U#T9:Y-R9&F9A':I0&>>U IPZC3Z8#8-NL%FX$XL"W4(X&BSY NX!'Y>WAF9APY*+$I056C$#\V$P[EY,4Q?O M [X*6-FM,7-.9EH_N.X!X#8B]T5J9MW7)D8\&1J^8<='$Y@:^ M-AY-;H1RNWB/AKX*PN'H6B$8L,BN7NA@6&#'EX!<2'O"/K+'^TMV?'3"CIA0 M[*'0E>4JMX,0*;&#A]DZR:1.$KV3)&8W6F%AV97*(7^+#TEPHSK:J)Y$!PEO MN#EE&;1 MT%G]<2!-KTG3\VEZ?]LKJ.G;-J)FZ'L&=X.?1Q^[W209A,_;Y6F)2CK]J(EZ M(R]IY"7_)8_1+55:&<"8ZBFS/J&WH6[E M?VCJAX4N[T(HRR3,B;)SFE)A3=VLZPGJI>]W,XW4/?VPH/<-C N@[W.M<3-Q M"9H7<_0;4$L#!!0 ( .V)K%33R'0"< , %(* 9 >&PO=V]R:W-H M965T$8<.T&VT42>.-F MN\!B'QAI;!/E12&IN-ZOWZ&D*.ZNK/5+7VQ1XIES>#B[0W3P70IE MKX*=<_F',+3I#B6S/9VCHB\;;21S-#3;T.8&65:"I B3*!J%DG$5S*;ENY69 M377A!%>X,F +*9DY?$2A]U=!'+R\N.?;G?,OPMDT9UM)!Y0S?N>XMT?/X)?RJ/4W/_B<70615X0"4^=#,/I[Q@4* MX2.1CJN#Q\TOTZW+QM)A'9G&AQ5>>N=U5O][]@O:"A MCY=J8VW$$2 >G D-2 Y%]"O ?US 8,: M,#@7,*P!PW,!HQHP*KVOS"J=7C+'9E.C]V#\;(KF'\KM*M%D,%<^L];.T%=. M.#=;:"FYHU1Q%IC*8*&5XVJ+*N5HX3W<,6.8WWQXNT3'N+#OZ.W#>@EOW[R# M-\ 5W'(A*$GL-'0DR(<-TYK\8T6>G""?YZ8'47P!211/6N"+;O@M(WC_-'QY M-CQ)6N"?NN%+3!MXW *_[H:O,2=X5(H?_ @/:0^;C4R:C4S*>/T3\6ZTVKYW M:"2L"I/NZ+#!Z]["GS)UMEE6LHY+5U\3G63^:AL\M M2@>-TD&WTOGMI[OE'/ZX#^^8_)L9GL)O!8"D<5E9M/: M#);<3.I"N;9Z49%,CK.W-VEW-HY>ZW/4J>UHU3D:KK/60M<=8P@'9,9V.!4? M]8NX,]::[C09Y5ZCZJ0?RSK2<:Z=2+3XM>NL> M+#%GIA)$9>=7:IP\16!"8'7"V[K3HN8ZWK%XW!O^2V-XU%W];8OZQI8K"P(W M!(MZ8RH,IKK 5 .G\[+A/FI'[;M\W-&E#XV?0-\W6KN7@>_AS35R]@]02P,$ M% @ [8FL5$QYRCL)Z!0"Y$*[!'G&$\+*DQ3,M;.ZD?KHTOH* 9/ZQ*JS#7=-7M]CRA! 8U1A!RFGN9*TUK#V: :6=L:$N(?7 M[D>VP[W,MNK7@>K)=F@%-4-'XR; O\WFN+=I>Z_B#4K^I,SGA5V.K.?0<.Q. MLXPOZ_DR:P5@[%VIDR^."E8>D.G]MB_PV^?3UE&%\(\M."(;,;?6,H71=(^ M=0>):)[:C+_"\KIQ>PZTL;A,V9*EDV:J\VD]#.S 1FTN<-A';NO+CV ^#O,C M@&%Q, 68C_/"XOQ/ZQF@ZW$8IFW@10:HSP#U<5X^9%)_L#A^G\1>_I4F213% M,9;1R<2K8(+E+8[AZV?#M($'%@I\*-[^%C7\#4$L# M!!0 ( .V)K%27BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 189 323 1 true 68 0 false 10 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.supernus.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.supernus.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings Condensed Consolidated Statements of Earnings Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings Condensed Consolidated Statements of Comprehensive Earnings Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity Condensed Consolidated Statements of Changes in Stockholder's Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Business Organization Sheet http://www.supernus.com/role/BusinessOrganization Business Organization Notes 8 false false R9.htm 2102102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2107103 - Disclosure - Acquisition Sheet http://www.supernus.com/role/Acquisition Acquisition Notes 10 false false R11.htm 2113104 - Disclosure - Disaggregated Revenues Sheet http://www.supernus.com/role/DisaggregatedRevenues Disaggregated Revenues Notes 11 false false R12.htm 2117105 - Disclosure - Investments Sheet http://www.supernus.com/role/Investments Investments Notes 12 false false R13.htm 2122106 - Disclosure - Fair Value of Financial Measurements Sheet http://www.supernus.com/role/FairValueofFinancialMeasurements Fair Value of Financial Measurements Notes 13 false false R14.htm 2127107 - Disclosure - Contingent Consideration Sheet http://www.supernus.com/role/ContingentConsideration Contingent Consideration Notes 14 false false R15.htm 2131108 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNet Goodwill and Intangible Assets, Net Notes 15 false false R16.htm 2136109 - Disclosure - Convertible Senior Notes Due 2023 Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023 Convertible Senior Notes Due 2023 Notes 16 false false R17.htm 2140110 - Disclosure - Share-Based Payments Sheet http://www.supernus.com/role/ShareBasedPayments Share-Based Payments Notes 17 false false R18.htm 2146111 - Disclosure - Earnings per Share Sheet http://www.supernus.com/role/EarningsperShare Earnings per Share Notes 18 false false R19.htm 2149112 - Disclosure - Income Tax (Benefit) Expense Sheet http://www.supernus.com/role/IncomeTaxBenefitExpense Income Tax (Benefit) Expense Notes 19 false false R20.htm 2152113 - Disclosure - Leases Sheet http://www.supernus.com/role/Leases Leases Notes 20 false false R21.htm 2156114 - Disclosure - Composition of Balance Sheet Items Sheet http://www.supernus.com/role/CompositionofBalanceSheetItems Composition of Balance Sheet Items Notes 21 false false R22.htm 2164115 - Disclosure - Interest Expense Sheet http://www.supernus.com/role/InterestExpense Interest Expense Notes 22 false false R23.htm 2167116 - Disclosure - Commitments and Contingencies Sheet http://www.supernus.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 2169117 - Disclosure - Subsequent Events Sheet http://www.supernus.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.supernus.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 2308301 - Disclosure - Acquisition (Tables) Sheet http://www.supernus.com/role/AcquisitionTables Acquisition (Tables) Tables http://www.supernus.com/role/Acquisition 26 false false R27.htm 2314302 - Disclosure - Disaggregated Revenues (Tables) Sheet http://www.supernus.com/role/DisaggregatedRevenuesTables Disaggregated Revenues (Tables) Tables http://www.supernus.com/role/DisaggregatedRevenues 27 false false R28.htm 2318303 - Disclosure - Investments (Tables) Sheet http://www.supernus.com/role/InvestmentsTables Investments (Tables) Tables http://www.supernus.com/role/Investments 28 false false R29.htm 2323304 - Disclosure - Fair Value of Financial Measurements (Tables) Sheet http://www.supernus.com/role/FairValueofFinancialMeasurementsTables Fair Value of Financial Measurements (Tables) Tables http://www.supernus.com/role/FairValueofFinancialMeasurements 29 false false R30.htm 2328305 - Disclosure - Contingent Consideration (Tables) Sheet http://www.supernus.com/role/ContingentConsiderationTables Contingent Consideration (Tables) Tables http://www.supernus.com/role/ContingentConsideration 30 false false R31.htm 2332306 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) Tables http://www.supernus.com/role/GoodwillandIntangibleAssetsNet 31 false false R32.htm 2337307 - Disclosure - Convertible Senior Notes Due 2023 (Tables) Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Tables Convertible Senior Notes Due 2023 (Tables) Tables http://www.supernus.com/role/ConvertibleSeniorNotesDue2023 32 false false R33.htm 2341308 - Disclosure - Share-Based Payments (Tables) Sheet http://www.supernus.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.supernus.com/role/ShareBasedPayments 33 false false R34.htm 2347309 - Disclosure - Earnings per Share (Tables) Sheet http://www.supernus.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.supernus.com/role/EarningsperShare 34 false false R35.htm 2350310 - Disclosure - Income Tax (Benefit) Expense (Tables) Sheet http://www.supernus.com/role/IncomeTaxBenefitExpenseTables Income Tax (Benefit) Expense (Tables) Tables http://www.supernus.com/role/IncomeTaxBenefitExpense 35 false false R36.htm 2353311 - Disclosure - Leases (Tables) Sheet http://www.supernus.com/role/LeasesTables Leases (Tables) Tables http://www.supernus.com/role/Leases 36 false false R37.htm 2357312 - Disclosure - Composition of Balance Sheet Items (Tables) Sheet http://www.supernus.com/role/CompositionofBalanceSheetItemsTables Composition of Balance Sheet Items (Tables) Tables http://www.supernus.com/role/CompositionofBalanceSheetItems 37 false false R38.htm 2365313 - Disclosure - Interest Expense (Tables) Sheet http://www.supernus.com/role/InterestExpenseTables Interest Expense (Tables) Tables http://www.supernus.com/role/InterestExpense 38 false false R39.htm 2404401 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails Summary of Significant Accounting Policies - Basis of Presentation (Details) Details 39 false false R40.htm 2405402 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails Summary of Significant Accounting Policies - Advertising Expense (Details) Details 40 false false R41.htm 2406403 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) Details 41 false false R42.htm 2409404 - Disclosure - Acquisition - Narrative (Details) Sheet http://www.supernus.com/role/AcquisitionNarrativeDetails Acquisition - Narrative (Details) Details 42 false false R43.htm 2410405 - Disclosure - Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) Sheet http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) Details 43 false false R44.htm 2411406 - Disclosure - Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) Sheet http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) Details 44 false false R45.htm 2412407 - Disclosure - Acquisition - Pro Forma Information (Details) Sheet http://www.supernus.com/role/AcquisitionProFormaInformationDetails Acquisition - Pro Forma Information (Details) Details 45 false false R46.htm 2415408 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details) Sheet http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails Disaggregated Revenues - Summary of Revenues (Details) Details 46 false false R47.htm 2416409 - Disclosure - Disaggregated Revenues - Narrative (Details) Sheet http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails Disaggregated Revenues - Narrative (Details) Details 47 false false R48.htm 2419410 - Disclosure - Investments - Unrestricted Marketable Securities (Details) Sheet http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails Investments - Unrestricted Marketable Securities (Details) Details 48 false false R49.htm 2420411 - Disclosure - Investments - Contractual Maturities (Details) Sheet http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails Investments - Contractual Maturities (Details) Details 49 false false R50.htm 2421412 - Disclosure - Investments - Narrative (Details) Sheet http://www.supernus.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 50 false false R51.htm 2424413 - Disclosure - Fair Value of Financial Measurements - Narrative (Details) Sheet http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails Fair Value of Financial Measurements - Narrative (Details) Details 51 false false R52.htm 2425414 - Disclosure - Fair Value of Financial Measurements - Carrying Value (Details) Sheet http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails Fair Value of Financial Measurements - Carrying Value (Details) Details 52 false false R53.htm 2426415 - Disclosure - Fair Value of Financial Measurements - Financial Instruments (Details) Sheet http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails Fair Value of Financial Measurements - Financial Instruments (Details) Details 53 false false R54.htm 2429416 - Disclosure - Contingent Consideration - Narrative (Details) Sheet http://www.supernus.com/role/ContingentConsiderationNarrativeDetails Contingent Consideration - Narrative (Details) Details 54 false false R55.htm 2430417 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) Sheet http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) Details 55 false false R56.htm 2433418 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) Details 56 false false R57.htm 2434419 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) Details 57 false false R58.htm 2435420 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails Goodwill and Intangible Assets, Net - Narrative (Details) Details 58 false false R59.htm 2438421 - Disclosure - Convertible Senior Notes Due 2023 - Narrative (Details) Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails Convertible Senior Notes Due 2023 - Narrative (Details) Details 59 false false R60.htm 2439422 - Disclosure - Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) Details 60 false false R61.htm 2442423 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails Share-Based Payments - Share-based Compensation Expense (Details) Details 61 false false R62.htm 2443424 - Disclosure - Share-Based Payments - SAR Activity (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails Share-Based Payments - SAR Activity (Details) Details 62 false false R63.htm 2444425 - Disclosure - Share-Based Payments - Restricted Stock Units (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails Share-Based Payments - Restricted Stock Units (Details) Details 63 false false R64.htm 2445426 - Disclosure - Share-Based Payments - Performance Stock Units (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails Share-Based Payments - Performance Stock Units (Details) Details 64 false false R65.htm 2448427 - Disclosure - Earnings per Share (Details) Sheet http://www.supernus.com/role/EarningsperShareDetails Earnings per Share (Details) Details http://www.supernus.com/role/EarningsperShareTables 65 false false R66.htm 2451428 - Disclosure - Income Tax (Benefit) Expense (Details) Sheet http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails Income Tax (Benefit) Expense (Details) Details http://www.supernus.com/role/IncomeTaxBenefitExpenseTables 66 false false R67.htm 2454429 - Disclosure - Leases - Narrative (Details) Sheet http://www.supernus.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 67 false false R68.htm 2455430 - Disclosure - Leases - Leases Balance Sheet Information (Details) Sheet http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails Leases - Leases Balance Sheet Information (Details) Details 68 false false R69.htm 2458431 - Disclosure - Composition of Balance Sheet Items - Accounts Receivables (Details) Sheet http://www.supernus.com/role/CompositionofBalanceSheetItemsAccountsReceivablesDetails Composition of Balance Sheet Items - Accounts Receivables (Details) Details 69 false false R70.htm 2459432 - Disclosure - Composition of Balance Sheet Items - Inventories (Details) Sheet http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails Composition of Balance Sheet Items - Inventories (Details) Details 70 false false R71.htm 2460433 - Disclosure - Composition of Balance Sheet Items - Property and Equipment (Details) Sheet http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails Composition of Balance Sheet Items - Property and Equipment (Details) Details 71 false false R72.htm 2461434 - Disclosure - Composition of Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) Sheet http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails Composition of Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details) Details 72 false false R73.htm 2462435 - Disclosure - Composition of Balance Sheet Items - Accrued Product Returns and Rebates (Details) Sheet http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails Composition of Balance Sheet Items - Accrued Product Returns and Rebates (Details) Details 73 false false R74.htm 2463436 - Disclosure - Composition of Balance Sheet Items - Other Liabilities (Details) Sheet http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails Composition of Balance Sheet Items - Other Liabilities (Details) Details 74 false false R75.htm 2466437 - Disclosure - Interest Expense (Details) Sheet http://www.supernus.com/role/InterestExpenseDetails Interest Expense (Details) Details http://www.supernus.com/role/InterestExpenseTables 75 false false R76.htm 2468438 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 76 false false All Reports Book All Reports supn-20220331.htm supn-20220331.xsd supn-20220331_cal.xml supn-20220331_def.xml supn-20220331_lab.xml supn-20220331_pre.xml supn-20220331x10qxex311.htm supn-20220331x10qxex312.htm supn-20220331x10qxex321.htm supn-20220331x10qxex322.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "supn-20220331.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 189, "dts": { "calculationLink": { "local": [ "supn-20220331_cal.xml" ] }, "definitionLink": { "local": [ "supn-20220331_def.xml" ] }, "inline": { "local": [ "supn-20220331.htm" ] }, "labelLink": { "local": [ "supn-20220331_lab.xml" ] }, "presentationLink": { "local": [ "supn-20220331_pre.xml" ] }, "schema": { "local": [ "supn-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 535, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 8, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 13 }, "keyCustom": 41, "keyStandard": 282, "memberCustom": 29, "memberStandard": 37, "nsprefix": "supn", "nsuri": "http://www.supernus.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.supernus.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Acquisition", "role": "http://www.supernus.com/role/Acquisition", "shortName": "Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Disaggregated Revenues", "role": "http://www.supernus.com/role/DisaggregatedRevenues", "shortName": "Disaggregated Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Investments", "role": "http://www.supernus.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - Fair Value of Financial Measurements", "role": "http://www.supernus.com/role/FairValueofFinancialMeasurements", "shortName": "Fair Value of Financial Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "supn:ContingentConsiderationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127107 - Disclosure - Contingent Consideration", "role": "http://www.supernus.com/role/ContingentConsideration", "shortName": "Contingent Consideration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "supn:ContingentConsiderationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131108 - Disclosure - Goodwill and Intangible Assets, Net", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNet", "shortName": "Goodwill and Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136109 - Disclosure - Convertible Senior Notes Due 2023", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023", "shortName": "Convertible Senior Notes Due 2023", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140110 - Disclosure - Share-Based Payments", "role": "http://www.supernus.com/role/ShareBasedPayments", "shortName": "Share-Based Payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146111 - Disclosure - Earnings per Share", "role": "http://www.supernus.com/role/EarningsperShare", "shortName": "Earnings per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149112 - Disclosure - Income Tax (Benefit) Expense", "role": "http://www.supernus.com/role/IncomeTaxBenefitExpense", "shortName": "Income Tax (Benefit) Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152113 - Disclosure - Leases", "role": "http://www.supernus.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156114 - Disclosure - Composition of Balance Sheet Items", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItems", "shortName": "Composition of Balance Sheet Items", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2164115 - Disclosure - Interest Expense", "role": "http://www.supernus.com/role/InterestExpense", "shortName": "Interest Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2167116 - Disclosure - Commitments and Contingencies", "role": "http://www.supernus.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2169117 - Disclosure - Subsequent Events", "role": "http://www.supernus.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Acquisition (Tables)", "role": "http://www.supernus.com/role/AcquisitionTables", "shortName": "Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314302 - Disclosure - Disaggregated Revenues (Tables)", "role": "http://www.supernus.com/role/DisaggregatedRevenuesTables", "shortName": "Disaggregated Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318303 - Disclosure - Investments (Tables)", "role": "http://www.supernus.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323304 - Disclosure - Fair Value of Financial Measurements (Tables)", "role": "http://www.supernus.com/role/FairValueofFinancialMeasurementsTables", "shortName": "Fair Value of Financial Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328305 - Disclosure - Contingent Consideration (Tables)", "role": "http://www.supernus.com/role/ContingentConsiderationTables", "shortName": "Contingent Consideration (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332306 - Disclosure - Goodwill and Intangible Assets, Net (Tables)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables", "shortName": "Goodwill and Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337307 - Disclosure - Convertible Senior Notes Due 2023 (Tables)", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Tables", "shortName": "Convertible Senior Notes Due 2023 (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341308 - Disclosure - Share-Based Payments (Tables)", "role": "http://www.supernus.com/role/ShareBasedPaymentsTables", "shortName": "Share-Based Payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347309 - Disclosure - Earnings per Share (Tables)", "role": "http://www.supernus.com/role/EarningsperShareTables", "shortName": "Earnings per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350310 - Disclosure - Income Tax (Benefit) Expense (Tables)", "role": "http://www.supernus.com/role/IncomeTaxBenefitExpenseTables", "shortName": "Income Tax (Benefit) Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353311 - Disclosure - Leases (Tables)", "role": "http://www.supernus.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357312 - Disclosure - Composition of Balance Sheet Items (Tables)", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItemsTables", "shortName": "Composition of Balance Sheet Items (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2365313 - Disclosure - Interest Expense (Tables)", "role": "http://www.supernus.com/role/InterestExpenseTables", "shortName": "Interest Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails", "shortName": "Summary of Significant Accounting Policies - Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Earnings", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "shortName": "Condensed Consolidated Statements of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails", "shortName": "Summary of Significant Accounting Policies - Advertising Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i608fec9e3180418e984c04b9df85321c_I20220101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Acquisition - Narrative (Details)", "role": "http://www.supernus.com/role/AcquisitionNarrativeDetails", "shortName": "Acquisition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i1ec12c552baf4ab2bda910f52ab7492f_D20211124-20211124", "decimals": "INF", "lang": "en-US", "name": "supn:NumberOfEstablishedMarketedProducts", "reportCount": 1, "unique": true, "unitRef": "marketproduct", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ie5afcfb887ca425fa9fcb03c906c08cc_I20211124", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ie5afcfb887ca425fa9fcb03c906c08cc_I20211124", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details)", "role": "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "shortName": "Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ia6ae72809c03427094fc84b8aa30eddb_I20211124", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ifc761748b9214d1c97e45c01205b6506_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Acquisition - Pro Forma Information (Details)", "role": "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "shortName": "Acquisition - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ifc761748b9214d1c97e45c01205b6506_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details)", "role": "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails", "shortName": "Disaggregated Revenues - Summary of Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i3e1d7fb8937a484e983f855cf4085c7b_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "supn:RevenueFromRoyaltyAgreement", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:RevenueFromRoyaltyAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Disaggregated Revenues - Narrative (Details)", "role": "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "shortName": "Disaggregated Revenues - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "supn:RevenueFromRoyaltyAgreement", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:RevenueFromRoyaltyAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Investments - Unrestricted Marketable Securities (Details)", "role": "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails", "shortName": "Investments - Unrestricted Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Investments - Contractual Maturities (Details)", "role": "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails", "shortName": "Investments - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings", "shortName": "Condensed Consolidated Statements of Comprehensive Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Investments - Narrative (Details)", "role": "http://www.supernus.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i608fec9e3180418e984c04b9df85321c_I20220101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Fair Value of Financial Measurements - Narrative (Details)", "role": "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails", "shortName": "Fair Value of Financial Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Fair Value of Financial Measurements - Carrying Value (Details)", "role": "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "shortName": "Fair Value of Financial Measurements - Carrying Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i8b1b0e3ad35e48c59d1136c91ba0d3b1_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleLongTermNotesPayable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426415 - Disclosure - Fair Value of Financial Measurements - Financial Instruments (Details)", "role": "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Measurements - Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i9f9342957b6e45a8becde2c5b817c45d_D20200609-20200609", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - Contingent Consideration - Narrative (Details)", "role": "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "shortName": "Contingent Consideration - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ife863c7ddb5a43128ab913be15f1cf21_D20200609-20200609", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i1a174041a3704f0abe0c07f0c95ce4e8_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430417 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details)", "role": "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "shortName": "Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i1a174041a3704f0abe0c07f0c95ce4e8_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i1a174041a3704f0abe0c07f0c95ce4e8_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails", "shortName": "Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435420 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails", "shortName": "Goodwill and Intangible Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438421 - Disclosure - Convertible Senior Notes Due 2023 - Narrative (Details)", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "shortName": "Convertible Senior Notes Due 2023 - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ibc823e92d96d4f27b607ebf7c025f4e0_I20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0dd9cbadd34142278e915add4a5a5a98_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Stockholder's Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0dd9cbadd34142278e915add4a5a5a98_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleLongTermNotesPayable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439422 - Disclosure - Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details)", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "shortName": "Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ibc823e92d96d4f27b607ebf7c025f4e0_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails", "shortName": "Share-Based Payments - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ic9909a1678c14249ba819f91dfdf0dd0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443424 - Disclosure - Share-Based Payments - SAR Activity (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails", "shortName": "Share-Based Payments - SAR Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ic46375d5a37446ab83ce4cca9288afd7_D20220101-20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ia59910defbfe4edcb880324f53b56c40_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444425 - Disclosure - Share-Based Payments - Restricted Stock Units (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "shortName": "Share-Based Payments - Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ia59910defbfe4edcb880324f53b56c40_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "iad947bbf1a5e49719cf790ca3e54f07f_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Share-Based Payments - Performance Stock Units (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "shortName": "Share-Based Payments - Performance Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "iad947bbf1a5e49719cf790ca3e54f07f_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - Earnings per Share (Details)", "role": "http://www.supernus.com/role/EarningsperShareDetails", "shortName": "Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451428 - Disclosure - Income Tax (Benefit) Expense (Details)", "role": "http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails", "shortName": "Income Tax (Benefit) Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ie47d5f4bf8e1441cae299f55a48336ad_I20211124", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454429 - Disclosure - Leases - Narrative (Details)", "role": "http://www.supernus.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "ie47d5f4bf8e1441cae299f55a48336ad_I20211124", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455430 - Disclosure - Leases - Leases Balance Sheet Information (Details)", "role": "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails", "shortName": "Leases - Leases Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "lang": "en-US", "name": "supn:LeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:AllowanceForExpectedSalesDeductions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458431 - Disclosure - Composition of Balance Sheet Items - Accounts Receivables (Details)", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccountsReceivablesDetails", "shortName": "Composition of Balance Sheet Items - Accounts Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:AllowanceForExpectedSalesDeductions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459432 - Disclosure - Composition of Balance Sheet Items - Inventories (Details)", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails", "shortName": "Composition of Balance Sheet Items - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460433 - Disclosure - Composition of Balance Sheet Items - Property and Equipment (Details)", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails", "shortName": "Composition of Balance Sheet Items - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461434 - Disclosure - Composition of Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details)", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails", "shortName": "Composition of Balance Sheet Items - Accrued Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:AccruedRebates", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462435 - Disclosure - Composition of Balance Sheet Items - Accrued Product Returns and Rebates (Details)", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails", "shortName": "Composition of Balance Sheet Items - Accrued Product Returns and Rebates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:AccruedRebates", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:NonRecourseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463436 - Disclosure - Composition of Balance Sheet Items - Other Liabilities (Details)", "role": "http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails", "shortName": "Composition of Balance Sheet Items - Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i5f124b5a3a7344b0915e8f37b0a9f80f_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:NonRecourseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466437 - Disclosure - Interest Expense (Details)", "role": "http://www.supernus.com/role/InterestExpenseDetails", "shortName": "Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i656b85a2c23a46039e80a8340788d366_I20140930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468438 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i656b85a2c23a46039e80a8340788d366_I20140930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Business Organization", "role": "http://www.supernus.com/role/BusinessOrganization", "shortName": "Business Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220331.htm", "contextRef": "i0edab0eb7c844812884891adf8e06b0c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r112", "r266", "r270", "r275", "r434", "r435", "r439", "r440", "r503", "r606" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r112", "r266", "r270", "r275", "r434", "r435", "r439", "r440", "r503", "r606" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r2", "r117", "r126", "r215", "r376", "r377", "r378", "r398", "r399", "r451", "r456", "r457", "r626" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Balance, January 1, 2022" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r117", "r126", "r133", "r215", "r376", "r377", "r378", "r398", "r399", "r451", "r454", "r456", "r457", "r626" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect of adoption of ASU 2020-06" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r117", "r126", "r133", "r215", "r376", "r377", "r378", "r398", "r399", "r451", "r454", "r456", "r457", "r626" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r117", "r126", "r133", "r215", "r376", "r377", "r378", "r398", "r399", "r451", "r454", "r456", "r457", "r626" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r188", "r323", "r327", "r586" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r281", "r305", "r347", "r349", "r515", "r516", "r517", "r518", "r519", "r520", "r539", "r584", "r587", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r281", "r305", "r347", "r349", "r515", "r516", "r517", "r518", "r519", "r520", "r539", "r584", "r587", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r188", "r323", "r327", "r586" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r186", "r323", "r325", "r541", "r583", "r585" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r186", "r323", "r325", "r541", "r583", "r585" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r281", "r305", "r337", "r347", "r349", "r515", "r516", "r517", "r518", "r519", "r520", "r539", "r584", "r587", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r281", "r305", "r337", "r347", "r349", "r515", "r516", "r517", "r518", "r519", "r520", "r539", "r584", "r587", "r607", "r608" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r3", "r114", "r115", "r116", "r118", "r119", "r123", "r124", "r125", "r126", "r128", "r129", "r130", "r131", "r132", "r133", "r152", "r216", "r217", "r379", "r399", "r452", "r456", "r457", "r458", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r3", "r114", "r115", "r116", "r118", "r119", "r123", "r124", "r125", "r126", "r128", "r129", "r130", "r131", "r132", "r133", "r152", "r216", "r217", "r379", "r399", "r452", "r456", "r457", "r458", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r3", "r114", "r116", "r118", "r119", "r123", "r124", "r125", "r126", "r128", "r129", "r131", "r132", "r152", "r216", "r217", "r379", "r399", "r452", "r456", "r457", "r458", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "terseLabel": "As Initially Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "supn_APOKYNAndSPN830Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "APOKYN And SPN-830", "label": "APOKYN And SPN-830 [Member]", "terseLabel": "APOKYN and SPN-830" } } }, "localname": "APOKYNAndSPN830Member", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_APOKYNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "APOKYN", "label": "APOKYN [Member]", "terseLabel": "APOKYN" } } }, "localname": "APOKYNMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_AccruedClinicalTrialAndClinicalSupplyCostsCurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of clinical trial and clinical supply costs accrued.", "label": "Accrued Clinical Trial and Clinical Supply Costs Current", "terseLabel": "Accrued clinical trial costs" } } }, "localname": "AccruedClinicalTrialAndClinicalSupplyCostsCurrent", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AccruedProductReturns": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "order": 2.0, "parentTag": "supn_AccruedProductReturnsAndRebates", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued product returns.", "label": "Accrued Product Returns", "terseLabel": "Accrued product returns" } } }, "localname": "AccruedProductReturns", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AccruedProductReturnsAndRebates": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued product returns and rebates.", "label": "Accrued Product Returns and Rebates.", "terseLabel": "Accrued product returns and rebates", "totalLabel": "Total" } } }, "localname": "AccruedProductReturnsAndRebates", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "supn_AccruedRebates": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "order": 1.0, "parentTag": "supn_AccruedProductReturnsAndRebates", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued rebates.", "label": "Accrued Rebates", "terseLabel": "Accrued product rebates" } } }, "localname": "AccruedRebates", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedProductReturnsandRebatesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AdamasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adamas", "label": "Adamas [Member]", "terseLabel": "Adamas Acquisition" } } }, "localname": "AdamasMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_AdamasPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adamas Pharmaceuticals", "label": "Adamas Pharmaceuticals [Member]", "terseLabel": "Adamas Pharmaceuticals" } } }, "localname": "AdamasPharmaceuticalsMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_AllowanceForExpectedSalesDeductions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the allowance for sales discounts related to prompt-pay discounts and contractual fee for service arrangements to wholesalers and distributors.", "label": "Allowance for Expected Sales deductions", "terseLabel": "Allowance for expected sales discounts and allowances" } } }, "localname": "AllowanceForExpectedSalesDeductions", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccountsReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AmerisourceBergenDrugCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AmerisourceBergen Drug Corporation", "label": "AmerisourceBergen Drug Corporation [Member]", "terseLabel": "AmerisourceBergen Drug Corporation" } } }, "localname": "AmerisourceBergenDrugCorporationMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value", "terseLabel": "1 year to 2 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securities Debt Maturities, Thereafter, Fair Value", "label": "Available For Sale Securities Debt Maturities, Thereafter, Fair Value", "terseLabel": "Greater than 4 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the third fiscal year through the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value", "terseLabel": "3 years to 4 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the second fiscal year through the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value", "terseLabel": "2 years to 3 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One", "label": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One", "terseLabel": "Additional cash payments upon milestone achievements minimum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodOne", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two", "label": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two", "terseLabel": "Additional cash payments upon milestone achievements maximum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodTwo", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationNumberOfContingentValueRightsPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share", "label": "Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share", "terseLabel": "Contingents value rights" } } }, "localname": "BusinessCombinationContingentConsiderationNumberOfContingentValueRightsPerCommonShare", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "integerItemType" }, "supn_BusinessCombinationContingentConsiderationRightsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Rights Per Share", "label": "Business Combination, Contingent Consideration, Rights Per Share", "terseLabel": "Rights per share (in dollars per share)" } } }, "localname": "BusinessCombinationContingentConsiderationRightsPerShare", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "perShareItemType" }, "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialIdentifiableAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Identifiable Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Identifiable Assets", "terseLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialIdentifiableAssets", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesAssumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities Assumed", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities Assumed", "terseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesAssumed", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets", "terseLabel": "Other assets", "verboseLabel": "Change in fair value of operating lease acquired" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities", "negatedTerseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired", "totalLabel": "Total fair value of assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredIncomeTaxLiabilities": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredIncomeTaxLiabilities", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent", "negatedTerseLabel": "Operating lease liabilities, long-term" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNoncurrent", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_CardinalHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardinal Health", "label": "Cardinal Health [Member]", "terseLabel": "Cardinal Health" } } }, "localname": "CardinalHealthMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_ClassOfWarrantOrRightNumberOfSharesInWhichHolderCanBeEntitledPerWarrantsAtStrikePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the shares per warrant entitled to holders at strike price.", "label": "Class of Warrant or Right, Number of Shares in Which Holder Can be Entitled per Warrants at Strike Price", "terseLabel": "Number of shares per warrant entitled to holder (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSharesInWhichHolderCanBeEntitledPerWarrantsAtStrikePrice", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "sharesItemType" }, "supn_CollaborativeArrangementThresholdForDevelopmentCostsPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Threshold For Development Costs Payments", "label": "Collaborative Arrangement, Threshold For Development Costs Payments", "terseLabel": "Threshold for development costs payments" } } }, "localname": "CollaborativeArrangementThresholdForDevelopmentCostsPayments", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_ContingentConsiderationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration Disclosure", "label": "Contingent Consideration Disclosure [Text Block]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationDisclosureTextBlock", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsideration" ], "xbrltype": "textBlockItemType" }, "supn_ConversionCircumstanceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Circumstance One", "label": "Conversion Circumstance One [Member]", "terseLabel": "Conversion Circumstance One" } } }, "localname": "ConversionCircumstanceOneMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_ConversionCircumstanceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Circumstance Two", "label": "Conversion Circumstance Two [Member]", "terseLabel": "Conversion Circumstance Two" } } }, "localname": "ConversionCircumstanceTwoMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_GOCOVRIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GOCOVRI", "label": "GOCOVRI [Member]", "terseLabel": "GOCOVRI" } } }, "localname": "GOCOVRIMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_IncreaseDecreaseInAccruedProductReturnsAndRebates": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in product returns and rebates.", "label": "Increase (Decrease) In Accrued Product Returns And Rebates", "terseLabel": "Accrued product returns and rebates" } } }, "localname": "IncreaseDecreaseInAccruedProductReturnsAndRebates", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and other current assets.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Current Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_LabEquipmentAndFurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to lab equipment and furniture.", "label": "Lab Equipment And Furniture [Member]", "terseLabel": "Lab equipment and furniture" } } }, "localname": "LabEquipmentAndFurnitureMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "supn_LeaseLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities, Current", "label": "Lease Liabilities, Current [Abstract]", "terseLabel": "Lease liabilities, current" } } }, "localname": "LeaseLiabilitiesCurrentAbstract", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "supn_LeaseLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities, Noncurrent", "label": "Lease Liabilities, Noncurrent [Abstract]", "terseLabel": "Lease liabilities, long-term" } } }, "localname": "LeaseLiabilitiesNoncurrentAbstract", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "supn_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "supn_LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating and Finance Lease, Balance Sheet Disclosure", "label": "Lessee, Operating and Finance Lease, Balance Sheet Disclosure [Table Text Block]", "terseLabel": "Schedule of balance sheet information related to leases" } } }, "localname": "LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "supn_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "supn_MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MDD US Enterprises LLC (Formerly USWM Enterprises)", "label": "MDD US Enterprises LLC (Formerly USWM Enterprises) [Member]", "terseLabel": "USWM Acquisition" } } }, "localname": "MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_MarketBasedUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Based Units", "label": "Market Based Units [Member]", "terseLabel": "Market-Based Units" } } }, "localname": "MarketBasedUnitsMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "supn_McKessonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "McKesson", "label": "McKesson [Member]", "terseLabel": "McKesson" } } }, "localname": "McKessonMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_NAMENDAXRNamzaricQuiTamLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NAMENDA XR/Namzaric Qui Tam Litigation", "label": "NAMENDA XR/Namzaric Qui Tam Litigation [Member]", "terseLabel": "NAMENDA XR/Namzaric Qui Tam Litigation" } } }, "localname": "NAMENDAXRNamzaricQuiTamLitigationMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_NavitorPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Navitor Pharmaceuticals, Inc.", "label": "Navitor Pharmaceuticals, Inc. [Member]", "terseLabel": "Navitor Pharmaceuticals, Inc." } } }, "localname": "NavitorPharmaceuticalsIncMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_NonCashCapitalizedCostOfIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the non-cash expenses related to intangible assets that were capitalized and shown within accrued expenses.", "label": "Non Cash Capitalized Cost Of Intangible Assets", "terseLabel": "Deferred legal fees and fixed assets included in accounts payable and accrued expenses" } } }, "localname": "NonCashCapitalizedCostOfIntangibleAssets", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of debt, net of the amount due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property.", "label": "Non Recourse Debt Sale of Future Royalties Noncurrent", "terseLabel": "Nonrecourse liability related to sale of future royalties, long term" } } }, "localname": "NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_NonRecourseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-Recourse Liability, Noncurrent", "label": "Non-Recourse Liability, Noncurrent", "terseLabel": "Nonrecourse liability related to sale of future royalties, long-term" } } }, "localname": "NonRecourseLiabilityNoncurrent", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_NumberOfEstablishedMarketedProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Established Marketed Products", "label": "Number Of Established Marketed Products", "terseLabel": "Number of established marketed products" } } }, "localname": "NumberOfEstablishedMarketedProducts", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "integerItemType" }, "supn_OxtellarXRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Oxtellar XR product.", "label": "Oxtellar X R [Member]", "terseLabel": "Oxtellar XR" } } }, "localname": "OxtellarXRMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_PatentDefenseCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information concerning the capitalized patent defense costs related to the Watson litigation.", "label": "Patent Defense Costs [Member]", "terseLabel": "Capitalized patent defense costs" } } }, "localname": "PatentDefenseCostsMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "supn_PaymentsForProceedsFromCollaborativeArrangementInvestment": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For (Proceeds From) Collaborative Arrangement, Investment", "label": "Payments For (Proceeds From) Collaborative Arrangement, Investment", "negatedTerseLabel": "Other income from Navitor (see Note 5)" } } }, "localname": "PaymentsForProceedsFromCollaborativeArrangementInvestment", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees", "label": "Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees", "negatedTerseLabel": "Purchases of property and equipment and deferred legal fees paid" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_PerformanceBasedUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Based Units", "label": "Performance Based Units [Member]", "terseLabel": "Performance-Based Units" } } }, "localname": "PerformanceBasedUnitsMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "supn_PurchaseCommitmentAnnualMinimumAmountCommitted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Annual Minimum Amount Committed", "label": "Purchase Commitment, Annual Minimum Amount Committed", "terseLabel": "Annual minimum purchase quantity requirement amount" } } }, "localname": "PurchaseCommitmentAnnualMinimumAmountCommitted", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_QelbreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Qelbree", "label": "Qelbree [Member]", "terseLabel": "Qelbree" } } }, "localname": "QelbreeMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory And Developmental Contingent Consideration Liability", "label": "Regulatory And Developmental Contingent Consideration Liability [Member]", "terseLabel": "Regulatory and developmental contingent consideration liabilities" } } }, "localname": "RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_RevenueFromRoyaltyAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents revenue from the sale of certain royalty and milestone rights.", "label": "Revenue From Royalty Agreement", "terseLabel": "Non-cash royalty revenue" } } }, "localname": "RevenueFromRoyaltyAgreement", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability", "label": "Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability", "terseLabel": "Lease assets and tenant receivable obtained for new operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_SPN830FDAAcceptanceMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 FDA Acceptance Milestone", "label": "SPN-830 FDA Acceptance Milestone [Member]", "terseLabel": "SPN-830 FDA Acceptance Milestone" } } }, "localname": "SPN830FDAAcceptanceMilestoneMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830FirstCommercialAndSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 First Commercial And Sale", "label": "SPN-830 First Commercial And Sale [Member]", "terseLabel": "SPN-830 First Commercial And Sale Milestone" } } }, "localname": "SPN830FirstCommercialAndSaleMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830FutureSalesPerformanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 Future Sales Performance", "label": "SPN-830 Future Sales Performance [Member]", "terseLabel": "Future Sales Performance" } } }, "localname": "SPN830FutureSalesPerformanceMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830NDAApprovalMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 NDA Approval Milestone", "label": "SPN-830 NDA Approval Milestone [Member]", "terseLabel": "SPN-830 NDA Approval Milestone" } } }, "localname": "SPN830NDAApprovalMilestoneMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830RegulatoryAndCommercialActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 Regulatory And Commercial Activities", "label": "SPN-830 Regulatory And Commercial Activities [Member]", "terseLabel": "SPN-30 Regulatory and Commercial Activities" } } }, "localname": "SPN830RegulatoryAndCommercialActivitiesMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SalesBasedContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales-Based Contingent Consideration Liability", "label": "Sales-Based Contingent Consideration Liability [Member]", "terseLabel": "Sales-based contingent consideration liabilities" } } }, "localname": "SalesBasedContingentConsiderationLiabilityMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities.", "label": "Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "supn_ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the accrued product returns and rebates.", "label": "Schedule of Accrued Product Returns and Rebates [Table Text Block]", "terseLabel": "Schedule of accrued product returns and rebates" } } }, "localname": "ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "supn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term\u00a0(in\u00a0years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "supn_StockOptionStockAppreciationRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights.", "label": "Stock Option Stock Appreciation Rights [Member]", "terseLabel": "Stock option and Stock Appreciation Rights" } } }, "localname": "StockOptionStockAppreciationRightsMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "domainItemType" }, "supn_ThreeMajorCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Major Customers", "label": "Three Major Customers [Member]", "terseLabel": "Three Major Customers" } } }, "localname": "ThreeMajorCustomersMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_TrokendiXrMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Trokendi XR patent litigation.", "label": "Trokendi Xr [Member]", "terseLabel": "Trokendi XR" } } }, "localname": "TrokendiXrMember", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_VariableInterestEntityAgreementTerminationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Agreement Termination Notice, Period", "label": "Variable Interest Entity, Agreement Termination Notice, Period", "terseLabel": "Agreement termination notice period" } } }, "localname": "VariableInterestEntityAgreementTerminationNoticePeriod", "nsuri": "http://www.supernus.com/20220331", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r118", "r119", "r120", "r121", "r192", "r193", "r212", "r213", "r214", "r215", "r216", "r217", "r265", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r398", "r399", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r502", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r624", "r625", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r47", "r506" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r8", "r27", "r189", "r190" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13", "r14", "r51" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r13", "r14", "r51" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r45", "r253" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r63", "r64", "r65", "r574", "r595", "r599" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive earnings (loss), net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r62", "r65", "r72", "r73", "r74", "r114", "r115", "r116", "r438", "r590", "r591", "r628" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated\u00a0Other Comprehensive Earnings\u00a0(Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r379", "r506" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r114", "r115", "r116", "r376", "r377", "r378", "r456" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional\u00a0 Paid-in\u00a0Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r118", "r119", "r120", "r121", "r133", "r192", "r193", "r212", "r213", "r214", "r215", "r216", "r217", "r265", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r396", "r397", "r398", "r399", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r502", "r543", "r544", "r545", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r624", "r625", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r350", "r352", "r381", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r352", "r370", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r97", "r294", "r302", "r303", "r491" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing costs and debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r97", "r238", "r245" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock equivalents excluded in the calculation of diluted income per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Income per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r175", "r178", "r184", "r211", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r434", "r439", "r472", "r504", "r506", "r551", "r570" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r60", "r108", "r211", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r434", "r439", "r472", "r504", "r506" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r459" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets at fair value", "totalLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r200" ], "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r201" ], "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r197", "r223" ], "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r202", "r203", "r564" ], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r194", "r198", "r223", "r557" ], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Total fair value", "totalLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails", "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r196", "r223" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Corporate and municipal debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r196", "r223" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Corporate and municipal debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r353", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r346", "r348" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r346", "r348", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business acquisition, pro forma information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r411", "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Pro forma net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r411", "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Pro forma total revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r421", "r422", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r96", "r429" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration", "verboseLabel": "Contingent consideration expense" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High", "terseLabel": "Fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Additional cash payments upon milestone achievements maximum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Additional cash payments upon milestone achievements minimum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r420", "r423", "r427" ], "calculation": { "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration", "totalLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r420", "r424" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration, current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r420", "r424" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration, long-term" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/Acquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "negatedTerseLabel": "Current debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangibles", "verboseLabel": "Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r415", "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total fair value of liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r415", "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r415", "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r416" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r101", "r102", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital Expenditures Incurred but Not yet Paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r42", "r99" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r99", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r481" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Strike price of the warrant transactions (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants issued (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r257", "r258", "r259", "r263", "r605" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r114", "r115", "r456" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r506" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value; 130,000,000 shares authorized; 53,386,305 and 53,256,094 shares issued and outstanding as of March 31, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r68", "r70", "r71", "r78", "r560", "r579" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive earnings" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r239", "r243", "r418" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r163", "r164", "r188", "r470", "r471", "r604" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r163", "r164", "r188", "r470", "r471", "r601", "r604" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r163", "r164", "r188", "r470", "r471", "r601", "r604" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r163", "r164", "r188", "r470", "r471" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage (more than)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r163", "r164", "r188", "r470", "r471", "r604" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r106", "r436" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Fair\u00a0Value (Level\u00a02)" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r277", "r278", "r279", "r281", "r285", "r286", "r287", "r290", "r291", "r292", "r293", "r294", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "verboseLabel": "Summary of liability component of 2023 Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r55" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Carrying\u00a0Value", "totalLabel": "Total carrying value", "verboseLabel": "Convertible notes, net" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r21", "r552", "r568", "r602" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Notes" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r338", "r345", "r600" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate and municipal debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r83", "r541" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r82" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r161", "r188" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r101", "r103" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]", "terseLabel": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r101", "r103" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Convertible note hedge options issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r101", "r103" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]", "terseLabel": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r101", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "verboseLabel": "Conversion of debt to equity" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r280", "r298" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price, per share of common stock (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r54", "r280", "r308", "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate for the notes (in shares per $1,000 principal amount)" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.", "label": "Debt Instrument, Convertible, Stock Price Trigger", "terseLabel": "Conversion option stock price trigger (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading day period (in days)" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Conversion rate of the notes on trading day (as percent)" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days (whether or not consecutive)" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r278", "r300", "r301", "r490", "r492", "r493" ], "calculation": { "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "2023 Notes", "verboseLabel": "Principal amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r53", "r279" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Notes payable", "verboseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r55", "r107", "r112", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r300", "r301", "r302", "r303", "r308", "r310", "r311", "r312", "r489", "r490", "r492", "r493", "r567" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r285", "r296", "r300", "r301", "r491" ], "calculation": { "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt discount and deferred financing costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r199", "r223", "r226", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "terseLabel": "Impairment due to credit losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Current [Abstract]", "terseLabel": "Marketable securities" } } }, "localname": "DebtSecuritiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Noncurrent [Abstract]", "terseLabel": "Long-term marketable securities" } } }, "localname": "DebtSecuritiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r109", "r395", "r402", "r403", "r404" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r387", "r388" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r388", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r20", "r334", "r335", "r336", "r345", "r550", "r569" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "verboseLabel": "Marketable securities - restricted (SERP)" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r97", "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r173" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology and product rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of disaggregation of revenues by nature" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r123", "r124", "r126", "r127", "r128", "r134", "r137", "r146", "r147", "r148", "r152", "r153", "r457", "r458", "r561", "r580" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "verboseLabel": "Earnings per share" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r123", "r124", "r126", "r127", "r128", "r137", "r146", "r147", "r148", "r152", "r153", "r457", "r458", "r561", "r580" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r149", "r150", "r151", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based payments" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r72", "r73", "r74", "r114", "r115", "r116", "r119", "r129", "r132", "r155", "r215", "r307", "r313", "r376", "r377", "r378", "r398", "r399", "r456", "r482", "r483", "r484", "r485", "r486", "r487", "r590", "r591", "r592", "r628" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Investments" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r459", "r460", "r461", "r468" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value of the financial assets and liabilities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r287", "r300", "r301", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r460", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r459", "r460", "r462", "r463", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r287", "r338", "r339", "r344", "r345", "r460", "r512" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r287", "r300", "r301", "r338", "r339", "r344", "r345", "r460", "r513" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r287", "r300", "r301", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r460", "r514" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of financial liabilities that are not carried at fair value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r464", "r468" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Change in fair value recognized in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r466" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "terseLabel": "Milestone payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at March 31, 2022 (unaudited)", "periodStartLabel": "Balance at December 31, 2021" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r287", "r300", "r301", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r204", "r205", "r207", "r208", "r209", "r218", "r219", "r220", "r221", "r222", "r224", "r225", "r228", "r229", "r295", "r306", "r447", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r615", "r616", "r617", "r618", "r619", "r620", "r621" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-lived and indefinite-lived intangible assets acquired as part of business combination" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated Useful Life as of Closing Date (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r244" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r239", "r241", "r244", "r248", "r542", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r244", "r546" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "order": 3.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Carrying Amount, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "verboseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r239", "r243" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r244", "r542" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Carrying Amount, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining Weighted Average\u00a0Life (Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r232", "r233", "r506", "r549" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance as of March\u00a031, 2022 (unaudited)", "periodStartLabel": "Balance as of December\u00a031, 2021", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets, Net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r234", "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Acquired in-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r76", "r175", "r177", "r180", "r183", "r185", "r547", "r558", "r563", "r581" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r110", "r391", "r392", "r394", "r400", "r405", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax (Benefit) Expense" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/IncomeTaxBenefitExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r111", "r131", "r132", "r174", "r389", "r401", "r406", "r582" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r142", "r143", "r148" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Convertible notes" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r138", "r139", "r140", "r148" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Stock options, RSU and SAR (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r240", "r247" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r247" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Acquired in-process research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r240", "r247" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total intangible assets, carrying amount, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r237", "r242" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r75", "r172", "r488", "r491", "r562" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.supernus.com/role/InterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r86", "r292", "r299", "r302", "r303" ], "calculation": { "http://www.supernus.com/role/InterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest expense on nonrecourse liability related to sale of future royalties" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of interest expense" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InterestExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r136", "r141", "r148" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.", "label": "Interest on Convertible Debt, Net of Tax", "terseLabel": "After-tax interest expense for 2023 Notes" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r92", "r94", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest on convertible notes" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r59", "r230" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Inventory Adjustments", "terseLabel": "Accrued product costs" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r34", "r231" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r7", "r58", "r506" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves": { "auth_ref": [ "r35", "r36", "r231" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryWorkInProcessAndRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r35", "r231" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r86" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedLabel": "Amortization of premium/discount on marketable securities" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r206", "r548", "r565", "r603", "r622" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Optional lease renewal term (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r49", "r108", "r179", "r211", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r435", "r439", "r440", "r472", "r504", "r505" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r108", "r211", "r472", "r506", "r556", "r576" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r52", "r108", "r211", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r435", "r439", "r440", "r472", "r504", "r505", "r506" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r459" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Payment to resolve U.S. Department of Justice allegations" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r286", "r297", "r300", "r301", "r554", "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Convertible Senior Notes Due 2023" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r55", "r264" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsFinancialInstrumentsDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-term Purchase Commitment, Period", "terseLabel": "Commitment period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r260", "r261", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss contingency, damages sought, value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManufacturedProductOtherMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by labor or machinery, classified as other.", "label": "Manufactured Product, Other [Member]", "terseLabel": "Other" } } }, "localname": "ManufacturedProductOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r9", "r50" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "negatedTerseLabel": "Realized gains from sales of marketable securities" } } }, "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market securities and funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r156", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Business Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/BusinessOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r66", "r69", "r74", "r77", "r98", "r108", "r118", "r123", "r124", "r126", "r127", "r131", "r132", "r144", "r175", "r177", "r180", "r183", "r185", "r211", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r458", "r472", "r559", "r578" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/EarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings", "totalLabel": "Net earnings" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r123", "r124", "r126", "r127", "r134", "r135", "r145", "r148", "r175", "r177", "r180", "r183", "r185" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Numerator for dilutive earnings per share" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r117", "r118", "r119", "r120", "r121", "r122", "r126", "r133", "r152", "r192", "r193", "r212", "r213", "r214", "r215", "r216", "r217", "r265", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r396", "r397", "r398", "r399", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r502", "r543", "r544", "r545", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r624", "r625", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r175", "r177", "r180", "r183", "r185" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r495" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "supn_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails", "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r495" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "supn_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term", "verboseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r497", "r500" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r51" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsAccruedPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r432", "r433", "r437" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized loss on marketable securities, net of tax", "verboseLabel": "Unrealized loss on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r67", "r70", "r432", "r433", "r437" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r51", "r506" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other liabilities.", "label": "Other Liabilities [Table Text Block]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other noncash adjustments, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "auth_ref": [ "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Other Nonoperating Income and Expense [Text Block]", "terseLabel": "Interest Expense" } } }, "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InterestExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r23", "r553", "r571" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payment of contingent consideration", "terseLabel": "Payment of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r89", "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration paid", "verboseLabel": "Cash consideration paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r195" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "verboseLabel": "Total PSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r40", "r41" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Cash distributions received" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Net product sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r45", "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r44", "r252" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r254", "r506", "r566", "r577" ], "calculation": { "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r18", "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r252" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r24", "r555", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Spend commitment amount" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r386", "r540", "r609" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Navitor investment R&D expense (see Note 5)" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r313", "r379", "r506", "r575", "r594", "r599" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r114", "r115", "r116", "r119", "r129", "r132", "r215", "r376", "r377", "r378", "r398", "r399", "r456", "r590", "r592" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r170", "r171", "r176", "r181", "r182", "r186", "r187", "r188", "r322", "r323", "r541" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r163", "r188" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer Benchmark" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Disaggregated Revenues" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty revenues" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of common stock equivalents excluded in the calculation of diluted earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of unrestricted available-for-sale marketable securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of income tax expense at the U.S Federal statutory income tax rate to the entity's effective income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/IncomeTaxBenefitExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r352", "r369", "r380" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r352", "r369", "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r239", "r243", "r542" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r247", "r249" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r37", "r38", "r39" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r45", "r254" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of recognized identified assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r353", "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r356", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock options and SAR activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of restricted stock units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r434", "r435", "r439", "r440", "r441", "r442", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)", "terseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value, grant date, (in dollars per share)", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, ending balance (in shares)", "periodStartLabel": "Nonvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number\u00a0of RSUs", "verboseLabel": "Number of PSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "periodStartLabel": "Nonvested, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-Based Payments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r358", "r371" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number\u00a0of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise\u00a0Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r351", "r354" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Summary of performance stock unit" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r105", "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r57", "r72", "r73", "r74", "r114", "r115", "r116", "r119", "r129", "r132", "r155", "r215", "r307", "r313", "r376", "r377", "r378", "r398", "r399", "r456", "r482", "r483", "r484", "r485", "r486", "r487", "r590", "r591", "r592", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement", "verboseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r114", "r115", "r116", "r155", "r541" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Stock options, RSUs" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r307", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r307", "r313", "r360" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r25", "r26", "r307", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award plans" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r108", "r191", "r211", "r472", "r506" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Stockholders' equity", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Composition of Balance Sheet Items" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CompositionofBalanceSheetItems" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r204", "r205", "r207", "r208", "r209", "r295", "r306", "r447", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r615", "r616", "r617", "r618", "r619", "r620", "r621" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialMeasurementsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r118", "r119", "r120", "r121", "r133", "r192", "r193", "r212", "r213", "r214", "r215", "r216", "r217", "r265", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r396", "r397", "r398", "r399", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r502", "r543", "r544", "r545", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r624", "r625", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/FairValueofFinancialMeasurementsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r97" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedTerseLabel": "Change in fair value of contingent consideration" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r157", "r158", "r159", "r160", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "VIE, qualitative or quantitative information, ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r136", "r148" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r134", "r148" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2029-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r508": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r548": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r565": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r603": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r610": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r611": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r612": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r613": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r614": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r615": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r616": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r617": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r618": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r619": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r620": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r621": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r622": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r623": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 95 0001356576-22-000046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356576-22-000046-xbrl.zip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�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end

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